Note: Descriptions are shown in the official language in which they were submitted.
DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 A 157
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des
brevets
JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 157
NOTE: For additional volumes, please contact the Canadian Patent Office
NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
S. agalactiae.antigens I + II
The present invention relates to isolated nucleic acid molecules, which encode
antigens for Streptococcus
agalactiae, which are suitable for use in preparation of pharmaceutical
medicaments for the prevention
and treatment of bacterial infections caused by Streptococcus agalactiae.
Streptococcus agalactiae is a gram-positive bacterium, and belongs to the
Group B Streptococci (GBS) based
on its hemotysis pattern in blood agar. 'The organism is encapsulated, and
capsule is an important
element of pathogenicity. Capsules are antigenic and form the basis for
classifying GBS by serotypes.
Nine distinct GBS serotypes have been identified: Ia, Ib, II, III, IV, V, VI,
VII and VIII. Most S, agalactiae
serotypes have been shown to cause serious disease, and the two most common
serotypes - type III and V
- are estimated to account for the majority of invasive disease worldwide. The
ranking and serotype
prevalence differs by age group and geographic area. In the US, GBS type III
causes more than 50% of
infant disease, type V about 40% of nonpregnant adult disease, and type Ia
about a third of disease in any
patient population.
Streptococcus agalactiae is an important agent of human disease at the
extremities of age and in those who
have underlying disease. Group B Streptococci are the major cause of
generalized and focal infections in
the newborn infant. GBS is the predominant pathogen in newborns in the US
since the 1970's. Bacterial
infection can lead to life threatening diseases, such as sepsis, pneumonia and
meningitis. Survivers can
become permanently handicapped with hearing, learning and visual disabilities.
Newborns usually
acquire the organism intrapartum or during delivery from their GBS-colonized
mothers. In addition, GBS
are also a frequent cause of infections in pregnant women and in chronically
ill and elderly patients, such
as those suffering from diabetes, malignancies, immunodeficiencies, etc.,
(reviewed by Batter, S. et al. in
Gram positive pathogens ed. by Fischetti V.A. et al. ASM Press 2000, pp 154-
160).
10-35% of pregnant women are colonized with GBS, but are asymptomatic.
However, GBS colonization is
important because of the risk of vertical transmission. 50-70% of neonates
born to colonized women - that
is 5-15% of all newborns - become colonized by GBS during delivery.
Colonization is a prerequisite for
infection and disease. The most preterm infants are at the highest risk for
invasive disease due to low
maternal transfer of antibodies and immature immune system. GBS carriage
during pregnancy may be
chronic, intermittent, or transient. It is difficult to assess the duration of
carriage, since women are
screened once during a prenatal visit from the late trimester. Several studies
suggest that there is a
correlation (~90%) between the colonization status in the third trimester and
at the time of delivery.
Serotyping of the isolates indicates that persistence of the same type is most
common (reviewed by Batter,
S. et al. in Gram positive pathogens ed. by Fischetti V.A. et al. ASM Press
2000, pp 154-160).
Without preventive intervention, 1 to 2% of all neonates and 15% of neonates
born to heavily colonized
women develop invasive disease (sepsis, pneumonia and/or meningitis). In the
US, GBS infections affect
1-5 newborns/1000 live birth. About 17.000 cases of invasive GBS disease
occurred in the US annually,
and 7.500 occurred in newborns before prevention. GBS is the most common cause
of bacterial meningitis
accounting for ~ 40 % of all cases reported in this age group. The overall
incidence of invasive GBS
disease is 0.2-0.7/100.000 in the US. It is somewhat lower in Europe.
Mortality without preventive
intervention is 6% with invasive disease, every 16. infected newborn dies and
20% of survivers become
permanently handicapped.
The rates of serious group B strap infections are much higher among newborns
than among any other age
group. Nonetheless, serious group B strap infections occur in other age groups
in both men and women.
Among non-pregnant adults, rates of serious disease range from 4.1 to 7.2
cases per 100,000 populations.
The average death rate for invasive infections (infections where the bacteria
have entered a part of the
body that is normally not exposed to bacteria) is 8-10% for adult's ages 18-64
and 15-25% for adults 65
years of age and over. Mortality rates are lower among younger adults, and
adults who do not have other
medical conditions. The rate of serious group B strap disease increases with
age. The average age of cases
CONFIRMATION COPY
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
in non-pregnant adults is about 60 years old. Most adult group B strep disease
occurs in adults who leave
serious medical conditions. These include: diabetes mellitus; liver disease;
history of stroke; history of
cancer; or bedsores. Among the elderly, rates of serious group B strep disease
are more common among
residents of nursing facilities, and among bedridden hospitalized patients.
Group B strep disease among
non-pregnant adults may often be acquired after recent trauma, or after having
certain invasive hospital
procedures like surgery ({Parley, M., 2001}; {Jackson, L. et al., 1995};
www.cdc.gov/groupbstrep/).
Direct medical costs of neonatal disease before prevention were $294 million
annually and GBS continues
to pose a considerable economic burden.
A definitive diagnosis of infection with Streptococcvcs agalactiae generally
relies on isolation of the
organism from cervical swabs, blood or other normally sterile body sites.
Tests are also available to detect
capsular polysaccharide antigen in body fluids.
Penicillin G is the treatment of choice for established cases of GBS. Ten days
of treatment is
recommended for bacteremia, pneumonia and soft tissue infections, while 2-3
weeks is recommended for
meningitis and 3-4 weeks for osteomyelitis.
Prevention has been established since 1994 in North America by screening
pregnant women for carriage
of GBS, taking vaginal and anorectal swabs at 35-37 weeks' gestation, or by
identifying risk factors at
admission for delivery without cultures. Women who are candidates for
prophylaxis are given
intrapartum antibiotic therapy during labor to prevent early-onset neonatal
disease. This prevention
method has decreased the incidence of GBS disease from 1.~ to 0.4/1000 live
births between 1993 and 1999
in the LTS. Although most neonatal GBS disease can be prevented through
intrapartum prophylaxis
(Penicillin G or Ampicillin), currently available strategies are not ideal,
especially for the prevention of
late-onset (>7 days of age) infections and disease in premature babies. There
are always individuals who
escape of screening for carriage due to several reasons, such as intermittent
carriers, who are tested
negative at wks 32-35, but become positive during delivery, unattendance,
negligence, or delivery before
screening date (32-35 wks).
In the long run, widespread use of antibiotics usually induces resistant
strains that appear after a period
of time. Extensive use of Penicillin (every 3-5th women are treated with high
dose), and other antibiotics
has already been shown to steadily increase the percentage of antibotic
resistant clinical isolates (ref).
Moreover, efficiency of antibiotic based prevention is not that effective for
late onset disease, as it is for
early onset (within 48 hrs after delivery). An additional concern is that
prevention in susceptible adult
populations has not been addressed.
Vaccine development is hindered by the lack of sufficient knowledge about the
elements of protective
immunity against GBS carriage and disease. The relationship of carriage to the
development of natural
immunity is poorly understood. In addition, the immunologic mechanism that
allows disease to occur in
a carrier is ill defined. However, it is suggested that the maternal serum
levels of pathogen-specific
antibodies are correlated with neonatal GBS disease. It has been firmly
established that there is an inverse
correlation between maternal anti-capsular polysaccharide antibody levels at
delivery and the frequency
of invasive neonatal diseases {Campbell, J. et al., 2000}.
Although the group B carbohydrate antigen is common to all strains of GBS,
unfortunately, it is not
strongly immunogenic and antibodies are not protective from lethal challenge
in experimental models.
The GBS capsule itself that is made of polysaccharides, is immunogenic and is
able to induce protective
antibodies. However, this protection is type-specific. Although capsular
specific antibodies have been
shown to be highly protective, it remains unclear what concentration of these
serotype-specific antibodies
protect against disease and more recently it has become clear that opsonic
activity and avidity of these
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-3-
antibodies are more critical determinants of protection than concentration.
The importance of surface proteins in human immunity to S. agalactiae already
has been appreciated. It is
apparent that all serotypes express surface proteins with activity relevant to
host immune defense. The
alpha C protein, beta C protein, Rib and Sip proteins are well-characterized
biochemically and
genetically, and have also been shown to immunogenic and protective in animal
models ({Michel, J. et al.,
1991}; {Brodeur, B. et al., 2000}; {Larsson, C. et al., 1999}; {Cheng, (~. et
al., 2002}). The major problem with
these proteins as vaccine candidates seems to be their variability in
prevalenve among the different
clinical isolates of GBS. The Rib protein for example is present in serotype
III GBS, but missing from type
V, which responsible for significant portion of disease worldwide. Some other
surface proteins are
characterized as being immunogenic, but there is a limited systematic work
done to identify most of the
immunogenic proteins of GBS.
Thus, there remains a need for an effective treatment to prevent or ameliorate
GBS infections. A vaccine
could not only prevent infections by GBS, but more specifically prevent or
ameliorate colonization of host
tissues (esp. in the birth canal), thereby reducing the incidence of
transmission from mother to fehxs.
Reducing the incidence of acute infection and carriage of the organism would
lead to prevention of
invasive diseases in newborns - pneumonia, bacteremia, meningitis, and sepsis.
Vaccines capable of
showing cross-protection against the majority of S. agalactiae strains causing
human infections could also
be useful to prevent or ameliorate infections caused by all other
streptococcal species, namely groups A,
C and G.
A vaccine can contain a whole variety of different antigens. Examples of
antigens are whole-killed or
attenuated organisms, subfractions of these organisms/tissues, proteins, or,
in their most simple form,
peptides. Antigens can also be recognized by the immune system in form of
glycosylated proteins or
peptides and may also be or contain polysaccharides or lipids. Short peptides
can be used since for
example cytotoxic T-cells (CTL) recognize antigens in form of short usually 8-
11 amino acids long
peptides in conjunction with major histocompatibility complex (MHC). B-cells
can recognize linear
epitopes as short as 4-5 amino acids, as well as three-dimensional structures
(conformational epitopes). In
order to obtain sustained, antigen-specific immune responses, adjuvants need
to trigger immune
cascades that involve all cells of the immune system. Primarily, adjuvants are
acting, but are not
restricted in their mode of action, on so-called antigen presenting cells
(APCs). These Bells usually first
encounter the antigens) followed by presentation of processed or unmodified
antigen to immune effector
cells. Intermediate cell types may also be involved. Only effector cells with
the appropriate specificity are
activated in a productive immune response. The adjuvant may also locally
retain antigens and co-injected
other factors. In addition the adjuvant may act as a chemoattractant for other
immune cells or may act
locally and/or systemically as a stimulating agent for the immune system.
Vaccine development since the late 1970s has focused on the capsular
polysaccharides, but a safe,
effective product is still not available. However, vaccine against S.
agalactiae is ranked as one of the most
important for development and administration to infants and high-risk adults.
Currently vaccines against
this infection are only in the research stages of development. Efforts are
focused on using capsular
polysaccharide (CPS) as immunogens, either with or without conjugation to
protein {Paoletti, L. et al.,
2002}. However, there are several arguments against the use of polysaccharide-
based vaccine.
Polysaccharides induce IgG2 antibodies, which cross the placenta less
efficiently then IgG1 or IgG3
antibodies. It is especially a problem for the most susceptible neonates, the
still-borns since placental
antibody transfer is low before weeks 32-34. It is estimated that ~10% of
deliveries occur before the 34th
pregnancy week.
Protein conjugate vaccines are no doubt a great new addition to the
amarmatorium in the battle against
GBS disease, but the vaccine can contain only a limited number of GBS
serotypes and given adequate
ecological pressure, replacement disease by non-vaccine serotypes remains a
real threat, particularly in
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-4-
areas with very high disease burden. Morover polysaccharide antigens used for
active immunization do
not provide immunological memory in humans. Conjugation of CPS to non-GBS
related immunogenic
protein carriers (e.g. tetanus toxoid, cholera toxin B subunit, etc.) has been
shown to beneficial in
inducing higher concentrations of antibodies in vaccinees, but it does not
provide pathogen-specific B cell
and T cell epitopes which would recruit memory B and T Bells during a real
infection to support the most
effective host response. To be able to supplement the CPS vaccines with
proteins fulfilling these criteria it
is necessary to identify conserved immunogenic GBS-specific surface proteins.
All these insufficiencies suggest that there is a need to develop new
generation vaccines composed of
proteins, or their derivatives, expressed by all strains under in vivo
conditions with the ability to induce
opsonizing and/or neutralizing antibodies in humans.
There is a great potential for passive antibody-based therapy. There have been
already attempts to use
human intravenous immunoglobulin (IVIG) preparations for prevention. Recent
advances in the
technology of monoclonal antibody production provide the means to generate
human antibody reagents
and reintroduce antibody therapies, while avoiding the toxicities associated
with serum therapy.
Immunoglobulins are an extremely versatile class of antimicrobial proteins
that can be used to prevent
and treat emerging infectious diseases. Antibody therapy has been effective
against a variety of diverse
microorganisms (reviewed in {Burnie, J. et al., 1998}). Anti=GBS mAbs could be
given therapeutically to
every newborn that develop invasive diseases or preventively to low birth-
weight and premature
neonates.
During the last decade the immunogenicity and protective capacity of several
GBS proteins have been
described in animal models and these are now being explored for the
development of species-common
protein based vaccines. Such proteins are the GBS surface proteins Sip
{Brodeur, B. et al., 2000}, rib, ~-
protein and {Michel, J. et al.,1991}.
Certain proteins or enzymes displayed on the surface of gram-positive
organisms significantly contribute
to pathogenesis, are involved in the disease process caused by these
pathogens. Often, these proteins are
involved in direct interactions with host tissues or in conceiling the
bacterial surface from the host
defense mechanisms {Navarre, W. et al., 1999}. S. agalactiae is not an
exception in this regard. Several
surface proteins are characterized as virulence factors, important for GBS
pathogenicity ((reviewed in
(Paoletti L.C. et al. in Gram positive pathogens, ed. by Fischetti V.A et al.,
ASM Press 2000, pp 137-153);
{Paoletti, L. et al., 2002}). If antibodies to these proteins could offer
better protection to humans then
polysaccharides, they could provide the source of a novel, protein-based GBS
vaccine to be used in
conjunction with or in place of the more traditional capsular polysaccharise
vaccine. The use of some of
the above-described proteins as antigens for a potential vaccine as well as a
number of additional
candidates resulted mainly from a selection based on easiness of
identification or chance of availability.
There is a demand to identify relevant antigens for S. agalactiae in a more
comprehensive way.
The present inventors have developed a method for identification, isolation
and production of
hyperimmune serum reactive antigens from a specific pathogen, especially from
Staphylococcus au~~eus
and Staphylococcus epidermidis (WO 02/059148). However, given the differences
in biological property,
pathogenic function and genetic background, Streptococcus agalactiae is
distinctive from Staphylococcus
strains. Importantly, the selection of sera for the identification of antigens
from S. agalaetiae is different
from that applied to the S. at~reus screens. Four major types of human
antibody sources were collected for
that purpose. First, healthy pregnant women who were tested negative for
cervical and anorectal carriage
of GBS. This donor group represents the most important source of antibodies.
In addition to their serum
samples, human cervical secretions collected with cervical wicks, containing
secretory IgA (sIgA) were
also used for antigen idntification and validation. The main value of this
collection is that sIgA can be
considered the major immune effector molecule on mucosal surfaces. Second,
healthy pregnant women
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-5-
colonized with GBS whos newborn remained GBS-free (although with antibiotic
prevention). Third,
adults below <45 years of age without clinical disease. Four, naive
individuals, youg children between 5
and 10 months of age, after they already lost maternal antibodies and have not
acquired GBS-specific
ones due to the lack of GBS disease.
To be able to select for relevant serum sources, a series of ELISAs and
immunoblotting experiments
measuring anti-S. agalactiae IgG and IgA antibody levels were performed with
bacterial lysates and
culture supernatant proteins. Sera from high titer carriers and non-carriers
were included in the genomic-
based antigen identification. This approach for selection of human sera is
basically very different from
that used for S. aureus, where carriage or non-carriage state couldn't be
associated with antibody levels.
The present invention uses high throughput genomic method to identify in vivo
expressed pathogen-
specific proteins with the ability to induce antibodies in humans during the
course of infections and
colonization.
The genomes of the two bacterial species S. agalactiae and S. aureus by itself
show a number of important
differences. The genome of S. agalactiae contains app. 2.2 Mb, while S. aureus
harbours 2.85 Mb. They have
an average GC content of 35.7 and 33%, respectively and approximately 30 to
45% of the encoded genes
are not shared between the two pathogens. In addition, the two bacterial
species require different growth
conditions and media for propagation. A list of the most important diseases,
which can be inflicted by the
two pathogens is presented below. S. aureus causes mainly nosocomial,
opportunistic infections:
impetigo, folliculitis, abscesses, boils, infected lacerations, endocarditis,
meningitis, septic arthritis,
pneumonia, osteomyelitis, scalded skin syndrome (SSS), toxic shock syndrome.
S. agalactiae causes mainly
neonatal infections and diseases in elderly, such as bacteremia, sepsis, wound
infection, osteomyelitis and
meningitis.
The complete genome sequence of a capsular serotype III isolate of S.
agalactiae, designated NEM316
(ATCC 12403) was determined by the random shotgun sequencing strategy (GenBank
accession number
AL732656; see www.tigr.org/tigrscripts/CMR2/CMIZHomePage.spl). {Glaser, P. et
al., 2002}.
The problem underlying the present invention was to provide means for the
development of
medicaments such as vaccines against S. agalactiae infection. More
particularly, the problem was to
provide an efficient, relevant and comprehensive set of nucleic acid molecules
or hyperimmune serum
reactive antigens from S. agalactiae that can be used for the manufacture of
said medicaments.
Therefore, the present invention provides an isolated nucleic acid molecule
encoding a hyperimmune
serum reactive antigen or a fragment thereof comprising a nucleic acid
sequence, which is selected from
the group consisting of:
a) a nucleic acid molecule having at least 70% sequence identity to a nucleic
acid molecule selected
from Seq ID No 14, 90,157-216.
b) a nucleic acid molecule which is complementary to the nucleic acid molecule
of a),
c) a nucleic acid molecule comprising at least 15 sequential bases of the
nucleic acid molecule of a)
or b)
d) a nucleic acid molecule which anneals under stringent hybridisation
conditions to the nucleic
acid molecule of a), b), or c)
e) a nucleic acid molecule which, but for the degeneracy of the genetic code,
would hybridise to the
nucleic acid molecule defined in a), b), c) or d).
According to a preferred embodiment of the present invention the sequence
identity is at least 80%,
preferably at least 95%, especially 100%.
Furthermore, the present invention provides an isolated nucleic acid molecule
encoding a hyperimmune
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-6-
serum reactive antigen or a fragment thereof comprising a nucleic acid
sequence selected from the group
consisting of
a) a nucleic acid molecule having 96 % or more than 96 %, preferably at least
98 %, especially 100
sequence identity to a nucleic acid molecule selected from Seq ID No 1, 3, 5-
13, 15, 18-25, 27-31,
33-36, 39-68, 70-85, 92-100,103-126,128-145,147,149-156, 217, 435-448 and 463-
474.
b) a nucleic acid molecule which is complementary to the nucleic acid molecule
of a),
c) a nucleic acid molecule comprising at least 15 sequential bases of the
nucleic acid molecule of a)
~r b)
d) a nucleic acid molecule which anneals under stringent hybridisation
conditions to the nucleic
acid molecule of a), b) or c),
e) a nucleic acid molecule which, but for the degeneracy of the genetic code,
would hybridise to the
nucleic acid defined in a), b), c) or d).
According to another aspect, the present invention provides an isolated
nucleic acid molecule encoding a
hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic
acid sequence selected
from the group consisting of
a) a nucleic acid molecule having 98 % or more than 98%, escpecially 100 %
sequence identity to a
nucleic acid molecule selected from Seq ID No 32, 86, 91, 101, 12'7.
b) a nucleic acid molecule which is complementary to the nucleic acid of a),
c) a nucleic acid molecule which, but for the degeneracy of the genetic code,
would hybridise to the
nucleic acid defined in a), b), c) or d).
Preferably, the nucleic acid molecule is DNA or RNA.
According to a preferred embodiment of the present invention, the nucleic acid
molecule is isolated from
a genomic DNA, especially from a S. agalactiae genomic DNA.
According to the present invention a vector comprising a nucleic acid molecule
according to any of the
present invention is provided.
In a preferred embodiment the vector is adapted for recombinant expression of
the hyperimmune serum
reactive antigens or fragments thereof encoded by the nucleic acid molecule
according to the present
invention.
The present invention also provides a host cell comprising the vector
according to the present invention.
According to another aspect the present invention further provides a
hyperimmune serum-reactive
antigen comprising an amino acid sequence being encoded by a nucleic acid
molecule according to the
present invention.
In a preferred embodiment the amino acid sequence (polypeptide) is selected
from the group consisting
of Seq ID No 231, 307, 374-433.
In another preferred embodiment the amino acid sequence (polypeptide) is
selected from the group
consisting of Seq ID No 218, 220, 222-230, 232, 235-242, 244-248, 250-253, 256-
285, 287-302, 309-317, 320-
343, 345-362, 364, 366-3~3, 434, 449-462 and 4~5-486.
In a further preferred embodiment the amino acid sequence (polypeptide) is
selected from the group
consisting of Seq ID No 249, 303, 308, 318, 344.
According to a further aspect the present invention provides fragments of
hyperimmune serum-reactive
antigens selected from the group consisting of peptides comprising amino acid
sequences of column
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
"predicted immunogenic as°' and "location of identified immunogenic
region" of Table 1A, especially
peptides comprising amino acid 4-20, 35-44, 65-70, '73-87, 92-98, 112-137, 152-
161, 177-186, 193-200, 206-
213, 229-255, 282-294, 308-313, 320-326, 349-355, 373-384, 388-406, 420-425
and 115-199 of Seq ID No 218;
5-24, 35-41, 44-70, 73-89, 103-109, 127-143, 155-161, 185-190, 192-207, 212-
219, 246-262, 304-336, 372-382,
384-393, 398-40'7, 412-418, 438-444, 1-75, 76-161 and 164-239 of Seq ID No
219; 4-10, 16-58, 60-~1, ~~-92,
100-126, 132-146, 149-164, 166-172, 190-209, 214-220, 223-229, 241-256, 297-
312, 314-319, 337-343, 351-359,
378-387, 398-418, 421-428, 430-437, 440-448, 462-471, 510-519, 525-536, 552-
559, 561-568, 573-582, 596-602,
608-630, 637-649, 651-665, 681-702, 714-732, 739-745, 957-778, 790-805, 807-
815, 821-829, 836-842, 846-873,
880-903, 908-914, 916-923, 931-940, 943-948, 956-970, 9~5-986, 996-1015, 1031-
1040, 1051-1069, 102-1095,
1114-1119, 1130-1148, 1150-115, 1169-1176, 1229-1238 and 802-812 of Seq ID No
220; 5-12, 14-26, 35-47,
52-67, ~2-78, 83-98, 121-141, 152-159,163-183,186-20~, 209-257, 264-27~, 282-
299, 301-309, 312-318, 324-339,
358-368, 372-378, 38~-39~, 425-431 and 46-291 of Seq ID No 221; 29-38, 44-64,
70-'76, ~8-8~, 94-100, 102-112,
119-134, 140-149, 163-1~3, 1~8-186, 188-194, 207-234, 247-262, 269-290 and 73-
92 of Seq ID No 222; 10-28,
36-63, 77-87, 103-119, 127-136, 141-169, 171-183, 195-200, 207-232, 236-246,
251-265, 268-283, 287-297, 314-
322, 335-343, 354-363, 384-390, 405-411, 419-436, 443-455, 467-473, 480-513,
518-529, 550-557, 565-585, 602-
608, 616-625, 632-660, 665-6~7, 685-701, 726-X36, 738-747, X52-761, 785-796,
801-813, 838-853, 866-871 and
'757-X74 of Seq ID No 223; 31-38, 61-66, 74-81, 90-115, 123-145, 154-167, 169-
1~9, 182-193, 200-206, 238-244,
267-272 and 235-251 of Seq ID No 224; 19-25, 38-54, 56-64, 66-72, 74-92, 94-
100, 116-129, 143-149, 156-183,
204-232, 253-266, 269-275, 294-307 and 241-313 of Seq ID No 225; 5-34, 50-56,
60-65, 74-85, 89-97, 108-119,
159-165, 181-199, 209-225, 230-240, 245-251, 257-262, 274-282, 300-305 and 64-
75 of Seq ID No 226; 5-13,
16-21, 27-42, 45-52, 58-66, 74-87, 108-114, 119-131 and 39-51 of Seq ID No
227; 6-23, 46-54, 59-65, 78-84,
100-120, 128-133, 140-146, 159-165, 171-183, 190-204, 224-232, 240-248, 250-
259, 274-280, 288-296, 306-315
and 267-274 of Seq ID No 228; 5-12, 15-24, 26-36, 42-65, 68-80, 82-104, 111-
116, 125-144, 159-167, 184-189,
209-218, 235-243, 254-265, 269-283, 287-300, 306-316, 318-336, 338-352, 374-
392 and 162-174 of Seq ID No
229; 30-42, 45-54 and 25-3~ of Seq ID No 230; 10-30, 53-59, 86-95, 116-130,
132-14~, 169-189, 195-201, 212-
221, 247-256, 258-265, 278-283, 291-298, 310-316, 329-339, 341-352, 360-367,
388-396, 398-411, 416-432, 443-
452, 460-466, 506-512, 515-521, 542-548 and 419-431 of Seq ID No 231; 4-27, 30-
53, 60-67, 70-90, 92-151,
159-185, 189-195, 198-210, 215-239 and 173-189 of Seq ID No 232; 4-26, 41-54,
~1-~8, 116-127, 140-149, 151-
158, 161-175, 190-196, 201-208, 220-226, 240-252, 266-281, 298-305, 308-318,
321-329, 344-353, 372-378, 384-
405, 418-426, 429-442, 457-463, 494-505, 514-522 and 174-188 of Seq ID No 233;
17-25, 27-39, 61-67, 81-89,
99-110, 120-131, 133-139, 147-161, 167-1~2, 179-185, 192-198, 203-213, 226-
238, 243-258, 261-267, 284-290,
296-30~, 311-328, 340-352, 356-371 and 239-256 of Seq ID No 234; 8-30, 40-49,
67-80, 114-123, 126-142, 152-
162, 188-194 and 5~-70 of Seq ID No 235; 4-23, 28-34, 36-47, 50-61, 76-81, 89-
94, 96-104, 112-119, 126-146,
155-181, 195-200, 208-214, 220-229, 244-260, 263-276, 282-288, 292-300, 317-
323, 336-351, 353-359, 363-375,
382-399, 415-432, 444-455, 458-471, 476-481, 484-492, 499-51~, 522-529, 535-
541, 543-568, 572-584, 586-600,
607-617, 626-637, 656-6~5 and 282-29~ of Seq ID No 236; 6-24, 30-35, 38-45, 63-
91, 134-140, 146-160, 167-
188, 214-220, 226-234, 244-250, 260-2~0, 286-301, 316-329, 340-371, 429-446,
448-459, 474-481, 485-491, 512-
526, 537-544, 550-565, 573-583, 596-613, 621-630, 652-658 and 87-97 of Seq ID
No 237; 8-20, 26-48, 56-67,
76-86, 94-109, 115-121, 123-129, 143-160, 178-186, 191-198, 201-208, 221-236,
238-244, 260-268 and 23~-247
of Seq ID No 238; 4-40, 42-57, 73-87, 98-117, 126-135, 150-156, 166-174, 196-
217, 231-236, 248-258, 276-284,
293-301, 307-313, 339-347, 359-365, 375-387, 395-402, 428-440, 445-456, 485-
490, 497-505, 535-541, 547-555,
610-625, 648-656, 665-671 and 448-528 of Seq ID No 239; 10-18, 39-45, 51-61,
80-96, 98-106, 110-115, 158-
172, 1~4-183, 191-200, 220-237, 249-255, 274-289, 308-324, 331-341, 3~2-381,
384-397, 405-414 and 322-338 of
Seq ID No 240; 30-36, 38-56, 85-108, 134-147, 149-160, 163-183, 188-201, 206-
211, 219-238, 247-254 and 5-13
of Seq ID No 241; 11-40, 98-103, 110-115, 133-145, 151-159, 172-179, 192-201,
204-212, 222-228, 235-245,
258-268, 283-296, 298-309, 322-329, 342-351, 354-362, 372-378, 385-393, 407-
418, 495-516 and 1-148 of Seq
ID No 242; 5-19, 21-36, 73-94, 112-119, 122-137, 139-145, 152-167, 184-190,
198-204, 208-224, 249-265, 267-
281, 299-304, 309-31~, 326-333, 356-364, 368-374, 381-389, 391-414, 419-425,
430-435 and 113-140 of Seq ID
No 243; 45-54, 59-67, 78-91 and 15-23 of Seq ID No 244; 11-22, 33-47, 52-80,
88-112, 124-129 and 6-25 of
Seq ID No 245; 26-41, 51-63, 80-89, 93-115, 150-163, 187-193, 220-237, 240-
249, 286-294, 296-306, 316-329,
345-353, 361-370, 407-425, 428-437, 474-482, 484-494, 504-51~, 533-541, 549-
558, 595-613, 616-625, 660-668,
673-685, 711-726, 736-744, 749-761, 787-802, 812-820, 825-837, 863-878, 888-
896, 901-913, 939-954, 964-972,
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
_g_
977-989, 1003-1008, 1016-1022, 1028-1034, 1041-1053, 1059-1074, 1101-1122, 420-
511 and 581-704 of Seq ID
No 246;18-25, 27-55, 71-83, 89-95, 102-113, 120-146, 150-156, 174-185 and 159-
175 of Seq ID No 247; 24-30,
38-56, 63-68, 87-93,136-142,153-164, 183-199, 213-219, 226-234, 244-261, 269-
278, 283-289, 291-297, 320-328,
330-336, 340-346, 348-356, 358-366, 382-387, 401-408, 414-419, 449-455, 468-
491, 504-512, 531-537, 554-560,
597-608, 621-627, 632-643, 650-662, 667-692, 703-716, 724-737, 743-758, 783-
794, 800-818, 846-856 and 806-
884 of Seq ID l~0 248; 4-14, 21-39, 86-92, 99-107, 121-131, 136-144,147-154,
158-166, 176-185, 193-199, 207-
222, 224-230 and 117-136 of Seq ID l~0 249; 65-76, 85-97, 103-109, 115-121,
125-146, 163-169, 196-205, 212-
219, 228-237, 241-247, 254-262, 269-288, 294-303, 305-313, 328-367, 395-401,
405-412, 418-429, 437-447, 481-
488, 506-513, 519-524, 530-541, 546-557 and 266-284 of Seq ID l~~To 250; 5-14,
37-42, 49-71, 78-92, 97-112,
127-136, 147-154, 156-163, 186-198, 216-225, 233-243, 248-253, 295-307, 323-
332, 359-366, 368-374, 380-398
and 194-223 of Seq ID No 251; 4-11, 33-39, 45-72,100-113,119-129,136-144,169-
175, 177-185, 200-208, 210-
219, 262-276, 278-297, 320-326, 336-344, 347-362, 381-394, 443-453 and 438-454
of Seq ID No 252; 4-29, 31-
52, 55-61, 95-110, 138-158, 162-171, 179-187, 202-229, 239-248, 251-256, 262-
267, 269-285, 304-310, 351-360,
362-368, 381-388, 415-428, 435-440, 448-458 and 161-178 of Seq ID No 253; 4-
17, 19-28, 32-43, 47-59, 89-110,
112-126, 128-134, 140-148, 152-161, 169-184, 191-204, 230-235, 255-264, 328-
338, 341-347, 401-409, 413-419,
433-441, 449-458, 463-468, 476-482, 486-492, 500-506, 529-545 and 305-381 of
Seq ID No 254; 10-29, 38-45,
53-61, 134-145, 152-160, 163-170, 202-208, 219-229, 248-258, 266-275, 282-288,
315-320, 328-334, 377-385,
392-402, 418-424, 447-453, 460-471, 479-487, 491-497, 500-507, 531-537, 581-
594, 615-623, 629-635, 644-652,
659-666, 668-678, 710-717, 719-728, 736-741, 747-760, 766-773, 784-789, 794-
800, 805-817, 855-861, 866-887
and 698-715 of Seq ID No 255; 16-26, 29-37, 44-58, 62-68, 74-80, 88-95, 97-
120, 125-144, 165-196 and 58-72
of Seq ID No 256;14-21, 23-46, 49-60, 63-74, 78-92, 96-103,117-129,134-161,169-
211, 217-231, 239-248, 252-
281, 292-299, 313-343 and 243-257 of Seq ID No 257; 11-27, 46-52, 67-72, 76-
84, 91-112, 116-153, 160-175,
187-196, 202-211, 213-220 and 43-76 of Seq ID No 258; 5-29, 37-56, 78-86, 108-
118, 152-161 and 120-130 of
Seq ID No 259; 8-14, 19-41, 52-66, 75-82, 87-92, 106-121, 127-133, 136-143,
158-175, 180-187, 196-204, 221-
228, 239-245, 259-265, 291-306, 318-323, 328-340, 352-358, 361-368, 375-381,
391-399, 411-418, 431-442, 446-
455, 484-496, 498-510, 527-533, 541-549, 558-565, 575-585, 587-594, 644-655,
661-668, 671-677 and 184-196 of
Seq ID No 260; 4-22, 29-38, 55-62, 75-81, 102-107, 110-134, 143-150,161-167,
172-179, 191-215, 223-233, 241-
247, 251-264, 266-272, 288-309, 340-352, 354-366, 394-402, 414-438 and 198-218
of Seq ID No 261; 24-44, 49-
70, 80-91, 105-118, 128-136, 140-154 and 77-92 of Seq ID No 262; 5-22, 31-36,
41-47, 67-74, 83-90, 105-122,
135-143, 160-167 and 118-129 of Seq ID No 263; 4-25, 33-73, 81-93, 96-106, 114-
120, 122-128, 130-7,72, 179-
208, 210-241, 251-283, 296-301 and 92-100 of Seq ID No 264; 14-24, 29-38, 43-
50, 52-72, 86-97, 101-107, 110-
125, 127-141, 145-157, 168-175, 177-184, 186-195, 205-226, 238-250, 255-261,
284-290, 293-304, 307-314, 316-
323, 325-356, 363-371, 383-390, 405-415, 423-432, 442-454, 466-485, 502-511,
519-527, 535-556, 558-565, 569-
574, 612-634, 641-655, 672-686, 698-709, 715-722, 724-732, 743-753, 760-769,
783-792, 818-825, 830-839, 842-
849, 884-896, 905-918, 926-940, 957-969, 979-1007, 1015-1021, 1049-1057 and
336-349 of Seq ID No 265; 6-
16, 26-31, 33-39, 62-73, 75-85, 87-100,113-123, 127-152,157-164,168-181, 191-
198, 208-214, 219-226, 233-254,
259-266, 286-329 and 181-195 of Seq ID No 266; 4-13, 32-39, 53-76, 99-108, 110-
116, 124-135, 137-146, 149-
157, 162-174, 182-190, 207-231, 242-253, 255-264, 274-283, 291-323, 334-345,
351-360, 375-388, 418-425, 456-
474, 486-492, 508-517, 520-536, 547-560, 562-577, 31-45 and 419-443 of Seq ID
No 267; 15-26, 30-37, 42-49,
58-90, 93-99, 128-134, 147-154, 174-179, 190-197, 199-205, 221-230, 262-274,
277-287, 300-314, 327-333, 343-
351, 359-377, 388-396, 408-413, 416-425, 431-446 and 246-256 of Seq ID No 268;
5-26, 34-42, 47-54, 61-67,
71-104, 107-115, 131-138, 144-153, 157-189, 196-202, 204-210, 228-245, 288-
309, 316-329, 332-341, 379-386,
393-399, 404-412, 414-421, 457-468, 483-489, 500-506, 508-517, 523-534, 543-
557, 565-580, 587-605, 609-617,
619-627, 631-636, 640-646, 662-668, 675-682, 705-710, 716-723, 727-732, 750-
758, 784-789, 795-809, 869-874,
14-138, 166-286, 372-503, 674-696 and 754-859 of Seq ID No 269; 5-17, 32-38,
40-47, 80-89,113-119, 125-137,
140-154, 157-163, 170-177, 185-199, 213-225, 228-236, 242-248, 277-290, 292-
305, 323-333, 347-353, 364-370,
385-394, 399-406, 423-433, 441-451, 462-474, 477-487 and 116-124 of Seq ID No
270; 7-16, 18-30, 32-49, 53-
61, 63-85, 95-101, 105-115, 119-134, 143-150, 159-178, 185-202, 212-229, 236-
250, 254-265, 268-294 and 63-72
of Seq ID No 271; 4-12,19-47, 73-81, 97-103, 153-169, 188-198, 207-213, 217-
223, 236-242, 255-265, 270-278,
298-305, 309-317, 335-347, 354-363, 373-394, 419-424, 442-465, 486-492, 500-
507, 542-549, 551-558, 560-572,
580-589, 607-614, 617-623, 647-653, 666-676, 694-704, 706-714, 748-754, 765-
772, 786-792, 795-806 and 358-
370 of Seq ID No 272; 18-28, 30-38, 40-46, 49-55, 69-78, 82-98, 104-134, 147-
153, 180-190, 196-202, 218-236,
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-9-
244-261, 266-273, 275-286, 290-295, 301-314, 378-387, 390-395, 427-434 and 290-
305 of Seq ID No 273; 4-13,
20-31, 39-51, 54-61, 69-84, 87-105, 117-124 and 108-125 of Seq ID No 274; 24-
34, 43-54, 56-66, 68-79 and 50-
69 of Seq ID No 275; 5-43, 71-77, 102-131, 141-148, 150-156, 159-186, 191-207,
209-234, 255-268, 280-286,
293-299, 317-323, 350-357, 363-372, 391-397, 406-418, 428-435, 455-465, 484-
497, 499-505, 525-531, 575-582,
593-607, 621-633, 638-649, 655-673, 684-698, 711-725, 736-741, 743-752, 759-
769, 781-793, 813-831, 843-853,
894-905, 908-916, 929-946, 953-963, 970-978, 1001-1007, 1011-1033, 165-178 and
818-974 of Seq ID I~o 276;
16-44, 63-86, 98-108, 185-191, 222-237, 261-274, 282-294, 335-345, 349-362,
374-384, 409-420, 424-430, 440-
447, 453-460, 465-473, 475-504, 522-534, 538-551, 554-560, 567-582, 598-607,
611-619, 627-640, 643-653, 655-
661, 669-680, 684-690, 701-707, 715-731, 744-750, 756-763, 768-804, 829-837,
845-853, 855-879, 884-890, 910-
928, 77-90, 144-212, 279-355, 434-536, 782-810 and 875-902 of Seq ID No 277; 4-
22, 29-41, 45-51, 53-66, 70-
77, 86-95, 98-104, 106-124, 129-135, 142-151, 153-161, 169-176, 228-251, 284-
299, 331-337, 339-370, 380-387,
393-398, 406-411, 423-433, 440-452, 461-469, 488-498, 501-516, 523-530, 532-
559, 562-567, 570-602, 612-628,
630-645, 649-659, 666-672, 677-696, 714-723, 727-747 and 212-227 of Seq ID No
278; 4-9,17-31, 35-41, 56-61,
66-75, 81-87, 90-124, 133-138, 149-163, 173-192, 213-219, 221-262, 265-275,
277-282, 292-298, 301-307, 333-
346, 353-363, 371-378, 419-430, 435-448, 456-469, 551-570, 583-599, 603-612
and 275-291 of Seq ID No 279;
28-34, 53-58, 72-81, 100-128,145-154, 159-168,172-189, 217-225, 227-249, 256-
263, 299-309, 322-330, 361-379,
381-388, 392-401, 404-417, 425-436, 440-446, 451-464, 469-487, 502-511, 543-
551, 559-564, 595-601, 606-612,
615-626, 633-642, 644-650, 664-670, 674-684, 692-701, 715-723, 726-734, 749-
756, 763-771, 781-787, 810-843,
860-869, 882-889, 907-917, 931-936, 941-948, 951-958, 964-971, 976-993, 1039-
1049, 1051-1065, 1092-1121,
1126-1132, 1145-1151, 1158-1173, 1181-1192, 1194-1208, 1218-1223, 1229-1243,
1249-1254, 1265-1279, 1287-
1297, 1303-1320, 1334-1341, 1343-1358, 1372-1382, 1406-1417, 1419-1425, 1428-
1434, 1441-1448, 1460-1473,
1494-1504, 1509-1514, 1529-1550, 654-669 and 1400-1483 of Seq ID No 280;10-16,
20-25, 58-65, 97-109, 118-
132, 134-146, 148-155, 186-195, 226-233, 244-262, 275-284, 295-310, 317-322,
330-339, 345-351, 366-375, 392-
403, 408-415, 423-430, 435-444, 446-457, 467-479, 486-499, 503-510, 525-537,
540-585, 602-612, 614-623, 625-
634, 639-645, 650-669, 700-707, 717-724, 727-739, 205-230 and 733-754 of Seq
ID No 281; 5-22, 37-43, 72-81,
105-113, 128-133, 148-160, 188-194, 204-230, 238-245, 251-257 and 194-213 of
Seq ID No 282; 16-21, 35-41,
56-72, 74-92, 103-109 and 62-68 of Seq ID No 283; 4-15, 17-82, 90-104, 107-
159, 163-170, 188-221, 234-245,
252-265 and 220-235 of Seq ID No 284; 16-22, 36-46, 61-75, 92-107, 113-121,
139-145, 148-160 and 30-42 of
Seq ID No 285; 4-12, 20-26, 43-49, 55-62, 66-78, 121-127, 135-141, 146-161,
164-170, 178-189, 196-205, 233-
238, 269-279, 288-318, 325-332, 381-386, 400-407 and 328-346 of Seq ID No 286;
5-12, 31-49, 57-63, 69-79,
89-97, 99-114, 116-127, 134-142, 147-154, 160-173, 185-193, 199-204, 211-222,
229-236, 243-249, 256-274 and
58-68 of Seq ID No 287; 10-20, 28-34, 39-53, 68-79, 84-90, 99-106 and 73-79 of
Seq ID No 288; 14-37, 45-50,
61-66, 77-82, 93-98, 109-114,125-130,141-146, 157-162, 173-178,189-194, 205-
210, 221-226, 237-242, 253-258,
269-274, 285-290, 301-306, 316-332, 349-359, 371-378, 385-406, 34-307 and 312-
385 of Seq ID No 289; 4-10,
17-38, 50-85, 93-99, 109-116, 128-185, 189-197, 199-210, 223-256, 263-287, 289-
312, 327-337, 371-386, 389-394,
406-419, 424-432, 438-450, 458-463, 475-502, 507-513, 519-526, 535-542, 550-
567 and 361-376 of Seq ID No
290; 10-39, 42-93, 100-144, 155-176, 178-224, 230-244, 246-255, 273-282, 292-
301, 308-325, 332-351, 356-361,
368-379, 386-393, 400-421 and 138-155 of Seq ID No 291; 5-11, 17-34, 40-45, 50-
55, 72-80, 101-123, 145-151,
164-172, 182-187, 189-195, 208-218, 220-241, 243-252, 255-270, 325-331, 365-
371, 391-398, 402-418, 422-428,
430-435, 443-452, 463-469, 476-484, 486-494, 503-509, 529-553, 560-565, 570-
590, 608-614, 619-627, 654-661,
744-750, 772-780, 784-790, 806-816, 836-853, 876-885, 912-918, 926-933, 961-
975, 980-987, 996-1006, 1016-
1028, 1043-1053, 1057-1062, 994-1003 and 1033-1056 of Seq ID No 292; 17-45, 64-
71, 73-81, 99-109, 186-192,
223-238, 262-275, 283-295, 336-346, 350-363, 375-385, 410-421, 425-431, 441-
448, 454-463, 468-474, 476-512,
523-537, 539-552, 568-583, 599-608, 612-620, 628-641, 644-654, 656-662, 670-
681, 685-695, 702-708, 716-723,
725-735, 757-764, 769-798, 800-806, 808-816, 826-840, 846-854, 856-862, 874-
881, 885-902, 907-928, 274-350
and 443-513 of Seq ID No 293; 4-22, 29-41, 45-51, 53-61, 70-76, 85-92, 99-104,
111-122, 134-140, 142-154,
163-174, 224-232, 255-265, 273-279, 283-297, 330-335, 337-348, 356-367, 373-
385, 391-396, 421-431, 442-455,
475-485, 493-505, 526-538, 544-561, 587-599, 605-620, 622-651, 662-670, 675-
681, 687-692, 697-712, 714-735
and 252-262 of Seq ID No 294; 4-12,15-35, 40-46, 50-59, 67-94,110-128,143-
169,182-188, 207-215, 218-228,
238-250 and 74-90 of Seq ID No 295; 9-18, 42-58, 78-85, 88-95, 97-106, 115-
122, 128-134, 140-145, 154-181,
186-202, 204-223, 261-267, 269-278, 284-293, 300-336, 358-368 and 12-29 of Seq
ID No 296; 7-34, 46-53, 62-
72, 82-88, 100-105, 111-117, 132-137, 144-160, 166-180, 183-189, 209-221, 231-
236, 246-253, 268-282, 286-293,
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-10-
323-336, 364-3~2, 378-392, 422-433 and 388-405 of Seq ID No 297; 21-27, 34-50,
~2-77, 80-95, 164-177, 192-
198, 202-220, 226-236, 239-247, 270-279, 285-292, 315-320, 327-334, 348-355,
364-371, 388-397, 453-4~6, 488-
497, 534-545, 556-576, 582-588, 601-607, 609-616, 642-662, 674-681, 687-697,
X09-715, 721-727, 741-755 and
621-739 of Seq ID No 298; 4-14, 16-~7, 79-109 and 25-99 of Seq ID No 299; 4-9,
1~-23, 30-3~, 44-55, 65-72,
77-93, 102-121, 123-132, 146-153 and 17-29 of Seq ID No 300; 4-18, 25-41, 52-
60, 83-92, 104-112, 117-123,
149-155~ 159-16~, 170-192, 201-210, 220-227, 245-250 and 124-137 of Seq ID No
301; 8-25, 50-55, 89-95, 138-
143, 148-153, 159-169, 173-179, 223-238, 262-268, 288-295, 297-308, 325-335,
403-409, 411-417, 432-446, 463-
4~5, 492-501, 524-530, 542-548, 561-574, 5~6-593, 604-609, 612-622, 637-654,
665-6~2, 678-685, X20-725, 731-
739, 762-767, 772-783, 820-838, 851-865, 901-908, 913-920, 958-970, 1000-1006,
1009-1015, 1020-1026, 1043-
1052,1055-1061,1-128, 252-341, 771-793 and 1043-1058 of Seq ID No 302;16-26,
33-46 and 64-76 of Seq ID
No 303; 4-27, 69-~~, 79-101, 117-123, 126-142,155-161, 171-186, 200-206, 213-
231, 233-244, 267-273, 313-329,
335-344, 347-3~0, 374-3~9, 399-408, 422-443, 445-453, 461-468, 476-482, 518-
534, 544-553, 556-567, 578-595,
601-620, 626-636, 646-658, 666-681, %15-221, 762-768, X78-X85, 789-803, 809-
819, 22-108, 153-318, 391-522
and 638-757 of Seq ID No 304; 6-21, 32-43, 62-92,104-123,135-141,145-152,199-
216, 218-226, 23~-247, 260-
269, 274-283, 297-303, 1-72 and 127-211 of Seq ID No 305; 6-26, 50-56, 83-89,
108-114, 123-131, 172-181,
194-200, 221-238, 241-247, 251-259, 263-271, 284-292, 304-319, 321-335, 353-
358, 384-391, 408-417, 424-430,
442-448, 459-466, 487-500, 514-528, 541-556, 572-578, 595-601, 605-613, 620-
631, 635-648, 660-670, 6~3-6~9,
686-693, 702-708, 716-725, 730-735, 749-755, 770-777, 805-811, 831-837, 843-
851, 854-860, 863-869, 895-901,
904-914, 922-929, 933-938, 947-952, 956-963, 1000-1005, 1008-1014, 1021-1030,
1097-1103, 1120-1130, 1132-
1140, 1-213, 269-592 and 992-1120 of Seq ID No 306; 9-16, 33-39, 47-59, 65-79,
81-95, 103-108, 115-123, 138-
148, 163-1~1, 1~6-185, 191-196, 205-211, 213-221, 224-256, 261-276, 294-302,
357-363, 384-390, 95-111 and
161-189 of Seq ID No 30~; 21-2~, 35-45, 70-76, 92-105,129-143, 145-155, 161-
166, 170-191, 204-211, 214-231,
234-246, 249-255, 259-275 and 1-18 of Seq ID'No 308; 21-35, 45-53, 56-64, 69-
97 and 1-16 of Seq ID No 309;
25-33, 41-47, 61-68, 86-101, 106-114, 116-129, 134-142, 144-156, 163-176, 181-
190, 228-251, 255-261, 276-292,
295-305, 334-357, 368-380, 395-410, 424-429, 454-460, 469-482, 510-516, 518-
527, 531-546, 558-570, 579-606,
628-636, 638-645, 651-656, 668-674, 691-698, 717-734, 742-754, 765-770, 792-
797, 82~-835, 847-859, 874-881,
903-909, 926-933, 942-961, 964-977, 989-1004, 1010-1028, 1031-104, 105-1075,
1081-1095, 1108-1117, 1138-
1144, 1182-1189, 1193-1206, 1220-1229, 1239-1246, 1257-1267, 1271-1279, 1284-
1301, 1312-1320, 1329-1335,
1341-1347, 1358-1371, 1399-1404, 1417-1426, 1458-1463, 1468-1476, 148-1485,
1493-1506, 1535-1541, 1559-
1574, 1583-1590, 1595-1601, 1603-1611, 1622-1628, 1634-1644, 1671-1685, 1689-
1696, 1715-1720, 1734-1746,
1766-1775, 1801-1806, 1838-1844, 1858-1871, 1910-1917, 1948-1955, 1960-1974,
2000-2015, 2019-2036, 2041-
2063, X48-84~ and 1381-1391 of Seq ID No 310; 5-12, 18-24, 2~-53, 56-63, 96-
113, 119-124, 131-136, 157-163,
203-209, 215-223, 233-246, 264-273, 311-316, 380-389, 393-399, 425-433, 445-
450, 457-462, 464-470, 475-482,
507-513, 527-535, 542-548, 550-565, 591-602, 607-613, 627-642, 644-664, 673-
X12, 714-732, 739-764, 769-X82,
812-818, 826-838, 848-854, 860-871, 892-906, 930-938, 940-954, 957-973, 990-
998,1002-1021, 1024-1033,1037-
1042, 1050-1060, 1077-1083, 1085-1092, 1100-1129, 1144-1161, 1169-115, 1178-
1189, 1192-1198, 1201-1207,
1211-1221, 1229-1239, 1250-1270, 1278-1292, 1294-1300, 1314-1335, 1344-1352,
1360-1374, 1394-1405, 140~-
1414, 1416-1424, 1432-1452, 1456-1462, 1494-1497, 1500-1510, 1516-1522, 1534-
1542, 1550-1559, 1584-1603,
1608-162,187-273 and 306-441 of Seq ID No 311; 70-80, 90-97, 118-125,128-140,
142-148, 154-162,189-202,
214-222, 224-232, 254-260, 275-313, 317-332, 355-360, 392-398, 425-432, 448-
456, 464-470, 476-482, 491-505,
521-528, 533-546, 560-567, 592-597, 605-614, 618-626, 637-644, 646-653, 660-
666, 677-691 and 207-227 of Seq
ID No 312; 5-19, 26-34, 37-55, 57-66, 69-83, 86-102, 115-134, 138-143, 154-
172, 178-195, 209-246, 251-257,
290-302, 306-311 and 256-266 of Seq ID No 313; 10-20, 22-28, 35-57, 72-79, 87-
103, 108-128, 130-144, 158-
1~1, 190-198, 225-242, 274-291, 301-315, 317-324, 374-385 and 353-365 of Seq
ID No 314; 4-9, 17-30, 34-54,
59-66, 73-94, 118-130, 135-150, 158-171, 189-198, 219-239, 269-275, 283-301,
89-106 arid 1~6-193 of Seq ID
No 315; 14-20, 22-74, ~7-86, 89-99, 104-109, 126-135, 154-165, 181-195, 19~-
212, 216-224, 264-275 arid 107-
118 of Seq ID No 316; 4-18, 21-38, 63-72,101-109,156-162,165-179, 183-192,195-
210, 212-218, 230-239, 241-
256, 2~8-290, 299-311, 313-322, 332-341, 348-366, 386-401, 420-426, 435-450,
455-460, 468-479, 491-498, 510-
518, 532-538, 545-552, 557-563, 567-573, 586-595, 599-609, 620-626, 628-636,
652-657, 665-681 and 1-198 of
Seq ID No 317; 4-10, 16-38, 51-68, 73-79, 94-115, 120-125, 132-178, 201-208,
216-223, 238-266, 269-295, 297-
304, 337-342, 34~-356, 374-401, 403-422, 440-447, 478-504, 510-516, 519-530,
537-544 and 191-206 of Seq ID
No 318; 12-40, 42-48, 66-71, T7-86, 95-102, 113-120, 129-137, 141-148, 155-
174, 208-214, 218-225, 234-240,
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-11-
256-267, 275-283, 300-306, 313-321, 343-350, 359-367, 370-383, 398-405, 432-
439, 443-461, 492-508, 516-526,
528-535 and 370-478 of Seq ID No 319; 6-14, 20-37, 56-62, 90-95, 97-113,118-
125,140-145,161-170,183-202,
237-244, 275-284, 286-305, 309-316, 333-359, 373-401, 405-412 and 176-187 of
Seq ID No 320; 33-44, 50-55,
59-80, 86-101, 129-139, 147-153, 157-163, 171-176, 189-201, 203-224, 239-245,
257-262, 281-287, 290-297, 304-
320, 322-331, 334-350, 372-390, 396-401, 71-88 and 353-372 of Seq ID No 321; 5-
11, 15-24, 26-33, 40-47, 75-
88, 95-103, 105-112 and 17-30 of Seq ID T~to 322; 5-11, 16-39, 46-54, 62-82,
100-107, 111-124, 126-150, 154-
165, 167-183, 204-238, 245-295, 301-313, 316-335 and 8-16 of Seq ID h~To 323;
4-19, 34-48, 69-74, 79-107, 115-
127, 129-135,143-153,160-169, 171-182 and 142-153 of Seq ID No 324; 4-30, 65-
74, 82-106,110-120,124-132,
135-140, 146-175, 179-184,190-196, 217-223, 228-233, 250-267, 275-292, 303-
315, 322-332 and 174-186 of Seq
ID No 325; 9-16, 29-41, 47-57, 68-84, 87-109, 113-119, 162-180, 186-193, 195-
201, 203-208, 218-230, 234-243,
265-271, 281-292, 305-312, 323-332, 341-347, 349-363, 368-374, 383-390, 396-
410, 434-440, 446-452, 455-464,
466-473, 515-522, 529-542, 565-570, 589-600, 602-613, 618-623, 637-644, 1019-
1027, 1238-1244, 1258-1264,
1268-1276, 1281-1292, 1296-1302 and 883-936 of Seq ID No 326; 10-17, 23-32, 39-
44, 54-72, 75-81, 88-111,
138-154, 160-167, 178-185, 201-210, 236-252, 327-334, 336-342, 366-376, 388-
400, 410-430, 472-482, 493-526,
552-558, 586-592, 598-603, 612-621, 630-635, 641-660 and 384-393 of Seq ID No
327; 4-22, 24-39, 50-59, 73-
84, 100-105, 111-117, 130-138, 155-161, 173-178, 182-189, 205-215, 266-284,
308-313, 321-328, 330-337, 346-
363, 368-374, 388-395, 397-405, 426-434, 453-459, 482-492, 501-507, 509-515,
518-523, 527-544, 559-590, 598-
612, 614-629, 646-659, 663-684, 686-694, 698-721 and 445-461 of Seq ID No 328;
14-22, 27-33 and 3-17 of
Seq ID No 329; 29-41, 66-73, 81-87, 90-108, 140-146, 150-159, 165-184, 186-
196, 216-226, 230-238, 247-253,
261-269 and 126-140 of Seq ID No 330; 5-12,16-25, 27-33, 36-45, 60-68, 83-
88,103-126 and 86-101 of Seq ID
No 331; 14-23, 36-47, 56-66, 84-89, 94-105, 111-127, 140-153, 160-174, 176-
183, 189-203, 219-225, 231-237,
250-257 and 194-227 of Seq ID No 332; 4-25, 54-60, 64-71, 73-82, 89-106, 117-
124, 157-169,183-188,199-210,
221-232, 236-244, 255-264 and 58-98 of Seq ID No 333; 13-19, 26-36, 41-53, 55-
71, 77-84, 86-108, 114-135,
157-172, 177-183, 187-194, 208-213, 218-226, 110-125 and 156-170 of Seq ID No
334; 5-24, 63-69, 77-85, 94-
112, 120-137, 140-146, 152-159, 166-172, 179-187, 193-199, 206-212, 222-228,
234-240, 244-252, 257-264, 270-
289, 298-309, 316-328, 337-348, 363-375, 1-56 and 340-352 of Seq ID No 335; 18-
39, 42-71, 78-120, 124-144,
152-173,179-189, 199-209, 213-222, 228-258, 269-304, 329-361, 364-372, 374-
389, 396-441 and 313-327 of Seq
ID No 336; 19-25, 91-98, 108-120, 156-162, 168-174, 191-204, 211-216, 232-266,
272-278, 286-308, 316-321,
327-333, 344-355, 358-364, 384-391, 395-428, 464-476, 487-495, 497-511, 544-
561, 563-573, 575-582, 588-594,
10-25 and 322-338 of Seq ID No 337; 14-26, 32-49, 51-57, 59-72, 80-91, 102-
112, 119-125, 147-161, 164-173,
175-183, 188-213, 217-222, 246-254, 260-276, 282-303, 308-318, 321-328, 333-
350, 352-359, 371-378, 392-401,
407-414, 416-443, 448-463, 471-484, 490-497, 501-514, 519-527, 539-551, 557-
570, 578-590, 592-598, 600-610,
618-629, 633-647, 654-667, 676-689, 702-709, 718-726, 728-737, 741-760, 764-
780, 786-795, 808-826, 836-842,
845-852, 865-874, 881-887, 931-945, 949-957, 968-974, 979-986, 1003-1009, 1023-
1029 and 90-103 of Seq ID
No 338;11-16, 37-56, 60-66, 69-77, 80-88, 93-106,117-139, 166-171 and 72-90 of
Seq ID No 339; 59-84, 123-
133, 145-150, 161-167, 178-189 and 115-128 of Seq ID No 340; 15-33, 39-46, 52-
64, 74-87, 108-124, 127-144,
150-156, 173-179, 184-194, 201-208, 219-236, 243-269, 272-295, 302-309, 343-
349, 356-361, 370-379, 405-411,
414-423, 430-451, 457-464, 466-475, 477-483, 496-502, 507-522, 541-548, 557-
563, 571-577, 579-585, 590-605,
626-642, 650-662, 671-691, 704-710, 751-769, 775-781, 786-791, 794-829, 851-
858, 868-878, 884-904, 913-919,
931-939 and 132-142 of Seq ID No 341; 33-58, 64-71, 74-80, 83-88, 96-120, 122-
139, 146-157, 167-177, 207-
213, 220-225, 236-242, 264-279, 300-305, 326-336, 340-347, 350-360, 97-115 and
199-211 of Seq ID No 342; 4-
26, 43-57, 70-99, 102-117, 121-133, 142-148, 151-168, 170-183, 192-220, 235-
249, 258-279 and 30-41 of Seq ID
No 343; 34-42, 48-58, 70-94, 110-130, 154-160, 164-172, 178-183, 195-203, 211-
222, 229-250, 256-261, 274-284,
286-292, 312-323 and 222-233 of Seq ID No 344; 4-9, 15-36, 38-45, 49-74, 78-
88, 100-112, 136-191, 211-220,
226-233, 239-246, 254-274, 287-307, 316-322, 342-353, 356-366, 373-378, 384-
393, 405-431, 449-457, 459-468,
487-511, 515-524, 529-541, 544-552, 562-568, 571-576 and 208-280 of Seq ID No
345;10-27, 31-37, 39-54, 71-
108,124-143 and 2-107 of Seq ID No 346;16-27, 38-57, 64-70, 90-102,104-113,116-
137,160-166 and 1-80 of
Seq ID No 347; 13-21, 31-36, 56-67, 127-136, 153-171, 173-180, 184-200, 214-
222, 225-231, 239-263, 267-273
and 135-159 of Seq ID No 348; 12-27, 31-51, 68-74, 77-87, 94-101, 108-114, 117-
123, 127-134, 138-168, 173-
196, 201-207, 212-217, 227-237, 247-257, 264-280 and 205-223 of Seq ID No 349;
17-22, 25-54, 70-76, 92-100
and 98-110 of Seq ID No 350; 7-29, 40-50, 60-67, 87-96, 105-111, 119-164, 172-
199, 206-212, 220-227, 237-
259, 272-279, 282-293, 295-309, 313-319, 321-328, 345-363, 376-386 and 159-176
of Seq ID No 351; 4-19, 24-
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-12-
30, 36-43, 50-68, 71-89, 93-106, 141-152, 154-172, 179-197, 199-215, 229-239,
246-252, 255-263, 281-298, 319-
325, 329-356, 358-368, 374-390, 397-409, 420-429, 432-444, 450-456, 459-475,
483-494, 496-502, 520-528, 532-
556 and 362-377 of Seq ID No 352; 18-25, 40-62, 77-85, 91-97, 105-116, 123-
133, 139-184, 189-197 and 122-
140 of Seq ID No 353; 4-49, 52-58, 62-70, 79-105, 109-133, 142-150, 163-168,
206-214, 220-228, 233-240, 243-
254, 274-281, 303-311, 327-338, 357-373, 378-396, 403-413, 420-436, 441-453,
461-467, 475-481, 484-498, 506-
512, 514-521, 523-529, 562-579, 589-595, 598-603, 615-648, 714-722, 728-742,
749-758, 777-792, 795-807 and
643-658 of Seq ID No 354; 8-27, 37-48, 51-56, 72-79, 87-106, 120-138, 140-147,
167-176, 187-197, 205-216,
222-229, 234-239, 243-249, 277-288, 292-315, 334-343, 347-353, 363-391, 398-
404, 430-447, 461-467, 478-492,
498-507 and 456-470 of Seq ID 110 355; 5-12,18-24, 59-69, 80-93, 95-109, 119-
125, 130-137, 139-147, 158-163,
168-176, 182-202, 206-215, 222-239, 241-249, 267-277, 291-298, 311-318, 321-
327, 338-344, 348-355, 373-386,
393-406, 411-417, 434-443, 446-465, 473-484, 514-521, 532-553, 584-594 and 221-
237 of Seq ID No 356; 4-14,
27-34, 50-58, 63-72, 79-106, 109-114, 121-142, 146-154, 161-167, 169-175, 178-
201, 223-238, 249-254, 259-264,
278-292, 294-312, 319-330 and 167-191 of Seq ID No 357; 7-28, 36-42, 50-61, 63-
80, 122-152, 161-174, 176-
191 and 140-190 of Seq ID No 358; 20-57, 59-65, 70-78, 86-102, 119-133, 142-
161, 163-173, 177-188, 192-202,
204-220, 222-236, 240-253, 279-319, 326-331, 337-383, 390-399, 406-412, 420-
427, 431-438 and 381-395 of Seq
ID No 359; 13-18, 28-34, 37-43, 50-59, 75-81, 83-97, 105-121, 139-147, 200-
206, 209-227, 231-247, 260-271,
318-327, 366-381, 388-394, 399-406 and 182-201 of Seq ID No 360; 6-29, 37-43,
51-56, 70-77, 82-102,110-119,
127-143, 178-190, 201-209, 216-243, 261-269, 281-292, 305-313, 327-339, 341-
354, 356-373, 391-397, 423-429,
438-445, 450-478 and 21-314 of Seq ID No 361; 4-12,15-21, 32-41, 59-76, 80-89,
96-104 and 90-103 of Seq ID
No 362; 9-28, 30-41, 44-54, 69-74, 77-82, 90-97,104-123,125-135,149-155,164-
173, 177-184, 217-226, 230-235,
238-244, 258-272, 282-297, 300-305, 309-315, 317-322, 327-336, 348-362, 368-
374, 380-387, 400-411, 414-424,
451-458, 460-466, 483-494, 497-503, 506-511, 521-528, 540-553, 569-587, 598-
606, 628-642, 661-681, 688-700,
718-733, 740-749, 752-764, 769-783, 823-834, 848-854, 862-872, 878-884, 886-
898, 915-920, 938-951, 954-961,
963-972, 982-989, 996-1003, 1010-1016, 1021-1032, 1038-1044, 1047-1057, 1060-
1070, 1079-1088, 1094-1102,
1117-1127, 1129-1135, 1142-1153, 1158-1204, 1212-1229, 1234-1263, 1269-1277,
1308-1313, 1327-1338, 1344-
1376, 1400-1415, 1436-1443, 1448-1458, 1497-1504, 1511-1522, 1544-1566, 3-82
and 509-576 of Seq ID No
363; 8-36, 40-64, 71-79, 88-94, 102-109, 118-127, 138-148, 151-159, 163-174,
192-198, 200-206, 220-233, 268-
273, 290-301, 304-309, 316-323, 331-349, 378-391, 414-420, 427-437, 455-475,
494-510, 541-547, 549-555, 616-
640, 1-60, 55-139, 212-308, 386-458 and 458-624 of Seq ID No 364;16-31, 35-42,
70-77, 91-101, 120-130, 132-
140, 143-153, 185-190, 195-202, 215-222, 228-238, 241-251, 257-264, 268-277,
288-302, 312-324, 326-333, 341-
348, 364-382, 415-429, 438-454, 458-466, 491-499, 501-521 and 273-281 of Seq
ID No 365; 8-14, 32-57, 74-149,
155-177, 179-212, 221-266, 271-296, 304-324, 329-346, 349-359, 368-401, 413-
419, 426-454, 465-478, 493-510
and 466-490 of Seq ID No 366; 22-28, 33-51, 64-89, 96-119, 126-132, 138-
146,152-159, 161-169, 172-179, 193-
198, 205-211, 221-231, 235-254, 273-280, 297-303, 312-320, 328-346, 351-373,
378-384, 391-398, 448-454, 460-
468, 470-481, 516-558, 574-593, 597-602, 613-623, 626-646, 649-656, 668-673,
675-683, 696-708, 715-722, 724-
739, 745-751, 759-777, 780-804, 816-822 and 102-113 of Seq ID No 367; 12-28,
41-91, 98-107, 112-120, 125-
131, 151-193, 215-221, 240-250, 263-280 and 128-138 of Seq ID No 368; 16-24,
32-38, 46-62, 68-81, 90-105,
127-133, 144-150, 160-166, 178-184, 186-202, 210-219, 232-240, 252-258, 264-
273, 293-324, 337-344, 349-357,
360-369, 385-398, 410-416, 419-427, 441-449, 458-476, 508-515, 523-539, 544-
549, 562-569, 571-579, 96-109
and 127-139 of Seq ID No 369;19-25, 28-34, 56-61, 85-97, 110-116 and 39-53 of
Seq ID No 370; 4-37, 41-50,
62-72, 91-97, 99-109, 114-125, 136-141, 149-158, 160-166, 201-215 and 27-225
of Seq ID No 371; 15-31, 44-51,
96-105, 122-130, 149-157, 162-168, 178-183, 185-192, 198-204, 206-213, 221-
234, 239-245, 248-255, 257-266,
289-335, 349-357, 415-422, 425-441, 448-454, 462-468 and 463-481 of Seq ID No
372; 5-31, 39-55, 63-72, 76-
99, 106-155, 160-177, 179-199, 207-217, 223-240, 245-255, 261-267, 294-316,
321-343, 354-378, 382-452, 477-
488, 529-536, 555-569, 584-591, 593-612, 620-627, 632-640, 647-654, 671-680,
698-704, 723-730, 732-750, 769-
775, 781-788, 822-852 and 505-525 of Seq ID No 373; 3-18 of Seq ID No 374; 4-
14 and 12-24 of Seq ID No
375; 4-11, 22-30 and 12-25 of Seq ID No 376; 5-12 and 4-18 of Seq ID No 377; 4-
28 and 7-14 of Seq ID No
378; 6-16 and 8-16 of Seq ID No 379; 4-15,18-33 and 24-36 of Seq ID No 380; 4-
10,16-21 and 20-31 of Seq
ID No 381; 6-19 of Seq ID No 382;11-18 and 3-10 of Seq ID No 383;13-24 and 3-
15 of Seq ID No 384;15-
27 and 7-16 of Seq ID No 385;11-16 and 1-15 of Seq ID No 386; 4-16 and 9-21 of
Seq ID No 387; 4-24, 40-
48, 54-67 and 22-39 of Seq ID No 388; 6-30, 34-55, 62-68, 78-106 and 68-74 of
Seq ID No 389; 3-14 of Seq
ID No 390; 9-19 and 6-21 of Seq ID No 391; 4-17 and 1-9 of Seq ID No 392; 5-30
and 1-8 of Seq ID No
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-13-
393; 4-16, 23-46, 51-56 and 45-55 of Seq ID No 394; ~-16 of Seq ID No 395; 2-
14 of Seq ID No 396; 4-36, 43-
65 and 50-62 of Seq ID No 397; 10-30 and 14-21 of Seq ID No 398; 9-17 and 1-10
of Seq ID No 399; 4-12
and 3-16 of Seq ID No 400; 4-15 and 5-23 of Seq ID No 401; 10-21 of Seq ID No
402; 6-16 of Seq ID No
403; 4-29, 31-38 and 2-14 of Seq ID No 404; 4-35 and 33-42 of Seq ID No 405; 2-
17 of Seq ID No 406; 9-18,
30-35 and 15-33 of Seq ID No 40~; 4-9 and 6-12 of Seq ID No 408; 3-1~ of Seq
ID No 409;12-21, 3~-44, 52-
61, ~2-80 and 38-48 of Seq ID No 410: 4-10, 29-44, 54-61, 69-~8 and 13-27 of
Seq ID l~0 411; 13-23, 36-53
and 2-15 of Seq ID I~do 412; 4-25, 28-46, 56-22, 81-99, 120-132, 134-142, 154-
160 and 129-141 of Seq ID l~To
413; 4-15, 24-33, 35-41, 64-86 and 21-33 of Seq ID No 414; 9-15 and 4-13 of
Seq ID No 415; 4-11, 13-19, 34-
48 and 15-32 of Seq ID I~o 416; 4-21 and 11-31 of Seq ID h~o 41~: 23-5~ and 38-
50 of Seq ID I~o 418; 4-32
and 3-13 of Seq ID No 419; 4-10, 13-25, 32-42, 56-68, 72-84 and 26-38 of Seq
ID No 420; 4-20, 31-48, 52-58,
65-71, 80-93, 99-108,114-123 and 37-49 of Seq ID No 421; 6-12,14-20 and 3-25
of Seq ID No 422;14-25, 2~-
38 and 5-14 of Seq ID No 423; 4-41, 57-105,109-118,123-136,144-152 and 86-99
of Seq ID No 424; 6-19 of
Seq ID No 425; 2-19 of Seq ID No 426; 14-47 and 1-14 of Seq ID No 427; 4-21,
29-44 and 2-18 of Seq ID
No 428; 23-29 and 10-28 of Seq ID No 429; 6-16, 22-36 and 11-22 of Seq ID No
430; 4-19, 30-44 and 18-27
of Seq ID No 431; 5-15, 37-45, 58-65 and 38-47 of Seq ID No 432; 4-15, 23-34
and 4-15 of Seq ID No 433;
30-36, 44-54, 79-85, 101-114, 138-152, 154-164, 170-175, 179-200, 213-220, 223-
240, 243-255, 258-264, 268-284
and 10-28 of Seq ID No 434; the peptides comprising amino acid sequences of
column "Identical
region" of the Table 1B, especially peptides comprising amino acid 210-226 and
938-753 of Seq ID No
449; 326-344, 326-348, 338-354, 371-392, 801-809 and 877-901 of Seq ID No 450;
893-906 of Seq ID No 451;
51-69 of Seq ID No 452;110-125 of Seq ID No 453; 291-305 of Seq ID No 454; 210-
226 and 738-753 of Seq
ID No 455; 326-344, 326-348, 338-354, 371-392, 801-809 and 877-901 of Seq ID
No 456; 893-906 of Seq ID
No 457; 51-69 of Seq ID No 458;110-125 of Seq ID No 459; 291-305 of Seq ID No
460; 32-44 of Seq ID No
461; 399-410 of Seq ID No 462; the serum reactive epitopes as specified in the
column of "aa from" to
"aa to" of Table 2, especially peptides comprising amino acid 120-143, 138-161
and 156-179 of Seq ID
No 218; 110-129 and 168-184 of Seq ID No 219; 74-90 of Seq ID No 222; 759-7~3
of Seq ID No 223; 237-
260 of Seq ID No 224; 265-284 of Seq ID No 225; 65-74 of Seq ID No 226; 41-50
of Seq ID No 227;163-174
of Seq ID No 229; 26-3~ of Seq ID No 230; 174-189 of Seq ID No 232; 240-256 of
Seq ID No 234; 285-29~
of Seq ID No 236; 238-247 of Seq ID No 238; 491-519 of Seq ID No 239; 114-140
of Seq ID No 243; 267-
284 of Seq ID No 250; 439-453 of Seq ID No 252; 162-178 of Seq ID No 253; 347-
364 of Seq ID No 254;
699-715 of Seq ID No 255; 60-71 of Seq ID No 256; 244-257 of Seq ID No 257; 44-
63 and 57-76 of Seq ID
No 258; 185-196 of Seq ID No 260; 119-129 of Seq ID No 263; 182-195 of Seq ID
No 266; 32-44 and 424-
442 of Seq ID No 267; 247-256 of Seq ID No 268; 678-694, 785-805, 55-77 and 72-
94 of Seq ID No 269; 210-
226 of Seq ID No 281; 37-59 of Seq ID No 289;13-29 of Seq ID No 296;136-159 of
Seq ID No 348; 205-222
of Seq ID No 349; 99-110 of Seq ID No 350;160-176 of Seq ID No 351; 45~-470 of
Seq ID No 355; 221-237
of Seq ID No 356; 16~-190 of Seq ID No 357; 96-120 of Seq ID No 361; 399-41~,
503-519 and 544-563 of
Seq ID No 364; 46-68, 159-183 and 184-198 of Seq ID No 371; 463-481 of Seq ID
No 3~2; the
imrnunogenic epitopes as specified in the column of "aa from" to "aa to" of
Table 4; especially
peptides comprising amino acid 110-129 and 168-184 of Seq ID No 219; 877-901,
333-354, 326-344 and
801-809 of Seq ID No 277; 1-54 of Seq ID No 347; 544-563, 31-51, 107-119, 399-
417 and 503-519 of Seq ID
No 364; 120-198 of Seq ID No 218; 20-35 of Seq ID No 219; 118-201 of Seq ID No
221; 48-132 of Seq ID
No 242; 118-136 of Seq ID No 249; 162-178 of Seq ID No 253; 34~-364 of Seq ID
No 254; 699-715 of Seq
ID No 255; 50-76 of Seq ID No 258; 785-819 and 44-128 of Seq ID No 269; 90-128
of Seq ID No 274; 314-
384 of Seq ID No 289; 327-349 of Seq ID No 293; 242-314, 405-478 and 23-100 of
Seq ID No 304; 129-210
of Seq ID No 305;162-188 of Seq ID No 307; 750-772 of Seq ID No 310;1-56 of
Seq ID No 335; 322-337 of
Seq ID No 337; ~2-90 of Seq ID No 339; 374-395 of Seq ID No 345; 136-159 of
Seq ID No 348;141-164 of
Seq ID No 358; 96-157 of Seq ID No 361; 1-82 of Seq ID No 363; 489-556 of Seq
ID No 364; 159-183 and
49-133 of Seq ID No 371; The peptides comprising amino acid sequences of
column "predicted
immunogenic aa" and °'location of identified immunogenic region (aa)"
of Table 5, especially peptides
comprising amino acid 4-26, 35-41, 53-61, 73-84,103-108,114-120, 140-146, 156-
162,192-208, 214-219, 227-
233, 239-252, 260-268, 284-297, 1-48 and 113-133 of Seq ID No 4~5; 4-27, 38-
44, 50-56, 59-64, 72-79, 83-89,
92-97, 108-116, 123-148, 152-16~, 183-196, 200-220, 232-244, 255-261, 265-2~4,
282-302, 309-317, 1-79 and
231-302 of Seq ID No 476; 6-28, 66-72, 85-105, 115-121, 144-151, 160-170, 1~6-
185, 223-230, 252-288, 296-
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
- 14-
310, 319-333, 367-374, 458-464, 471-480, 483-488, 520-528, 530-549, 559-564,
593-601, 606-616, 636-643, 655-
662, 676-682, 684-699, 719-726, 735-750, 757-764, 777-785, 799-810, 812-843,
846-853, 868-873, 880-889, 891-
899, 909-929, 934-940, 963-969, 998-1004, 1007-1014, 1016-1022, 1030-1046, 1-
80 and 808-821 of Seq ID No
477; 7-24, 35-41, 75-81, 91-114, 122-132, 137-144, 148-156, 183-192, 194-200,
212-228, 233-238, 251-258, 275-
295, 326-332, 33~-346, 1-79 and 305-321 of Seq ID No 4~8; 31-38, 42-52, 66-72,
86-92, 98-104, 115-122, 127-
146, 154-164, 169-187, 198-212, 225-232, 255-269, 13-92 and 135-142 of Seq ID
No 479; 4-36, 39-49, 63-69,
21-27, 81-88, 123-131, 133-139, 160-169, 124-180, 188-194, 210-21~, 273-2~8,
289-300, 317-334, 336-341, 383-
401, 425-438, 1-68, 212-270 and 402-446 of Seq ID No 480; 21-29, 31-42, 49-63,
72-'79, 81-93, 112-132, 159-
165, 188-195, 19~-232, 262-267, 229-286, 294-301, 318-326, 348-366, 381-405,
409-426, 436-465, 4~1-480, 484-
492, 497-505, 521-544, 554-561, 56'7-577, 581-589, 601-609, 611-622, 636-651,
653-667, 669-685, '700-708, 716-
722, 729-744, 749-766, X80-786, 789-811, 814-864, 1-5~ and 84-106 of Seq ID No
481; 6-24, 35-48, 5~-63, 72-
78, 87-92, 113-119, 123-137, 147-153, 173-181, 212-233 and 1-124 of Seq ID No
482; 13-34, 62-69, 78-83, 86-
91, 98-104, 107-115,146-159,179-188,195-205, 209-221, 226-233, 239-253, 276-
282, 284-294, 297-308, 331-354,
3~5-382, 388-399, 421-433, 449-458, 464-469, 472-491, 508-513, 525-531, 534-
550, 575-593, 601-618, 629-635,
654-661, 666-680, 706-721, 723-740, 771-805, 810-830, 845-851 and 1-84 of Seq
ID No 483; 4-32, 45-64, ~3-83,
86-92, 100-111, 125-147, 157-163, 170-175, 177-188, 226-232, 245-252, 258-274,
320-335, 348-359 and 1-~1 of
Seq ID No 484; 13-40, 43-71, 76-83, 87-101, 109-119, 125-156, 162-175, 182-
219, 226-232, 240-262, 270-287,
306-318, 326-342, 344-408, 414-444, 449-456 and 1-51 of Seq ID No 485; 4-16,
18-34, 45-54, 99-108, 134-140,
203-212, 241-257, 266-2~4, 279-291, 308-315, 330-336, 355-370, 374-382, 402-
410, 428-455, 466-472, 474-480,
531-554, 560-566, 572-580, 597-618, 632-660, 664-674, 676-685, 691-705, 708-
735, 750-768, 1-87 and 342-480
of Seq ID No 486; The serum reactive epitopes as specified in the column of
"aa from" to "aa to" of
Table 6, especially peptides comprising amino acid 115-132 and 1-26 of Seq ID
No 475; 33-55 of Seq ID
No 476;1-25 of Seq ID No 478; 37-61 of Seq ID No 479;1-24 of Seq ID No 480;1-
23 of Seq ID No 481; 46-
60 of Seq ID No 482; 1-28, 23-50 and 45-71 of Seq ID No 483; 1-22 and 1~-38 of
Seq ID No 484; 1-22 and
17-38 of Seq ID No 485; 1-27, 22-47 and 422-447 of Seq ID No 486; The
imrnunogenic epitopes as
specified in the column of "aa from" to "aa to°' of Table 7, especially
peptides comprising amino acid
115-132 and 1-47 of Seq ID No 475; 1-55 of Seq ID No 476; 22-85 of Seq ID No
4~7; 307-320 and 1-44 of
Seq ID No 478; 15-76 and 40-92 of Seq ID No 479; 1-59, 213-269 and 403-445 of
Seq ID No 480; 1-56 and
85-105 of Seq ID No 481; 37-121 of Seq ID No 482; 1-~1 of Seq ID No 483; 1-38
of Seq ID No 484; 1-38 of
Seq ID No 485;1-47 of Seq ID No 486.
The present invention also provides a process for producing a S. agalactiae
hyperimmune serum reactive
antigen or a fragment thereof according to the present invention comprising
expressing one or more of
the nucleic acid molecules according to the present invention in a suitable
expression system.
Moreover, the present invention provides a process for producing a cell, which
expresses a S agalactiae
hyperimmune serum reactive antigen or a fragment thereof according to the
present invention
comprising transforming or transfecting a suitable host cell with the vector
according to the present
invention.
According to the present invention a pharmaceutical composition, especially a
vaccine, comprising a
hyperimmune serum-reactive antigen or a fragment thereof as defined in the
present invention or a
nucleic acid molecule as defined in the present invention is provided.
In a preferred embodiment the pharmaceutical composition further comprises an
immunostimulatory
substance, preferably selected from the group comprising polycationic
polymers, especially polycationic
peptides, immunostimulatory deoxynucleotides (ODNs), peptides containing at
least two LysLeuLys
motifs, especially KLKLSKLK, neuroactive compounds, especially human growth
hormone, alumn, Freund's
complete or incomplete adjuvants or combinations thereof.
In a more preferred embodiment the immunostimulatory substance is a
combination of either a
polycationic polymer and immunostimulatory deoxynucleotides or of a peptide
containing at least two
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-15-
LysLeuLys motifs and immunostimulatory deoxynucleotides.
In a still more preferred embodiment the polycationic polymer is a
polycationic peptide, especially
polyarginine.
According to the present invention the use of a nucleic acid molecule
according to the present invention
or a hyperimmune serum-reactive antigen or fragment thereof according to the
present invention for the
manufacture of a pharmaceutical preparation, especially for the manufacture of
a vaccine against S.
agalactiae infection, is provided.
Also an antibody, or at least an effective part thereof, which binds at least
to a selective part of the
hyperimmune serum-reactive antigen or a fragment thereof according to the
present invention, is
provided herewith.
In a preferred embodiment the antibody is a monoclonal antibody.
In another preferred embodiment the effective part of the antibody comprises
Fab fragments.
In a further preferred embodiment the antibody is a chimeric antibody.
In a still preferred embodiment the antibody is a humanized antibody.
The present invention also provides a hybridoma cell line, which produces an
antibody according to the
present invention.
Moreover, the present invention provids a method for producing an antibody
according to the present
invention, characterized by the following steps:
initiating an immune response in a non-human animal by administrating an
hyperimmune
serum-reactive antigen or a fragment thereof, as defined in the invention, to
said animal,
removing an antibody containing body fluid from said animal, and
producing the antibody by subjecting said antibody containing body fluid to
further
purification steps.
Accordingly, the present invention also provides a method for producing an
antibody according to the
present invention, characterized by the following steps:
initiating an immune response in a non-human animal by administrating an
hyperimmune
serum-reactive antigen or a fragment thereof, as defined in the present
invention, to said animal,
removing the spleen or spleen cells from said animal,
producing hybridoma cells of said spleen or spleen cells,
~ selecting and cloning hybridoma cells specific for said hyperimmune serum-
reactive antigens or a
fragment thereof,
producing the antibody by cultivation of said cloned hybridoma cells and
optionally further
purification steps.
The antibodies provided or produced according to the above methods may be used
for the preparation of
a medicament for treating or preventing S. agalactiae infections.
According to another aspect the present invention provides an antagonist,
which binds to a
hyperimmune serum-reactive antigen or a fragment thereof according to the
present invention.
Such an antagonist capable of binding to a hyperimmune serum-reactive antigen
or fragment thereof
according to the present invention may be identified by a method comprising
the following steps:
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-16-
a) contacting an isolated or immobilized hyperimmune serum-reactive antigen or
a fragment
thereof according to the present invention with a candidate antagonist under
conditions to
permit binding of said candidate antagonist to said hyperimmune serum-reactive
antigen or
fragment, in the presence of a component capable of providing a detectable
signal in response to
the binding of the candidate antagonist to said hyperimmune serum reactive
antigen or fragment
thereof; and
b) detecting the presence or absence of a signal generated in response to the
binding of the
antagonist to the hyperimmune serum reactive antigen or the fragment thereof.
An antagonist capable of reducing or inhibiting the interaction activity of a
hyperimmune serum-reactive
antigen or a fragment thereof according to the present invention to its
interaction partner may be
identified by a method comprising the following steps:
a) providing a hyperimrnune serum reactive antigen or a hyperimmune fragment
thereof according
to the present invention,
b) providing an interaction partner to said hyperimmune serum reactive antigen
or a fragment
thereof, especially an antibody according to the present invention,
c) allowing interaction of said hyperimmune serum reactive antigen or fragment
thereof to said
interaction partner to form an interaction complex,
d) providing a candidate antagonist,
e) allowing a competition reaction to occur between the candidate antagonist
and the interaction
complex ,
f) determining whether the candidate antagonist inhibits or reduces the
interaction activities of the
hyperimmune serum reactive antigen or the fragment thereof with the
interaction partner.
The hyperimmune serum reactive antigens or fragments thereof according to the
present invention may
be used for the isolation and/or purification and/or identification of an
interaction partner of said
hyperimmune serum reactive antigen or fragment thereof.
The present invention also provides a process for in vitro diagnosing a
disease related to expression of a
hyperimmune serum-reactive antigen or a fragment thereof according to the
present invention
comprising determining the presence of a nucleic acid sequence encoding said
hyperimmune serum
reactive antigen or fragment thereof according to the present invention or the
presence of the
hyperimmune serum reactive antigen or fragment thereof according to the
present invention.
The present invention also provides a process for in vitro diagnosis of a
bacterial infection, especially a S.
agalactiae infection, comprising analyzing for the presence of a nucleic acid
sequence encoding said
hyperirnmune serum reactive antigen or fragment thereof according to the
present invention or the
presence of the hyperimmune serum reactive antigen or fragment thereof
according to the present
invention.
Moreover, the present invention provides the use of a hyperimmune serum
reactive antigen or fragment
thereof according to the present invention for the generation of a peptide
binding to said hyperimmune
serum reactive antigen or fragment thereof, wherein the peptide is an
anticaline.
The present invention also provides the use of a hyperimmune serum-reactive
antigen or fragment
thereof according to the present invention for the manufacture of a functional
nucleic acid, wherein the
functional nucleic acid is selected from the group comprising aptamers and
spiegelmers.
The nucleic acid molecule according to the present invention may also be used
for the manufacture of a
functional ribonucleic acid, wherein the functional ribonucleic acid is
selected from the group comprising
ribozymes, antisense nucleic acids and siRNA.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-17-
The present invention advantageously provides an efficient, relevant and
comprehensive set of isolated
nucleic acid molecules and their encoded hyperimmune serum reactive antigens
or fragments thereof
identified from S. agalactiae using an antibody preparation from multiple
human plasma pools and
surface expression libraries derived from the genome of S. agalactiae. Thus,
the present invention fulfils a
widely felt demand for S. agalactiae antigens, vaccines, diagnostics and
products useful in procedures for
preparing antibodies and for identifying compounds effective against S.
agalactiae infection.
An effective vaccine should be composed of proteins or polypeptides, which are
expressed by all strains
and are able to induce high affinity, abundant antibodies against cell surface
components of S. agalactiae.
The antibodies should be IgG1 and/or IgG3 for opsonization, and any IgG
subtype and IgA for
neutralisation of adherence and toxin action. A chemically defined vaccine
must be definitely superior
compared to a whole cell vaccine (attenuated or killed), since components of
S. agalactiae, which cross-
react with human tissues or inhibit opsonization can be eliminated, and the
individual proteins inducing
protective antibodies and/or a protective immune response can be selected.
The approach, which has been employed for the present invention, is based on
the interaction of GBS
proteins or peptides with the antibodies present in human sera. The antibodies
produced against S.
agalactiae by the human immune system and present in human sera are indicative
of the in vivo
expression of the antigenic proteins and their immunogenicity. In addition,
the antigenic proteins as
identified by the bacterial surface display expression libraries using pools
of pre-selected sera, are
processed in a second and third round of screening by individual selected or
generated sera. Thus the
present invention supplies an efficient, relevant, comprehensive set of GBS
antigens as a pharmaceutical
composition, especially a vaccine preventing infection by S. agalactiae.
In the antigen identification program for identifying a comprehensive set of
antigens according to the
present invention, at least two different bacterial surface expression
libraries are screened with several
serum pools or plasma fractions or other pooled antibody containing body
fluids (antibody pools). The
antibody pools are derived from a serum collection, which has been tested
against antigenic compounds
of S. agalactiae, such as whole cell extracts and culture supernatant
proteins. Preferably, three distinct
serum collections are used, obtained ad 1. from healthy pregnant women tested
negative for cervical and
anorectal carriage of GBS, ad 2. healthy pregnant women tested positive for
cervical and/or anorectal
carriage of GBS who's newborn remained GBS-free (although with antibiotic
prevention), ad 3. from
adults below <45 years of age without clinical disease. Sera have to react
with multiple GBS-specific
antigens in order to be considered hyperimmune and therefore relevant in the
screening method applied
for the present invention.
The expression libraries as used in the present invention should allow
expression of all potential antigens,
e.g. derived from all secreted and surface proteins of S. agalactiae.
Bacterial surface display libraries will
be represented by a recombinant library of a bacterial host displaying a
(total) set of expressed peptide
sequences of S. agalactiae on two selected outer membrane proteins (Lama and
FhuA) at the bacterial host
membrane {Georgiou, G., 1997}; {Etz, H. et al., 2001}. One of the advantages
of using recombinant
expression libraries is that the identified hyperimmune serum-reactive
antigens may be instantly
produced by expression of the coding sequences of the screened and selected
clones expressing the
hyperimmune serum-reactive antigens without further recombinant 1~NA
technology or cloning steps
necessary.
The comprehensive set of antigens identified by the described program
according to the present
invention is analysed further by one or more additional rounds of screening.
Therefore individual
antibody preparations or antibodies generated against selected peptides, which
were identified as
immunogenic are used. According to a preferred embodiment the individual
antibody preparations for
the second round of screening are derived from pregnant women and non-pregant
adults who show an
antibody titer above a certain minimum level, for example an antibody titer
being higher than 80
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-18-
percentile, preferably higher than 90 percentile, especially higher than 95
percentile of the human (patient
or healthy individual) sera tested. Using such high titer individual antibody
preparations in the second
screening round allows a very selective identification of the hyperimmune
serum-reactive antigens and
fragments thereof from S. agalactiae.
Following the comprehensive screening procedure, the selected antigenic
proteins, expressed as
recombinant proteins or in vitro translated products, in case it can not be
expressed in prokaryotic
expression systems, or the identified antigenic peptides (produced
synthetically) are tested in a second
screening by a series of ELISA and Western blotting assays for the assessment
of their immunogenicity
with a large human serum collection (minimum 150 healthy and patients sera).
It is important that the individual antibody preparations (which may also be
the selected serum) allow a
selective identification of the most promising candidates of all the
hyperimmune serum-reactive antigens
from all the promising candidates from the first round. Therefore, preferably
at least 10 individual
antibody preparations (i.e. antibody preparations (e.g. sera) from at least 10
different individuals having
suffered from an infection to the chosen pathogen) should be used in
identifying these antigens in the
second screening round. Of course, it is possible to use also less than 10
individual preparations,
however, selectivity of the step may not be optimal with a low number of
individual antibody
preparations. On the other hand, if a given hyperimmune serum-reactive antigen
(or an antigenic
fragment thereof) is recognized by at least 10 individual antibody
preparations, preferably at least 30,
especially at least 50 individual antibody preparations, identification of the
hyperimmune serum-reactive
antigen is also selective enough for a proper identification. Hyperimmune
serum-reactivity may of course
be tested with as many individual preparations as possible (e.g. with more
than 100 or even with more
than 1,000).
Therefore, the relevant portion of the hyperimmune serum-reactive antibody
preparations according to
the method of the present invention should preferably be at least 10, more
preferred at least 30, especially
at least 50 individual antibody preparations. Alternatively (or in
combination) hyperimmune serum-
reactive antigens may preferably be also identified with at least 20%,
preferably at least 30%, especially at
least 40% of all individual antibody preparations used in the second screening
round.
According to a preferred embodiment of the present invention, the sera from
which the individual
antibody preparations for the second round of screening are prepared (or which
are used as antibody
preparations), are selected by their titer against S. agalactiae (e.g. against
a preparation of this pathogen,
such as a lysate, cell wall components and recombinant proteins). Preferably,
some are selected with a
total IgA titer above 300 U, especially above 500 U, and/or an IgG titer above
5,000 U, especially above
10,000 U (U = units, calculated from the OD4osnm reading at a given dilution)
when the whole organism
(total lysate or whole cells) is used as antigen in the ELISA.
The antibodies produced against streptococci by the human immune system and
present in human sera
are indicative of the in vivo expression of the antigenic proteins and their
immunogenicity. The
recognition of linear epitopes recognized by serum antibodies can be based on
sequences as short as 4-5
amino acids. Of course it does not necessarily mean that these short peptides
are capable of inducing the
given antibody in vivo. For that reason the defined epitopes, polypeptides and
proteins are further to be
tested in animals (mainly in mice) for their capacity to induce antibodies
against the selected proteins in
vivo.
The preferred antigens are located on the cell surface or secreted, and are
therefore accessible
extracellularly. Antibodies against cell wall proteins are expected to serve
multiple purposes: to inhibit
adhesion, to interfere with nutrient acquisition, to inhibit immune evasion
nand to promote phagocytosis
{Hornef, M. et al., 2002}. Antibodies against secreted proteins are beneficial
in neutralisation of their
function as toxin or virulence component. It is also known that bacteria
communicate with each other
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-19-
through secreted proteins. Neutralizing antibodies against these proteins will
interrupt growth-
promoting cross-talk between or within streptococcal species. Bioinformatic
analyses (signal sequences,
cell wall localisation signals, transmembrane domains) proved to be very
useful in assessing cell surface
localisation or secretion. The experimental approach includes the isolation of
antibodies with the
corresponding epitopes and proteins from human serum, and the generation of
immune sera in mice
against (poly) peptides selected by the bacterial surface display screens.
These sera are then used in a
third round of screening as reagents in the following assays: cell surface
staining of S. agalactiae grown
under different conditions (FRCS or microscopy), determination of neutralizing
capacity (toxin,
adherence), and promotion of opsonization and phagocytosi5 (in vitro
phagocytosis assay).
For that purpose, bacterial E. coli clones are directly injected into mice and
immune sera are taken and
tested in the relevant in vitro assay for functional opsonic or neutralizing
antibodies. Alternatively,
specific antibodies may be purified from human or mouse sera using peptides or
proteins as substrate.
Host defence against S. agalactiae relies mainly on opsonophagocytic killing
mechanism. Inducing high
affinity antibodies of the opsonic and neutralizing type by vaccination helps
the innate immune system to
eliminate bacteria and toxins. This makes the method according to the present
invention an optimal tool
for the identification of GBS antigenic proteins.
The skin and mucous membranes are formidable barriers against invasion by
streptococci. However,
once the skin or the mucous membranes are breached the first line of non-
adaptive cellular defence
begins its co-ordinate action through complement and phagocytes, especially
the polymorphonuclear
leukocytes (PMNs). These cells can be regarded as the cornerstones in
eliminating invading bacteria. As
Streptococcus agalactiae is a primarily extracellular pathogen, the major anti-
streptococcal adaptive
response comes from the humoral arm of the immune system, and is mediated
through three major
mechanisms: promotion of opsonization, toxin neutralisation, and inhibition of
adherence. It is believed
that opsonization is especially important, because of its requirement for an
effective phagocytosis. For
efficient opsonization the microbial surface has to be coated with antibodies
and complement factors for
recognition by PMNs through receptors to the Fc fragment of the IgG molecule
or to activated C3b. After
opsonization, streptococci are phagocytosed and killed. Antibodies bound to
specific antigens on the cell
surface of bacteria serve as ligands for the attachment to PMNs and to promote
phagocytosis. The very
same antibodies bound to the adhesins and other cell surface proteins are
expected to neutralize adhesion
and prevent colonization. The selection of antigens as provided by the present
invention is thus well
suited to identify those that will lead to protection against infection in an
animal model or in humans.
According to the antigen identification method used herein, the present
invention can surprisingly
provide a set of comprehensive novel nucleic acids and novel hyperimmune serum
reactive antigens and
fragments thereof of 5. agalactiae, among other things, as described below.
According to one aspect, the
invention particularly relates to the nucleotide sequences encoding
hyperimmune serum reactive
antigens which sequences are set forth in the Sequence listing Seq ID No: 1-
217, 435-448 and 463-474 and
the corresponding encoded amino acid sequences representing hyperimmune serum
reactive antigens are
set forth in the Sequence Listing Seq ID No 218-434, 449-462 and 475-486.
In a preferred embodiment of the present invention, a nucleic acid molecule is
provided which exhibits
70% identity over their entire length to a nucleotide sequence set forth with
Seq ID No 14, 90, 157-216..
Most highly preferred are nucleic acids that comprise a region that is at
least 80% or at least 85% identical
over their entire length to a nucleic acid molecule set forth with Seq ID No
14, 90, 157-216. In this regard,
nucleic acid molecules at least 90%, 91%, 92%, 93%, 94%, 95%, or 96% identical
over their entire length to
the same are particularly preferred. Furthermore, those with at least 97% are
highly preferred, those with
at least 98% and at least 99% are particularly highly preferred, with at least
99% or 99.5% being the more
preferred, with 100% identity being especially preferred. Moreover, preferred
embodiments in this
respect are nucleic acids which encode hyperimmune serum reactive antigens or
fragments thereof
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-20-
(polypeptides) which retain substantially the same biological function or
activity as the mature
polypeptide encoded by said nucleic acids set forth in the Seq ID No 14,
90,157-216.
Identity, as known in the art and used herein, is the relationship between two
or more polypeptide
sequences or two or more polynucleotide sequences, as determined by comparing
the sequences. In the
art, identity also means the degree of sequence relatedness between
polypeptide or polynucleotide
sequences, as the case may be, as determined by the match between strings of
Such sequences. Identity
can be readily calculated. While there exist a number of methods to measure
identity between two
polynucleotide or two polypeptide sequences, the term is well known to skilled
artisans (e.g. Sequetvce
A~aalysis in Molecular Biology, von Heinje, G., Academic Press, 198'7).
Preferred methods to determine
identity are designed to give the largest match between the sequences tested.
Methods to determine
identity are codified in computer programs. Preferred computer program methods
to determine identity
between two sequences include, but are not limited to, GCG program package
{Devereux, J. et al., 1984},
BLASTP, BLASTN, and FASTA {Altschul, S. et al.,1990}.
According to another aspect of the invention, nucleic acid molecules are
provided which exhibit 96 % or
more than 96 %, especially 100 % sequence identity to the nucleic acid
sequence set forth with Seq ID No
1, 3, 5-13, 15, 18-25, 27-31, 33-36, 39-68, 70-85, 92-100, 103-126, 128-145,
147, 149-156, 217, 435-448 and 463-
474.
According to a further aspect of the present invention, nucleic acid molecules
having 98 % or more than
98%, escpecially 100 % sequence identity to a nucleic acid molecule are
provided which are identical to
the nucleic acid sequences set forth with Seq ID No 32, 86, 91,101,12.
The nucleic acid molecules according to the present invention can as a second
alternative also be a nucleic
acid molecule which is at least essentially complementary to the nucleic acid
described as the first
alternative above. As used herein complementary means that a nucleic acid
strand is base pairing via
Watson-Crick base pairing with a second nucleic acid strand. Essentially
complementary as used herein
means that the base pairing is not occurring for all of the bases of the
respective strands but leaves a
certain number or percentage of the bases unpaired or wrongly paired. The
percentage of correctly
pairing bases is preferably at least 70 %, more preferably 80 %, even more
preferably 90 % and most
preferably any percentage higher than 90 %. It is to be noted that a
percentage of 70 % matching bases is
considered as homology and the hybridization having this extent of matching
base pairs is considered as
stringent. Hybridization conditions for this kind of stringent hybridization
may be taken from Current
Protocols in Molecular Biology (John Wiley and Sons, Inc., 1987). More
particularly, the hybridization
conditions can be as follows:
~ Hybridization performed e.g. in 5 x SSPE, 5 x Denhardt's reagent, 0.1% SDS,
100 g/mL sheared
DNA at 68°C
~ Moderate stringency wash in 0.2xSSC, 0.1% SDS at 42°C
~ High stringency wash in 0.lxSSC, 0.1% SDS at 68°C
Genomic DNA with a GC content of 50% has an approximate TM of 96°C. For
1% mismatch, the TM is
reduced by approximately 1°C.
In addition, any of the further hybridization conditions described herein are
in principle applicable as
well.
Of course, all nucleic acid sequence molecules which encode the same
polypeptide molecule as those
identified by the present invention are encompassed by any disclosure of a
given coding sequence, since
the degeneracy of the genetic code is directly applicable to unambiguously
determine all possible nucleic
acid molecules which encode a given polypeptide molecule, even if the number
of such degenerated
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-21 -
nucleic acid molecules may be high. This is also applicable for fragments of a
given polypeptide, as long
as the fragments encode a polypeptide being suitable to be used in a
vaccination connection, e.g. as an
active or passive vaccine.
The nucleic acid molecule according to the present invention can as a third
alternative also be a nucleic
acid which comprises a stretch of at least 15 bases of the nucleic acid
molecule according to the first and
second alternative of the nucleic acid molecules according to the present
invention as outlined above.
Preferably, the bases form a contiguous stretch of bases. However, it is also
within the scope of the
present invention that the stretch consists of two or more moieties, which are
separated by a number of
bases.
The present nucleic acids may preferably consist of at least 20, even more
preferred at least 30, especially
at least 50 contiguous bases from the sequences disclosed herein. The suitable
length may easily be
optimized due to the planned area of use (e.g. as (PCR) primers, probes,
capture molecules (e.g. on
a (DNA) chip), etc.). Preferred nucleic acid molecules contain at least a
contiguous 15 base portion of one
or more of the predicted immunogenic amino acid sequences listed in tables 1
and 2, especially the
sequences of table 2 with scores of more than 10, preferably more than 20,
especially with a score of more
than 25. Specifically preferred are nucleic acids containing a contiguous
portion of a DNA sequence of
any sequence in the sequence protocol of the present application which shows 1
or more, preferably more
than 2, especially more than 5, non-identical nucleic acid residues compared
to the published
Streptococcus agalactiae strain NEM316 (ATCC 12403) genome ({Glaser, P. et
al., 2002}; GenBank accession
AL732656) and/or any other published S. agalactiae genome sequence or parts
thereof, especially of the
serotype V 2603 V/R (A909) strain {Tettelin, H. et al., 2002}); GenBank
accession AE009948). Specifically
preferred non-identical nucleic acid residues are residues, which lead to a
non-identical amino acid
residue. Preferably, the nucleic acid sequences encode polypeptides having at
least 1~ preferably at least 2,
preferably at least 3 different amino acid residues compared to the published
S. agalactiae counterparts
mentioned above. Also such isolated polypeptides, being fragments of the
proteins (or the whole protein)
mentioned herein e.g. in the sequence listing, having at least 6, 7, or 8
amino acid residues and being
encoded by these nucleic acids are preferred.
The nucleic acid molecule according to the present invention can as a fourth
alternative also be a nucleic
acid molecule which anneals under stringent hybridisation conditions to any of
the nucleic acids of the
present invention according to the above outlined first, second, and third
alternative. Stringent
hybridisation conditions are typically those described herein.
Finally, the nucleic acid molecule according to the present invention can as a
fifth alternative also be a
nucleic acid molecule which, but for the degeneracy of the genetic code, would
hybridise to any of the
nucleic acid molecules according to any nucleic acid molecule of the present
invention according to the
first, second, third, and fourth alternative as outlined above. This kind of
nucleic acid molecule refers to
the fact that preferably the nucleic acids according to the present invention
code for the hyperimmune
serum reactive antigens or fragments thereof according to the present
invention. This kind of nucleic acid
molecule is particularly useful in the detection of a nucleic acid molecule
according to the present
invention and thus the diagnosis of the respective microorganisms such as S.
agalactiae and any disease or
diseased condition where this kind of microorganims is involved. Preferably,
the hybridisation would
occur or be preformed under stringent conditions as described in connection
with the fourth alternative
described above.
Nucleic acid molecule as used herein generally refers to any ribonucleic acid
molecule or
deoxyribonucleic acid molecule, which may be unmodified RNA or DNA or modified
RNA or DNA.
Thus, for instance, nucleic acid molecule as used herein refers to, among
other, single-and double-
stranded DNA, DNA that is a mixture of single- and double-stranded RNA, and
RNA that is a mixture of
single- and double-stranded regions, hybrid molecules comprising DNA and RNA
that may be single-
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-22-
stranded or, more typically, double-stranded, or triple-stranded, or a mixture
of single- and double-
stranded regions. In addition, nucleic acid molecule as used herein refers to
triple-stranded regions
comprising RNA or DNA or both RNA and DNA. The strands in such regions may be
from the same
molecule or from different molecules. The regions may include all of one or
more of the molecules, but
more typically involve only a region of some of the molecules. ~ne of the
molecules of a triple-helical
region often is an oligonucleotide. As used herein, the term nucleic acid
molecule includes DNAs or
RNAs as described above that contain one or more modified bases. Thus, DNAs or
RNAs with backbones
modified for stability or for other reasons are '°nucleic acid
molecule°' as that term is intended herein.
Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified
bases, such as
tritylated bases, to name just two examples, are nucleic acid molecule as the
term is used herein. It will be
appreciated that a great variety of modifications have been made to DNA and
RNA that serve many
useful purposes known to those of skill in the art. The term nucleic acid
molecule as it is employed herein
embraces such chemically, enzymatically or metabolically modified forms of
nucleic acid molecule, as
well as the chemical forms of DNA and RNA characteristic of viruses and cells,
including simple and
complex cells, i3zter alia. The term nucleic acid molecule also embraces short
nucleic acid molecules often
referred to as oligonucleotide(s). "Polynucleotide" and "nucleic acid°'
or "nucleic acid molecule" are often
used interchangeably herein.
Nucleic acid molecules provided in the present invention also encompass
numerous unique fragments,
both longer and shorter than the nucleic acid molecule sequences set forth in
the sequencing listing of the
S. agalactiae coding regions, which can be generated by standard cloning
methods. To be unique, a
fragment must be of sufficient size to distinguish it from other known nucleic
acid sequences, most
readily determined by comparing any selected S. agalactiae fragment to the
nucleotide sequences in
computer databases such as GenBank.
Additionally, modifications can be made to the nucleic acid molecules and
polypeptides that are
encompassed by the present invention. For example, nucleotide substitutions
can be made which do not
affect the polypeptide encoded by the nucleic acid, and thus any nucleic acid
molecule which encodes a
hyperimmune serum reactive antigen or fragments thereof is encompassed by the
present invention.
Furthermore, any of the nucleic acid molecules encoding hyperimmune serum
reactive antigens or
fragments thereof provided by the present invention can be functionally
linked, using standard
techniques such as standard cloning techniques, to any desired regulatory
sequences, whether a S.
agalactiae regulatory sequence or a heterologous regulatory sequence,
heterologous leader sequence,
heterologous marker sequence or a heterologous coding sequence to create a
fusion protein.
Nucleic acid molecules of the present invention may be in the form of RNA,
such as mRNA or cRNA, or
in the form of DNA, including, for instance, cDNA and genomic DNA obtained by
cloning or produced
by chemical synthetic techniques or by a combination thereof. The DNA may be
triple-stranded, double-
stranded or single-stranded. Single-stranded DNA may be the coding strand,
also known as the sense
strand, or it may be the non-coding strand, also referred to as the anti-sense
strand.
The present invention further relates to variants of the herein above
described nucleic acid molecules
which encode fragments, analogs and derivatives of the hyperimmune serum
reactive antigens and
fragments thereof having a deducted S. agalactiae amino acid sequence set
forth in the Sequence Listing. A
variant of the nucleic acid molecule may be a naturally occurring variant such
as a naturally occurring
allelic variant, or it may be a variant that is not known to occur naturally.
Such non-naturally occurring
variants of the nucleic acid molecule may be made by mutagenesis techniques,
including those applied to
nucleic acid molecules, cells or organisms.
Among variants in this regard are variants that differ from the aforementioned
nucleic acid molecules by
nucleotide substitutions, deletions or additions. 'The substitutions,
deletions or additions may involve one
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
- 23 -
or more nucleotides. The variants may be altered in coding or non-coding
regions or both. Alterations in
the coding regions may produce conservative or non-conservative amino acid
substitutions, deletions or
additions. Preferred are nucleic acid molecules encoding a variant, analog,
derivative or fragment, or a
variant, analogue or derivative of a fragment, which have a S. agalactiae
sequence as set forth in the
Sequence Listing, in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no
amino acids) is substituted,
deleted or added, in any combination. Especially preferred among these are
silent substitutions, additions
and deletions, which do not alter the properties and activities of the S.
agalactiae polypeptides set forth in
the Sequence Listing. Also especially preferred in this regard are
conservative substitutions.
The peptides and fragments according to the present invention also include
modified epitopes wherein
preferably one or two of the amino acids of a given epitope are modified or
replaced according to the
rules disclosed in e.g. {Tourdot, S. et al., 2000}, as well as the nucleic
acid sequences encoding such
modified epitopes.
It is clear that also epitopes derived from the present epitopes by amino acid
exchanges improving,
conserving or at least not significantly impeding the T cell activating
capability of the epitopes are
covered by the epitopes according to the present invention. Therefore the
present epitopes also cover
epitopes, which do not contain the original sequence as derived from S.
agalactiae, but trigger the same or
preferably an improved T cell response. These epitope are referred to as
"heteroclitic'"; they need to have a
similar or preferably greater affinity to MHC/HLA molecules, and the need the
ability to stimulate the T
cell receptors (TCR) directed to the original epitope in a similar or
preferably stronger manner.
Heteroclitic epitopes can be obtained by rational design i.e. taking into
account the contribution of
individual residues to binding to MHC/HLA as for instance described by
{Rammensee, H. et al., 1999},
combined with a systematic exchange of residues potentially interacting with
the TCR and testing the
resulting sequences with T cells directed against the original epitope. Such a
design is possible for a
skilled man in the art without much experimentation.
Another possibility includes the screening of peptide libraries with T cells
directed against the original
epitope. A preferred way is the positional scanning of synthetic peptide
libraries. Such approaches have
been described in detail for instance by {Hemmer, B. et al.,1999}and the
references given therein.
As an alternative to epitopes represented by the present derived amino acid
sequences or heteroclitic
epitopes, also substances mimicking these epitopes e.g. "peptidemimetica" or
"retro-inverso-peptides" can
be applied.
Another aspect of the design of improved epitopes is their formulation or
modification with substances
increasing their capacity to stimulate T cells. These include T helper cell
epitopes, lipids or liposomes or
preferred modifications as described in WO 01/78767.
Another way to increase the T cell stimulating capacity of epitopes is their
formulation with immune
stimulating substances for instance cytokines or chemokines like interleukin-
2, -7, -12, -18, class I and II
interferons (IFN), especially IFN-gamma, GM-CSF, TNF-alpha, flt3-ligand and
others.
As discussed additionally herein regarding nucleic acid molecule assays of the
invention, for instance,
nucleic acid molecules of the invention as discussed above, may be used as a
hybridization probe for
RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones
encoding polypeptides
of the present invention and to isolate cDNA and genomic clones of other genes
that have a high
sequence similarity to the nucleic acid molecules of the present invention.
Such probes generally will
comprise at least 15 bases. Preferably, such probes will have at least 20, at
least 25 or at least 30 bases, and
may have at least 50 bases. Particularly preferred probes will have at least
30 bases, and will have 50
bases or less, such as 30, 35, 40, 45, or 50 bases.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-24-
For example, the coding region of a nucleic acid molecule of the present
invention may be isolated by
screening a relevant library using the known DNA sequence to synthesize an
oligonucleotide probe. A
labeled oligonucleotide having a sequence complementary to that of a gene of
the present invention is
then used to screen a library of cDNA, genomic DNA or mRNA to determine to
which members of the
library the probe hybridizes.
The nucleic acid molecules and polypeptides of the present invention may be
employed as reagents and
materials for development of treatments of and diagnostics for disease,
particularly human disease, as
further discussed herein relating to nucleic acid molecule assays, inter alia.
The nucleic acid molecules of the present invention that are oligonucleotides
can be used in the processes
herein as described, but preferably for PCR, to determine whether or not the
S. agalactiae genes identified
herein in whole or in part are present and/or transcribed in infected tissue
such as blood. It is recognized
that such sequences will also have utility in diagnosis of the stage of
infection and type of infection the
pathogen has attained. For this and other purposes the arrays comprising at
least one of the nucleic acids
according to the present invention as described herein, may be used.
The nucleic acid molecules according to the present invention may be used for
the detection of nucleic
acid molecules and organisms or samples containing these nucleic acids.
Preferably such detection is for
diagnosis, more preferable for the diagnosis of a disease related or linked to
the present or abundance of
S. agalactiae.
Eukaryotes (herein also "individual(s)"), particularly mammals, and especially
humans, infected with S.
agalactiae may be identifiable by detecting any of the nucleic acid molecules
according to the present
invention detected at the DNA level by a variety of techniques. Preferred
nucleic acid molecules
candidates for distinguishing a S. agalactiae from other organisms can be
obtained.
The invention provides a process for diagnosing disease, arising from
infection with S. agalactiae,
comprising determining from a sample isolated or derived from an individual an
increased level of
expression of a nucleic acid molecule having the sequence of a nucleic acid
molecule set forth in the
Sequence Listing. Expression of nucleic acid molecules can be measured using
any one of the methods
well known in the art for the quantitation of nucleic acid molecules, such as,
for example, PCR, RT-PCR,
Rnase protection, Northern blotting, other hybridisation methods and the
arrays described herein.
Isolated as used herein means separated "by the hand of man" from its natural
state; i.e., that, if it occurs
in nature, it has been changed or removed from its original environment, or
both. For example, a
naturally occurring nucleic acid molecule or a polypeptide naturally present
in a living organism in its
natural state is not "isolated,' but the same nucleic acid molecule or
polypeptide separated from the
coexisting materials of its natural state is "isolated", as the term is
employed herein. As part of or
following isolation, such nucleic acid molecules can be joined to other
nucleic acid molecules, such as
DNAs, for mutagenesis, to form fusion proteins, and for propagation or
expression in a host, for instance.
The isolated nucleic acid molecules, alone or joined to other nucleic acid
molecules such as vectors, can be
introduced into host cells, in culture or in whole organisms. Introduced into
host cells in culture or in
whole organisms, such DNAs still would be isolated, as the term is used
herein, because they would not
be in their naturally occurring form or environment. Similarly, the nucleic
acid molecules and
polypeptides may occur in a composition, such as a media formulations,
solutions for introduction of
nucleic acid molecules or polypeptides, for example, into cells, compositions
or solutions for chemical or
enzymatic reactions, for instance, which are not naturally occurring
compositions, and, therein remain
isolated nucleic acid molecules or polypeptides within the meaning of that
term as it is employed herein.
The nucleic acids according to the present invention may be chemically
synthesized. Alternatively, the
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-25-
nucleic acids can be isolated from S. agalactiae by methods known to the one
skilled in the art.
According to another aspect of the present invention, a comprehensive set of
novel hyperimmune serum
reactive antigens and fragments thereof are provided by using the herein
described antigen identification
method. In a preferred embodiment of the invention, a hyperimmune serum-
reactive antigen comprising
an amino acid sequence being encoded by any one of the nucleic acids molecules
herein described and
fragments thereof are provided. In another preferred embodiment of the
invention a novel set of
hyperimmune serum-reactive antigens which comprises amino acid sequences
selected from a group
consisting of the polypeptide sequences as represented in Seq ID h~To 231,
30~, 374-433 and fragments
thereof are provided. In a further preferred embodiment of the invention
hyperimmune serum-reactive
antigens which comprise amino acid sequences selected from a group consisting
of the polypeptide
sequences as represented in Seq ID No 218, 220, 222-230, 232, 235-242, 244-
248, 250-253, 256-285, 287-302,
309-317, 320-343, 345-362, 364, 366-3~3, 434, 449-462 and 475-486 and
fragments thereof are provided. In a
still preferred embodiment of the invention hyperimmune serum-reactive
antigens which comprise
amino acid sequences selected from a group consisting of the polypeptide
sequences as represented in
Seq ID No 249, 303, 308, 318, 344 and fragments thereof are provided.
The hyperimmune serum reactive antigens and fragments thereof as provided in
the invention include
any polypeptide set forth in the Sequence Listing as well as polypeptides
which have at least 70% identity
to a polypeptide set forth in the Sequence Listing, preferably at least 80% or
85% identity to a polypeptide
set forth in the Sequence Listing, and more preferably at least 90% similarity
(more preferably at least
90% identity) to a polypeptide set forth in the Sequence Listing and still
more preferably at least 95%,
96%, 97%, 98%, 99% or 99.5% similarity (still more preferably at least 95%,
96%, 97%, 98%, 99%, or 99.5%
identity) to a polypeptide set forth in the Sequence Listing and also include
portions of such polypeptides
with such portion of the polypeptide generally containing at least 4 amino
acids and more preferably at
least 8, still more preferably at least 30, still more preferably at least 50
amino acids, such as 4, 8, 10, 20,
30, 35, 40, 45 or 50 amino acids.
The invention also relates to fragments, analogs, and derivatives of these
hyperimmune serum reactive
antigens and fragments thereof. The terms "fragment", "derivative" and
"analog" when referring to an
antigen whose amino acid sequence is set forth in the Sequence Listing, means
a polypeptide which
retains essentially the same or a similar biological function or activity as
such hyperimmune serum
reactive antigen and fragment thereof.
The fragment, derivative or analog of a hyperimmune serum reactive antigen and
fragment thereof may
be 1) one in which one or more of the amino acid residues are substituted with
a conserved or non-
conserved amino acid residue (preferably a conserved amino acid residue) and
such substituted amino
acid residue may or may not be one encoded by the genetic code, or 2) one in
which one or more of the
amino acid residues includes a substituent group, or 3) one in which the
mature hyperimmune serum
reactive antigen or fragment thereof is fused with another compound, such as a
compound to increase the
half-life of the hyperimmune serum reactive antigen and fragment thereof (for
example, polyethylene
glycol), or 4) one in which the additional amino acids are fused to the mature
hyperimmune serum
reactive antigen or fragment thereof, such as a leader or secretory sequence
or a sequence which is
employed for purification of the mature hyperimmune serum reactive antigen or
fragment thereof or a
proprotein sequence. Such fragments, derivatives and analogs are deemed to be
within the scope of
those skilled in the art from the teachings herein.
The present invention also relates to antigens of different S. agalactiae
isolates. Such homologues
may easily be isolated based on the nucleic acid and amino acid sequences
disclosed herein. There are 9
serotypes distinguished to date and the typing is based on serotype specific
antisera. The presence of any
antigen can accordingly be determined for every serotype. In addition it is
possible to determine the
variability of a particular antigen in the various serotypes as described for
the S. pyogenes sic gene {Hoe,
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-26-
N. et al., 2001}. The contribution of the various serotypes to the different
GBS infections varies in the
different age groups and geographical regions. It is an important aspect that
the most valuable protective
antigens are expected to be conserved among various clinical strains.
Among the particularly preferred embodiments of the invention in this regaxd
are the hyperimmune
serum reactive antigens set forth in the Sequence Listing, variants, analogs,
derivatives and fragments
thereof, and variants, analogs and derivatives of fragments. Additionally,
fusion polypeptides
comprising such hyperimmune serum reactive antigens, variants, analogs,
derivatives and fragments
thereof, and variants, analogs and derivatives of the fragments are also
encompassed by the present
invention. Such fusion polypeptides and proteins, as well as nucleic acid
molecules encoding them, can
readily be made using standard techniques, including standard recombinant
techniques for producing
and expression of a recombinant polynueleic acid encoding a fusion protein.
Among preferred variants are those that vary from a reference by conservative
amino acid substitutions.
Such substitutions are those that substitute a given amino acid in a
polypeptide by another amino acid of
like characteristics. Typically seen as conservative substitutions are the
replacements, one fox another,
among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the
hydroxyl residues Sex and Thr,
exchange of the acidic residues Asp and Glu, substitution between the amide
residues Asn and Gln,
exchange of the basic residues Lys and Arg and replacements among the aromatic
residues Phe and Tyr.
Further particularly preferred in this regard are variants, analogs,
derivatives and fragments, and
variants, analogs and derivatives of the fragments, having the amino acid
sequence of any polypeptide
set forth in the Sequence Listing, in which several, a few, 5 to 10, 1 to 5, 1
to 3, 2, 1 or no amino acid
residues are substituted, deleted or added, in any combination. Especially
preferred among these are
silent substitutions, additions and deletions, which do not alter the
properties and activities of the
polypeptide of the present invention. Also especially preferred in this regard
are conservative
substitutions. Most highly preferred are polypeptides having an amino acid
sequence set forth in the
Sequence Listing without substitutions.
T'he hypeximmune serum reactive antigens and fragments thereof of the present
invention are preferably
provided in an isolated form, and preferably are purified to homogeneity.
Also among preferred embodiments of the present invention axe polypeptides
comprising fragments of
the polypeptides having the amino acid sequence set forth in the Sequence
Listing, and fragments of
variants and derivatives of the polypeptides set forth in the Sequence
Listing.
In this regard a fragment is a polypeptide having an amino acid sequence that
entirely is the same as part
but not all of the amino acid sequence of the afore mentioned hyperimmune
serum reactive antigen and
fragment thereof, and variants or derivative, analogs, fragments thereof. Such
fragments may be "free-
standing", i.e., not part of or fused to other amino acids or polypeptides, or
they may be comprised
within a larger polypeptide of which they form a part or region. Also
preferred in this aspect of the
invention are fragments characterised by structural or functional attributes
of the polypeptide of the
present invention, i.e. fragments that comprise alpha-helix and alpha-helix
forming regions, beta-sheet
and beta-sheet forming regions, turn and turn-forming regions, coil and coil-
forming regions, hydrophilic
regions, hydrophobic regions, alpha amphipathic regions, beta-amphipathic
regions, flexible regions,
surface-forming regions, substrate binding regions, and high antigenic index
regions of the polypeptide
of the present invention, and combinations of such fragments. Preferred
regions are those that mediate
activities of the hyperimmune serum reactive antigens and fragments thereof of
the present invention.
Most highly preferred in this regard are fragments that have a chemical,
biological or other activity of the
hyperimmune serum reactive antigen and fragments thereof of the present
invention, including those
with a similar activity or an improved activity, or with a decreased
undesirable activity. Particularly
preferred are fragments comprising receptors or domains of enzymes that confer
a function essential for
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
viability of S. agalactiae or the ability to cause disease in humans. Further
preferred polypeptide
fragments are those that comprise or contain antigenic or immunogenic
determinants in an animal,
especially in a human.
An antigenic fragment is defined as a fragment of the identified antigen,
which is for itself antigenic or
may be made antigenic when provided as a hapten. Therefore, also antigens or
antigenic fragments
showing one or (for longer fragments) only a few amino acid exchanges are
enabled with the present
invention, provided that the antigenic capacities of such fragments with amino
acid exchanges are not
severely deteriorated on the exchange(s), i.e., suited for eliciting an
appropriate immune response in an
individual vaccinated with this antigen and identified by individual antibody
preparations from
individual sera.
Preferred examples of such fragments of hyperimmune serum-reactive antigens
selected from the group
consisting of peptides comprising amino acid sequences of column "predicted
immunogenic aa" and
"location of identified immunogenic region°' of Table 1A, especially
peptides comprising amino acid 4-
20, 35-44, 65-70, 73-87, 92-98, 112-137, 152-161, 177-186, 193-200, 206-213,
229-255, 282-294, 308-313, 320-
326, 349-355, 373-384, 388-406, 420-425 and 115-199 of Seq ID No 218; 5-24, 35-
41, 44-70, 73-89, 103-109,
127-143, 155-161, 185-190, 192-207, 212-219, 246-262, 304-336, 3~2-382, 384-
393, 398-40~, 412-418, 438-444,
1-75, 76-161 and 164-239 of Seq ID No 219; 4-10, 16-58, 60-71, 77-92, 100-126,
132-146, 149-164, 166-172,
190-209, 214-220, 223-229, 241-256, 297-312, 314-319, 337-343, 351-359, 378-
387, 398-418, 421-428, 430-437,
440-448, 462-471, 510-519, 525-536, 552-559, 561-568, 573-582, 596-602, 608-
630, 637-649, 651-665, 681-702,
X14-732, 739-745, 757-778, 790-805, 807-815, 821-829, 836-842, 846-873, 880-
903, 908-914, 916-923, 931-940,
943-948, 956-970, 975-986, 996-1015, 1031-1040, 1051-1069, 102-1095, 1114-
1119, 1130-1148, 1150-1157,
1169-1176, 1229-1238 and 802-812 of Seq ID No 220; 5-12, 14-26, 35-47, 52-67,
72-78, 83-98, 121-141, 152-
159, 163-183, 186-207, 209-257, 264-277, 282-299, 301-309, 312-318, 324-339,
358-368, 3~2-378, 387-397, 425-
431 and 46-291 of Seq ID No 221; 29-38, 44-64, 70-76, ~8-87, 94-100, 102-112,
119-134, 140-149, 163-173,
178-186, 188-194, 20~-234, 247-262, 269-290 and 73-92 of Seq ID No 222; 10-28,
36-63, 77-87, 103-119, 127-
136, 141-169, 171-183, 195-200, 20~-232, 236-246, 251-265, 268-283, 287-297,
314-322, 335-343, 354-363, 384-
390, 405-411, 419-436, 443-455, 467-473, 480-513, 518-529, 550-557, 565-585,
602-608, 616-625, 632-660, 665-
677, 685-701, 726-736, 738-747, 752-761, X85-796, 801-813, 838-853, 866-871
and 757-774 of Seq ID No 223;
31-38, 61-66, 74-81, 90-115, 123-145, 154-167, 169-179, 182-193, 200-206, 238-
244, 26~-272 and 235-251 of
Seq ID No 224; 19-25, 38-54, 56-64, 66-72, 94-92, 94-100, 116-129, 143-149,
156-183, 204-232, 253-266, 269-
275, 294-307 and 241-313 of Seq ID No 225; 5-34, 50-56, 60-65, ~4-85, 89-97,
108-119, 159-165, 181-199, 209-
225, 230-240, 245-251, 257-262, 274-282, 300-305 and 64-75 of Seq ID No 226; 5-
13, 16-21, 27-42, 45-52, 58-
66, 74-87, 108-114, 119-131 and 39-51 of Seq ID No 227; 6-23, 46-54, 59-65, 78-
84,100-120,128-133, 140-146,
159-165, 171-183, 190-204, 224-232, 240-248, 250-259, 2~4-280, 288-296, 306-
315 and 26'7-2~4 of Seq ID No
228; 5-12, 15-24, 26-36, 42-65, 68-80, 82-104, 111-116, 125-144, 159-16~, 184-
189, 209-218, 235-243, 254-265,
269-283, 287-300, 306-316, 318-336, 338-352, 374-392 and 162-174 of Seq ID No
229; 30-42, 45-54 and 25-37
of Seq ID No 230; 10-30, 53-59, 86-95, 116-130, 132-147, 169-189, 195-201, 212-
221, 247-256, 258-265, 278-
283, 291-298, 310-316, 329-339, 341-352, 360-367, 388-396, 398-411, 416-432,
443-452, 460-466, 506-512, 515-
521, 542-548 and 419-431 of Seq ID No 231; 4-27, 30-53, 60-67, 70-90, 92-151,
159-185, 189-195, 198-210,
215-239 and 173-189 of Seq ID No 232; 4-26, 41-54, ~1-78, 116-127, 140-149,
151-158, 161-175, 190-196, 201-
208, 220-226, 240-252, 266-281, 298-305, 308-318, 321-329, 344-353, 3~2-3~8,
384-405, 418-426, 429-442, 457-
463, 494-505, 514-522 and 1~4-188 of Seq ID No 233; 17-25, 27-39, 61-67, 81-
89, 99-110, 120-131, 133-139,
14'7-161, 167-1'72, 179-185, 192-198, 203-213, 226-238, 243-258, 261-267, 284-
290, 296-307, 311-328, 340-352,
356-3~1 and 239-256 of Seq ID No 234; 8-30, 40-49, 67-80, 114-123, 126-142,
152-162, 188-194 and 57-70 of
Seq ID No 235; 4-23, 28-34, 36-47, 50-61, 76-81, 89-94, 96-104, 112-119, 126-
146, 155-181, 195-200, 208-214,
220-229, 244-260, 263-2~6, 282-288, 292-300, 317-323, 336-351, 353-359, 363-
375, 382-399, 415-432, 444-455,
458-471, 476-481, 484-492, 499-517, 522-529, 535-541, 543-568, 572-584, 586-
600, 607-617, 626-637, 656-6~5
and 282-297 of Seq ID No 236; 6-24, 30-35, 38-45, 63-91, 134-140, 146-160, 167-
188, 214-220, 226-234, 244-
250, 260-270, 286-301, 316-329, 340-371, 429-446, 448-459, 474-481, 485-491,
512-526, 537-544, 550-565, 5~3-
583, 596-613, 621-630, 652-658 and 87-97 of Seq ID No 237; 8-20, 26-48, 56-67,
76-86, 94-109, 115-121, 123-
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
- 2~ -
129, 143-160, 178-186, 191-198, 201-208, 221-236, 238-244, 260-268 and 237-247
of Seq ID No 238; 4-40, 42-
57, 73-87, 98-117, 126-135, 150-156, 166-174, 196-217, 231-236, 248-258, 276-
284, 293-301, 307-313, 339-347,
359-365, 375-387, 395-402, 428-440, 445-456, 485-490, 497-505, 535-541, 547-
555, 610-625, 648-656, 665-671
and 448-528 of Seq ID No 239; 10-18, 39-45, 51-61, 80-96, 98-106, 110-115, 158-
172, 174-183, 191-200, 220-
237, 249-255, 274-289, 308-324, 331-341, 372-381, 384-397, 405-414 and 322-338
of Seq ID No 240; 30-36, 38-
56, 85-108, 134-147, 149-160, 163-183, 188-201, 206-211, 219-238, 247-254 and
5-13 of Seq ID N~ 241; 11-40,
98-103, 110-115, 133-145, 151-159, 172-179, 192-201, 204-212, 222-228, 235-
245, 258-268, 283-296, 298-309,
322-329, 342-351, 354-362, 372-378, 385-393, 407-418, 495-516 and 1-148 of Seq
ID No 242; 5-19, 21-36, 73-
94, 112-119, 122-137, 139-145, 152-167, 184-190, 198-204, 208-224, 249-265,
267-281, 299-304, 309-317, 326-
333, 356-364, 368-374, 381-389, 391-414, 419-425, 430-435 and 113-140 of Seq
ID No 243; 45-54, 59-67, 78-91
and 15-23 of Seq ID No 244; 11-22, 33-47, 52-80, 88-112, 124-129 and 6-25 of
Seq ID No 245; 26-41, 51-63,
80-89, 93-115, 150-163, 187-193, 220-237, 240-249, 286-294, 296-306, 316-329,
345-353, 361-370, 407-425, 428-
437, 474-482, 484-494, 504-517, 533-541, 549-558, 595-613, 616-625, 660-668,
673-685, 711-726, 736-744, 749-
761, 787-802, 812-820, 825-837, 863-878, 888-896, 901-913, 939-954, 964-972,
977-989, 1003-1008, 1016-1022,
1028-1034, 1041-1053, 1059-1074, 1101-1122, 420-511 and 581-704 of Seq ID No
246; 18-25, 27-55, 71-83, 89-
95, 102-113, 120-146, 150-156, 174-185 and 159-175 of Seq ID No 247; 24-30, 38-
56, 63-68, 87-93, 136-142,
153-164, 183-199, 213-219, 226-234, 244-261, 269-278, 283-289, 291-297, 320-
328, 330-336, 340-346, 348-356,
358-366, 382-387, 401-408, 414-419, 449-455, 468-491, 504-512, 531-537, 554-
560, 597-608, 621-627, 632-643,
650-662, 667-692, 703-716, 724-737, 743-758, 783-794, 800-818, 846-856 and 806-
884 of Seq ID No 248; 4-14,
21-39, 86-92, 99-107, 121-131, 136-144, 147-154, 158-166, 176-185, 193-199,
207-222, 224-230 and 117-136 of
Seq ID No 249; 65-76, 85-97, 103-109, 115-121, 125-146, 163-169, 196-205, 212-
219, 228-237, 241-247, 254-
262, 269-288, 294-303, 305-313, 328-367, 395-401, 405-412, 418-429, 437-447,
481-488, 506-513, 519-524, 530-
541, 546-557 and 266-284 of Seq ID No 250; 5-14, 37-42, 49-71, 78-92, 97-112,
127-136, 147-154, 156-163,
186-198, 216-225, 233-243, 248-253, 295-307, 323-332, 359-366, 368-374, 380-
398 and 194-223 of Seq ID No
251; 4-11, 33-39, 45-72, 100-113, 119-129, 136-144, 169-175, 177-185, 200-208,
210-219, 262-276, 278-297, 320-
326, 336-344, 347-362, 381-394, 443-453 and 438-454 of Seq ID No 252; 4-29, 31-
52, 55-61, 95-110, 138-158,
162-171, 179-187, 202-229, 239-248, 251-256, 262-267, 269-285, 304-310, 351-
360, 362-368, 381-388, 415-428,
435-440, 448-458 and 161-178 of Seq ID No 253; 4-17, 19-28, 32-43, 47-59, 89-
110, 112-126, 128-134, 140-148,
152-161, 169-184, 191-204, 230-235, 255-264, 328-338, 341-347, 401-409, 413-
419, 433-441, 449-458, 463-468,
476-482, 486-492, 500-506, 529-545 and 305-381 of Seq ID No 254; 10-29, 38-45,
53-61, 134-145, 152-160,
163-170, 202-208, 219-229, 248-258, 266-275, 282-288, 315-320, 328-334, 377-
385, 392-402, 418-424, 447-453,
460-471, 479-487, 491-497, 500-507, 531-537, 581-594, 615-623, 629-635, 644-
652, 659-666, 668-678, 710-717,
719-728, 736-741, 747-760, 766-773, 784-789, 794-800, 805-817, 855-861, 866-
887 and 698-715 of Seq ID No
255;16-26, 29-37, 44-58, 62-68, 74-80, 88-95, 97-120,125-144,165-196 and 58-72
of Seq ID No 256;14-21, 23-
46, 49-60, 63-74, 78-92, 96-103, 117-129, 134-161, 169-211, 217-231, 239-248,
252-281, 292-299, 313-343 and
243-257 of Seq ID No 257; 11-27, 46-52, 67-72, 76-84, 91-112, 116-153, 160-
175, 187-196, 202-211, 213-220
and 43-76 of Seq ID No 258; 5-29, 37-56, 78-86, 108-118, 152-161 and 120-130
of Seq ID No 259; 8-14, 19-
41, 52-66, 75-82, 87-92, 106-121, 127-133, 136-143, 158-175, 180-187, 196-204,
221-228, 239-245, 259-265, 291-
306, 318-323, 328-340, 352-358, 361-368, 375-381, 391-399, 411-418, 431-442,
446-455, 484-496, 498-510, 527-
533, 541-549, 558-565, 575-585, 587-594, 644-655, 661-668, 671-677 and 184-196
of Seq ID No 260; 4-22, 29-
38, 55-62, 75-81, 102-107, 110-134, 143-150, 161-167, 172-179, 191-215, 223-
233, 241-247, 251-264, 266-272,
288-309, 340-352, 354-366, 394-402, 414-438 and 198-218 of Seq ID No 261; 24-
44, 49-70, 80-91, 105-118,
128-136,140-154 and 77-92 of Seq ID No 262; 5-22, 31-36, 41-47, 67-74, 83-
90,105-122,135-143, 160-167 and
118-129 of Seq ID No 263; 4-25, 33-73, 81-93, 96-106, 114-120, 122-128, 130-
172, 179-208, 210-241, 251-283,
296-301 and 92-100 of Seq ID No 264; 14-24, 29-38, 43-50, 52-72, 86-97, 101-
107, 110-125, 127-141, 145-157,
168-175, 177-184, 186-195, 205-226, 238-250, 255-261, 284-290, 293-304, 307-
314, 316-323, 325-356, 363-371,
383-390, 405-415, 423-432, 442-454, 466-485, 502-511, 519-527, 535-556, 558-
565, 569-574, 612-634, 641-655,
672-686, 698-709, 715-722, 724-732, 743-753, 760-769, 783-792, 818-825, 830-
839, 842-849, 884-896, 905-918,
926-940, 957-969, 979-1007, 1015-1021, 1049-1057 and 336-349 of Seq ID No 265;
6-16, 26-31, 33-39, 62-73,
75-85, 87-100, 113-123, 127-152, 157-164, 168-181, 191-198, 208-214, 219-226,
233-254, 259-266, 286-329 and
181-195 of Seq ID No 266; 4-13, 32-39, 53-76, 99-108, 110-116, 124-135, 137-
146, 149-157, 162-174, 182-190,
207-231, 242-253, 255-264, 274-283, 291-323, 334-345, 351-360, 375-388, 418-
425, 456-474, 486-492, 508-517,
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-29-
520-536, 547-560, 562-577, 31-45 and 419-443 of Seq ID No 267; 15-26, 30-37,
42-49, 58-90, 93-99, 128-134,
147-154, 174-179, 190-197, 199-205, 221-230, 262-274, 277-287, 300-314, 327-
333, 343-351, 359-377, 388-396,
408-413, 416-425, 431-446 and 246-256 of Seq ID No 268; 5-26, 34-42, 47-54, 61-
67, 71-104,107-115, 131-138,
144-153, 157-189, 196-202, 204-210, 228-245, 288-309, 316-329, 332-341, 379-
386, 393-399, 404-412, 414-421,
457-468, 483-489, 500-506, 508-517, 523-534, 543-557, 565-580, 587-605, 609-
617, 619-627, 631-636, 640-646,
662-668, 675-682, 705-710, 716-723, 727-732, 750-758, 784-789, 795-809, 869-
874, 14-138, 166-286, 372-503,
674-696 and 754-859 of Seq ID No 269; 5-17, 32-38, 40-47, 80-89, 113-119, 125-
137, 140-154, 157-163, 170-
177, 185-199, 213-225, 228-236, 242-248, 277-290, 292-305, 323-333, 347-353,
364-370, 385-394, 399-406, 423-
433, 441-451, 462-474, 477-487 and 116-124 of Seq ID T~Io 270; 7-16, 18-30, 32-
49, 53-61, 63-85, 95-101, 105-
115, 119-134, 143-150, 159-178, 185-202, 212-229, 236-250, 254-265, 268-294
and 63-72 of Seq ID No 271; 4-
12, 19-47, 73-81, 97-103, 153-169, 188-198, 207-213, 217-223, 236-242, 255-
265, 270-278, 298-305, 309-317,
335-347, 354-363, 373-394, 419-424, 442-465, 486-492, 500-507, 542-549, 551-
558, 560-572, 580-589, 607-614,
617-623, 647-653, 666-676, 694-704, 706-714, 748-754, 765-772, 786-792, 795-
806 and 358-370 of Seq ID No
272; 18-28, 30-38, 40-46, 49-55, 69-78, 82-98, 104-134, 147-153, 180-190, 196-
202, 218-236, 244-261, 266-273,
275-286, 290-295, 301-314, 378-387, 390-395, 427-434 and 290-305 of Seq ID No
273; 4-13, 20-31, 39-51, 54-
61, 69-84, 87-105,117-124 and 108-125 of Seq ID No 274; 24-34, 43-54, 56-66,
68-79 and 50-69 of Seq ID No
275; 5-43, 71-77, 102-131, 141-148, 150-156, 159-186, 191-207, 209-234, 255-
268, 280-286, 293-299, 317-323,
350-357, 363-372, 391-397, 406-418, 428-435, 455-465, 484-497, 499-505, 525-
531, 575-582, 593-607, 621-633,
638-649, 655-673, 684-698, 711-725, 736-741, 743-752, 759-769, 781-793, 813-
831, 843-853, 894-905, 908-916,
929-946, 953-963, 970-978, 1001-1007, 1011-1033, 165-178 and 818-974 of Seq ID
No 276; 16-44, 63-86, 98-
108, 185-191, 222-237, 261-274, 282-294, 335-345, 349-362, 374-384, 409-420,
424-430, 440-447, 453-460, 465-
473, 475-504, 522-534, 538-551, 554-560, 567-582, 598-607, 611-619, 627-640,
643-653, 655-661, 669-680, 684-
690, 701-707, 715-731, 744-750, 756-763, 768-804, 829-837, 845-853, 855-879,
884-890, 910-928, 77-90, 144-212,
279-355, 434-536, 782-810 and 875-902 of Seq ID No 277; 4-22, 29-41, 45-51, 53-
66, 70-77, 86-95, 98-104,106-
124, 129-135, 142-151, 153-161, 169-176, 228-251, 284-299, 331-337, 339-370,
380-387, 393-398, 406-411, 423-
433, 440-452, 461-469, 488-498, 501-516, 523-530, 532-559, 562-567, 570-602,
612-628, 630-645, 649-659, 666-
672, 677-696, 714-723, 727-747 and 212-227 of Seq ID No 278; 4-9, 17-31, 35-
41, 56-61, 66-75, 81-87, 90-124,
133-138, 149-163, 173-192, 213-219, 221-262, 265-275, 277-282, 292-298, 301-
307, 333-346, 353-363, 371-378,
419-430, 435-448, 456-469, 551-570, 583-599, 603-612 and 275-291 of Seq ID No
279; 28-34, 53-58, 72-81,
100-128, 145-154, 159-168, 172-189, 217-225, 227-249, 256-263, 299-309, 322-
330, 361-379, 381-388, 392-401,
404-417, 425-436, 440-446, 451-464, 469-487, 502-511, 543-551, 559-564, 595-
601, 606-612, 615-626, 633-642,
644-650, 664-670, 674-684, 692-701, 715-723, 726-734, 749-756, 763-771, 781-
787, 810-843, 860-869, 882-889,
907-917, 931-936, 941-948, 951-958, 964-971, 976-993, 1039-1049, 1051-1065,
1092-1121, 1126-1132, 1145-
1151, 1158-1173, 1181-1192, 1194-1208, 1218-1223, 1229-1243, 1249-1254, 1265-
1279, 1287-1297, 1303-1320,
1334-1341, 1343-1358, 1372-1382, 1406-1417, 1419-1425, 1428-1434, 1441-1448,
1460-1473, 1494-1504, 1509-
1514, 1529-1550, 654-669 and 1400-1483 of Seq ID No 280; 10-16, 20-25, 58-65,
97-109, 118-132, 134-146,
148-155, 186-195, 226-233, 244-262, 275-284, 295-310, 317-322, 330-339, 345-
351, 366-375, 392-403, 408-415,
423-430, 435-444, 446-457, 467-479, 486-499, 503-510, 525-537, 540-585, 602-
612, 614-623, 625-634, 639-645,
650-669, 700-707, 717-724, 727-739, 205-230 and 733-754 of Seq ID No 281; 5-
22, 37-43, 72-81, 105-113, 128-
133, 148-160, 188-194, 204-230, 238-245, 251-257 and 194-213 of Seq ID No 282;
16-21, 35-41, 56-72, 74-92,
103-109 and 62-68 of Seq ID No 283; 4-15, 17-82, 90-104, 107-159, 163-170, 188-
221, 234-245, 252-265 and
220-235 of Seq ID No 284; 16-22, 36-46, 61-75, 92-107, 113-121, 139-145, 148-
160 and 30-42 of Seq ID No
285; 4-12, 20-26, 43-49, 55-62, 66-78, 121-127, 135-141, 146-161, 164-170, 178-
189, 196-205, 233-238, 269-279,
288-318, 325-332, 381-386, 400-407 and 328-346 of Seq ID No 286; 5-12, 31-49,
57-63, 69-79, 89-97, 99-114,
116-127, 134-142, 147-154, 160-173, 185-193, 199-204, 211-222, 229-236, 243-
249, 256-274 and 58-68 of Seq
ID No 287; 10-20, 28-34, 39-53, 68-79, 84-90, 99-106 and 73-79 of Seq ID No
288; 14-37, 45-50, 61-66, 77-82,
93-98, 109-114, 125-130, 141-146, 157-162, 173-178, 189-194, 205-210, 221-226,
237-242, 253-258, 269-274,
285-290, 301-306, 316-332, 349-359, 371-378, 385-406, 34-307 and 312-385 of
Seq ID No 289; 4-10, 17-38, 50-
85, 93-99, 109-116, 128-185, 189-197, 199-210, 223-256, 263-287, 289-312, 327-
337, 371-386, 389-394, 406-419,
424-432, 438-450, 458-463, 475-502, 507-513, 519-526, 535-542, 550-567 and 361-
376 of Seq ID No 290;10-39,
42-93, 100-144, 155-176, 178-224, 230-244, 246-255, 273-282, 292-301, 308-325,
332-351, 356-361, 368-379,
386-393, 400-421 and 138-155 of Seq ID No 291; 5-11, 17-34, 40-45, 50-55, 72-
80, 101-123, 145-151, 164-172,
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-30-
182-187, 189-195, 208-218, 220-241, 243-252, 255-270, 325-331, 365-371, 391-
398, 402-418, 422-428, 430-435,
443-452, 463-469, 476-484, 486-494, 503-509, 529-553, 560-565, 570-590, 608-
614, 619-627, 654-661, 744-750,
772-780, 784-790, 806-816, 836-853, 876-885, 912-918, 926-933, 961-975, 980-
987, 996-1006, 1016-1028, 1043-
1053, 1057-1062, 994-1003 and 1033-1056 of Seq ID No 292; 17-45, 64-71, 73-81,
99-109, 186-192, 223-238,
262-275, 283-295, 336-346, 350-363, 375-385, 410-421, 425-431, 441-448, 454-
463, 468-474, 476-512, 523-537,
539-552, 568-583, 599-608, 612-620, 628-641, 644-654, 656-662, 670-681, 685-
695, 702-708, 716-723, 725-735,
757-764, 769-798, 800-806, 808-816, 826-840, 846-854, 856-862, 874-881, 885-
902, 907-928, 274-350 and 443-
513 of Seq ID No 293; 4-22, 29-41, 45-51, 53-61, 70-76, 85-92, 99-104, 111-
122, 134-140, 142-154, 163-174,
224-232, 255-265, 273-279, 283-297, 330-335, 337-348, 356-367, 373-385, 391-
396, 421-431, 442-455, 475-485,
493-505, 526-538, 544-561, 587-599, 605-620, 622-651, 662-670, 675-681, 687-
692, 697-712, 714-735 and 252-
262 of Seq ID No 294; 4-12, 15-35, 40-46, 50-59, 67-94, 110-128, 143-169, 182-
188, 207-215, 218-228, 238-250
and 74-90 of Seq ID No 295; 9-18, 42-58, 78-85, 88-95, 97-106, 115-122, 128-
134, 140-145, 154-181, 186-202,
204-223, 261-267, 269-278, 284-293, 300-336, 358-368 and 12-29 of Seq ID No
296; 7-34, 46-53, 62-72, 82-88,
100-105, 111-117, 132-137, 144-160, 166-180, 183-189, 209-221, 231-236, 246-
253, 268-282, 286-293, 323-336,
364-372, 378-392, 422-433 and 388-405 of Seq ID No 297; 21-27, 34-50, 72-77,
80-95, 164-177, 192-198, 202-
220, 226-236, 239-247, 270-279, 285-292, 315-320, 327-334, 348-355, 364-371,
388-397, 453-476, 488-497, 534-
545, 556-576, 582-588, 601-607, 609-616, 642-662, 674-681, 687-697, 709-715,
721-727, 741-755 and 621-739 of
Seq ID No 298; 4-14, 16-77, 79-109 and 25-99 of Seq ID No 299; 4-9, 17-23, 30-
37, 44-55, 65-72, 77-93, 102-
121, 123-132, 146-153 and 17-29 of Seq ID No 300; 4-18, 25-41, 52-60, 83-92,
104-112, 117-123, 149-155, 159-
167, 170-192, 201-210, 220-227, 245-250 and 124-137 of Seq ID No 301; 8-25, 50-
55, 89-95, 138-143, 148-153,
159-169, 173-179, 223-238, 262-268, 288-295, 297-308, 325-335, 403-409, 411-
417, 432-446, 463-475, 492-501,
524-530, 542-548, 561-574, 576-593, 604-609, 612-622, 637-654, 665-672, 678-
685, 720-725, 731-739, 762-767,
777-783, 820-838, 851-865, 901-908, 913-920, 958-970, 1000-1006, 1009-1015,
1020-1026, 1043-1052, 1055-
1061,1-128, 252-341, 771-793 and 1043-1058 of Seq ID No 302;16-26, 33-46 and
64-76 of Seq ID No 303; 4-
27, 69-77, 79-101, 117-123, 126-142, 155-161, 171-186, 200-206, 213-231, 233-
244, 267-273, 313-329, 335-344,
347-370, 374-379, 399-408, 422-443, 445-453, 461-468, 476-482, 518-534, 544-
553, 556-567, 578-595, 601-620,
626-636, 646-658, 666-681, 715-721, 762-768, 778-785, 789-803, 809-819, 22-
108, 153-318, 391-527 and 638-757
of Seq ID No 304; 6-21, 32-43, 62-92,104-123,135-141,145-152, 199-216, 218-
226, 237-247, 260-269, 274-283,
297-303, 1-72 and 127-211 of Seq ID No 305; 6-26, 50-56, 83-89, 108-114, 123-
131, 172-181, 194-200, 221-238,
241-247, 251-259, 263-271, 284-292, 304-319, 321-335, 353-358, 384-391, 408-
417, 424-430, 442-448, 459-466,
487-500, 514-528, 541-556, 572-578, 595-601, 605-613, 620-631, 635-648, 660-
670, 673-679, 686-693, 702-708,
716-725, 730-735, 749-755, 770-777, 805-811, 831-837, 843-851, 854-860, 863-
869, 895-901, 904-914, 922-929,
933-938, 947-952, 956-963, 1000-1005,1008-1014,1021-1030, 1097-1103,1120-1130,
1132-1140, 1-213, 269-592
and 992-1120 of Seq ID No 306; 9-16, 33-39, 47-59, 65-79, 81-95, 103-108, 115-
123, 138-148, 163-171, 176-
185, 191-196, 205-211, 213-221, 224-256, 261-276, 294-302, 357-363, 384-390,
95-111 and 161-189 of Seq ID
No 307; 21-27, 35-45, 70-76, 92-105, 129-143, 145-155, 161-166, 170-191, 204-
211, 214-231, 234-246, 249-255,
259-275 and 1-18 of Seq ID No 308; 21-35, 45-53, 56-64, 69-97 and 1-16 of Seq
ID No 309; 25-33, 41-47, 61-
68, 86-101, 106-114, 116-129,134-142,144-156,163-176, 181-190, 228-251, 255-
261, 276-292, 295-305, 334-357,
368-380, 395-410, 424-429, 454- 460, 469-482, 510-516, 518-527, 531-546, 558-
570, 579-606, 628-636, 638-645,
651-656, 668-674, 691-698, 717-734, 742-754, 765-770, 792-797, 827-835, 847-
859, 874-881, 903-909, 926-933,
942-961, 964-977, 989-1004, 1010-1028, 1031-1047, 1057-1075, 1081-1095, 1108-
1117, 1138-1144, 1182-1189,
1193-1206, 1220-1229, 1239-1246, 1257-1267, 1271-1279, 1284-1301, 1312-1320,
1329-1335, 1341-1347, 1358-
1371, 1399-1404, 1417-1426, 1458-1463, 1468-1476, 1478-1485, 1493-1506, 1535-
1541, 1559-1574, 1583-1590,
1595-1601, 1603-1611, 1622-1628, 1634-1644, 1671-1685, 1689-1696, 1715-1720,
1734-1746, 1766-1775, 1801-
1806, 1838-1844, 1858-1871,1910-1917,1948-1955, 1960-1974, 2000-2015, 2019-
2036, 2041-2063, 748-847 and
1381-1391 of Seq ID No 310; 5-12, 18-24, 27-53, 56-63, 96-113, 119-124, 131-
136, 157-163, 203-209, 215-223,
233-246, 264-273, 311-316, 380-389, 393-399, 425-433, 445-450, 457-462, 464-
470, 475-482, 507-513, 527-535,
542-548, 550-565, 591-602, 607-613, 627-642, 644-664, 673-712, 714-732, 739-
764, 769-782, 812-818, 826-838,
848-854, 860-871, 892-906, 930-938, 940-954, 957-973, 990-998, 1002-1021, 1024-
1033, 1037-1042, 1050-1060,
1077-1083, 1085-1092, 1100-1129, 1144-1161, 1169-1175, 1178-1189, 1192-1198,
1201-1207, 1211-1221, 1229-
1239, 1250-1270, 1278-1292, 1294-1300, 1314-1335, 1344-1352, 1360-1374, 1394-
1405, 1407-1414, 1416-1424,
1432-1452, 1456-1462, 1474-1497, 1500-1510, 1516-1522, 1534-1542, 1550-1559,
1584-1603, 1608-1627, 187-
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-31-
273 and 306-441 of Seq ID No 311; 70-80, 90-97, 118-125, 128-140, 142-148, 154-
162, 189-202, 214-222, 224-
232, 254-260, 275-313, 317-332, 355-360, 392-398, 425-432, 448-456, 464-470,
476-482, 491-505, 521-528, 533-
546, 560-567, 592-597, 605-614, 618-626, 637-644, 646-653, 660-666, 677-691
and 207-227 of Seq ID No 312;
5-19, 26-34, 37-55, 57-66, 69-83, 86-102, 115-134, 138-143, 154-172, 178-195,
209-246, 251-257, 290-302, 306-
311 and 256-266 of Seq ID No 313; 10-20, 22-28, 35-57, 72-79, 87-103, 108-128,
130-144, 158-171, 190-198,
225-242, 274-291, 301-315, 317-324, 374-385 and 353-365 of Seq ID i~To 314; 4-
9, 17-30, 34-54, 59-66, 73-94,
118-130, 135-150, 158-171, 189-198, 219-239, 269-275, 283-301, 89-106 and 176-
193 of Seq ID l~~To 315; 14-20,
22-74, 77-86, 89-99,104-109, 126-135,154-165,181-195, 197-212, 216-224, 264-
275 and 107-118 of Seq ID No
316; 4-18, 21-38, 63-72, 101-109, 156-162, 165-179, 183-192, 195-210, 212-218,
230-239, 241-256, 278-290, 299-
311, 313-322, 332-341, 348-366, 386-401, 420-426, 435-450, 455-460, 468-479,
492-498, 510-528, 532-538, 545-
552, 557-563, 567-573, 586-595, 599-609, 620-626, 628-636, 652-657, 665-681
and 1-198 of Seq ID No 317; 4-
10, 16-38, 52-68, 73-79, 94-115, 120-125, 132-178, 201-208, 216-223, 238-266,
269-295, 297-304, 337-342, 347-
356, 374-401, 403-422, 440-447, 478-504, 520-526, 519-530, 537-544 and 292-206
of Seq ID i~lo 318; 12-40, 42-
48, 66-71, 77-86, 95-102, 113-120, 129-137, 141-148, 155-174, 208-214, 218-
225, 234-240, 256-267, 275-283,
300-306, 313-321, 343-350, 359-367, 370-383, 398-405, 432-439, 443-461, 492-
508, 516-526, 528-535 and 370-
478 of Seq ID No 329; 6-14, 20-37, 56-62, 90-95, 97-113, 118-125, 140-145, 161-
170, 183-202, 237-244, 275-
284, 286-305, 309-316, 333-359, 373-401, 405-412 and 176-187 of Seq ID No 320;
33-44, 50-55, 59-80, 86-101,
129-239, 147-153, 157-163, 171-176, 189-202, 203-224, 239-245, 257-262, 281-
287, 290-297, 304-320, 322-331,
334-350, 372-390, 396-401, 71-88 and 353-372 of Seq ID No 321; 5-11, 15-24, 26-
33, 40-47, 75-88, 95-103, 105-
112 and 17-30 of Seq ID No 322; 5-11, 16-39, 46-54, 62-82, 100-107, 111-124,
126-150, 154-165, 167-183, 204-
238, 245-295, 301-313, 316-335 and 8-16 of Seq ID No 323; 4-19, 34-48, 69-74,
79-107, 115-127, 129-135, 143-
153, 160-169, 171-182 and 142-153 of Seq ID No 324; 4-30, 65-74, 82-106, 110-
120,124-132,135-140,146-175,
179-184, 190-196, 217-223, 228-233, 250-267, 275-292, 303-315, 322-332 and 174-
186 of Seq ID No 325; 9-16,
29-41, 47-57, 68-84, 87-109, 113-119, 162-180, 186-193, 195-201, 203-208, 218-
230, 234-243, 265-271, 281-292,
305-312, 323-332, 341-347, 349-363, 368-374, 383-390, 396-410, 434-440, 446-
452, 455-464, 466-473, 515-522,
529-542, 565-570, 589-600, 602-613, 618-623, 637-644, 1019-1027, 1238-1244,
1258-1264, 1268-1276, 1281-
1292, 1296-1302 and 883-936 of Seq ID No 326; 10-17, 23-32, 39-44, 54-72, 75-
81, 88-111, 138-154, 160-167,
178-185, 201-210, 236-252, 327-334, 336-342, 366-376, 388-400, 410-430, 472-
482, 493-526, 552-558, 586-592,
598-603, 612-621, 630-635, 641-660 and 384-393 of Seq ID No 327; 4-22, 24-39,
50-59, 73-84, 100-105, 111-
117, 130-138, 155-161, 173-178, 182-189, 205-215, 266-284, 308-313, 321-328,
330-337, 346-363, 368-374, 388-
395, 397-405, 426-434, 453-459, 482-492, 501-507, 509-515, 518-523, 527-544,
559-590, 598-612, 614-629, 646-
659, 663-684, 686-694, 698-721 and 445-461 of Seq ID No 328; 14-22, 27-33 and
3-17 of Seq ID No 329; 29-
41, 66-73, 81-87, 90-108, 140-146, 150-159, 165-184, 186-196, 216-226, 230-
238, 247-253, 261-269 and 126-140
of Seq ID No 330; 5-12, 16-25, 27-33, 36-45, 60-68, 83-88, 103-126 and 86-101
of Seq ID No 331; 14-23, 36-
47, 56-66, 84-89, 94-105, 111-127, 140-153, 160-174, 176-183, 189-203, 219-
225, 231-237, 250-257 and 194-227
of Seq ID No 332; 4-25, 54-60, 64-71, 73-82, 89-106, 117-124, 157-169, 283-
188, 199-210, 221-232, 236-244,
255-264 and 58-98 of Seq ID No 333; 13-19, 26-36, 41-53, 55-71, 77-84, 86-108,
114-135, 157-172, 177-183,
187-194, 208-213, 218-226, 110-125 and 156-170 of Seq ID No 334; 5-24, 63-69,
77-85, 94-112, 120-137, 140-
146, 152-159, 166-172, 179-187, 193-199, 206-212, 222-228, 234-240, 244-252,
257-264, 270-289, 298-309, 316-
328, 337-348, 363-375, 1-56 and 340-352 of Seq ID No 335; 18-39, 42-71, 78-
120, 124-144, 152-173, 179-189,
199-209, 213-222, 228-258, 269-304, 329-361, 364-372, 374-389, 396-441 and 313-
327 of Seq ID No 336;19-25,
91-98, 108-120, 156-162, 168-174, 191-204, 211-216, 232-266, 272-278, 286-308,
316-321, 327-333, 344-355,
358-364, 384-391, 395-428, 464-476, 487-495, 497-511, 544-561, 563-573, 575-
582, 588-594,10-25 and 322-338
of Seq ID No 337; 14-26, 32-49, 51-57, 59-72, 80-91, 102-112, 119-125, 147-
162, 164-173, 275-183, 188-223,
217-222, 246-254, 260-276, 282-303, 308-318, 321-328, 333-350, 352-359, 371-
378, 392-401, 407-414, 416-443,
448-463, 471-484, 490-497, 501-514, 519-527, 539-551, 557-570, 578-590, 592-
598, 600-610, 618-629, 633-647,
654-667, 676-689, 702-709, 718-726, 728-737, 741-760, 764-780, 786-795, 808-
826, 836-842, 845-852, 865-874,
881-887, 931-945, 949-957, 968-974, 979-986, 1003-1009,1023-1029 and 90-103 of
Seq ID No 338; 11-16, 37-
56, 60-66, 69-77, 80-88, 93-106, 117-139, 166-171 and 72-90 of Seq ID No 339;
59-84, 123-133, 145-150, 161-
267, 178-289 and 215-128 of Seq ID No 340;15-33, 39-46, 52-64, 74-87, 208-124,
127-244, 150-156, 173-179,
184-194, 201-208, 219-236, 243-269, 272-295, 302-309, 343-349, 356-361, 370-
379, 405-411, 414-423, 430-451,
457-464, 466-475, 477-483, 496-502, 507-522, 541-548, 557-563, 571-577, 579-
585, 590-605, 626-642, 650-662,
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-32-
671-691, 704-710, 751-769, 775-781, 786-791, 794-829, 851-858, 868-878, 884-
904, 913-919, 931-939 and 132-
142 of Seq ID No 341; 33-58, 64-71, 74-80, 83-88, 96-120, 122-139, 146-157,
167-177, 207-213, 220-225, 236-
242, 264-279, 300-305, 326-336, 340-347, 350-360, 97-115 and 199-211 of Seq ID
No 342; 4-26, 43-57, 70-99,
102-117, 121-133, 142-148, 151-168, 170-183, 192-220, 235-249, 258-279 and 30-
41 of Seq ID No 343; 34-42,
48-58, 70-94, 110-130, 154-160, 164-172, 178-183, 195-203, 211-222, 229-250,
256-261, 274-284, 286-292, 312-
323 and 222-233 of Seq ID l~0 344; 4-9, 15-36, 38-45, 49-74, 78-88, 100-112,
136-191, 211-220, 226-233, 239-
246, 254-274, 287-307, 316-322, 342-353, 356-366, 373-378, 384-393, 405-431,
449-457, 459-468, 487-511, 515-
524, 529-541, 544-552, 562-568, 571-576 and 208-280 of Seq ID No 345; 10-27,
31-37, 39-54, 71-108, 124-143
and 2-107 of Seq ID I~~ 346; 16-27, 38-57, 64-70, 90-102, 104-113, 116-137,
160-166 and 1-80 of Seq ID I~lo
347; 13-21, 31-36, 56-67, 127-136, 153-171, 173-180, 184-200, 214-222, 225-
231, 239-263, 267-273 and 135-159
of Seq ID No 348; 12-27, 31-51, 68-74, 77-87, 94-101, 108-114, 117-123, 127-
134, 138-168, 173-196, 201-207,
212-217, 227-237, 247-257, 264-280 and 205-223 of Seq ID No 349; 17-22, 25-54,
70-76, 92-100 and 98-110 of
Seq ID No 350; 7-29, 40-50, 60-67, 87-96, 105-111, 119-164, 172-199, 206-212,
220-227, 237-259, 272-279, 282-
293, 295-309, 313-319, 321-328, 345-363, 376-386 and 159-176 of Seq ID No 351;
4-19, 24-30, 36-43, 50-68,
71-89, 93-106, 141-152, 154-172, 179-297, 199-215, 229-239, 246-252, 255-263,
281-298, 319-325, 329-356, 358-
368, 374-390, 397-409, 420-429, 432-444, 450-456, 459-475, 483-494, 496-502,
520-528, 532-556 and 362-377 of
Seq ID No 352; 18-25, 40-62, 77-85, 91-97, 105-116, 123-133, 139-184, 189-197
and 122-140 of Seq ID No
353; 4-49, 52-58, 62-70, 79-105, 109-133, 142-150, 163-168, 206-214, 220-228,
233-240, 243-254, 274-281, 303-
311, 327-338, 357-373, 378-396, 403-413, 420-436, 441-453, 461-467, 475-481,
484-498, 506-512, 514-521, 523-
529, 562-579, 589-595, 598-603, 615-648, 714-722, 728-742, 749-758, 777-792,
795-807 and 643-658 of Seq ID
No 354; 8-27, 37-48, 51-56, 72-79, 87-106, 120-138, 140-147, 167-176, 187-197,
205-216, 222-229, 234-239, 243-
249, 277-288, 292-315, 334-343, 347-353, 363-391, 398-404, 430-447, 461-467,
478-492, 498-507 and 456-470 of
Seq ID No 355; 5-12, 18-24, 59-69, 80-93, 95-109, 119-125, 130-137, 139-147,
158-163, 168-176, 182-202, 206-
215, 222-239, 241-249, 267-277, 291-298, 311-318, 321-327, 338-344, 348-355,
373-386, 393-406, 411-417, 434-
443, 446-465, 473-484, 514-521, 532-553, 584-594 and 221-237 of Seq ID No 356;
4-14, 27-34, 50-58, 63-72,
79-106, 109-114, 121-142, 146-154, 161-167, 169-175, 178-201, 223-238, 249-
254, 259-264, 278-292, 294-312,
319-330 and 167-191 of Seq ID No 357; 7-28, 36-42, 50-61, 63-80, 122-152, 161-
174, 176-191 and 140-190 of
Seq ID No 358; 20-57, 59-65, 70-78, 86-102, 119-133, 142-161, 163-173, 177-
188, 192-202, 204-220, 222-236,
240-253, 279-319, 326-331, 337-383, 390-399, 406-412, 420-427, 431-438 and 381-
395 of Seq ID No 359; 13-18,
28-34, 37-43, 50-59, 75-81, 83-97,105-121,139-147, 200-206, 209-227, 231-247,
260-271, 318-327, 366-381, 388-
394, 399-406 and 182-201 of Seq ID No 360; 6-29, 37-43, 51-56, 70-77, 82-102,
110-119, 127-143, 178-190,
201-209, 216-243, 261-269, 281-292, 305-313, 327-339, 341-354, 356-373, 391-
397, 423-429, 438-445, 450-478
and 21-314 of Seq ID No 361; 4-12, 15-21, 32-41, 59-76, 80-89, 96-104 and 90-
103 of Seq ID No 362; 9-28,
30-41, 44-54, 69-74, 77-82, 90-97,104-223, 225-135,149-155, 264-173, 277-184,
227-226, 230-235, 238-244, 258-
272, 282-297, 300-305, 309-315, 317-322, 327-336, 348-362, 368-374, 380-387,
400-411, 414-424, 451-458, 460-
466, 483-494, 497-503, 506-511, 521-528, 540-553, 569-587, 598-606, 628-642,
661-681, 688-700, 718-733, 740-
749, 752-764, 769-783, 823-834, 848-854, 862-872, 878-884, 886-898, 915-920,
938-951, 954-961, 963-972, 982-
989, 996-1003, 1010-1016, 1021-1032, 1038-1044, 1047-1057, 1060-1070, 1079-
1088, 1094-1102, 1117-1127,
1129-1135, 1142-2153, 1158-1204, 1212-1229, 1234-1263, 2269-1277, 1308-1313,
1327-1338, 1344-1376, 1400-
1415, 1436-1443, 1448-1458, 1497-1504, 1511-1522, 1544-1566, 3-82 and 509-576
of Seq ID No 363; 8-36, 40-
64, 71-79, 88-94, 102-109, 118-127, 138-148, 151-159, 163-174, 192-198, 200-
206, 220-233, 268-273, 290-301,
304-309, 316-323, 331-349, 378-391, 414-420, 427-437, 455-475, 494-510, 541-
547, 549-555, 616-640, 1-60, 55-
139, 212-308, 386-458 and 458-624 of Seq ID No 364; 16-31, 35-42, 70-77, 91-
101, 120-130, 132-140, 143-153,
185-190, 195-202, 215-222, 228-238, 241-251, 257-264, 268-277, 288-302, 312-
324, 326-333, 341-348, 364-382,
415-429, 438-454, 458-466, 491-499, 501-521 and 273-281 of Seq ID No 365; 8-
14, 32-57, 74-149, 155-177,
179-222, 222-266, 272-296, 304-324, 329-346, 349-359, 368-401, 423-419, 426-
454, 465-478, 493-510 and 466-
490 of Seq ID No 366; 22-28, 33-51, 64-89, 96-119,126-132,138-146,152-159,161-
169,172-179,193-198, 205-
211, 221-231, 235-254, 273-280, 297-303, 312-320, 328-346, 351-373, 378-384,
391-398, 448-454, 460-468, 470-
481, 516-558, 574-593, 597-602, 613-623, 626-646, 649-656, 668-673, 675-683,
696-708, 715-722, 724-739, 745-
751, 759-777, 780-804, 816-822 and 102-113 of Seq ID No 367; 12-28, 41-91, 98-
107, 112-120, 125-131, 151-
193, 215-221, 240-250, 263-280 and 128-138 of Seq ID No 368; 16-24, 32-38, 46-
62, 68-81, 90-105, 127-133,
144-150, 160-166, 178-184, 186-202, 210-219, 232-240, 252-258, 264-273, 293-
324, 337-344, 349-357, 360-369,
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-33-
385-398, 410-416, 419-427, 441-449, 458-476, 508-515, 523-539, 544-549, 562-
569, 571-579, 96-109 and 127-139
of Seq ID No 369;19-25, 28-34, 56-61, 85-97,110-116 and 39-53 of Seq ID No
370; 4-37, 41-50, 62-72, 91-97,
99-109, 114-125, 136-141, 149-158, 160-166, 201-215 and 27-225 of Seq ID No
371; 15-31, 44-51, 96-105, 122-
130, 149-157, 162-168, 178-183, 185-192, 198-204, 206-213, 221-234, 239-245,
248-255, 257-266, 289-335, 349-
357, 415-422, 425-441, 448-454, 462-468 and 463-481 of Seq ID No 372; 5-31, 39-
55, 63-72, 76-99, 106-155,
160-177, 179-199, 207-217, 223-240, 245-255, 261-267, 294-316, 321-343, 354-
378, 382-452, 477-488, 529-536,
555-569, 584-591, 593-612, 620-627, 632-640, 647-654, 671-680, 698-704, 723-
730, 732-750, 769-775, 781-788,
822-852 and 505-525 of Seq ID No 373; 3-18 of Seq ID No 374; 4-14 and 12-24 of
Seq ID No 375; 4-11, 22-
30 and 12-25 of Seq ID INTO 376; 5-12 and 4-18 of Seq ID T'~To 377; 4-28 and 7-
14 of Seq ID 1~~10 378; 6-16 and
8-16 of Seq ID No 379; 4-15,18-33 and 24-36 of Seq ID No 380; 4-10,16-21 and
20-31 of Seq ID No 381; 6-
19 of Seq ID No 382; 11-18 and 3-10 of Seq ID No 383;13-24 and 3-15 of Seq ID
No 384;15-27 and 7-16 of
Seq ID No 385; 11-16 and 1-15 of Seq ID No 386; 4-16 and 9-21 of Seq ID No
387; 4-24, 40-48, 54-67 and
22-39 of Seq ID No 388; 6-30, 34-55, 62-68, 78-106 and 68-74 of Seq ID l~0
389; 3-14 of Seq ID No 390; 9-19
and 6-21 of Seq ID No 391; 4-17 and 1-9 of Seq ID No 392; 5-30 and 1-8 of Seq
ID No 393; 4-16, 23-46, 51-
56 and 45-55 of Seq ID No 394; 7-16 of Seq ID No 395; 2-14 of Seq ID No 396; 4-
36, 43-65 and 50-62 of
Seq ID No 397; 10-30 and 14-21 of Seq ID No 398; 9-17 and 1-10 of Seq ID No
399; 4-12 and 3-16 of Seq
ID No 400; 4-15 and 5-23 of Seq ID No 401; 10-21 of Seq ID No 402; 6-16 of Seq
ID No 403; 4-29, 31-38
and 2-14 of Seq ID No 404; 4-35 and 33-42 of Seq ID No 405; 2-17 of Seq ID No
406; 9-18, 30-35 and 15-33
of Seq ID No 407; 4-9 and 6-12 of Seq ID No 408; 3-17 of Seq ID No 409;12-21,
37-44, 52-61, 72-80 and 38-
48 of Seq ID No 410; 4-10, 29-44, 54-61, 69-78 and 13-27 of Seq ID No 411; 13-
23, 36-53 and 2-15 of Seq ID
No 412; 4-25, 28-46, 56-72, 81-99, 120-132, 134-142, 154-160 and 129-141 of
Seq ID No 413; 4-15, 24-33, 35-
41, 64-86 and 21-33 of Seq ID No 414; 9-15 and 4-13 of Seq ID No 415; 4-11,13-
19, 34-48 and 15-32 of Seq
ID No 416; 4-21 and 11-31 of Seq ID No 417; 23-57 and 38-50 of Seq ID No 418;
4-32 and 3-13 of Seq ID
No 419; 4-10,13-25, 32-42, 56-68, 72-84 and 26-38 of Seq ID No 420; 4-20, 31-
48, 52-58, 65-71, 80-93, 99-108,
114-123 and 37-49 of Seq ID No 421; 6-12, 14-20 and 3-25 of Seq ID No 422; 14-
25, 27-38 and 5-14 of Seq
ID No 423; 4-41, 57-105, 109-118, 123-136, 144-152 and 86-99 of Seq ID No 424;
6-19 of Seq ID No 425; 2-
19 of Seq ID No 426; 14-47 and 1-14 of Seq ID No 427; 4-21, 29-44 and 2-18 of
Seq ID No 428; 23-29 and
10-28 of Seq ID No 429; 6-16, 22-36 and 11-22 of Seq ID No 430; 4-19, 30-44
and 18-27 of Seq ID No 431;
5-15, 37-45, 58-65 and 38-47 of Seq ID No 432; 4-15, 23-34 and 4-15 of Seq ID
No 433; 30-36, 44-54, 79-85,
101-114, 138-152, 154-164, 170-175, 179-200, 213-220, 223-240, 243-255, 258-
264, 268-284 and 10-28 of Seq
ID No 434; the peptides comprising amino acid sequences of column "Identical
region" of the Table
1B, especially peptides comprising amino acid 210-226 and 738-753 of Seq ID No
449; 326-344, 326-348,
338-354, 371-392, 801-809 and 877-901 of Seq ID No 450; 893-906 of Seq ID No
451; 51-69 of Seq ID No
452;110-125 of Seq ID No 453; 291-305 of Seq ID No 454; 210-226 and 738-753 of
Seq ID No 455; 326-344,
326-348, 338-354, 371-392, 801-809 and 877-901 of Seq ID No 456; 893-906 of
Seq ID No 457; 51-69 of Seq
ID No 458;110-125 of Seq ID No 459; 291-305 of Seq ID No 460; 32-44 of Seq ID
No 461; 399-410 of Seq
ID No 462; the serum reactive epitopes as specified in the column of "aa from"
to "aa to" of Table 2,
especially peptides comprising amino acid 120-143, 138-161 and 156-179 of Seq
ID No 218; 110-129 and
168-184 of Seq ID No 219; 74-90 of Seq ID No 222; 759-773 of Seq ID No 223;
237-260 of Seq ID No 224;
265-284 of Seq ID No 225; 65-74 of Seq ID No 226; 41-50 of Seq ID No 227;163-
174 of Seq ID No 229; 26-
37 of Seq ID No 230; 174-189 of Seq ID No 232; 240-256 of Seq ID No 234; 285-
297 of Seq ID No 236; 238-
247 of Seq ID No 238; 491-519 of Seq ID No 239; 114-140 of Seq ID No 243; 267-
284 of Seq ID No 250;
439-453 of Seq ID No 252; 162-178 of Seq ID No 253; 347-364 of Seq ID No 254;
699-715 of Seq ID No
255; 60-71 of Seq ID No 256; 244-257 of Seq ID No 257; 44-63 and 57-76 of Seq
ID No 258; 185-196 of Seq
ID No 260; 119-129 of Seq ID No 263; 182-195 of Seq ID No 266; 32-44 and 424-
442 of Seq ID No 267;
247-256 of Seq ID No 268; 678-694, 785-805, 55-77 and 72-94 of Seq ID No 269;
210-226 of Seq ID No 281;
37-59 of Seq ID No 289; 13-29 of Seq ID No 296;136-159 of Seq ID No 348; 205-
222 of Seq ID No 349; 99-
110 of Seq ID No 350; 160-176 of Seq ID No 351; 457-470 of Seq ID No 355; 221-
237 of Seq ID No 356;
167-190 of Seq ID No 357; 96-120 of Seq ID No 361; 399-417, 503-519 and 544-
563 of Seq ID No 364; 46-
68, 159-183 and 184-198 of Seq ID No 371; 463-481 of Seq ID No 372; the
immunogenic epitopes as
specified in the column of "aa from" to "aa to" of Table 4; especially
peptides comprising amino acid
110-129 and 168-184 of Seq ID No 219; 877-901, 333-354, 326-344 and 801-809 of
Seq ID No 277; 1-54 of
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-34-
Seq ID No 347; 544-563, 31-51, 107-119, 399-417 and 503-519 of Seq ID No
364;120-198 of Seq ID No 218;
20-35 of Seq ID No 219; 118-201 of Seq ID No 221; 48-132 of Seq ID No 242; 118-
136 of Seq ID No 249;
162-178 of Seq ID No 253; 347-364 of Seq ID No 254; 699-715 of Seq ID No 255;
50-76 of Seq ID No 258;
785-819 and 44-128 of Seq ID No 269; 90-128 of Seq ID No 274; 314-384 of Seq
ID No 289; 327-349 of Seq
ID No 293; 242-314, 405-478 and 23-100 of Seq ID No 304; 129-210 of Seq ID No
305; 162-188 of Seq ID
l~~To 307; 750-772 of Seq ID l~To 310;1-56 of Seq ID I~o 335; 322-337 of Seq
ID I~lo 337; 72-90 of Seq ID l~To
339; 374-395 of Seq ID l~0 345; 136-159 of Seq ID l~To 348;141-164 of Seq ID
l~~To 358; 96-157 of Seq ID h~To
361; 1-82 of Seq ID No 363; 489-556 of Seq ID No 364; 159-183 and 49-133 of
Seq ID No 371; The
peptides comprising amino acid sequences of column "predicted immunogenic aa"
and "location of
identified immunogenic region (aa)" of Table 5, especially peptides comprising
amino acid 4-26, 35-41,
53-61, 73-84, 103-108, 114-120, 140-146, 156-162, 192-208, 214-219, 227-233,
239-252, 260-268, 284-297, 1-48
and 113-133 of Seq ID No 475; 4-27, 38-44, 50-56, 59-64, 72-79, 83-89, 92-
97,108-116,123-148, 152-167, 183-
196, 200-220, 232-244, 255-261, 265-274, 282-302, 309-317, 1-79 and 231-302 of
Seq ID I~To 476; 6-28, 66-72,
85-105, 115-121, 144-151, 160-170, 176-185, 223-230, 252-288, 296-310, 319-
333, 367-374, 458-464, 471-480,
483-488, 520-528, 530-549, 559-564, 593-601, 606-616, 636-643, 655-662, 676-
682, 684-699, 719-726, 735-750,
757-764, 777-785, 799-810, 812-843, 846-853, 868-873, 880-889, 891-899, 909-
929, 934-940, 963-969, 998-1004,
1007-1014, 1016-1022, 1030-1046, 1-80 and 808-821 of Seq ID No 477; 7-24, 35-
41, 75-81, 91-114, 122-132,
137-144, 148-156, 183-192, 194-200, 212-228, 233-238, 251-258, 275-295, 326-
332, 337-346, 1-79 and 305-321
of Seq ID No 478; 31-38, 42-52, 66-72, 86-92, 98-104, 115-122, 127-146, 154-
164, 169-187, 198-212, 225-237,
255-269, 13-92 and 135-142 of Seq ID No 479; 4-36, 39-49, 63-69, 71-77, 81-88,
123-131, 133-139, 160-169,
174-180, 188-194, 210-217, 273-278, 289-300, 317-334, 336-341, 383-401, 425-
438, 1-68, 212-270 and 402-446
of Seq ID No 480; 21-29, 31-42, 49-63, 72-79, 81-93, 112-132, 159-165, 188-
195, 197-232, 262-267, 279-286,
294-301, 318-326, 348-366, 381-405, 409-426, 436-465, 471-480, 484-492, 497-
505, 521-544, 554-561, 567-577,
581-589, 601-609, 611-622, 636-651, 653-667, 669-685, 700-708, 716-722, 729-
744, 749-766, 780-786, 789-811,
814-864, 1-57 and 84-106 of Seq ID No 481; 6-24, 35-48, 57-63, 72-78, 87-92,
113-119, 123-137, 147-153, 173-
181, 212-233 and 1-124 of Seq ID No 482; 13-34, 62-69, 78-83, 86-91, 98-104,
107-115, 146-159, 179-188, 195-
205, 209-221, 226-233, 239-253, 276-282, 284-294, 297-308, 331-354, 375-382,
388-399, 421-433, 449-458, 464-
469, 472-491, 508-513, 525-531, 534-550, 575-593, 601-618, 629-635, 654-661,
666-680, 706-721, 723-740, 771-
805, 810-830, 845-851 and 1-84 of Seq ID No 483; 4-32, 45-64, 73-83, 86-92,
100-111, 125-147, 157-163, 170-
175, 177-188, 226-232, 245-252, 258-274, 320-335, 348-359 and 1-71 of Seq ID
No 484; 13-40, 43-71, 76-83,
87-101, 109-119, 125-156, 162-175, 182-219, 226-232, 240-262, 270-287, 306-
318, 326-342, 344-408, 414-444,
449-456 and 1-51 of Seq ID No 485; 4-16, 18-34, 45-54, 99-108, 134-140, 203-
212, 241-257, 266-274, 279-291,
308-315, 330-336, 355-370, 374-382, 402-410, 428-455, 466-472, 474-480, 531-
554, 560-566, 572-580, 597-618,
632-660, 664-674, 676-685, 691-705, 708-735, 750-768, 1-87 and 342-480 of Seq
ID No 486; The serum
reactive epitopes as specified in the column of "aa from" to "aa to" of Table
6, especially peptides
comprising amino acid 115-132 and 1-26 of Seq ID No 475; 33-55 of Seq ID No
476; 1-25 of Seq ID No
478; 37-61 of Seq ID No 479;1-24 of Seq ID No 480;1-23 of Seq ID No 481; 46-60
of Seq ID No 482;1-28,
23-50 and 45-71 of Seq ID No 483;1-22 and 17-38 of Seq ID No 484;1-22 and 17-
38 of Seq ID No 485; 1-
27, 22-47 and 422-447 of Seq ID No 486; The immunogenic epitopes as specified
in the column of "aa
frorn'° to "aa to" of Table 7, especially peptides comprising amino
acid 115-132 and 1-47 of Seq ID No
475; 1-55 of Seq ID No 476; 22-85 of Seq ID No 477; 307-320 and 1-44 of Seq ID
No 478;15-76 and 40-92
of Seq ID No 479;1-59, 213-269 and 403-445 of Seq ID No 480;1-56 and 85-105 of
Seq ID No 481; 37-121
of Seq ID No 482; 1-71 of Seq ID No 483; 1-38 of Seq ID No 484;1-38 of Seq ID
No 485; 1-47 of Seq ID
No 486 and fragments comprising at least 6, preferably more than 8, especially
more than 10 as and
preferably not more than 70, 50, 40, 20, 15 or 11 as of said sequences. All
these fragments individually
and each independently form a preferred selected aspeet of the present
invention.
All linear hyperimmune serum reactive fragments of a particular antigen may be
identified by analysing
the entire sequence of the protein antigen by a set of peptides overlapping by
1 amino acid with a length
of at least 10 amino acids. Subsequently, non-linear epitopes can be
identified by analysis of the protein
antigen with hyperimmune sera using the expressed full-length protein or
domain polypeptides thereof.
Assuming that a distinct domain of a protein is sufficient to form the 3D
structure independent from the
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-35-
native protein, the analysis of the respective recombinant or synthetically
produced domain polypeptide
with hyperimmune serum would allow the identification of conformational
epitopes within the
individual domains of mufti-domain proteins. For those antigens where a domain
possesses linear as well
as conformational epitopes, competition experiments with peptides
corresponding to the linear epitopes
may be used to confirm the presence of conformational epitopes.
It will be appreciated that the invention also relates to, among others,
nucleic acid molecules encoding the
aforementioned fragments, nucleic acid molecules that hybridise to nucleic
acid molecules encoding the
fragments, particularly those that hybridise under stringent conditions, and
nucleic acid molecules, such
as PCR primers, for amplifying nucleic acid molecules that encode the
fragments. In these regards,
preferred nucleic acid molecules are those that correspond to the preferred
fragments, as discussed
above.
The present invention also relates to vectors, which comprise a nucleic acid
molecule or nucleic acid
molecules of the present invention, host cells which are genetically
engineered with vectors of the
invention and the production of hyperimmune serum reactive antigens and
fragments thereof by
recombinant techniques.
A great variety of expression vectors can be used to express a hyperimmune
serum reactive antigen or
fragment thereof according to the present invention. Generally, any vector
suitable to maintain,
propagate or express nucleic acids to express a polypeptide in a host may be
used for expression in this
regard. In accordance with this aspect of the invention the vector may be, for
example, a plasmid vector,
a single or double-stranded phage vector, a single or double-stranded RNA or
DNA viral vector. Starting
plasmids disclosed herein are either commercially available, publicly
available, or can be constructed
from available plasmids by routine application of well-known, published
procedures. Preferred among
vectors, in certain respects, are those for expression of nucleic acid
molecules and hyperimmune serum
reactive antigens or fragments thereof of the present invention. Nucleic acid
constructs in host cells can
be used in a conventional manner to produce the gene product encoded by the
recombinant sequence.
Alternatively, the hyperimmune serum reactive antigens and fragments thereof
of the invention can be
synthetically produced by conventional peptide synthesizers. Mature proteins
can be expressed in
mammalian cells, yeast, bacteria, or other cells under the control of
appropriate promoters. Cell-free
translation systems can also be employed to produce such proteins using RNAs
derived from the DNA
construct of the present invention.
Host cells can be genetically engineered to incorporate nucleic acid molecules
and express nucleic acid
molecules of the present invention. Representative examples of appropriate
hosts include bacterial cells,
such as streptococci, staphylococci, E. coli, Streptowyces and Bacillus
subtillis cells; fungal cells, such as
yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and
Spodoptera Sf9 cells; animal cells
such as CHO, COS, Hela, C127, 3T3, BHIC, 293 and Bowes melanoma cells; and
plant cells.
The invention also provides a process for producing a S. agalactiae
hyperimmune serum reactive antigen
arid a fragment thereof comprising expressing from the host cell a hyperimmune
serum reactive antigen
or fragment thereof encoded by the nucleic acid molecules provided by the
present invention. The
invention further provides a process for producing a cell, which expresses a
S. agalactiae hyperimmune
serum reactive antigen or a fragment thereof comprising transforming or
transfecting a suitable host cell
with the vector according to the present invention such that the transformed
or transfected cell expresses
the polypeptide encoded by the nucleic acid contained in the vector.
The polypeptide may be expressed in a modified form, such as a fusion protein,
and may include not
only secretion signals but also additional heterologous functional regions.
Thus, for instance, a region of
additional amino acids, particularly charged amino acids, may be added to the
N- or C-terminus of the
polypeptide to improve stability and persistence in .the host cell, during
purification or during
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-36-
subsequent handling and storage. Also, regions may be added to the polypeptide
to facilitate
purification. Such regions may be removed prior to final preparation of the
polypeptide. The addition of
peptide moieties to polypeptides to engender secretion or excretion, to
improve stability ox to facilitate
purification, among others, are familiar and routine techniques in the art. A
preferred fusion protein
comprises a heterologous region from immunoglobulin that is useful to
solubilize or purify polypeptides.
For example, EP-A-O 464 533 (Canadian counterpart 2045369) discloses fusion
proteins comprising
various portions of constant region of immunoglobin molecules together with
another protein or part
thereof. In drug discovery, for example, proteins have been fused with
antibody Fc portions for the
purpose of high-throughout screening assays to identify antagonists. See for
example, {Bennett, T~. et al.,
1995} and {Johanson, K. et al., 1995}.
The S. agc~lactzae hyperimmune serum reactive antigen or a fragment thereof
can be recovered and
purified from recombinant cell cultures by well-known methods including
ammonium sulfate or ethanol
precipitation, acid extraction, anion or cation exchange chromatography,
phosphocellulose
chromatography, hydrophobic interaction chromatography, hydroxylapatite
chromatography and lectin
chromatography.
The hyperimmune serum reactive antigens and fragments thereof according to the
present invention can
be produced by chemical synthesis as well as by biotechnological means. The
latter comprise the
transfection or transformation of a host cell with a vector containing a
nucleic acid according to the
present invention and the cultivation of the transfected or transformed host
cell under conditions, which
are known to the ones skilled in the art. The production method may also
comprise a purification step in
order to purify or isolate the polypeptide to be manufactured. In a preferred
embodiment the vector is a
vector according to the present invention.
The hyperimmune serum reactive antigens and fragments thereof according to the
present invention may
be used for the detection of the organism or organisms in a sample containing
these organisms or
polypeptides derived thereof. Preferably such detection is for diagnosis, more
preferable for the diagnosis
of a disease, most preferably for the diagnosis of a diseases related or
linked to the presence or abundance
of Gram-positive bacteria, especially bacteria selected from the group
comprising streptococci,
staphylococci and lactococci. More preferably, the microorganisms are selected
from the group
comprising Streptococcus pneutnoraiae, Streptococcus pyogenes and
Streptococcus ntutans, especially the
microorganism is Streptococcus pyogenes.
'The pxesent invention also relates to diagnostic assays such as quantitative
and diagnostic assays for
detecting levels of the hyperimmune serum reactive antigens and fragments
thereof of the present
W vention in cells and tissues, including determination of normal and abnormal
levels. Thus, for instance,
a diagnostic assay in accordance with the invention for detecting over-
expression of the polypeptide
compared to normal control tissue samples may be used to detect the presence
of an infection, for
example, and to identify the infecting organism. Assay techniques that can be
used to determine levels of
a polypeptide, in a sample derived from a host are well known to those of
skill in the art. Such assay
methods include radioimmunoassays, competitive-binding assays, Western Blot
analysis and ELISA
assays. Among these, ELISAs frequently are preferred. An ELISA assay initially
comprises preparing an
antibody specific to the polypeptide, preferably a monoclonal antibody. In
addition, a repoxter antibody
generally is prepared which binds to the monoclonal antibody. The reporter
antibody is attached to a
detectable reagent such as radioactive, fluorescent or enzymatic reagent, such
as horseradish peroxidase
enzyme.
The hyperimmune serum reactive antigens and fragments thereof according to the
present invention may
also be used for the purpose of or in connection with an array. More
particularly, at least one of the
hyperimmune serum reactive antigens and fragments thereof according to the
present invention may be
immobilized on a support. Said support typically comprises a variety of
hyperimmune serum reactive
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-37-
antigens and fragments thereof whereby the variety may be created by using one
or several of the
hyperimmune serum reactive antigens and fragments thereof according to the
present invention and/or
hyperimmune serum reactive antigens and fragments thereof being different. The
characterizing feature
of such array as well as of any array in general is the fact that at a
distinct or predefined region or
position on said support or a surface thereof, a distinct polypeptide is
immobilized. >iecause of this any
activity at a distinct position or region of an array can be correlated with a
specific polypeptide. The
number of different hyperimmune serum reactive antigens and fragments thereof
immobilized on a
support may range from as little as 10 to several 1000 different hyperimmune
serum reactive antigens
and fragments thereof. The density of hyperimmune serum reactive antigens and
fragments thereof per
cm2 is in a preferred embodiment as little as 10 peptides/polypeptides per cm2
to at least 400 different
peptides/polypeptides per cma and more particularly at least 1000 different
hyperimmune serum reactive
antigens and fragments thereof per cmz.
The manufacture of such arrays is known to the one skilled in the art and, for
example, described in US
patent 5,744,309. The array preferably comprises a planar, porous or non-
porous solid support having at
least a first surface. The hyperimmune serum reactive antigens and fragments
thereof as disclosed herein,
are immobilized on said surface. Preferred support materials are, among
others, glass or cellulose. It is
also within the present invention that the array is used for any of the
diagnostic applications described
herein. Apart from the hyperimmune serum reactive antigens and fragments
thereof according to the
present invention also the nucleic acid molecules according to the present
invention may be used for the
generation of an array as described above. This applies as well to an array
made of antibodies, preferably
monoclonal antibodies as, among others, described herein.
In a further aspect the present invention relates to an antibody directed to
any of the hyperimmune
serum reactive antigens and fragments thereof, derivatives or fragments
thereof according to the present
invention. The present invention includes, for example, monoclonal and
polyclonal antibodies, chimeric,
single chain, and humanized antibodies, as well as Fab fragments, or the
product of a Fab expression
library. It is within the present invention that the antibody may be chimeric,
i. e. that different parts
thereof stem from different species or at least the respective sequences are
taken from different species.
Antibodies generated against the hyperimmune serum reactive antigens and
fragments thereof
corresponding to a sequence of the present invention can be obtained by direct
injection of the
hyperimmune serum reactive antigens and fragments thereof into an animal or by
administering the
hyperimmune serum reactive antigens and fragments thereof to an animal,
preferably a non-human. The
antibody so obtained will then bind the hyperimmune serum reactive antigens
and fragments thereof
itself. In this manner, even a sequence encoding only a fragment of a
hyperimmune serum reactive
antigen and fragments thereof can be used to generate antibodies binding the
whole native hyperimmune
serum reactive antigen and fragments thereof. Such antibodies can then be used
to isolate the
hyperimmune serum reactive antigens and fragments thereof from tissue
expressing those hyperimmune
serum reactive antigens and fragments thereof.
For preparation of monoclonal antibodies, any technique known in the art,
which provides antibodies
produced by continuous cell line cultures can be used (as described originally
in {Kohler, G. et al., 1975}.
Techniques described for the production of single chain antibodies (U.S.
Patent No. 4,946,x'78) can be
adapted to produce single chain antibodies to immunogenic hyperimmune serum
reactive antigens and
fragments thereof according to this invention. Also, transgenic mice, or other
organisms such as other
mammals, may be used to express humanized antibodies to immunogenic
hyperimmune serum reactive
antigens and fragments thereof according to this invention.
Alternatively, phage display technology or ribosomal display could be utilized
to select antibody genes
with binding activities towards the hyperimmune serum reactive antigens and
fragments thereof either
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-3~-
from repertoires of PCR amplified v-genes of lymphocytes from humans screened
for possessing
respective target antigens or from naive libraries {McCafferty, J. et al.,
1990}; {Marks, J. et al., 1992}. The
affinity of these antibodies can also be improved by chain shuffling
{Clackson, T. et al.,1991}.
If two antigen binding domains are present, each domain may be directed
against a different epitope -
termed °bispecific' antibodies.
The above-described antibodies may be employed to isolate or to identify
clones expressing the
hyperirnmune serum reactive antigens and fragments thereof or purify the
hyperimmune serum reactive
antigens and fragments thereof of the present invention by attachment of the
antibody to a solid support
for isolation and/or purification by affinity chromatography.
Thus, among others, antibodies against the hyperimmune serum reactive antigens
and fragments thereof
of the present invention may be employed to inhibit and/or treat infections,
particularly bacterial
infections and especially infections arising from S. agalactiae.
Hyperimmune serum reactive antigens and fragments thereof include
antigenically, epitopically or
immunologically equivalent derivatives, which form a particular aspect of this
invention. The term
"antigenically equivalent derivative" as used herein encompasses a hyperimmune
serum reactive antigen
and fragments thereof or its equivalent which will be specifically recognized
by certain antibodies which,
when raised to the protein or hyperimmune serum reactive antigen and fragments
thereof according to
the present invention, interfere with the interaction between pathogen and
mammalian host. The term
"immunologically equivalent derivative°° as used herein
encompasses a peptide or its equivalent which
when used in a suitable formulation to raise antibodies in a vertebrate, the
antibodies act to interfere with
the interaction between pathogen and mammalian host.
The hyperimmune serum reactive antigens and fragments thereof, such as an
antigenically or
immunologically equivalent derivative or a fusion protein thereof can be used
as an antigen to immunize
a mouse or other animal such as a rat or chicken. The fusion protein may
provide stability to the
hyperimmune serum reactive antigens and fragments thereof. The antigen may be
associated, for
example by conjugation, with an immunogenic carrier protein, for example
bovine serum albumin (BSA)
or keyhole limpet haemocyanin (KLH). Alternatively, an antigenic peptide
comprising multiple copies of
the protein or hyperimmune serum reactive antigen and fragments thereof, or an
antigenically or
immunologically equivalent hyperimmune serum reactive antigen and fragments
thereof, may be
sufficiently antigenic to improve immunogenicity so as to obviate the use of a
carrier.
Preferably the antibody or derivative thereof is modified to make it less
immunogenic in the individual.
For example, if the individual is human the antibody may most preferably be
"humanized°°, wherein the
complimentarity determining regions) of the hybridoma-derived antibody has
been transplanted into a
human monoclonal antibody, for example as described in {Jones, P. et al.,
1986} or {Tempest, P. et al.,
1991}.
The use of a polynucleotide of the invention in genetic immunization will
preferably employ a suitable
delivery method such as direct injection of plasmid DNA into muscle, delivery
of DNA complexed with
specific protein carriers, coprecipitation of DNA with calcium phosphate,
encapsulation of DNA in
various forms of liposomes, particle bombardment {Tang, D. et al., 1992},
{Eisenbraun, M. et al., 1993} and
ira vivo infection using cloned retroviral vectors {Seeger, C. et al., 1984}.
In a further aspect the present invention relates to a peptide binding to any
of the hyperimmune serum
reactive antigens and fragments thereof according to the present invention,
and a method for the
manufacture of such peptides whereby the method is characterized by the use of
the hyperimmune
serum reactive antigens and fragments thereof according to the present
invention and the basic steps are
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-39-
known to the one skilled in the art.
Such peptides may be generated by using methods according to the state of the
art such as phage display
or ribos~me display. In case of phage display, basically a library of peptides
is generated, in form of
phages, and this kind of library is contacted with the target molecule, in the
present case a hyperimmune
serum reactive antigen and fragments thereof according to the present
invention. Those peptides binding
to the target molecule are subsequently removed, preferably as a complex with
the target molecule, from
the respective reaction. It is known to the one skilled in the art that the
binding characteristics, at least to a
certain extent, depend on the particularly realized experimental set-up such
as the salt concentration and
the like. After separating those peptides binding to the target molecule with
a higher affinity or a bigger
force, from the non-binding members of the library, and optionally also after
removal of the target
molecule from the complex of target molecule and peptide, the respective
peptides) may subsequently
be characterised. Prior to the characterisation optionally an amplification
step is realized such as, e. g. by
propagating the peptide encoding phages. The characterisation preferably
comprises the sequencing of
the target binding peptides. Basically, the peptides are not limited in their
lengths, however, preferably
peptides having a lengths from about 8 to 20 amino acids are preferably
obtained in the respective
methods. The size of the libraries may be about 10z to 101$, preferably 108 to
1015 different peptides,
however, is not limited thereto.
A particular form of target binding hyperimmune serum reactive antigens and
fragments thereof are the
so-called "anticalines°' which are, among others, described in German
patent application DE 197 42 706.
In a further aspect the present invention relates to functional nucleic acids
interacting with any of the
hyperimmune serum reactive antigens and fragments thereof according to the
present invention, and a
method for the manufacture of such functional nucleic acids whereby the method
is characterized by the
use of the hyperimmune serum reactive antigens and fragments thereof according
to the present
invention and the basic steps are known to the one skilled in the art. The
functional nucleic acids are
preferably aptamers and spiegelmers.
Aptamers are D-nucleic acids, which are either single stranded or double
stranded and which specifically
interact with a target molecule. The manufacture or selection of aptamers is,
e.g. described in European
patent EP 0 533 838. Basically the following steps are realized. First, a
mixture of nucleic acids, i. e.
potential aptamers, is provided whereby each nucleic acid typically comprises
a segment of several,
preferably at least eight subsequent randomised nucleotides. This mixture is
subsequently contacted with
the target molecule whereby the nucleic acids) bind to the target molecule,
such as based on an increased
affinity towards the target or with a bigger force thereto, compared to the
candidate mixture. The binding
nucleic acids) are/is subsequently separated from the remainder of the
mixture. Optionally, the thus
obtained nucleic acids) is amplified using, e.g. polymerase chain reaction.
These steps may be repeated
several times giving at the end a mixture having an increased ratio of nucleic
acids specifically binding to
the target from which the final binding nucleic acid is then optionally
selected. These specifically binding
nucleic acids) are referred to as aptamers. It is obvious that at any stage of
the method for the generation
or identification of the aptamers samples of the mixture of individual nucleic
acids may be taken to
determine the sequence thereof using standard techniques. It is within the
present invention that the
aptamers may be stabilized such as, e. g., by introducing defined chemical
groups which are known to
the one skilled in the art of generating aptamers. Such modification may for
example reside in the
introduction of an amino group at the 2'-position of the sugar moiety of the
nucleotides. Aptamers are
currently used as therapeutical agents. However, it is also within the present
invention that the thus
selected or generated aptamers may be used for target validation and/or as
lead substance for the
development of medicaments, preferably of medicaments based on small
molecules. This is actually done
by a competition assay whereby the specific interaction between the target
molecule and the aptamer is
inhibited by a candidate drug whereby upon replacement of the aptamer from the
complex of target and
aptamer it may be assumed that the respective drug candidate allows a specific
inhibition of the
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-40-
interaction between target and aptamer, and if the interaction is specific,
said candidate drug will, at least
in principle, be suitable to block the target and thus decrease its biological
availability or activity in a
respective system comprising such target. The thus obtained small molecule may
then be subject to
further derivatisation and modification to optimise its physical, chemical,
biological and/or medical
characteristics such as toxicity, specificity, biodegradability and
bioavailability.
Spiegelmers and their generation or manufacture is based on a similar
principle. The manufacture of
spiegelmers is described in international patent application WO 98/08856.
Spiegelmers are L-nucleic
acids, which means that they are composed of L-nucleotides rather than D-
nucleotides as aptamers are.
Spiegelmers are characterized by the fact that they have a very high stability
in biological systems and,
comparable to aptamers, specifically interact with the target molecule against
which they are directed. In
the process of generating spiegelmers, a heterogeonous population of D-nucleic
acids is created and this
population is contacted with the optical antipode of the target molecule, in
the present case for example
with the D-enantiomer of the naturally occurring L-enantiomer of the
hyperimmune serum reactive
antigens and fragments thereof according to the present invention.
Subsequently, those D-nucleic acids
are separated which do not interact with the optical antipode of the target
molecule. But those D-nucleic
acids interacting with the optical antipode of the target molecule are
separated, optionally identified
and/or sequenced and subsequently the corresponding L-nucleic acids are
synthesized based on the
nucleic acid sequence information obtained from the D-nucleic acids. These L-
nucleic acids which are
identical in terms of sequence with the aforementioned D-nucleic acids
interacting with the optical
antipode of the target molecule, will specifically interact with the naturally
occurring target molecule
rather than with the optical antipode thereof. Similar to the method for the
generation of aptamers it is
also possible to repeat the various steps several times and thus to enrich
those nucleic acids specifically
interacting with the optical antipode of the target molecule.
In a further aspect the present invention relates to functional nucleic acids
interacting with any of the
nucleic acid molecules according to the present invention, and a method for
the manufacture of such
functional nucleic acids whereby the method is characterized by the use of the
nucleic acid molecules and
their respective sequences according to the present invention and the basic
steps are known to the one
skilled in the art. The functional nucleic acids are preferably ribozymes,
antisense oligonucleotides and
siRNA.
Ribozymes are catalytically active nucleic acids, which preferably consist of
RNA, which basically
comprises two moieties. The first moiety shows a catalytic activity whereas
the second moiety is
responsible for the specific interaction with the target nucleic acid, in the
present case the nucleic acid
coding for the hyperimmune serum reactive antigens and fragments thereof
according to the present
invention. Upon interaction between the target nucleic acid and the second
moiety of the ribozyme,
typically by hybridisation and Watson-Crick base pairing of essentially
complementary stretches of bases
on the two hybridising strands, the catalytically active moiety may become
active which means that it
catalyses, either intramolecularly or intermolecularly, the target nucleic
acid in case the catalytic activity
of the ribozyme is a phosphodiesterase activity. Subsequently, there may be a
further degradation of the
target nucleic acid, which in the end results in the degradation of the target
nucleic acid as well as the
protein derived from the said target nucleic acid. Ribozymes, their use and
design principles are known
to the one skilled in the art, and, for example described in {Doherty, E. et
al., 2001} and {Lewin, A. et al.,
2001}.
The activity and design of antisense oligonucleotides for the manufacture of a
medicament and as a
diagnostic agent, respectively, is based on a similar mode of action.
Basically, antisense oligonucleotides
hybridise based on base complementarity, with a target RNA, preferably with a
mRNA, thereby
activating RNase H. RNase H is activated by both phosphodiester and
phosphorothioate-coupled DNA.
Phosphodiester-coupled DNA, however, is rapidly degraded by cellular nucleases
with the exception of
phosphorothioate-coupled DNA. These resistant, non-naturally occurring DNA
derivatives do not inhibit
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-41-
RNase H upon hybridisation with RNA. In other words, antisense polynucleotides
are only effective as
DNA RNA hybride complexes. Examples for this kind of antisense
oligonucleotides are described,
among others, in US-patent US 5,849,902 and US 5,989,912. In other words,
based on the nucleic acid
sequence of the target molecule which in the present case are the nucleic acid
molecules for the
hyperimmune serum reactive antigens and fragments thereof according to the
present invention, either
from the target protein from which a respective nucleic acid sequence may in
principle be deduced, or by
knowing the nucleic acid sequence as such, particularly the mRNA, suitable
antisense oligonucleotides
may be designed base on the principle of base complementarity.
Particularly preferred are antisense-oligonucleotides, which have a short
stretch of phosphorothioate
DNA (3 to 9 bases). A minimum of 3 DNA bases is required for activation of
bacterial RNase H and a
minimum of 5 bases is required for mammalian RNase H activation. In these
chimeric oligonucleotides
there is a central region that forms a substrate for RNase H that is flanked
by hybridising °°arms"
comprised of modified nucleotides that do not form substrates for RNase H. The
hybridising arms of the
chimeric oligonucleotides may be modified such as by 2'-O-methyl or 2'-fluoro.
Alternative approaches
used methylphosphonate or phosphoramidate linkages in said arms. Further
embodiments of the
antisense oligonucleotide useful in the practice of the present invention are
P-methoxyoligonucleotides,
partial P-methoxyoligodeoxyribonucleotides or P-methoxyoligonucleotides.
Of particular relevance and usefulness for the present invention are those
antisense oligonucleotides as
more particularly described in the above two mentioned US patents. These
oligonucleotides contain no
naturally occurring 5'~3°-linked nucleotides. Rather the
oligonucleotides have two types of nucleotides:
2'-deoxyphosphorothioate, which activate RNase H, and 2'-modified nucleotides,
which do not. The
linkages between the 2'-modified nucleotides can be phosphodiesters,
phosphorothioate or P-
ethoxyphosphodiester. Activation of RNase H is accomplished by a contiguous
RNase H-activating
region, which contains between 3 and 5 2'-deoxyphosphorothioate nucleotides to
activate bacterial RNase
H and between 5 and 10 2'- deoxyphosphorothioate nucleotides to activate
eucaryotic and, particularly,
mammalian RNase H. Protection from degradation is accomplished by making the
5' and 3' terminal
bases highly nuclease resistant and, optionally, by placing a 3' terminal
blocking group.
More particularly, the antisense oligonucleotide comprises a 5' terminus and a
3' terminus; and from
position 11 to 59 5'-~3'-linked nucleotides independently selected from the
group eonsisting of 2'-
modified phosphodiester nucleotides and 2'-modified P-alkyloxyphosphotriester
nucleotides; and
wherein the 5'-terminal nucleoside is attached to an RNase H-activating region
of between three and ten
contiguous phosphorothioate-linked deoxyribonucleotides, and wherein the 3'-
terminus of said
oligonucleotide is selected from the group consisting of an inverted
deoxyribonucleotide, a contiguous
stretch of one to three phosphorothioate 2'-modified ribonucleotides, a biotin
group and a P-
alkyloxyphosphotriester nucleotide.
Also an antisense oligonucleotide may be used wherein not the 5' terminal
nucleoside is attached to an
RNase H-activating region but the 3' terminal nucleoside as specified above.
Also, the 5° terminus is
selected from the particular group rather than the 3' terminus of said
oligonucleotide.
The nucleic acids as well as the hyperimmune serum reactive antigens and
fragments thereof according
to the present invention may be used as or for the manufacture of
pharmaceutical compositions,
especially vaccines. Preferably such pharmaceutical composition, preferably
vaccine is for the prevention
or treatment of diseases caused by, related to or associated with S.
agalactiae. In so far another aspect of
the invention relates to a method for inducing an immunological response in an
individual, particularly a
mammal, which comprises inoculating the individual with the hyperimmune serum
reactive antigens
and fragments thereof of the invention, or a fragment or variant thereof,
adequate to produce antibodies
to protect said individual from infection, particularly streptococcal
infection and most particularly S.
agalactiae infections.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-42-
Yet another aspect of the invention relates to a method of inducing an
immunological response in an
individual which comprises, through gene therapy or otherwise, delivering a
nucleic acid functionally
encoding hyperimmune serum reactive antigens and fragments thereof, or a
fragment or a variant
thereof, for expressing the hyperimmune serum reactive antigens and fragments
thereof, or a fragment or
a variant thereof in vivo in order to induce an immunological response to
produce antibodies or a cell
mediated T cell response, either cytokine-producing T cells or cytotoxic T
cells, to protect said individual
from disease, whether that disease is already established within the
individual or not. One-way of
administering the gene is by accelerating it into the desired cells as a
coating on particles or otherwise.
A further aspect of the invention relates to an immunological composition
which, when introduced into a
host capable of having induced within it an immunological response, induces an
irnmunological response
in such host, wherein the composition comprises recombinant DNA which codes
for and expresses an
antigen of the hyperimmune serum reactive antigens and fragments thereof of
the present invention. The
immunological response may be used therapeutically or prophylactically and may
take the form of
antibody immunity or cellular immunity such as that arising from CTL or CD4+ T
cells.
The hyperimmune serum reactive antigens and fragments thereof of the invention
or a fragment thereof
may be fused with a co-protein which may not by itself produce antibodies, but
is capable of stabilizing
the first protein and producing a fused protein which will have immunogenic
and protective properties.
This fused recombinant protein preferably further comprises an antigenic co-
protein, such as
Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-
proteins which solubilise the
protein and facilitate production and purification thereof. Moreover, the co-
protein may act as an
adjuvant in the sense of providing a generalized stimulation of the immune
system. The co-protein may
be attached to either the amino or carboxy terminus of the first protein.
Also, provided by this invention are methods using the described nucleic acid
molecule or particular
fragments thereof in such genetic immunization experiments in animal models of
infection with S.
agalactiae. Such fragments will be particularly useful for identifying protein
epitopes able to provoke a
prophylactic or therapeutic immune response. This approach can allow for the
subsequent preparation of
monoclonal antibodies of particular value from the requisite organ of the
animal successfully resisting or
clearing infection for the development of prophylactic agents or therapeutic
treatments of S. agalactiae
infection in mammals, particularly humans.
The hyperimmune serum reactive antigens and fragments thereof rnay be used as
an antigen for
vaccination of a host to produce specific antibodies which protect against
invasion of bacteria, for
example by blocking adherence of bacteria to damaged tissue. Examples of
tissue damage include
wounds in skin or connective tissue and mucosal tissues caused e.g. by viral
infection (esp. respiratory,
such as the flu) mechanical, chemical or thermal damage or by implantation of
indwelling devices, or
wounds in the mucous membranes, such as the mouth, mammary glands, urethra or
vagina.
The present invention also includes a vaccine formulation, which comprises the
immunogenic
recombinant protein together with a suitable carrier. Since the protein may be
broken down in the
stomach, it is preferably administered parenterally, including, for example,
administration that is
subcutaneous, intramuscular, intravenous, intradermal intranasal or
tramsdermal. Formulations suitable
for parenteral administration include aqueous and non-aqueous sterile
injection solutions which may
contain anti-oxidants, buffers, bacteriostats and solutes which render the
formulation isotonic with the
bodily fluid, preferably the blood, of the individual; and aqueous and non-
aqueous sterile suspensions
which may include suspending agents or thickening agents. The formulations may
be presented in unit-
dose or mufti-dose containers, for example, sealed ampoules and vials, and may
be stored in a freeze-
dried condition requiring only the addition of the sterile liquid carrier
immediately prior to use. The
vaccine formulation may also include adjuvant systems for enhancing the
immunogenicity of the
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
- 43 -
formulation, such as oil-in-water systems and other systems known in the art.
The dosage will depend on
the specific activity of the vaccine and can be readily determined by routine
experimentation.
According to another aspect, the present invention relates to a pharmaceutical
composition comprising
such a hyperimmune serum-reactive antigen or a fragment thereof as provided in
the present invention
for S. agalactiae. Such a pharmaceutical composition may comprise one
preferably at least two or more
hyperimmune serum reactive antigens or fragments thereof against S.
agalactiae. Optionally, such S.
agalactiae hyperimmune serum reactive antigens or fragments thereof may also
be combined with
antigens against other pathogens in a combination pharmaceutical composition.
Preferably, said
pharmaceutical composition is a vaccine for preventing or treating an
infection caused by S. agalactiae
and/or other pathogens against which the antigens have been included in the
vaccine.
According to a further aspect, the present invention relates to a
pharmaceutical composition comprising a
nucleic acid molecule encoding a hyperimmune serum-reactive antigen or a
fragment thereof as
identified above for S. agalactiae. Such a pharmaceutical composition may
comprise one or more nucleic
acid molecules encoding hyperimmune serum reactive antigens or fragments
thereof against S. agalactiae.
Optionally, such S. agalacttae nucleic acid molecules encoding hyperimmune
serum reactive antigens or
fragments thereof may also be combined with nucleic acid molecules encoding
antigens against other
pathogens in a combination pharmaceutical composition. Preferably, said
pharmaceutical composition is
a vaccine for preventing or treating an infection caused by S. agalactiae
and/or other pathogens against
which the antigens have been included in the vaccine.
The pharmaceutical composition may contain any suitable auxiliary substances,
such as buffer
substances, stabilisers or further active ingredients, especially ingredients
known in connection of
pharmaceutical composition and/or vaccine production.
A preferable carrier/or excipient for the hyperimrnune serum-reactive
antigens, fragments thereof or a
coding nucleic acid molecule thereof according to the present invention is an
immunostimulatory
compound for further stimulating the immune response to the given hyperimmune
serum-reactive
antigen, fragment thereof or a coding,nucleic acid molecule thereof.
Preferably the immunostimulatory
compound in the pharmaceutical preparation according to the present invention
is selected from the
group of polycationic substances, especially polycationic peptides,
immunostimulatory nucleic acids
molecules, preferably immunostimulatory deoxynucleotides, alum, Freund's
complete adjuvants,
Freund's incomplete adjuvants, neuroactive compounds, especially human growth
hormone, or
combinations thereof.
It is also within the scope of the present invention that the pharmaceutical
composition, especially
vaccine, comprises apart from the hyperimmune serum reactive antigens,
fragments thereof and/or
coding nucleic acid molecules thereof according to the present invention other
compounds which are
biologically or pharmaceutically active. Preferably, the vaccine composition
comprises at least one
polycationic peptide. T'he polycationic compounds) to be used according to the
present invention may be
any polycationic compound, which shows the characteristic effects according to
the WO 97/30721.
Preferred polycationic compounds are selected from basic polyppetides, organic
polycations, basic
polyamino acids or mixtures thereof. These polyamino acids should have a chain
length of at least 4
amino acid residues (WO 9/30721). Especially preferred are substances like
polylysine, polyarginine and
polypeptides containing more than 20 %, especially more than 50 % of basic
amino acids in a range of
more than 8, especially more than 20, amino acid residues or mixtures thereof.
Other preferred
polycations and their pharmaceutical compositions are described in WO 97/3021
(e.g.
polyethyleneimine) and WO 99/38528. Preferably these polypeptides contain
between 20 and 500 amino
acid residues, especially between 30 and 200 residues.
These polycationic compounds may be produced chemically or recombinantly or
may be derived from
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-44-
natural sources.
Cationic (poly)peptides may also be anti-microbial with properties as reviewed
in {Ganz, T., 1999}. These
(poly)peptides may be of prokaryotic or animal or plant origin or may be
produced chemically or
recombinantly (WO 02/13857): Peptides may also belong to the class of
defensins (WO 02/13857).
Sequences of such peptides can be, for example, found in the Antimicrobial
Sequences Database under
the following Internet address:
htty//www.bbcm.univ.trieste.it/~tossi/pa 2.g html
Such host defence peptides or defensives are also a preferred form of the
polycationic polymer according
to the present invention. Generally, a compound allowing as an end product
activation (or down-
regulation) of the adaptive immune system, preferably mediated by APCs
(including dendritic cells) is
used as polycationic polymer.
Especially preferred for use as polycationic substances in the present
invention are cathelicidin derived
antimicrobial peptides or derivatives thereof (International patent
application WO 02/13857, incorporated
herein by reference), especially antimicrobial peptides derived from mammalian
cathelicidin, preferably
from human, bovine or mouse.
Polycationic compounds derived from natural sources include HIV-REV or HIV-TAT
(derived cationic
peptides, antennapedia peptides, chitosan or other derivatives of chitin) or
other peptides derived from
these peptides or proteins by biochemical or recombinant production. Other
preferred polycationic
compounds are cathelin or related or derived substances from cathelin. For
example, mouse cathelin is a
peptide which has the amino acid sequence NHz-
RLAGLLRKGGEKIGEKLKKIGOKIKNFFQKLVPQPE-
COOH. Related or derived cathelin substances contain the whole or parts of the
cathelin sequence with at
least 15-20 amino acid residues. Derivations may include the substitution or
modification of the natural
amino acids by amino acids which are not among the 20 standard amino acids.
Moreover, further cationic
residues may be introduced into such cathelin molecules. These cathelin
molecules are preferred to be
combined with the antigen. These cathelin molecules surprisingly have turned
out to be also effective as
an adjuvant for an antigen without the addition of further adjuvants. It is
therefore possible to use such
catllelin molecules as efficient adjuvants in vaccine formulations with or
without further
immunactivating substances.
Another preferred polycationic substance to be used according to the present
invention is a synthetic
peptide containing at least 2 KLK-motifs separated by a linker of 3 to 7
hydrophobic amino acids
(International patent application WO 02/32451, incorporated herein by
reference).
The pharmaceutical composition of the present invention may further comprise
immunostimulatory
nucleic acid(s). Immunostirnulatory nucleic acids are e. g. neutral or
artificial CpG containing nucleic
acids, short stretches of nucleic acids derived from non-vertebrates or in
form of short oligonucleotides
(ODNs) containing non-methylated cytosine-guanine di-nucleotides (CpG) in a
certain base context (e.g.
described in WO 96/02555). Alternatively, also nucleic acids based on inosine
and cytidine as e.g.
described in the WO 01/93903, or deoxynucleic acids containing deoxy-inoshze
and/or deoxyuridine
residues (described in WO 01/93905 and PCT/EP 02/05448, incorporated herein by
reference) may
preferably be used as immunostimulatory nucleic acids for the present
invention. Preferablly, the
mixtures of different immunostimulatory nucleic acids may be used according to
the present invention.
It is also within the present invention that any of the aforementioned
polycationic compounds is
combined with any of the immunostimulatory nucleic acids as aforementioned.
Preferably, such
combinations are according to the ones as described in WO 01/93905, WO
02/32451, WO 01/5420, WO
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
- 45 -
01/93903, WO 02/1385 and PCT/EP 02/05448 and the Austrian patent application A
1924/2001,
incorporated herein by reference.
In addition or alternatively such vaccine composition may comprise apart from
the hyperimmune serum
reactive antigens and fragments thereof, and the coding nucleic acid molecules
thereof according to the
present invention a neuroactive compound. Preferably, the neuroactive compound
is human growth
factor as, e.g. described in WO 01/24822. Also preferably, the neuroactive
compound is combined with
any of the polycationic compounds and/or immunostimulatory nucleic acids as
of~re-mentioned.
In a further aspect the present invention is related to a pharmaceutical
composition. Such pharmaceutical
composition is, for example, the vaccine described herein. Also a
pharmaceutical compositi~n is a
pharmaceutical composition which comprises any of the following compounds or
combinations thereof:
the nucleic acid molecules according to the present invention, the hyperimmune
serum reactive antigens
and fragments thereof according to the present invention, the vector according
to the present invention,
the cells according to the present invention, the antibody according to the
present invention, the
functional nucleic acids according to the present invention and the binding
peptides such as the
anticalines according to the present invention, any agonists and antagonists
screened as described herein.
In connection therewith any of these compounds may be employed in combination
with a non-sterile or
sterile carrier or carriers for use with cells, tissues or organisms, such as
a pharmaceutical carrier suitable
for administration to a subject. Such compositions comprise, for instance, a
media additive or a
therapeutically effective amount of a hyperimmune serum reactive antigen and
fragments thereof of the
invention and a pharmaceutically acceptable carrier or excipient. Such
carriers may include, but are not
limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and
combinations thereof. The
formulation should suit the mode of administration.
The pharmaceutical compositions may be administered in any effective,
convenient manner including,
for instance, administration by topical, oral, anal, vaginal, intravenous,
intraperitoneal, intramuscular,
subcutaneous, intranasal, intratracheal or intradermal routes among others.
In therapy or as a prophylactic, the active agent may be administered to an
individual as an injectable
composition, for example as a sterile aqueous dispersion, preferably isotonic.
Alternatively the composition may be formulated for topical application, for
example in the form of
ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash,
impregnated dressings and
sutures and aerosols, and may contain appropriate conventional additives,
including, for example,
preservatives, solvents to assist drug penetration, and emollients in
ointments and creams. Such topical
formulations may also contain compatible conventional carriers, for example
cream or ointment bases,
and ethanol or oleyl alcohol for lotions. Such carriers may constitute from
about 1 % to about 98 % by
weight of the formulation; more usually they will constitute up to about 80 %
by weight of the
formulation.
In addition to the therapy described above, the compositions of this invention
may be used generally as a
wound treatment agent to prevent adhesion of bacteria to matrix proteins
exposed in wound tissue and
for prophylactic use in dental treatment as an alternative to, or in
conjunction with, antibiotic
prophylaxis.
A vaccine composition is conveniently in injectable form. Conventional
adjuvants may be employed to
enhance the immune response. A suitable unit dose for vaccination is 0.05-5 ~g
antigen / per kg of body
weight, and such dose is preferably administered 1-3 times and with an
interval of 1-3 weeks.
With the indicated dose range, no adverse toxicological effects should be
observed with the compounds
of the invention, which would preclude their administration to suitable
individuals.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-46-
In a further embodiment the present invention relates to diagnostic and
pharmaceutical packs and kits
comprising one or more containers filled with one or more of the ingredients
of the aforementioned
compositions of the invention. The ingredients) can be present in a useful
amount, dosage, formulation
or combination. Associated with such containers) can be a notice in the form
prescribed by a
governmental agency regulating the manufacture, use or sale of pharmaceuticals
or biological products,
reflecting approval by the agency of the manufacture, use or sale of the
product for human
administration.
In connection with the present invention any disease related use as disclosed
herein such as, e. g. use of
the pharmaceutical composition or vaccine, is particularly a disease or
diseased condition which is
caused by, linked or associated with Streptococci, more preferably, S. yyogens
and pneunaoniae. In
connection therewith it is to be noted that S. agalactiae comprises several
strains including those disclosed
herein. A disease related, caused or associated with the bacterial infection
to be prevented and/or treated
according to the present invention includes besides others bacterial
pharyngitis, otitis media, pneumonia,
bacteremia, meningitis, peritonitis, wound infection and sepsis in humans.
In a still further embodiment the present invention is related to a screening
method using any of the
hyperimmune serum reactive antigens or nucleic acids according to the present
invention. Screening
methods as such are known to the one skilled in the art and can be designed
such that an agonist or an
antagonist is screened. Preferably an antagonist is screened which in the
present case inhibits or prevents
the binding of any hyperimmune serum reactive antigen and fragment thereof
according to the present
invention to an interaction partner. Such interaction partner can be a
naturally occurring interaction
partner or a non-naturally occurring interaction partner.
The invention also provides a method of screening compounds to identify those,
which enhance (agonist)
or block (antagonist) the function of hyperimmune serum reactive antigens and
fragments thereof or
nucleic acid molecules of the present invention, such as its interaction with
a binding molecule. The
method of screening may involve high-throughput.
For example, to screen for agonists or antagonists, the interaction partner of
the nucleic acid molecule and
nucleic acid, respectively, according to the present invention, maybe a
synthetic reaction mix, a cellular
compartment, such as a membrane, cell envelope or cell wall, or a preparation
of any thereof, may be
prepared from a cell that expresses a molecule that binds to the hyperimmune
serum reactive antigens
and fragments thereof of the present invention. The preparation is incubated
with labelled hyperimmune
serum reactive antigens and fragments thereof in the absence or the presence
of a candidate molecule,
which may be an agonist or antagonist. The ability of the candidate molecule
to bind the binding
molecule is reflected in decreased binding of the labelled ligand. Molecules
which bind gratuitously, i. e.,
without inducing the functional effects of the hyperimmune serum reactive
antigens and fragments
thereof, are most likely to be good antagonists. Molecules that bind well and
elicit functional effects that
are the same as or closely related to the hyperimmune serum reactive antigens
and fragments thereof are
good agonists.
The functional effects of potential agonists and antagonists may be measured,
for instance, by
determining the activity of a reporter system following interaction of the
candidate molecule with a cell
or appropriate cell preparation, and comparing the effect with that of the
hyperimmune serum reactive
antigens and fragments thereof of the present invention or molecules that
elicit the same effects as the
hyperimmune serum reactive antigens and fragments thereof. Reporter systems
that may be useful in this
regard include but are not limited to colorimetric labelled substrate
converted into product, a reporter
gene that is responsive to changes in the functional activity of the
hyperimmune serum reactive antigens
and fragments thereof, and binding assays known in the art.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-47-
Another example of an assay for antagonists is a competitive assay that
combines the hyperimmune
serum reactive antigens and fragments thereof of the present invention and a
potential antagonist with
membrane-bound binding molecules, recombinant binding molecules, natural
substrates or ligands, or
substrate or ligand mimetics, under appropriate conditions for a competitive
inhibition assay. The
hyperimmune serum reactive antigens and fragments thereof can be labelled such
as by radioactivity or a
colorimetric compound, such that the molecule number of hyperimmune serum
reactive antigens and
fragments thereof bound to a binding molecule or converted to product can be
determined accurately to
assess the effectiveness of the potential antagonist.
Potential antagonists include small organic molecules, peptides, polypeptides
and antibodies that bind to
a hyperimmune serum reactive antigen and fragments thereof of the invention
and thereby inhibit or
extinguish its acitivity. Potential antagonists also may be small organic
molecules, a peptide, a
polypeptide such as a closely related protein or antibody that binds to the
same sites on a binding
molecule without inducing functional activity of the hyperimmune serum
reactive antigens and
fragments thereof of the invention.
Potential antagonists include a small molecule, which binds to and occupies
the binding site of the
hyperimmune serum reactive antigens and fragments thereof thereby preventing
binding to cellular
binding molecules, such that normal biological activity is prevented. Examples
of small molecules
include but are not limited to small organic molecules, peptides or peptide-
like molecules.
Other potential antagonists include antisense molecules (see {Okano, H. et
al., 1991};
OLIGODEOXYNLJCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION; CRC Press,
Boca
Ration, FL (1988), for a description of these molecules).
Preferred potential antagonists include derivatives of the hyperimmune serum
reactive antigens and
fragments thereof of the invention.
As used herein the activity of a hyperimmune serum reactive antigen and
fragment thereof according to
the present invention is its capability to bind to any of its interaction
partner or the extent of such
capability to bind to its or any interaction partner.
In a particular aspect, the invention provides the use of the hyperimmune
serum reactive antigens and
fragments thereof, nucleic acid molecules or inhibitors of the invention to
interfere with the initial
physical interaction between a pathogen and mammalian host responsible for
sequelae of infection. In
particular the molecules of the invention may be used: i) in the prevention of
adhesion of S. agalactiae to
mammalian extracellular matrix proteins at mucosal surfaces and on in-dwelling
devices or to
extracellular matrix proteins in wounds; ii) to block bacterial adhesion
between mammalian extracellular
matrix proteins and bacterial proteins which mediate tissue damage or invasion
iii) or lead to evasion of
immune defense; iv) to block the normal progression of pathogenesis in
infections initiated other than by
the implantation of in-dwelling devices or by other surgical techniques, e.g.
through inhibiting nutrient
acquisition.
Each of the DNA coding sequences provided herein rnay be used in the discovery
and development of
antibacterial compounds. The encoded protein upon expression can be used as a
target for the screening
of antibacterial drugs. Additionally, the DNA sequences encoding the amino
terminal regions of the
encoded protein or Shine-Delgarno or other translation facilitating sequences
of the respective mRNA can
be used to construct antisense sequences to control the expression of the
coding sequence of interest.
The antagonists and agonists may be employed, for instance, to inhibit
diseases arising from infection
with Streptococcus, especially S. agalactiae, such as sepsis.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
- 48 -
In a still further aspect the present invention is related to an affinity
device such affinity device comprises
as least a support material and any of the hyperimmune serum reactive antigens
and fragments thereof
according to the present invention, which is attached to the support material.
Because of the specificity of
the hyperimmune serum reactive antigens and fragments thereof according to the
present invention for
their target cells or target molecules or their interaction partners, the
hyperimmune serum reactive
antigens and fragments thereof allow a selective removal of their interaction
partners) from any kind of
sample applied to the support material provided that the conditions for
binding are met. The sample may
be a biological or medical sample, including but not limited to, fermentation
broth, cell debris, cell
preparation, tissue preparation, organ preparation, blood, urine, lymph
liquid, liquor and the like.
The hyperimmune serum reactive antigens and fragments thereof may be attached
to the matrix in a
covalent or non-covalent manner. Suitable support material is known to the one
skilled in the art and can
be selected from the group comprising cellulose, silicon, glass, aluminium,
paramagnetic beads, starch
and dextrane.
'The present invention is further illustrated by the following figures,
examples and the sequence listing,
from which further features, embodiments and advantages may be taken. It is to
be understood that the
present examples are given by way of illustration only and not by way of
limitation of the disclosure.
In connection with the present invention
Figure 1 shows the characterization of human antibody sources for S.
agalactiae.
Figure 2 shows the characterization of the small fragment genomic library,
LSAg-70, from Streptococcus
agalactiae ATCC 12403.
Figure 3 shows the selection of bacterial cells by MACS using biotinylated
human IgGs.
Figure 4 shows the serotypes of the applied strains and an example for the
gene distribution analysis with
one of the identified antigens.
Figure 5 shows examples for induction of epitope-specific antibodies in mice
by immunization with E. coli
lysates.
Figure 6 shows examples for cell surface staining with epitope-specific
antisera by flow cytometry.
Figure 7 shows the determination of bactericidal activity of antibodies
induced by selected epitopes in an
in vitro assay.
Table 1A shows the summary of all screens performed with genomic S. agalactiae
libraries and human
serum. Table 1B shows antigenic proteins identified by sequence identity
within antigenic regions of the
proteins listed in Table 1A.
Table 2 shows the summary of epitope serology analysis with human sera.
Table 3 shows the summary of the gene distribution analysis for the identified
antigens in 46 S. agalactiae
strains.
Table 4 shows the summary of mouse imunogenicity experiments.
Table 5 shows the summary of all screens performed with genomic S. agalactiae
libraries and human
serum.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-49-
Table 6 shows the summary of epitope serology analysis with human sera.
Table 7 shows the summary of mouse imunogenicity experiments.
The figures to which it might be referred to in the specification are
described in the following in more
details.
Figure 1 shows the characterization of human sera and cervical secretions for
anti-S. agalactiae antibodies
as measured by immune assays. Total anti-S. agalactiae IgG and IgA antibody
levels were measured by
standard ELISA using total bacterial lysates or culture supernant fractions
prepared from S. agalactiae
serotype III strain ATCC 12403 as coating antigens. (A) Results of
representative experiments are shown
with healthy adult sera with total bacterial lysate proteins. Data are
expressed as ELISA units calculated
from absorbance at 405nm at a serum dilution in the linear range of detection
(2.000X for IgA, 10,000 for
IgG). Selected sera (out of 52) included in the healthy adult non-pregnant
serum pool (NSagB-IgG,-IgA)
are indicated by bold numbers. (B) Immunoblot analysis was performed on high
titer sera selected by
ELISA in order to ensure multiple immune reactivity with protein antigens.
Results of a representative
experiment using total bacterial lysate prepared from S. agalactiae serotype
III ATCC 12403 strain and
selected patients' sera at 5.OOOX dilution are shown. Blots were developed
with anti-human IgG
secondary antibody reagent. Low titer sera were included as negative controls.
Mw: molecular weight
markers. (C) shows selection of cervical secretions from noncolonized pregnant
women by immunoblot
analysis. Antibodies exctracted from cervical wicks were quantitated for IgA
content. 2 ~g IgA from each
prepaprations were tested for immunoreactivity using total bacterial lysate in
a mufti-well blotting
apparatus. Blots were developed with anti-human IgA secondary antibodies. IgA
preparation showing
reactivity with GBS proteins (inidicated by arrows) were selected and pooled.
Figure 2 (A) shows the fragment size distribution of the Streptococcass
agalactiae ATCC 12403 small
fragment genomic library, LSAg-70. After sequencing 576 randomly selected
clones, sequences were
trimmed (464) to eliminate vector residues and the numbers of clones with
various genomic fragment
sizes were plotted. (B) shows the graphic illustration of the distribution of
the same set of randomly
sequenced clones of LSAg-70 over the S. agalactiae ATCC 12403 chromosome.
Rectangles indicate
matching sequences to annotated ORFs and diamonds represent fully matched
clones to non-coding
chromosomal sequences in +/+ or +/- orientation. Circles position all clones
with chimeric sequences.
Numeric distances in base pairs are indicated over the circular genome for
orientation. Partitioning of
various clone sets within the library is given in numbers and percentage at
the bottom of the figure.
Figure 3 (A) shows the MACS selection with biotinylated human IgGs. The LSAg-
70 library in pMAL9.1
was screened with 15-20 ~g biotinylated IgG (PSagl1-IgG, purified from human
serum). As negative
control, no serum was added to the library cells for screening. Number of
cells selected after the 1St, 2~a
and 3=a elution are shown for each selection round (upper, middle and lower
panel, respectively). (B)
shows the reactivity of specific clones (1-26) selected by bacterial surface
display as analysed by
immunoblot analysis with the human serum IgG pool (PSagl1-IgG, 4 ~g/~1) used
for selection by MACS
at a dilution of 1:3,000. As a loading control the same blot was also analysed
with antibodies directed
against the platform protein Lama at a dilution of 1:5,000 of hyperimmune
rabbit serum. M, Molecular
weigth marker; L, Extract from a clone expressing Lama without foreign peptide
insert.
Figure 4 (A) shows the representation of different serotypes of S. agalactiae
clinical isolates analysed for
the gene distribution study. A number of the strains were not typable and may
represent additional
serotypes. (B) shows the PCR analysis for the gene distribution of gbs0061
with the respective
oligonucleotides and 46 S. agalactiae strains. The predicted size of the PCR
fragments is 814 bp. 1-46, S.
agalactiae strains, clinical isolates as shown under A; -, no genomic DNA
added; +, genomic DNA from S.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-50-
agalactiae ATCC 12403, which served as template for library construction.
Figure 5 shows the measurement of epitope-specific mouse serum IgG antibody
levels induced by total
bacterial lysates of Lamb or FhuA expressing E. coli clones with S. agalactiae-
derived epitopes. (A) shows
representative peptide ELISA experiments with three sets of mouse sera (5 mice
in each group, 1-5)
generated by gb50428, gbs0628 and gbs632 epitopes, respectively. Sera were
tested at two different
dilutions: black bars: 100X; grey bars; 1000X. Biotin-labeled synthetic
peptides corresponding to the
respective epitopes were used in the peptide ELISA. Sera induced with E. coli
lysate without S. agalactiae
derived epitopes are indicated as FhuA or Lama. (B) shows a typical
immunoblotting experiment using
lysates prepared from individual E. coli clones selected for mouse injections.
Sera were depleted by E. coli
lysate not carrying epitope to remove antibodies against E. coli proteins.
Examples are shown for gbs0918,
gbs0428, gbs0628 and gbs632 epitopes. Negative controls (-) are E. coli clones
with empty platform
proteins. Location of platform proteins Lama and FhuA is indicated by arrows.
Figure 6 shows the detection of specific antibody binding on the cell surface
of Streptococcus agalactiae by
flow cytometry. In Figure 6A preimmune mouse sera and polyclonal sera raised
against S. agalactiae
serotype III lysate were incubated with S. agalactiae strain serotype III and
analysed by flow cytometry.
Control shows the level of non-specific binding of the secondary antibody to
the surface of S. agalactiae
cells. The histograms in figure 6B indicates the increased fluorescence due to
specific binding of anti-
gbs0031, anti-gbs1925 and anti-gbs0012 antibodies in comparison to the control
sera generated against E.
coli lysate containing only the'empty' platform protein FhuA.
Figure 7 shows the bactericidal activity of epitope specific antibodies as
determined in in vitro killing
assay. The killing activity of immune sera is measured parallel with and
calculated relative to the
appropriate control sera. Data are expressed as percentage of killing, that is
the reduction on bacterial cfu
numbers as a consequence of the presence of specific antibodies. Hyperimmune
polyclonal mouse sera
generated with S. agalactiae lysate and sera from non-immunized mice served as
positive and negative
controls for the assay, respectively. Immune sera generated with (A) gbs0012,
gbs0016, gbs0031, gbs0428,
gbs1306 and gbs2018 epitopes and with (B) gbs0233, gbs0419, gbs0942, gbs0975,
gbs1038, gbs1144 and
gbs2093 epitopes were tested for bactericidal activity and data are expressed
relative to appropriate
controls, such as sera induced with Lamb or FhuA expressing E. coli clones
without S. agalactiae-derived
epitopes. S. agalactiae serotype III cells were incubated with mouse
phagocytic cells for 60 min, and
surviving bacteria were quantified by counting cfus after plating on blood
agar.
Table 1: Immunogenic proteins identified by bacterial surface display.
(A) Columns A, 300bp library of S.agalactiae ATCC 12403 in fhuA with NSag8-IgA
(826), B, 300bp library
in fhuA with PSaglO-IgA (768), C, 300bp library in fhuA with PSaglO-IgG (711),
D, 300bp library in fhuA
with PSagl1-IgG (640), E, 70bp library in lama with NSagB-IgA (1057), F, 70bp
library in lama with
NSag8-IgG (869), G, 70bp library in lama with PSaglO-IgA (904), H, 70bp
library in lama with PSaglO-
IgA-adsorbed (493), I, ~Obp library in lama with PSaglO-IgG (910), J, 70bp
library in lama with PSagl1-
IgA (631), K, 70bp library in lama with PSagl1-IgG (926), L, 70bp library in
lama with PSagl8-IgA (691),
M, 70bp library in lama with PSag-sIgA (628); ~', prediction of antigenic
sequences longer than 5 amino
acids was performed with the program ANTIGENIC (Kolaskar and Tongaonkar,
1990). Table 1B lists the
immunogenic proteins identified by amino acid sequence identity with peptides
identified by bacterial
surface display. Antigenic peptides, which have been identified by bacterial
surface-display possess
identical counterparts in the listed proteins from S. agalactiae. The peptides
have been shown to react with
multiple human sera (see Table 2). Sera directed against these peptides can
therefore recognize multiple
proteins.
Table 2: Epitope serology with human sera.
Immune reactivity of individual synthetic peptides representing selected
epitopes with human sera is
shown. Extent of reactivity is expressed as +, ++ or +++, and summed from
individual reactivities of
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-51-
peptides with individual sera (13 patient and 9 healthy adult, 22 total). A
total score for each peptide was
calculated based on ELISA units as the sum of all reactivities. Scores were 2-
8 for +, 9-16 for ++ and 17-26
for +++. ELISA units were calculated from ODnosnm readings and the serum
dilution after correction for
background. Location of synthetic peptides within the antigenic ORFs according
to the genome
annotation of ATCC 12403 strain is given in columns as from and as to
indicating the first and last amino
acid residues, respectively. Peptide names: gbs0012.1 present in annotated
ORF: gbs0012.
Table 3: Gene distribution in S. agalacfiiae strains.
Fourty six S. agalactiae strains as shown in Figure 4A were tested by PCR with
oligonucleotides specific
for the genes encoding relevant antigens. The PCR fragment of one selected PCR
reaction was sequenced
in order to confirm the amplification of the correct DNA fragment. *, number
of amino acid substitutions
in a serotype IA strain as derived from sequencing as compared to S.
agalactiae ATCC 12403. #, alternative
strain used for sequencing, because gene was not present in the serotype IA
strain.
Table 4: Immunogenicity of antigenic epitopes.
S. agalactiae antigens were tested for immunogenicity by immunization with E.
coli clones harboring
plasmids encoding the platform proteins Lama or FhuA fused to S. agalactiae
peptides. The presence of
epitope-specific antibodies were detected and measured by peptide ELISA and/or
irnmunoblotting using
the corresponding E. coli clone lysate, which served as irnmunogen. Results
are expressed as + to +++++,
and calculated for peptide ELISA as the sum of the reactivity of individual
mouse sera based on ELISA
units (as indicated on Fig. 5A) and for immunoblotting (IB) as the strength of
reactivity of pooled (5
individual) mouse sera with the epitope containing platform protein (as
indicated on Fig. 5B). Location of
synthetic peptides within the antigenic ORFs according to the genome
annotation of ATCC 12403 strain is
given in columns as from and as to indicating the first and last amino acid
residues, respectively.
Table 5: Immunogenic proteins identified by bacterial surface display.
(A) 300bp library of S.agalactiae ATCC 12403 in fhuA with IC8-IgA (826), B,
300bp library in fhuA with
P10-IgA (768), C, 300bp library in fhuA with P10-IgG (711), D, 300bp library
in fhuA with P11-IgG (640),
E, 70bp library in lama with IC8-IgA (1057), F, ~Obp library in lama with IC8-
IgG (869), G, 70bp library in
lama with P10-IgA (904), H, 70bp library in lama with P10-IgA-adsorbed (493),
I, 70bp library in lama
with P10-IgG (910), J, ~Obp library in lama with P11-IgA (631), IC, 70bp
library in lama with P11-IgG
(926), ~', prediction of antigenic sequences longer than 5 amino acids was
performed with the program
ANTIGENIC (IColaskar and Tongaonkar,1990).
Table 6: Epitope serology with human sera.
Immune reactivity of individual synthetic peptides representing selected
epitopes with human sera is
shown. Extent of reactivity is expressed as +, ++ or +++, and summed from
individual reactivities of
peptides with individual sera (13 patient and 9 healthy adult, 22 total). A
total score for each peptide was
calculated based on ELISA units as the sum of all reactivities. Scores were 2-
8 for +, 9-16 for ++ and 17-30
for +++, ELISA units were calculated from OD4os~m readings and the serum
dilution after correction for
background. Location of synthetic peptides within the antigenic ORFs according
to the genome
annotation of ATCC 12403 strain is given in columns as from and as to
indicating the first and last amino
acid residues, respectively. Peptide names: gbs0233.1 present in annotated
ORF: gbs0233.
Table 7: Immunogenicity of antigenic epitopes in mice.
S. agalactiae antigens were tested for immunogenicity by immunization with E.
coli clones harboring
plasmids encoding the platform proteins Lama or FhuA fused to S. agalactiae
peptides. The presence of
epitope-specific antibodies were detected and measured by peptide ELISA.
Results are expressed as + to
++-t-~-H, and calculated for peptide ELISA as the sum of the reactivity of
individual mouse sera based on
ELISA units (as indicated on Fig. 5). Location of epitopes within the
antigenic ORFs according to the
genome annotation of ATCC 12403 strain is given in columns as from and as to
indicating the first and
last amino acid residues, respectively.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-52-
EXAMPLES
Example 1: Characterization and selection of human serum sources based on anti-
S. agalaetiae
antibodies, preparation of antibody screening reagents
Experimental pr~cedure~
E~izyme linked immune assay (ELISA).
ELISA plates (Maxisorb, Millipore) were coated with 5-10 ~.g/ml total protein
diluted in coating buffer
(0.1M sodium carbonate pH 9.2). Three dilutions of sera (2,000X, 10,000X,
50,000X) were made in PBS-
BSA. Highly specific Horse Radish Peroxidase (HRP)-conjugated anti-human IgG
or anti-human IgA
secondary antibodies (Southern Biotech) were used according to the
manufacturers' recommendations
(dilution: 1,000x). Antigen-antibody complexes were quantified by measuring
the conversion of the
substrate (ARTS) to colored product based on OD4os~,n, readings by automatic
ELIAS reader (TECAN
SUNRISE).
Preparation of bacterial antigen extracts
Total bacterial lysate: Bacteria were grown overnight in THB (Todd-Hewitt
Broth) and lysed by repeated
freeze-thaw cycles: incubation on dry ice/ethanol-mixture until frozen (1
min), then thawed at 37oC (5
min): repeated 3 times. This was followed by sonication and collection of
supernatant by centrifugation
(3,500 rpm, 15 min, 4oC).
Culture supernatant: After removal of bacteria by centrifugation, the
supernatant of overnight grown
bacterial cultures was precipitated with ice-cold ethanol by mixing 1 part
supernatant with 3 parts
absolute ethanol and incubated overnight at -20°C. Precipitates were
collected by centrifugation (2,600 g,
for 15 min). Dry pellets were dissolved either in PBS for ELISA, or in urea
and SDS-sample buffer for
SDS-PAGE and immunoblotting. The protein concentration of samples was
determined by Bradford
assay.
Immunoblotting
Total bacterial lysate and culture supernatant samples were prepared from in
vitro grown S. agalactiae
serotype III strain. 10 to 25~tg total protein/lane was separated by SDS-PAGE
using the BioRad Mini-
Protean Cell electrophoresis system and proteins transferred to nitrocellulose
membrane (ECL,
Amersham Pharmacia). After overnight blocking in 5% milk, human sera were
added at 2,OOOx dilution,
and HRPO labeled anti-human IgG was used for detection.
Extraction of antibodies from cervical wicks
Cervical secretions were collected by absorbent cylindrical wicks
(Polyfiltronics) which were introduced
into the cervical canal during speculum examination and thereafter kept frozen
until extraction.
Extraction was done according to Hordnes et al,1998 (provider of the samples).
Briefly, wicks were mixed
with PBS containing protease inhibitors, vortexed and fluid was drained from
the tubes containing the
wicks. The concentrations of total IgA and IgG antibodies in extracts were
determined.
Purification of antibodies for genotnic screening. Five sera from both the
patient and the healthy group were
selected based on the overall anti-GBS titers for serum or cervical secretion
pools used in the screening
procedure. Antibodies against E. coli proteins were removed by incubating the
heat-inactivated sera with
whole cell E. coli cells (DHSalpha, transformed with pHIEll, grown under the
same condition as used for
bacterial surface display). Highly enriched preparations of IgGs from the
pooled, depleted sera were
generated by protein G affinity chromatography, according to the
manufacturer's instructions (UltraLink
Immobilized Protein G, Pierce). IgA antibodies were purified also by affinity
chromatography using
biotin-labeled anti-human IgA (Southern Biotech) immobilized on Streptavidin-
agarose (GIBCO BRL).
The efficiency of depletion and purification was checked by SDS-PAGE, Western
blotting, ELISA and
protein concentration measurements.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-53-
Results
'The antibodies produced against S. agalactiae by the human immune system and
present in human sera
are indicative of the in vivo expression of the antigenic proteins and their
immunogenicity. These
molecules are essential for the identification of individual antigens in the
approach as described in the
present invention, which is based on the interaction of the specific anti-GBS
antibodies and the
corresponding S. agalactiae peptides or proteins. To gain access to relevant
antibody repertoires, human
sera were collected from
I. healthy pregnant women tested negative for cervical and anorectal carriage
of GBS
II. healthy pregnant women tested positive for cervical and/or anorectal
carriage of GBS who's
newborn remained GBS-free (although with antibiotic prevention).
III. adults below <45 years of age without clinical disease.
IV. naive individuals, youg children between 5 and 10 months of age, after
they already lost
maternal antibodies and have not acquired GBS-specific ones due to the lack of
GBS disease.
In addition cervical secretions were also collected from the first two groups
of donors. The extrem value
of these antibody sources is mainly the secretory IgA component, which is
directly implicated as
protective effector moluecule on mucosal surfaces.
It is important to screen with antibodies from at least two different
populations, pregnant women and
nonpregnant adults, since GBS disease affects elderly and immunocompromised
adults, as well. Within
the pregnant study group, there are again two different patient categories,
women who are GBS
colonized and those who are noncolonized, to be included in the antigen
screen.
Antibodies in serum and other body fluids, such as mucosal secretions induced
in individuals exposed to
the pathogens are crucial for antigen identification. The exposure to GBS
results in asymptomatic
colonization, current or past acute or chronic infection. S. agalactiae
colonization and infections are
common, and antibodies are present as a consequence of natural immunization
from previous
encounters. It is likely that sera from high titer noncolonized individuals
contain functional antibodies,
which are able to eliminate carriage. At the same time certain antibodies
might be induced against GBS
components only if the antigen persist. For that reason sera from colonized
individuals were also
included. It has been shown that colonization is associated with capsular
polysaccahride (CPS)-specific
antibody responses. However, it is not clear whether sufficient level of
antibodies to CPS°s would prevent
GBS colonization, since there are colonized women with both high and low
levels of anti-CPS antibody,
and the same is true for noncolonized pregnant women.
However, there are reports that effector function and avidity of antibodies
produced during pregnancy
might be altered. It is important to recognize that most healthy adults are
protected from invasive GBS
disease and are less susceptible than newborns and the elderly. Antibodies
from these individuals seem
to be especially valuable for identification of the corresponding antigens. It
is known that anti-GBS
antibody levels increase with age.
GBS is a mucosal pathogen and should induce IgA response; for that reason it
was important to perform
IgA-based screens, as well as IgG-based screens. The fact that some S.
agalactiae strains express high
affinity IgA-binding receptor also points to the importance of IgA in host
response. Recently it was
reported that not only IgG, but also IgA serum antibodies can be recognized by
the FcRIII receptors of
PMNs and promote opsonization {Phillips-Quagliata, J. et al., 2000}; {Shibuya,
A. et al., 2000}. The
primary role of IgA antibodies is neutralization, mainly at the mucosal
surface. The level of serum IgA
reflects the quality, quantity and specificity of the dimeric secretory IgA.
For that reason the serum
collection was not only analyzed for anti-streptococcal IgG, but also for IgA
levels. In the ELISA assays
highly specific secondary reagents were used to detect antibodies from the
high affinity types, such as
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-54-
IgG and IgA, but avoided IgM. Production of IgM antibodies occurs during the
primary adaptive
humoral response, and results in low affinity antibodies, while IgG and IgA
antibodies had already
undergone affinity maturation, and are more valuable in fighting or preventing
disease.
12~ serum samples and 97 cervical secretions from pregnant women and 50 sera
from healthy adults
were characterized for anti-S. agalactfae antibodies by a series of immune
assays. Primary characterization
was done by ELISA using two different antigen preparations, such as total
bacterial extract and culture
supernatant proteins prepared from S. agalactiae serotype III ATCC 12403
strain. A representative
experiment is shown in Fig. 1A using sera from the healthy adult population.
Antibody titers were
compared at given dilutions where the response was linear. Sera were ranked
based on the IgG and IgA
reactivity against the two complex antigenic mixtures (including serotype
specific type III capsule), and
the highest ones were selected for further testing by immunoblotting. This
analysis confirmed a high
antibody reactivity of the pre-selected sera against multiple GBS proteins,
especially when compared to
not selected, low-titer sera (Fig 1B). However, ELISA ranking of sera did not
always correlated with
immunoblot signals suggesting that anti-capsular antibodies were abundant and
dominated the ELISA
reactivities against total bacterial extracts. Thus the final selection of
sera to be included in antibody-pools
was based mainly on multiple immunogenic bands in immunoblotting experiments.
This extensive
antibody characterization approach has led to the unambiguous identification
of anti-GBS hyperimmune
sera.
The 97 cervical secretions were determined for IgA content, and same amount
(2~g) was tested for anti-
GBS reactivity by immunoblotting. Positively selected sera (as it is shown in
Fig. 1C) were devided into
colonized and noncolonized IgA pools and used separately in bacterial surface
display experiments.
sera from both donor groups were selected and pooled for antigen
identification by bacterial surface
display. Selected sera included in the four pregnant women pools (PSAglO-IgG,-
IgA, PSAgl1-IgG,
PSAgl8-IgG and PSAg-sIgA) and one healthy adult (non-pregnant) pool (NSAgB-
IgG,-IgA). IgG and IgA
antibodies were purified from pooled sera by affinity chromatography and
depleted of E. coli -reactive
antibodies to avoid background in the bacterial surface display screen.
Example 2: Generation of highly random, frame-selected, small-fragment,
genomic DNA libraries of
Streptococcus agalactiae
Experimental procedures
Preparation of streptococcal genomic DNA. 50 ml Todd-Hewitt Broth medium was
inoculated with S.
agalactiae ATCC 12403 bacteria from a frozen stab and grown with aeration and
shaking for 18 h at 37°C.
The culture was then harvested, centrifuged with 1,600x g for 15 min and the
supernatant was removed.
Bacterial pellets were washed 3 x with PBS and carefully re-suspended in 0.5
ml of Lysozyme solution
(100 mg/ml). 0.1 ml of 10 mg/ml heat treated RNase A and 20 U of RNase T1 were
added, mixed carefully
and the solution was incubated for 1 h at 37°C. Following the addition
of 0.2 ml of 20 % SDS solution and
0.1 ml of Proteinase IC (10 mg/ml) the tube was incubated overnight at
55°C. 1/3 volume of saturated
NaCl was then added and the solution was incubated for 20 min at 4°C.
The extract was pelleted in a
microfuge (13,000 rpm) and the supernatant transferred into a new tube. The
solution was extracted with
PhOH/CHCla/IAA (25:24:1) and with CHCIs/IAA (24:1). DNA was precipitated at
room temperature by
adding 0.6x volume of Isopropanol, spooled from the solution with a sterile
Pasteur pipette and
transferred into tubes containing 80% ice-cold ethanol. DNA was recovered by
centrifuging the
precipitates with 10-12,000x g, then dried on air and dissolved in ddH2O.
Preparation of small genomic DNA fragments. Genomic DNA fragments were
mechanically sheared into
fragments ranging in size between 150 and 300 by using a cup-horn sonicator
(Bandelin Sonoplus UV
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-55-
2200 sonicator equipped with a BB5 cup horn, 10 sec. pulses at 100 % power
output) or into fragments of
size between 50 and 70 by by mild DNase I treatment (Novagen). It was observed
that sonication yielded
a much tighter fragment size distribution when breaking the DNA into fragments
of the 150-300 by size
range. However, despite extensive exposure of the DNA to ultrasonic wave-
induced hydromechanical
shearing force, subsequent decrease in fragment size could not be efficiently
and reproducibly achieved.
Therefore, fragments of 50 to 70 by in size were obtained by mild DNase I
treatment using Novagen's
shotgun cleavage kit. A 1:20 dilution of DNase I provided with the kit was
prepared and the digestion
was performed in the presence of MnCla in a 60 ~1 volume at 20°C for 5
min to ensure double-stranded
cleavage by the enzyme. Reactions were stopped with 2 ~1 of 0.5 M EDTA and the
fragmentation
efficiency was evaluated on a 2% TAE-agarose gel. This treatment resulted in
total fragmentation of
genomic DNA into near 50-70 by fragments. Fragments were then blunt-ended
twice using T4 DNA
Polymerase in the presence of 100 ~M each of dNTPs to ensure efficient
flushing of the ends. Fragments
were used immediately in ligation reactions or frozen at -20°C for
subsequent use.
Description of the vectors. The vector pMAL4.31 was constructed on a pASK-IBA
backbone {Skerra, A.,
1994} with the beta-lactamase (bla) gene exchanged with the Kanamycin
resistance gene. In addition the
bla gene was cloned into the multiple cloning site. The sequence encoding
mature beta-lactamase is
preceded by the leader peptide sequence of ompA to allow efficient secretion
across the cytoplasmic
membrane. Furthermore a sequence encoding the first 12 amino acids (spacer
sequence) of mature beta-
lactamase follows the otnpA leader peptide sequence to avoid fusion of
sequences immediately after the
leader peptidase cleavage site, since e.g. clusters of positive charged amino
acids in this region would
decrease or abolish translocation across the cytoplasmic membrane {Kajava, A.
et al., 2000}. A StnaI
restriction site serves for library insertion. An upstream FseI site and a
downstream NotI site, which were
used for recovery of the selected fragment, flank the StnaI site. The three
restriction sites are inserted after
the sequence encoding the 12 amino acid spacer sequence in such a way that the
bla gene is transcribed in
the -1 reading frame resulting in a stop codon 15 by after the NotI site. A +1
by insertion restores the bla
ORF so that beta-lactamase protein is produced with a consequent gain of
Ampicillin resistance.
The vector pMAL9.1 was constructed by cloning the lama gene into the multiple
cloning site of pEH1
{Hashemzadeh-Bonehi, L. et al., 1998}. Subsequently, a sequence was inserted
in lama after amino acid
154, containing the restriction sites FseI, SntaI and NotI. The reading frame
for this insertion was
constructed in such a way that transfer of frame-selected DNA fragments
excised by digestion with FseI
and NotI from plasmid pMAL4.31 yields a continuous reading frame of lama and
the respective insert.
The vector pHIEl1 was constructed by cloning the fhuA gene into the multiple
cloning site of pEHl.
Thereafter, a sequence was inserted in fhuA after amino acid 405, containing
the restriction site FseI, XbaI
and NotI. The reading frame for this insertion was chosen in a way that
transfer of frame-selected DNA
fragments excised by digestion with FseI and NotI from plasmid pMAL4.31 yields
a continuous reading
frame of fhuA and the respective insert.
Cloning and evaluation of the library for frame selection. Genomic S.
agalactiae DNA fragments were ligated
into the SntaI site of the vector pMAL4.31. Recombinant DNA was electroporated
into DH10B
electrocompetent E. coli cells (GIBCO BRL) and transformants plated on LB-agar
supplemented with
Kanamycin (50 ~g/ml) and Ampicillin (50 ~g/ml). Plates were incubated over
night at 37°C and colonies
collected for large scale DNA extraction. A representative plate was stored
and saved for collecting
colonies for colony PCR analysis and large-scale sequencing. A simple colony
PCR assay was used to
initially determine the rough fragment size distribution as well as insertion
efficiency. From sequencing
data the precise fragment size was evaluated, junction intactness at the
insertion site as well as the frame
selection accuracy (3n+1 rule).
Cloning and evaluation of the libt~ary for bacterial surface display. Genomic
DNA fragments were excised from
the pMAL4.31 vector, containing the S. agalactiae library with the restriction
enzymes FseI and NotI. The
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-56-
entire population of fragments Was then transferred into plasmids pMAL9.1
(Lama) or pHIEl1 (FhuA),
which have been digested with FseI and NotI. Using these two restriction
enzymes, which recognise an 8
by GC rich sequence, the reading frame that was selected in the pMAL4.31
vector is maintained in each of
the platform vectors. The plasmid library was then transformed into E. coli
DHSalpha cells by
electroporation. Cells were plated onto large LB-agar plates supplemented with
50 ~g/ml Kanamycin and
grown over night at 37°C at a density yielding clearly visible single
colonies. Cells were then scraped off
the surface of these plates, washed with fresh LB medium and stored in
aliquots for library screening at -
80°C.
Results
Libraries for frame selection. Two libraries (LSAg-70 and LSAg-300) were
generated in the pMAL4.31
vector with sizes of approximately 70 and 300 bp, respectively. For each
library, ligation and subsequent
transformation of approximately 1 ~g of pMAL4.31 plasmid DNA and 50 ng of
fragmented genomic S.
agalactiae DNA yielded 4x 105 to 2x 106 clones after frame selection. To
assess the randomness of the
libraries, approximately 576 randomly chosen clones of LSAg-70 were sequenced.
The bioinformatic
analysis showed that of these clones only very few were present more than
once. Furthermore, it was
shown that approximately 80% of the clones fell in the size range between 25
and 100 by with an average
size of approximately 40 by (Figure 2). Allmost all sequences followed the
3n+1 rule, showing that all
clones were properly frame selected.
Bactef~ial surface display libraries. The display of peptides on the surface
of E. coli required the transfer of the
inserts from the LSAg-70 and LSAg-300 libraries from the frame selection
vector pMAL4.31 to the display
plasmids pMAL9.1 (Lama) or pHIEl1 (FhuA). Genomic DNA fragments were excised
by FseI and NotI
restriction and ligation of 5ng inserts with 0.1~g plasmid DNA and subsequent
transformation into
DH5alpha cells resulted in 2-5x 106 clones. The clones were scraped off the LB
plates and frozen without
further amplification.
Example 3: Identification of highly immunogenic peptide sequences from S.
agalactiae using bacterial
surface displayed genomic libraries and human serum
Experimental procedures
MACS screening. Approximately 2.5x 10$ cells from a given library were grown
in 5 ml LB-medium
supplemented with 50 ~g/ml Kanamycin for 2 h at 37°C. Expression was
induced by the addition of 1
mM IPTG for 30 min. Cells were washed twice with fresh LB medium and
approximately 2x 10~ cells re-
suspended in 100 ~l LB medium and transferred to an Eppendorf tube.
to 20 ~g of biotinylated, human IgGs purified from serum was added to the
cells and the suspension
incubated overnight at 4°C with gentle shaking. 900 ~1 of LB medium was
added, the suspension mixed
and subsequently centrifuged for 10 min at 6,000 rpm at 4°C (For IgA
screens, 10 ~g of purified IgAs
were used and these captured with biotinylated anti-human-IgG secondary
antibodies). Cells were
washed once with 1 ml LB and then re-suspended in 100 ~1 LB medium. 10 ~1 of
MACS microbeads
coupled to streptavidin (Miltenyi Biotech, Germany) were added and the
incubation continued for 20 min
at 4°C. Thereafter 900 ~1 of LB medium was added and the MACS microbead
cell suspension was loaded
onto the equilibrated MS column (Miltenyi Biotech, Germany) which was fixed to
the magnet. (The MS
columns were equilibrated by washing once with 1 ml 70% EtOH and twice with 2
ml LB medium.)
The column was then washed three times with 3 ml LB medium. After removal of
the magnet, cells were
eluted by washing with 2 ml LB medium. After washing the column with 3 ml LB
medium, the 2 ml
eluate was loaded a second time on the same column and the washing and elution
process repeated. The
loading, washing and elution process was performed a third time, resulting in
a final eluate of 2 ml.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-57-
A second and third round of screening was performed as follows. The cells from
the final eluate were
collected by centrifugation and re-suspended in 1 ml LB medium supplemented
with 50 ~g/ml
Kanamycin. The culture was incubated at 37°C for 90 min and then
induced with 1 mM IPTG for 30 min.
Cells were subsequently collected, washed once with 1 ml LB medium and
suspended in 10 ~tl LB
medium. 10 to 20 ~g of human, biotinylated IgGs were added again and the
suspension incubated over
night at 4°C with gentle shaking. All further steps were exactly the
same as in the first selection round.
Cells selected after two rounds of selection were plated onto LB-agar plates
supplemented with 50 ~g/ml
Kanamycin and grown over night at 3~°C.
Evaluation of selected cloves by sequencing and Western blot analysis.
Selected clones were grown overnight at
37°C in 3 ml LB medium supplemented with 50 ~g/ml Kanamycin to prepare
plasmid DNA using
standard procedures. Sequencing was performed at MWG (Germany) or in
collaboration with TIGR
(U.S.A.).
For Western blot analysis approximately 10 to 20 ~g of total cellular protein
was separated by 10% SDS-
PAGE and blotted onto HybondC membrane (Amersham Pharmacia Biotech, England).
The Lama or
FhuA fusion proteins were detected using human serum as the primary antibody
at a dilution of
approximately 1:3,000 to 1:5,000 and anti-human IgG or IgA antibodies coupled
to HRP at a dilution of
1:5,000 as secondary antibodies. Detection was performed using the ECL
detection kit (Amersham
Pharmacia Biotech, England). Alternatively, rabbit anti-FhuA or rabbit anti-
Lama polyclonal immune
sera were used as primary antibodies in combination with the respective
secondary antibodies coupled to
HRl' for the detection of the fusion proteins.
Results
Screening of bacterial surface display libraries by magnetic activated cell
sorting (MACS) using biotinylated Igs.
The libraries LSag-70 in pMAL9.1 and LSag-300 in pHIEl1 were screened with
pools of biotinylated,
human IgGs and IgAs prepared from sera of healthy adults (NSagB-IgG,-IgA) or
P10,11,18 (see Example
1: Preparation of a~itibodies from human serum). The selection procedure was
performed as described under
Experimental procedures. Figure 3A shows a representative example of a screen
with the LSag-70 library
and PSagl1-IgGs. As can be seen from the colony count after the first
selection cycle from MACS
screening, the total number of cells recovered at the end is drastically
reduced from 2x10 cells to
approximately 2x 104 cells, but the selection without antibodies added showed
a similar reduction in cell
numbers (Figure 3A). Therefore a second and third round of selection was
performed. At the end of
round three, approximately 104 cells was recovered with PSagl1-IgGs, while
only 2x 103 cells were
recovered when no IgGs from human serum were added, clearly showing that
selection was dependent
on S. agalactiae specific antibodies. To evaluate the performance of the
screen, 26 selected clones were
picked randomly and subjected to immunoblot analysis with screening IgG pool
(Figure 3B). This
analysis revealed that more than 80% of the selected clones showed reactivity
with antibodies present in
the relevant serum whereas the control strain expressing Lama without a S.
agalactiae specific insert did
not react with the same serum. In general, the rate of reactivity was observed
to lie within the range of 35
to 90%. Colony PCR analysis showed that all selected clones contained an
insert in the expected size
range.
Subsequent sequencing of a larger number of randomly picked clones (600 to
1200 per screen) led to the
identification of the gene and the corresponding peptide or protein sequence
that was specifically
recognized by the human serum antibodies used for screening. The frequency
with which a specific clone
is selected reflects at least in part the abundance and/or affinity of the
specific antibodies in the serum
used for selection and recognizing the epitope presented by this clone. In
that regard it is striking that
clones derived from some ORFs (e.g. gbs1087, gbs1306, gbs2018) were picked
more than 100 times,
indicating their highly immunogenic property. Table 1 and Table 5 summarizes
the data obtained for all
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-5~-
13 performed screens. All clones that are presented in Table 1 and Table 5
have been verified by
immunoblot analysis using whole cellular extracts from single clones to show
the indicated reactivity
with the pool of human serum used in the respective screen. As can be seen
from Table 1 and Table 5,
distinct regions of the identified ORF are identified as immunogenic, since
variably sized fragments of
the proteins are displayed on the surface by the platform proteins.
It is further worth noticing that most of the genes identified by the
bacterial surface display screen encode
proteins that are either attached to the surface of S. agalactiae and/or are
secreted. This is in accordance
with the expected role of surface attached or secreted proteins in virulence
of S. agalactiae.
Example 4: Assessment of the reactivity of highly immunogenic peptide
sequences with individual
human sera.
Experiznerztal procedures
Peptide synthesis
Peptides were synthesized in small scale (4 mg resin; up to 288 in parallel)
using standard F-moc
chemistry on a Rink amide resin (PepChem, Tiibingen, Germany) using a SyroII
synthesizer
(Multisyntech, Witten, Germany). After the sequence was assembled, peptides
were elongated with
Fmoc-epsilon-aminohexanoic acid (as a linker) and biotin (Sigma, St. Louis,
MO; activated like a normal
amino acid). Peptides were cleaved off the resin with 93%TFA, 5%
triethylsilane, and 2% water for one
hour. Peptides were dried under vacuum and freeze dried three times from
acetonitrile/water (1:1). The
presence of the correct mass was verified by mass spectrometry on a Reflex III
MALDI-TOF (Bruker,
Bremen Germany). The peptides were used without further purification.
Enzyfne linked immune assay (ELISA).
Biotin-labeled peptides (at the N-terminus) were coated on Streptavidin ELISA
plates (EXICON) at 10
~g/ml concentration according to the manufacturer's instructions. Highly
specific Horse Radish
Peroxidase (HRP)-conjugated anti-human IgG secondary antibodies (Southern
Biotech) were used
according to the manufacturers' recommendations (dilution: 1,000x). Sera were
tested at two serum
dilutions, 200X and 1,000X. Following manual coating, peptide plates were
processed and analyzed by
the Gemini 160 ELISA robot (TECAN) with a built-in ELISA reader (GENIOS,
TECAN).
Results
Following the bioinformatic analysis of selected clones, corresponding
peptides were designed and
synthesized. In case of epitopes with more than 26 amino acid residues,
overlapping peptides were made.
All peptides were synthesized with a N-terminal biotin-tag and used as coating
reagents on Streptavidin-
coated ELISA plates.
The analysis was performed with peptides that were selected based on their
reactivity with the individual
sera, which were included in the serum pools used for preparations of IgG and
IgA screening reagents for
bacterial surface display. A summary for serum reactivity of 74 peptides
representing 55 different S.
agalactiae antigenic proteins from the genomic screen analysed with 22 human
sera (from 13 patient and 9
healthy exposed high titer individuals) used for the antigen identification is
shown in Table 2 and Table
6. The peptides were compared by the score calculated for each peptide based
on the number of positive
sera and the extent of reactivity. Peptides range from highly and widely
reactive to weakly positive ones.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-59-
Example 5: Gene distribution studies with highly immunogeruc proteins
identified from S. agalactiae.
Experimental procedures
Gene distribution of GBS antigens by PCR. An ideal vaccine antigen would be an
antigen that is present in
all, or the vast majority of strains of the target organism to which the
vaccine is directed. In order to
establish whether the genes encoding the identified Streptococcus agalactiae
antigens occur ubiquitously in
S. agalactiae strains, PCR was performed on a series of independent S.
agalactiae isolates with primers
specific for the gene of interest. S. agalactiae isolates were obtained
covering the serotypes most frequently
present in patients as shown in Figure 4A. Oligonucleotide sequences as
primers were designed for all
identified ORFs yielding products of approximately 1,000 bp, if possible
covering all identified
immunogenic epitopes. Genomic DNA of all S. agalactiae strains was prepared as
described under
Example 2. PCR was performed in a reaction volume of 25 ~tl using Taq
polymerise (1LT), 200 nM dNTPs,
pMol of each oligonucleotide and the kit according to the manufacturers
instructions (Invitrogen, The
Netherlands). As standard, 30 cycles (1x: 5min. 95°C, 30x: 30sec.
95°C, 30sec. 56°C, 30sec. 72°C, 1x 4min.
72°C) were performed, unless conditions had to be adapted for
individual primer pairs.
Results
Identified genes encoding immunogenic proteins were tested by PCR for their
presence in 46 different
strains of S. agalactiae (Figure 4A). As an example, figure 4B shows the PCR
reaction for GBS0061 with all
indicated 46 strains. As clearly visible, the gene is present in all strains
analysed. The PCR fragment from
a type IA strain was sequenced and showed that all 657 by were identical as
compared to the S. agalactiae
ATCC 12403 strain, indicating a high level of conservation between the two
isolates.
From a total of 117 genes analysed, more than 100 were present in all or
almost all strains tested, while
only 5 genes were absent in more than 10% of the tested 46 strains (Table 3).
In addition, only few genes
(e.g. GBS0016, GBS1087, GBS1528 and GBS2018) showed variation in size but were
present in all or most
strain isolates. Sequencing of the generated PCR fragment from one strain and
subsequent comparison to
the type III strain ATCC 12403 confirmed the amplification of the correct DNA
fragment and revealed a
degree of sequence divergence as indicated in Table 3. Importantly, many of
the identified antigens are
well conserved in all strains in sequence and size and are therefore novel
vaccine candidates to prevent
infections by GBS.
Example 6: Characterization of immune sera obtained from mice immunized with
highly
immunogenic proteins/peptides from S. agalactiae displayed on the surface of
E. coli.
Experimental procedures
Generation of immune sera from mice
E. coli clones harboring plasmids encoding the platform protein fused to a S.
agalactiae peptide, were
grown in LB medium supplemented with 50~xg/ml Kanamycin at 37°C.
Overnight cultures were diluted
1:10, grown until an ODsoo of 0.5 and induced with 0.2 mM IPTG for 2 hours.
Pelleted bacterial cells were
suspended in PBS buffer and disrupted by sonication on ice, generating a crude
cell extract. According to
the OD6oo measurement, an aliquot corresponding to 5x10 cells was injected
into NMRI mice i.v.,
followed by a boost after 2 weeks. Serum was taken 1 week after the second
injection. Epitope specific
antibody levels were measured by peptide ELISA.
In vitro expression of antigens
Expression of antigens by in vitro grown S. agalactiae serotype III was tested
by immunoblotting. Different
growth media and culture conditions were tested to detect the presence of
antigens in total lysates and
bacterial culture supernatants. Expression was considered confirmed when a
specific band corresponding
to the predicted molecular weight and electrophoretic mobility was detected.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-60-
Cell surface staining
Flow cytometric analysis was carried out as follows. Bacteria were grown under
culture conditions,
which resulted in expression of the antigen as shown by the immunoblot
analysis. Cells were washed
twice in Hanks Balanced Salt Solution (HBSS) and the cell density was adjusted
to approximately 1 X 106
CFU in 100~t1 HBSS, 0.5% BSA. After incubation for 30 to 60 min at 4°C
with mouse antisera diluted 50 to
100-fold, unbound antibodies were washed away by centrifugation in excess
HBSS, 0.5% BSA. Secondary
goat anti-mouse antibody (F(ab°)z fragment specific) labeled with
fluorescein (FITC) was incubated with
the cells at 4°C for 30 to 60 min. After washing, cells were fixed with
2% paraformaldehyde. Bound
antibodies were detected using a Becton Dickinson FACScan flow cytometer and
data further analyzed
with the computer program CELLQuest. Negative control sera included mouse pre-
immune serum and
mouse polyclonal serum generated with lysates prepared from IPTG induced E.
coli cells transformed
with plasmids encoding the genes lanaB or fhuA without S. agalactiae genomic
insert.
Bactericidal (killi~ag) assay
Murine macrophage cells (RAW246.7 or P388.D1) and bacteria were incubated and
the loss of viable
bacteria after 60 min was determined by colony counting. In brief, bacteria
were washed twice in Hanks
Balanced Salt Solution (HBSS) and the cell density was adjusted to
approximately 1X 105 CFU in 501
HESS. Bacteria were incubated with mouse sera (up to 25%) and guinea pig
complement (up to 5%) in a
total volume of 100~t1 for 60min at 4°C. Pre-opsonized bacteria were
mixed with macrophages (murine
cell line RAW264.7 or P388.D1; 2X 106 cells per 1001) at a 1:20 ratio and were
incubated at 37°C on a
rotating shaker at 500 rpm. An aliquot of each sample was diluted in sterile
water and incubated for 5
min at room temperature to lyse macrophages. Serial dilutions were then plated
onto Todd-Hewitt Broth
agar plates. The plates were incubated overnight at 37°C, and the
colonies were counted with the
Countermat flash colony counter (IUL W struments). Control sera included mouse
pre-immune serum
and mouse polyclonal serum generated with lysates prepared from IPTG induced
E. coli transformed
with plasmids harboring the genes lama or fhuA without S. agalactiae genomic
insert.
Results
Immunogenicity in mice. The presence of specific antibodies was determined by
peptide ELISA and/or
immunoblotting using the E. coli clone expressing the given epitope embedded
in Lama or FhuA
platform proteins, as it is exemplified in Fig. 5A and B, respectively, and
summarized in Table 4 and
Table 7. 43 novel GBS antigens represented by 61 different epitope regions
were shown to be
immunogenic in mice. Positive sera were then analysed by immunblotting using
total bacterial lysates
and culture supernatants prepared from S. agalactiae serotype III strain (data
not shown). This analysis
served as a first step to determine whether the antigenic proteins were
expressed, and if, under which
growth conditions, in order to evaluate surface expression of the polypeptide
by FACS analysis. It was
anticipated based on literature data that not all proteins would be expressed
under in vitro conditions.
Cell surface staining of S. agalactiae. Cell surface accessibility for several
antigenic proteins was
subsequently demonstrated by an assay based on flow cytometry. GBS cells were
incubated with
preimmune and polyclonal mouse sera raised against S. agalactiae lysate or E.
coli clones harboring
plasmids encoding the platform protein fused to a S. agalactiae peptide,
followed by detection with
fluorescently tagged secondary antibody. As shown in Fig. 6A, antisera raised
against S. agalactiae lysate
contains antibodies against surface components, demonstrated by a significant
shift in fluorescence of the
S. agalactiae serotype III cell population. Similar cell surface staining of
S. agalactiae serotype III cells was
observed with polyclonal sera raised against peptides of many of the GBS
antigens identified (Fig. 6B ). In
some instancies, a subpopulation of the bacteria was not stained, as indicated
by the detection of two
peaks in the histograms (Fig. 6B). This phenomenon may be a result of
differential expression of the gene
products during the growth of the bacterium, insufficient antibody levels or
partial inhibition of antibody
binding caused by other surface molecules or plasma proteins. Importantly, a
well-known protective GBS
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-61-
antigen, Sip/gbs0031 is proved to be also positive in this assay.
by vitro bactericidal activity. Opsonophagocytic killing is the cornerstone of
host defense against
extracellular bacteria, such as S. agalactiae. Cell surface binding of
antibodies to bacterial antigens are
opsonizing and induce killing (bactericidal) by phagocytic cells (macrophages
and neutrophil
granulocytes) if the antibodies induced by the particular antigens can bind
activated complement
c~mponents (C3bi). In Figure 7 data are presented on bactericidal activity
measured by antigen-specific
antibodies generated in mice with corresponding epitopes. According to these
data, several of the novel
GBS antigens, for example gbs001~., gbs0016, gbs0428, gbs1306 and gbs2018
induce functional antibodies.
Importantly, a well-known protective GBS antigen, Sip/gbs0031 is proved to be
strongly positive in the
very same assay.
These experiments confirmed the bioinformatic prediction that many of the
proteins are exported due to
their signal peptide sequence and in addition showed that they are present on
the cell surface of S.
agalactiae serotype III. They also confirm that these proteins are available
for recognition by human
antibodies with functional properties and make them valuable candidates for
the development of a
vaccine against GBS diseases.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-62-
Table 1A: Immunogenic proteins identified by bacterial surface display.
S. agalactiaePutative predicted immunogenic aa"'*No. LocationSeq.
function of o
antigeatic(by homology) selectedidentifiedID
protein clones immunogeni(DNA,
per
~RF c regionProt.)
and (aa)
screen
gbs0012eakly similar-20,35-44,65-70,73-87,92-98,112-137,152-161,177-:13, 115-
1991,
to C:6 218
eta-lactamase186,193-200,206-213,229-255,282-294,308-313,320-
26,349-355,373-384,388-406,420-425
gbs0016glucan-binding-24,35-41,44-70,73-89,103-109,127-143,155-161,185-:12,
1-75, 2,
C:4, 76-161,219
protein 190,192-207,212-219,246-262,304-336,372-382,384-:3, 164-239
B E:S,
H:4,
93,398-407,412-418,438-444 :12,
M:2
gbs0024phosphoribosylformyl-10,16-58,60-71,77-92,100-126,132-146,149-164,166-
:4 802-8123,
220
glycinamidine172,190-209,214-220,223-229,241-256,297-312,314-
synthase 19,337-343,351-359,378-387,398-418,421-428,430-
37,440-448,462-471,510-519,525-536,552-559,561-
68,573-582,596-602,608-630,637-649,651-665,681-
702,714-732,739-745,757-778,790-805,807-815,821-
829,836-842,846-873,880-903,908-914,916-923,931-
940,943-948,956-970,975-986,996-1015,1031-1040,1051-
1069,1072-1095,1114-1119,1130-1148,1150-1157,1169-
1176,1229-1238
gbs0031surface -12,14-26,35-47,52-67,72-78,83-98,121-141,152-159,163-:17,
6-291 4,
immunogenic B:53, 221
protein 183,186-207,209-257,264-277,282-299,301-309,312-C:36,
D:4
18,324-339,358-368,372-378,387-397,425-431
gbs0048ypothetical9-38,44-64,70-76,78-87,94-100,102-112,119-134,140-:13 73-
92 5,
protein 222
149,163-173,178-186,188-194,207-234,247-262,269-290
gbs0053aldehyde-alcohol10-28,36-63,77-87,103-119,127-136,141-169,171-183,195-
E:4 757-7746,223
dehydrogenase00,207-232,236-246,251-265,268-283,287-297,314-
(adhE) 22,335-343,354-363,384-390,405-411,419-436,443-
55,467-473,480-513,518-529,550-557,565-585,602-
608,616-625,632-660,665-677,685-701,726-736,738-
747,752-761,785-796,801-813,838-853,866-871
gbs0061rplB ribosomal1-38,61-66,74-81,90-115,123-145,154-167,169-179,182-:2,
35-251 7,
I:12 224
protein 193,200-206,238-244,267-272
L2
gbs0084NA-directed19-25,38-54,56-64,66-72,74-92,94-100,116-129,143-C:4, 41-
313 8,
RNA D:6 225
polymerase,149,156-183,204-232,253-266,269-275,294-307
alpha
subunit
(rpoA)
gbs0107conserved -34,50-56,60-65,74-85,89-97,108-119,159-165,181-:2 64-75
9,
226
iypothetical199,209-225,230-240,245-251,257-262,274-282,300-305
protein
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
- 63 -
S, agalactiaePutative predicted immunogeruc as** No. LocationSeq.
funciion of of
antigenic(by homology) selectedidentifiedID
protein clones immunogeru(DNA,
per
~RF c regionProt.)
and (aa)
screen
gbs0108deoxyuridine-13,16-21,27-42,45-52,58-66,74-87,108-114,119-131:5 9-
51 10,
5'- 227
triphosphate
ucleotidohydrolase
gbs0113ribose ABC 6-23,46-54,59-65,78-84,100-120,128-133,140-146,159-:4 67-
274 11,
228
transporter165,171-183,190-204,224-232,240-248,250-259,274-
80,288-296,306-315
gbs0123imilar to -12,15-24,26-36,42-65,68-80,82-104,111-116,125-:17 162-
17412,
229
argininosuccinate144,159-167,184-189,209-218,235-243,254-265,269-
synthase 83,287-300,306-316,318-336,338-352,374-392
gbs0127rpmV 50S 0-42,45-54 :11 5-37 13,
ribosomal 230
protein
L28
gbs0144oligopeptide10-30,53-59,86-95,116-130,132-147,169-189,195-201,212-E:7
19-431 14,
ABC 231
transporter,21,247-256,258-265,278-283,291-298,310-316,329-
substrate-binding39,341-352,360-367,388-396,398-411,416-432,443-
52,460-466,506-512,515-521,542-548
gbs0183membrane -27,30-53,60-67,70-90,92-151,159-185,189-195,198-:9 173-
18915,
protein, 232
putative 10,215- 239
gbs0184oligopeptide-26,41-54,71-78,116-127,140-149,151-158,161-175,190-E:6
174-18816,
ABC 233
transporter,196,201-208,220-226,240-252,266-281,298-305,308-
oligopeptide-binding18,321-329,344-353,372-378,384-405,418-426,429-
42,457-463,494-505,514-522
gbs0235glycine 17-25,27-39,61-67,81-89,99-110,120-131,133-139,147-G:B, 39-
256 17,
H:15 234
etaine/carnitine/chol161,167-172,179-185,192-198,203-213,226-238,243-
ine ABC 58,261-267,284-290,296-307,311-328,340-352,356-371
transporter
gbs0255conserved 8-30,40-49,67-80,114-123,126-142,152-162,188-194E:2 7-70
18,235
ypothetical
protein
gbs0260glycyl-tRNA-23,28-34,36-47,50-61,76-81,89-94,96-104,112-119,126-:3
82-297 19,
236
synthetase(beta146,155-181,195-200,208-214,220-229,244-260,263-
subunit) 76,282-288,292-300,317-323,336-351,353-359,363-
75,382-399,415-432,444-455,458-471,476-481,484-
92,499-517,522-529,535-541,543-568,572-584,586-
00,607-617,626-637,656-675
gbs0268transketolase6-24,30-35,38-45,63-91,134-140,146-160,167-188,214-E:7
87-97 20,
(tkt) 237
20,226-234,244-250,260-270,286-301,316-329,340-
71,429-446,448-459,474-481,485-491,512-526,537-
44,550-565,573-583,596-613,621-630,652-658
gbs0286NH3-dependent8-20,26-48,56-67,76-86,94-109,115-121,123-129,143-:12,
37-247 21,
G:7, 238
H:8
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-64-
S. agalactiaePutative predicted immunogenic as** No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clonesimmunogeru(DNA,
per
~RF c regionProt.)
and (aa)
screen
AD+ synthetase160,178-186,191-198,201-208,221-236,238-244,260-268
gbs0288 similar -40,42-57,73-87,98-117,126-135,150-156,166-174,196-:5, 48-
528 22,
to penicillin- K:3 239
finding 17,231-236,248-258,276-284,293-301,307-313,339-
protein
lA
47,359-365,375-387,395-402,428-440,445-456,485-
90,497-505,535-541,547-555,610-625,648-656,665-671
gbs0343 seryl-tRNA10-18,39-45,51-61,80-96,98-106,110-115,158-172,174-:3 22-
338 23,
240
synthetase(serS)183,191-200,220-237,249-255,274-289,308-324,331-
41,372-381,384-397,405-414
gbs0411 ypothetical0-36,38-56,85-108,134-147,149-160,163-183,188-:11 -13
24,
protein 241
01,206-211,219-238,247-254
gbs0428 similar 11-40,98-103,110-115,133-145,151-159,172-179,192-:7, 1-148
25,
to fibrinogen B:2, 242
C:31
finding 01,204-212,222-228,235-245,258-268,283-296,298-
protein,
putative 09,322-329,342-351,354-362,372-378,385-393,407-
peptidoglycan18,495-516
linked
protein
(LPXTG
motif)
gbs0437 glucose-6-phosphate-19,21-36,73-94,112-119,122-137,139-145,152-167,184-
:26 113-14026,243
'somerase 190,198-204,208-224,249-265,267-281,299-304,309-
(pgi)
17,326-333,356-364,368-374,381-389,391-414,419-
25,430-435
gbs0460 decarboxylase5-54,59-67,78-91 :7, 15-23 27,
K:11 244
gbs0465 oxydoreductase11-22,33-47,52-80,88-112,124-129:4 6-25 28,
245
gbs0470 similar 6-41,51-63,80-89,93-115,150-163,187-193,220-237,240-:4, 20-
511,29,
to alpha C:2, 581- 246
D:8
protein, 49,286-294,296-306,316-329,345-353,361-370,407- 704
putative
peptidoglycan25,428-437,474-482,484-494,504-517,533-541,549-
linked
protein 58,595-613,616-625,660-668,673-685,711-726,736-
(LPXTG
motif) 744,749-761,787-802,812-820,825-837,863-878,888-
896,901-913,939-954,964-972,977-989,1003-1008,1016-
1022,1028-1034,1041-1053,1059-1074,1101-1122
gbs0489 acetyltransferase,18-25,27-55,71-83,89-95,102-113,120-146,150-156,174-
E:32 159-17530,
247
GNAT family185
gbs0492 gbs0492 4-30,38-56,63-68,87-93,136-142,153-164,183-199,213-:3 806-
88431,
valyl-tRNA 248
synthetase19,226-234,244-261,269-278,283-289,291-297,320-
28,330-336,340-346,348-356,358-366,382-387,401-
08,414-419,449-455,468-491,504-512,531-537,554-
60,597-608,621-627,632-643,650-662,667-692,703-
716,724-737,743-758,783-794,800-818,846-856
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-65-
S. agalactiaePutative predicted immunogenic as*"'No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clones immunogeni(DNA,
per
ORF c regionProt.)
and (aa)
screen
gbs0538amino acid -14,21-39,86-92,99-107,121-131,136-144,147-154,158-G:1
117-13632,
ABC 249
t ransporter 166,176-185,193-199,207-222,224-230
(ATP-
binding
protein)
gbs0539similar 65-76,85-97,103-109,115-121,125-146,163-169,196-:4 66-
284 33,
to 250
phosphomannomuta05,212-219,228-237,241-247,254-262,269-288,294-
se 03,305-313,328-367,395-401,405-412,418-429,437-
47,481-488,506-513,519-524,530-541,546-557
gbs0555eta-lactam -14,37-42,49-71,78-92,97-112,127-136,147-154,156-:3 194-
22334,
251
resistance 163,186-198,216-225,233-243,248-253,295-307,323-
factor
(fibA) 32,359-366,368-374,380-398
gbs0579dipeptidase-11,33-39,45-72,100-113,119-129,136-144,169-175,177-:4
38-454 35,252
185,200-208,210-219,262-276,278-297,320-326,336-
44,347-362,381-394,443-453
gbs0580inc ABC -29,31-52,55-61,95-110,138-158,162-171,179-187,202-:11
161-17836,
transporter, 253
inc-binding29,239-248,251-256,262-267,269-285,304-310,351-
adhesion, 60,362-368,381-388,415-428,435-440,448-458
lipoprotein
gbs0628cell wall -17,19-28,32-43,47-59,89-110,112-126,128-134,140-:9, 05-
381 37,
surface H:1 254
anchor family148,152-161,169-184,191-204,230-235,255-264,328-
protein
(lPxTG) 38,341-347,401-409,413-419,433-441,449-458,463-
68,476-482,486-492,500-506,529-545
gbs0632cell wall 10-29,38-45,53-61,134-145,152-160,163-170,202-208,219-:3
698-71538,
surface 255
anchor family29,248-258,266-275,282-288,315-320,328-334,377-
protein, 85,392-402,418-424,447-453,460-471,479-487,491-
putative
(FPKTG motive)97,500-507,531-537,581-594,615-623,629-635,644-
652,659-666,668-678,710-717,719-728,736-741,747-
760,766-773,784-789,794-800,805-817,855-861,866-887
gbs0634putative 16-26,29-37,44-58,62-68,74-80,88-95,97-120,125-144,165-:1
8-72 39,
surface 256
protein 196
gbs0667regulatory 14-21,23-46,49-60,63-74,78-92,96-103,117-129,134-:2 43-
257 40,
protein, 257
putative, 161,169-211,217-231,239-248,252-281,292-299,313-343
truncation
gbs0672transcriptional11-27,46-52,67-72,76-84,91-112,116-153,160-175,187-G:11
3-76 41,
258
regulator(GntR196,202-211,213-220
family)
gbs0687ypothetical-29,37-56,78-86,108-118,152-161:4 120-13042,
protein 259
gbs0785imilar to 8-14,19-41,52-66,75-82,87-92,106-121,127-133,136-:3 184-
19643,
penicillin 260
finding 143,158-175,180-187,196-204,221-228,239-245,259-
protein
2B
65,291-306,318-323,328-340,352-358,361-368,375-
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-66-
S. agalactiaePutative predicted immunogeruc as** No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clones mmunogeni(DNA,
per
i
ORF c regionProt.)
and (aa)
screen
81,391-399,411-418,431-442,446-455,484-496,498-
10,527-533,541-549,558-565,575-585,587-594,644-
655,661-668,671-677
gbs0811 eta-glucosidase-22,29-38,55-62,75-81,102-107,110-134,143-150,161-:13
198-21844,
261
167,172-179,191-215,223-233,241-247,251-264,266-
72,288-309,340-352,354-366,394-402,414-438
gbs0828 ypothetical4-44,49-70,80-91,105-118,128-136,140-154:3 77-92 45,
protein 262
gbs0851 ypothetical-22,31-36,41-47,67-74,83-90,105-122,135-143,160-167:2
118-12946,
protein 263
gbs0865 ypothetical-25,33-73,81-93,96-106,114-120,122-128,130-172,179-:4
92-100 47,
protein 264
08,210-241,251-283,296-301
gbs0890 exonuclease14-24,29-38,43-50,52-72,86-97,101-107,110-125,127-E:5 36-
349 48,
RexB 265
(rexB) 141,145-157,168-175,177-184,186-195,205-226,238-
50,255-261,284-290,293-304,307-314,316-323,325-
56,363-371,383-390,405-415,423-432,442-454,466-
85,502-511,519-527,535-556,558-565,569-574,612-
634,641-655,672-686,698-709,715-722,724-732,743-
753,760-769,783-792,818-825,830-839,842-849,884-
896,905-918,926-940,957-969,979-1007,1015-1021,1049-
1057
gbs0896 similar 6-16,26-31,33-39,62-73,75-85,87-100,113-123,127-:2 181-
19549,
to acetoin 266
dehydrogenase152,157-164,168-181,191-198,208-214,219-226,233-
54,259-266,286-329
gbs0898 acetoin -13,32-39,53-76,99-108,110-116,124-135,137-146,149-E:13, 1-
45, 50,
F:2, 419- 267
I:2,
dehydrogenase,157,162-174,182-190,207-231,242-253,255-264,274-:2 43
thymine 83,291-323,334-345,351-360,375-388,418-425,456-
PFi
dependent 74,486-492,508-517,520-536,547-560,562-577
gbs0904 phosphoglucomutase15-26,30-37,42-49,58-90,93-99,128-134,147-154,174-:3
46-256 51,
268
phosphomannomuta179,190-197,199-205,221-230,262-274,277-287,300-
se family 14,327-333,343-351,359-377,388-396,408-413,416-
protein
25,431-446
gbs0918 weakly similar-26,34-42,47-54,61-67,71-104,107-115,131-138,144-:5,
14-138,52,
to C:11, 166- 269
histidine 153,157-189,196-202,204-210,228-245,288-309,316-D:36, 86,
triad E:3, 372-503,
K:3
protein, 29,332-341,379-386,393-399,404-412,414-421,457- 674-696,
putative 754-
lipoprotein68,483-489,500-506,508-517,523-534,543-557,565- 859
80,587-605,609-617,619-627,631-636,640-646,662-
668,675-682,705-710,716-723,727-732,750-758,784-
789,795-809,869-874
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-67-
S. agalactiaePutative predicted immunogenic as** No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clones immunogeni(DNA,
per
~RF c regionProt.)
and (aa)
screen
gbs0931pyruvate -17,32-38,40-47,80-89,113-119,125-137,140-154,157-:78 116-
12453,270
kinase
163,170-177,185-199,213-225,228-236,242-248,277-
90,292-305,323-333,347-353,364-370,385-394,399-
06,423-433,441-451,462-474,477-487
gbs0947similar 7-16,18-30,32-49,53-61,63-85,95-101,105-115,119-:28 63-72
54,
to L-Lactate 271
ehydrogenase134,143-150,159-178,185-202,212-229,236-250,254-
65,268-294
gbs0948NA gyrase, -12,19-47,73-81,97-103,153-169,188-198,207-213,217-:4 58-
370 55,
A 272
uburut (gyrA)23,236-242,255-265,270-278,298-305,309-317,335-
47,354-363,373-394,419-424,442-465,486-492,500-
07,542-549,551-558,560-572,580-589,607-614,617-
623,647-653,666-676,694-704,706-714,748-754,765-
772,786-792,795-806
gbs0969similar 18-28,30-38,40-46,49-55,69-78,82-98,104-134,147-:3 90-
305 56,
to unknown 273
plasmid 153,180-190,196-202,218-236,244-261,266-273,275-
protein
86,290-295,301-314,378-387,390-395,427-434
gbs0971similar -13,20-31,39-51,54-61,69-84,87-105,117-124:17 108-12557,
to putative 274
plasmid
replication
protein
gbs0972ypothetical4-34,43-54,56-66,68-79 E:3 0-69 58,
protein 275
gbs0983similar -43,71-77,102-131,141-148,150-156,159-186,191-:11, 165-
178,59,
to plasmid E:2, 818- 276
F:2,
protein 07,209-234,255-268,280-286,293-299,317-323,350-:10, 974
IC:10,
57,363-372,391-397,406-418,428-435,455-465,484-:46,
M:3
97,499-505,525-531,575-582,593-607,621-633,638-
649,655-673,684-698,711-725,736-741,743-752,759-
769,781-793,813-831,843-853,894-905,908-916,929-
946,953-963,970-978,1001-1007,1011-1033
gbs0986surface 16-44,63-86,98-108,I85-191,222-237,261-274,282-:3, 77-90,
60,
antigen C:12, 144- 277
proteins, 94,335-345,349-362,374-384,409-420,424-430,440-:2, 12,
putative E:3, 279-355,
F:20,
peptidoglycan47,453-460,465-473,475-504,522-534,538-551,554-:3, 34-536,
bound I:3, 782-
J:S,
60,567-582,598-607,611-619,627-640,643-653,655-:2 810,875-902
661,669-680,684-690,701-707,715-731,744-750,756-
763,768-804,829-837,845-853,855-879,884-890,910-928
gbs0988similar -22,29-41,45-5I,53-66,70-77,86-95,98-104,106-124,129-:2
12-227 61,
to plasmid 278
surface I35,142-151,153-161,169-176,228-251,284-299,331-
exclusion
protein, 37,339-370,380-387,393-398,406-411,423-433,440-
putative
peptidoglycan52,461-469,488-498,501-516,523-530,532-559,562-
bound
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-68-
S. agalactiaePutative predicted immunogenic as*"' No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clones immunogeni(DNA,
per
~RF c regionprot.)
and (aa)
screen
protein 67,570-602,612-628,630-645,649-659,666-672,677-
(LPXTG
motif) 696,714-723,727-747
gbs0991 TP-dependent-9,17-31,35-41,56-61,66-75,81-87,90-124,133-138,149-:15
75-291 62,
Clp 279
protease, 163,173-192,213-219,221-262,265-275,277-282,292-
ATP-
inding 98,301-307,333-346,353-363,371-378,419-430,435-
suburut
CIpA 48,456-469,551-570,583-599,603-612
gbs0993 similar 8-34,53-58,72-81,100-128,145-154,159-168,172-189,217-B:2,
654-669,63,
to plasmid F:2, 280
J:4,
proteins 25,227-249,256-263,299-309,322-330,361-379,381-:2, 1400-1483
M:7
88,392-401,404-417,425-436,440-446,451-464,469-
87,502-511,543-551,559-564,595-601,606-612,615-
626,633-642,644-650,664-670,674-684,692-701,715-
723,726-734,749-756,763-771,781-787,810-843,860-
869,882-889,907-917,931-936,941-948,951-958,964-
971,976-993,1039-1049,1051-1065,1092-1121,1126-
1132,1145-1151,1158-1173,1181-1192,1194-1208,1218-
1223,1229-1243,1249-1254,1265-1279,1287-1297,1303-
1320,1334-1341,1343-1358,1372-1382,1406-1417,1419-
1425,1428-1434,1441-1448,1460-1473,1494-1504,1509-
1514,1529-1550
gbs0995 ypothetical10-16,20-25,58-65,97-109,118-132,134-146,148-155,186-:3,
05-230,64,
protein I:39, 733- 281
J:3,
195,226-233,244-262,275-284,295-310,317-322,330-:3 754
39,345-351,366-375,392-403,408-415,423-430,435-
44,446-457,467-479,486-499,503-510,525-537,540-
85,602-612,614-623,625-634,639-645,650-669,700-
707,717-724,727-739
gbs0997 ypothetical-22,37-43,72-81,105-113,128-133,148-160,188-194,204-:2,
194-21365,
protein F:52 282
30,238-245,251-257
gbs0998 ypothetical16-21,35-41,56-72,74-92,103-109:2 62-68 66,
protein 283
gbs1001 ypothetical-15,17-82,90-104,107-159,163-170,188-221,234-245,252-G:8
220-23567,
protein 284
65
gbs1015 hypothetical16-22,36-46,61-75,92-107,113-121,139-145,148-160:17 0-
42 68,
protein 285
gbs1035 conserved -12,20-26,43-49,55-62,66-78,121-127,135-141,146-E:3 28-
346 69,286
ypothetical161,164-170,178-189,196-205,233-238,269-279,288-
protein
18,325-332,381-386,400-407
gbs1041 ypothetical-12,31-49,57-63,69-79,89-97,99-114,116-127,134-:2 8-68
70,
protein 287
142,147-154,160-173,185-193,199-204,211-222,229-
36,243-249,256-274
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-69-
S. agalactiaePutative predicted immunogenic as** No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clones immunogeni(DNA,
per
~RF c regionProt.)
and (aa)
screen
gbs1066 ypothetical10-20,28-34,39-53,68-79,84-90,99-106:2 73-79 71,
protein 288
gbs1087 bsA 14-37,45-50,61-66,77-82,93-98,109-114,125-130,141-:7, 4-
307, 72,
B:2, 312- 289
C:4,
146,157-162,173-178,189-194,205-210,221-226,237-E:277, 85
6:523,
42,253-258,269-274,285-290,301-306,316-332,349-:25
59,371-378,385-406
gbs2103 BC transporter-20,27-38,50-85,93-99,209-226,228-185,289-197,299-:5
62-376 73,
290
(ATP-binding10,223-256,263-287,289-312,327-337,371-386,389-
protein) 94,406-419,424-432,438-450,458-463,475-502,507-
13,519-526,535-542,550-567
gbs1116 anthine 10-39,42-93,100-144,155-276,178-224,230-244,246-:48 138-
15574,291
permease
(pbuX) 55,273-282,292-301,308-325,332-351,356-361,368-
79,386-393,400-421
gbsI126 similax -11,17-34,40-45,50-55,72-80,101-123,145-151,164-E:2, 994-
1003,75,
to plasmid K:3 292
nknown protein172,182-187,189-195,208-218,220-241,243-252,255- 1033-1056
70,325-332,365-371,391-398,402-418,422-428,430-
35,443-452,463-469,476-484,486-494,503-509,529-
53,560-565,570-590,608-614,619-627,654-661,744-
750,772-780,784-790,806-816,836-853,876-885,912-
918,926-933,961-975,980-987,996-1006,2026-1028,1043-
1053,1057-1062
gbs1143 utative 17-45,64-71,73-81,99-109,186-192,223-238,262-275,283-C:3,
74-350,76,
D:2, 443- 293
F:15,
peptidoglycan95,336-346,350-363,375-385,410-421,425-431,441-:3 23
linked
protein 48,454-463,468-474,476-512,523-537,539-552,568-
(LPXTG)
83,599-608,612-620,628-641,644-654,656-662,670-
681,685-695,702-708,716-723,725-735,757-764,769-
798,800-806,808-816,826-840,846-854,856-862,874-
881,885-902,907-928
gbs2145 surface -22,29-41,45-51,53-61,70-76,85-92,99-104,111-122,134-C:2
52-262 77,
exclusion 294
protein 140,142-154,163-174,224-232,255-265,273-279,283-
SeclO
97,330-335,337-348,356-367,373-385,391-396,421-
31,442-455,475-485,493-505,526-538,544-561,587-
99,605-620,622-651,662-670,675-681,687-692,697-
712,714-735
gbs1158 imilar to -I2,15-35,40-46,50-59,67-94,110-128,143-169,182-:2 74-
90 78,
295
oxidoxeductase188,207-215,218-228,238-250
gbs1165 cysteine 9-18,42-58,78-85,88-95,97-106,115-122,228-134,140-:5 12-
29 79,296
desulphurase145,154-181,186-202,204-223,261-267,269-278,284-
(iscS-1)
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-70-
S. agalactiaePutative predicted immunogeruc as** No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clonesimmunogeni(DNA,
per
ORF c regionProt.)
and (aa)
screen
93,300-336,358-368
gbs1195staphylokinase7-34,46-53,62-72,82-88,100-105,111-117,132-137,144-:3,
88-405 SD,
and C:2, 297
D:2,
treptokinase160,166-180,183-189,209-221,231-236,246-253,268-G:3,
H:8
82,286-293,323-336,364-372,378-392,422-433
gbs1209TP-dependent1-27,34-50,72-77,80-95,164-177,192-198,202-220,226-C:3,
621-73981,
I:5 298
NA helicase36,239-247,270-279,285-292,315-320,327-334,348-
PcrA
55,364-371,388-397,453-476,488-497,534-545,556-
76,582-588,601-607,609-616,642-662,674-681,687-
697,709-715,721-727,741-755
gbs1214conserved -14,16-77,79-109 :2 25-99 82,
299
ypothetical
protein
gbs1242CpsG, beta-1,4--9,17-23,30-37,44-55,65-72,77-93,102-121,123-132,146-:24
17-29 83,
300
galactosyltransferase153
gbs1260BC transporter,-18,25-41,52-60,83-92,104-112,117-123,149-155,159-:17
124-13784,
301
TP-binding 167,170-192,201-210,220-227,245-250
protein
gbs1270gbs1270 8-25,50-55,89-95,138-143,148-153,159-169,173-179,223-C:19, 1-
128, 85,
hyaluronate D:S, 252- 302
lyase 38,262-268,288-295,297-308,325-335,403-409,411-:19 41,
771-793,
17,432-446,463-475,492-501,524-530,542-548,561- 1043-1058
74,576-593,604-609,612-622,637-654,665-672,678-
685,720-725,731-739,762-767,777-783,820-838,851-
865,901-908,913-920,958-970,1000-1006,1009-1015,1020-
1026,1043-1052,1055-1061
gbs1305ypothetical16-26,33-46 :2 64-76 86,303
protein
gbs1306aminin binding-27,69-77,79-101,117-123,126-142,155-161,171-186,200-:6,
2-108,153-87,
B:7, 304
protein 06,213-231,233-244,267-273,313-329,335-344,347-C:17, 18,
D:72, 391-527,
70,374-379,399-408,422-443,445-453,461-468,476-E:8, 638-757
F:91,
G:2,
82,518-534,544-553,556-567,578-595,601-620,626-:4,
I:26,
J:3,
636,646-658,666-681,715-721,762-768,778-785,789-:14
803,809-819
gbs1307mb, laminin-6-21,32-43,62-92,104-123,135-141,145-152,199-216,218-:2,
1-72,127-21188,
D:3 305
binding 26,237-247,260-269,274-283,297-303
surface
protein
gbs1308C5a peptidase,6-26,50-56,83-89,108-114,123-131,172-181,194-200,221-:4,
1-213, 89,
C:15, 269- 306
authentic 38,241-247,251-259,263-271,284-292,304-319,321-D:70, 92,
framesluft E:18, 992-1120
35,353-358,384-391,408-417,424-430,442-448,459-:26,
G:S,
66,487-500,514-528,541-556,572-578,595-601,605-:4,
J:2,
K:40
613,620-631,635-648,660-670,673-679,686-693,702-
CA 02522986 2005-10-17
WO 2004/099242 _ PCT/EP2004/004856
-71 -
S. agalactiaePutative predicted immunogeruc as** No. LocationSeq.
function of of
antigenic(by homology) selectedideniafiedID
protein clones immunogeni(DNA,
per
ORF c regionProt.)
and (aa)
screen
708,716-725,730-735,749-755,770-777,805-811,831-
837,843-851,854-860,863-869,895-901,904-914,922-
929,933-938,947-952,956-963,1000-2005,1008-1014,1021-
2030,1097-1103,2220-1230,2132-1240
gbs2309 ypothetical9-16,33-39,47-59,65-79,81-95,203-108,215-123,138-E:2, 95-
111,90,
protein F:4, 161- 307
H:2,
148,263-171,176-185,191-196,205-211,213-221,224-:2 189
56,261-276,294-302,357-363,384-390
gbs1311 transposase,1-27,35-45,70-76,92-105,129-143,145-155,161-166,170-:3
1-18 91,
C- 308
terminal 191,204-211,214-231,234-246,249-255,259-275
part
gbs1321 iypothetical1-35,45-53,56-64,69-97 :7 1-16 92,
protein 309
gbs1352 putative 5-33,41-47,61-68,86-101,106-114,116-129,134-142,144-:3,
748-847,93,
helicase H:2, 310
and M:4
methylase 156,163-176,181-190,228-251,255-261,276-292,295- 1381-1391
05,334-357,368-380,395-410,424-429,454-460,469-
82,510-516,518-527,531-546,558-570,579-606,628-
636,638-645,651-656,668-674,691-698,717-734,742-
754,765-770,792-797,827-835,847-859,874-881,903-
909,926-933,942-961,964-977,989-1004,1010-1028,1031-
1047,1057-1075,1081-1095,1108-1117,1138-1144,1182-
1189,1193-1206,1220-1229,1239-1246,1257-1267,1271-
1279,1284-1301,1312-1320,1329-1335,1341-1347,1358-
1371,1399-1404,1417-1426,1458-1463,1468-1476,1478-
1485,1493-1506,1535-1541,1559-1574,1583-1590,1595-
I60I,1603-2622,1622-1628,1634-2644,1672-I685,2689-
1696,1715-1720,1734-1746,1766-1775,1801-1806,1838-
1844,1858-1871,1910-1917,1948-1955,1960-1974,2000-
015,2019-2036,2041-2063
gbs1356 utative -12,18-24,27-53,56-63,96-113,119-124,131-136,157-C:S, 187-
273,94,
D:62, 306- 311
T:2
peptidoglycan163,203-209,215-223,233-246,264-273,311-316,380- 41
linked
protein 89,393-399,425-433,445-450,457-462,464-470,475-
(LPXTG
motif) - 82,507-513,527-535,542-548,550-565,591-602,607-
Agglutinin
receptor 613,627-642,644-664,673-712,714-732,739-764,769-
782,812-828,826-838,848-854,860-871,892-906,930-
938,940-954,957-973,990-998,1002-1021,2024-1033,1037-
1042,1050-1060,1077-1083,1085-1092,1100-1129,1144-
1161,1169-1175,1178-1189,1192-1198,1201-1207,1211-
1221,1229-1239,1250-1270,1278-1292,1294-1300,1314-
1335,1344-1352,1360-1374,1394-1405,1407-1414,1416-
1424,1432-1452,1456-1462,1474-1497,1500-1510,1516-
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-72-
S. agalactiaePutative predicted immunogenic as** No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clones immunogeni(DNA,
per
~RF c regionProt.)
and (aa)
screen
1522,1534-1542,1550-1559,1584-1603,1608-1627
gbs1376 similar 70-80,90-97,118-125,128-140,142-148,154-162,189-:4 07-
227 95,
to ATP- 312
dependent 02,214-222,224-232,254-260,275-313,317-332,355-
Clp
proteinase60,392-398,425-432,448-456,464-470,476-482,491-
(ATP-
inding 05,521-528,533-546,560-567,592-597,605-614,618-
subunit),
CIpL 626,637-644,646-653,660-666,677-691
gbs1377 imilar -19,26-34,37-55,57-66,69-83,86-102,115-134,138-:2 56-266
96,
to 313
omocysteine143,154-172,178-195,209-246,251-257,290-302,306-311
S-
methyltransferase
gbs1386 ydroxy-3- 10-20,22-28,35-57,72-79,87-103,108-128,130-144,158-G:2 53-
365 97,314
methylglutaryl-171,190-198,225-242,274-291,301-315,317-324,374-385
coenzyme
A synthase
gbs1390 ypothetical-9,17-30,34-54,59-66,73-94,118-130,135-150,158-:3, 89-
106,98,
protein K:4 176- 315
171,189-198,219-239,269-275,283-301 193
gbs1391 ypothetical14-20,22-74,77-86,89-99,104-109,126-135,154-165,181-:3
107-11899,
protein 316
195,197-212,216-224,264-275
gbs1403 similar -18,21-38,63-72,101-109,156-162,165-179,183-192,195-:3, 1-
198 100,
to 5'- C:12, 317
ucleotidase,10,212-218,230-239,241-256,278-290,299-311,313-:4,
J:2
putative 22,332-341,348-366,386-401,420-426,435-450,455-
peptidoglycan60,468-479,491-498,510-518,532-538,545-552,557-
bound
protein 63,567-573,586-595,599-609,620-626,628-636,652-
(LPXTN)
657,665-681
gbs1408 imilar -10,16-38,51-68,73-79,94-115,120-125,132-178,201-:2, 191-
206101,
to ABC K:4 318
transporter08,216-223,238-266,269-295,297-304,337-342,347-
(ATP-
binding 56,374-401,403-422,440-447,478-504,510-516,519-
protein)
30,537-544
gbs1420 similar 12-40,42-48,66-71,77-86,95-102,113-120,129-137,141-C:3, 70-
478 102,
to cell D:4 319
wall
proteins, 148,155-174,208-214,218-225,234-240,256-267,275-
putative
peptidoglycan83,300-306,313-321,343-350,359-367,370-383,398-
linked
protein 05,432-439,443-461,492-508,516-526,528-535
(LP?CTG
motif)
gbs1429 ypothetical-14,20-37,56-62,90-95,97-113,118-125,140-145,161-:2, 176-
187103,
protein C:2 320
170,183-202,237-244,275-284,286-305,309-316,333-
59,373-401,405-412
gbs1442 ypothetical3-44,50-55,59-80,86-101,129-139,147-153,157-163,171-:28
71-88, 104,
353- 321
thiamine 176,189-201,203-224,239-245,257-262,281-287,290- 72
biosynthesis
protein, 97,304-320,322-331,334-350,372-390,396-401
ThiI
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
- 73 -
S. agalactiaePutative predicted immunogenic as*~' No. LocafionSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clones immunogeru(DNA,
per
QRF a regionProt.)
and (aa)
screen
gbs1452rplT 50S -11,15-24,26-33,40-47,75-88,95-103,105-112E:2 17-30 105,
ribosomal 322
protein
L20
gbs1464ferrichrome-11,16-39,46-54,62-82,100-107,111-124,126-150,154-:4 8-
16 106,
ABC 323
transporter165,167-183,204-238,245-295,301-313,316-335
(permease)
gbs1470conserved -19,34-48,69-74,79-107,115-127,129-135,143-153,160-:4
142-153107,324
ypothetical169,171-182
protein
gbs1528conserved -30,65-74,82-106,110-120,124-132,135-140,146-175,179-:7
174-186108,
325
ypothetical184,190-196,217-223,228-233,250-267,275-292,303-
protein
15,322-332
gbs1529utative 9-16,29-41,47-57,68-84,87-109,113-119,162-180,186-C:2 883-
936109,326
peptidoglycan193,195-201,203-208,218-230,234-243,265-271,281-
bound
protein 92,305-312,323-332,341-347,349-363,368-374,383-
(LPXTG
motif) 90,396-410,434-440,446-452,455-464,466-473,515-
22,529-542,565-570,589-600,602-613,618-623,637-
644,1019-1027,1238-1244,1258-1264,1268-1276,1281-
1292,1296-1302
gbs1531vrB excinuclease10-17,23-32,39-44,54-72,75-81,88-111,138-154,160-:2
84-393 110,
327
BC chain 167,178-185,201-210,236-252,327-334,336-342,366-
B
76,388-400,410-430,472-482,493-526,552-558,586-
92,598-603,612-621,630-635,641-660
gbs1533glutamine -22,24-39,50-59,73-84,100-105,111-117,130-138,155-:4 45-
461 111,
ABC 328
transporter,161,173-178,182-189,205-215,266-284,308-313,321-
glutamine-binding28,330-337,346-363,368-374,388-395,397-405,426-
protein 34,453-459,482-492,501-507,509-515,518-523,527-
44,559-590,598-612,614-629,646-659,663-684,686-
694,698-721
gbs1536ypothetical14-22,27-33 E:10 -17 112,
protein 329
gbs1542oxidoreductase,9-41,66-73,81-87,90-108,140-146,150-159,165-184,186-:13
126-140113,
330
aldo/keto 196,216-226,230-238,247-253,261-269
reductase
family
gbs1547small protein,-12,16-25,27-33,36-45,60-68,83-88,103-126:11 86-101
114,
SmpB 331
gbs1565ypothetical14-23,36-47,56-66,84-89,94-105,111-127,140-153,160-:2,
194-227115,
protein J:2, 332
IC:8,
174,176-183,189-203,219-225,231-237,250-257:21
gbs1586peptidyl-prolyl-25,54-60,64-71,73-82,89-106,117-124,157-169,183-E:3
8-98 116,
cis- 333
trans isomerase,188,199-210,221-232,236-244,255-264
cyclophilin-type
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-74-
S. agalactiaePutative predicted immunogenic as** No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clones immunogeru(DNA,
per
ORF c regionProt.)
and (aa)
screen
gbs1591-methylthioadenosine13-19,26-36,41-53,55-71,77-84,86-108,114-135,157-
:18, 110-125,117,
L:2 156- 334
nucleosidase/S-
adenosylhomocysteine172,177-183,187-194,208-213,218-226 170
nucleosidase
(pfs)
gbs1632similar -24,63-69,77-85,94-112,120-137,140-146,152-159,166-:2, 1-
56, 118,
to branched- E:4, 340-352335
I:3
chain amino172,179-187,193-199,206-212,222-228,234-240,244-
acid
BC transporter,52,257-264,270-289,298-309,316-328,337-348,363-375
amino acid-binding
protein
gbs1638amino acid 18-39,42-71,78-120,124-144,152-173,179-189,199-E:B, 13-327
119,
permease G:9, 336
H:9
09,213-222,228-258,269-304,329-361,364-372,374-
89,396-441
gbs1662conserved 19-25,91-98,108-120,156-162,168-174,191-204,211-E:3, 10-
25, 120,
H:2 322- 337
ypothetical16,232-266,272-278,286-308,316-321,327-333,344- 38
protein
55,358-364,384-391,395-428,464-476,487-495,497-
11,544-561,563-573,575-582,588-594
gbs1666WI/SNF family14-26,32-49,51-57,59-72,80-91,102-112,119-125,147-:4
90-103 121,
338
elicase 161,164-173,175-183,188-213,217-222,246-254,260-
76,282-303,308-318,321-328,333-350,352-359,371-
78,392-401,407-414,416-443,448-463,471-484,490-
97,501-514,519-527,539-551,557-570,578-590,592-
98,600-610,618-629,633-647,654-667,676-689,702-
709,718-726,728-737,741-760,764-780,786-795,808-
826,836-842,845-852,865-874,881-887,931-945,949-
957,968-974,979-986,1003-1009,1023-1029
gbs1673conserved 11-16,37-56,60-66,69-77,80-88,93-106,117-139,166-171E:2
72-90 122,
339
ypothetical
protein
gbs1695dihydroxyacetone9-84,123-133,145-150,161-167,178-189:8 115-
128123,340
Icinase
family
protein
gbs1754excinuclease15-33,39-46,52-64,74-87,108-124,127-144,150-156,173-:2
132-142124,
ABC, A 341
subunit 179,184-194,201-208,219-236,243-269,272-295,302-
(uvrA)
09,343-349,356-361,370-379,405-411,414-423,430-
51,457-464,466-475,477-483,496-502,507-522,541-
48,557-563,571-577,579-585,590-605,626-642,650-
662,671-691,704-710,751-769,775-781,786-791,794-
829,851-858,868-878,884-904,913-919,931-939
gbs1760imilar to 3-58,64-71,74-80,83-88,96-120,122-139,146-157,167-:8 97-
115,199-125,
A/G- 342
specific 177,207-213,220-225,236-242,264-279,300-305,326- 11
adenine
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-75-
S. agalactiaePutative predicted immunogenic as** No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clones immunogeni(DNA,
per
ORF c regionProt.)
and (aa)
screen
glycosylase36,340-347,350-360
gbs1777glycerol -26,43-57,70-99,102-117,121-133,142-148,151-168,170-:4 0-
41 126,343
uptake
facilitator183,192-220,235-249,258-279
protein,
putative
gbs1783polyprenyl 4-42,48-58,70-94,110-130,154-160,164-172,178-183,195-:3
22-233 127,344
synthetasefamily03,211-222,229-250,256-261,274-284,286-292,312-323
protein
gbs1784BC transporter,-9,15-36,38-45,49-74,78-88,100-112,136-191,211-C:2, 08-
280 128,
D:2 345
TP-binding 20,226-233,239-246,254-274,287-307,316-322,342-
protein
CydC 53,356-366,373-378,384-393,405-431,449-457,459-
68,487-511,515-524,529-541,544-552,562-568,571-576
gbs1790iypothetical10-27,31-37,39-54,71-108,124-143:23, -107 129,
protein C:6 346
gbs1805Similar 16-27,38-57,64-70,90-102,104-113,116-137,160-166:197, 1-80
130,
to secreted C:2 347
nknown protein
gbs1816domain protein13-21,31-36,56-67,127-136,153-171,173-180,184-200,214-:8
135-159131,
348
22,225-231,239-263,267-273
,
gbs1821imilar to 12-27,31-51,68-74,77-87,94-101,108-114,117-123,127-:5 05-
223 132,
23S 349
ribosomal 134,138-168,173-196,201-207,212-217,227-237,247-
RNA
methyltransferase57,264-280
gbs1823triad family17-22,25-54,70-76,92-100 G:6, 98-110 133,
protein H:3 350
gbs1834two-component7-29,40-50,60-67,87-96,105-111,119-164,172-199,206-:3,
159-176134,
F:6 351
sensor histidine12,220-227,237-259,272-279,282-293,295-309,313-
kinase 19,321-328,345-363,376-386
gbs1842transcriptional-19,24-30,36-43,50-68,71-89,93-106,141-152,154-:19 62-
377 135,
352
antiterminator,172,179-197,199-215,229-239,246-252,255-263,281-
BgIG
family 98,319-325,329-356,358-368,374-390,397-409,420-
29,432-444,450-456,459-475,483-494,496-502,520-
28,532-556
gbs1850ypothetical18-25,40-62,77-85,91-97,105-116,123-133,139-184,189-G:2
122-140136,
353
transaldolase197
gbs1869phosphoglycerate-49,52-58,62-70,79-105,109-133,142-150,163-168,206-L:9
643-658137,354
kinase 14,220-228,233-240,243-254,274-281,303-311,327-
38,357-373,378-396,403-413,420-436,441-453,461-
67,475-481,484-498,506-512,514-521,523-529,562-
79,589-595,598-603,615-648,714-722,728-742,749-
758,777-792,795-807
gbs1875alkyl hydroperoxide8-27,37-48,51-56,72-79,87-106,120-138,140-147,167-:3
56-470 138,
355
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-76-
S. agalactiaePutative predicted immunogenic as** No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clones mmunogeru(DNA,
per
i
OItE c regionProt.)
and (aa)
screen
r eductase 76,187-197,205-216,222-229,234-239,243-249,277-
(large
1
s ubunit) 88,292-315,334-343,347-353,363-391,398-404,430-
and NADH
dehydrogenase7,461-467,478-492,498-507
gbs1879 endopeptidase-12,18-24,59-69,80-93,95-109,119-125,130-137,139-:26
21-237 139,
O 356
( pepO) 147,158-163,168-176,182-202,206-215,222-239,241-
49,267-277,291-298,311-318,321-327,338-344,348-
55,373-386,393-406,411-417,434-443,446-465,473-
84,514-521,532-553,584-594
gbs1893 -keto-3- -14,27-34,50-58,63-72,79-106,109-114,121-142,146-:8, 167-
191140,
K:9 357
deoxygluconate154,161-167,169-175,178-201,223-238,249-254,259-
kinase 64,278-292,294-312,319-330
gbs1899 N-acetylmuramoyl-7-28,36-42,50-61,63-80,122-152,161-174,176-191:2,
140-190141,
C:2, 358
E:3
-alanine
amidase,
family 4
protein
gbs1907 citrate 0-57,59-65,70-78,86-102,119-133,142-161,163-173,177-:2
81-395 142,
carrier 359
protein,
CCS family 188,192-202,204-220,222-236,240-253,279-319,326-
31,337-383,390-399,406-412,420-427,431-438
gbs1924 imilar to 13-18,28-34,37-43,50-59,75-81,83-97,105-121,139-:3 182-
201143,
360
pneumococcal147,200-206,209-227,231-247,260-271,318-327,366-
istidine 81,388-394,399-406
triad
protein
B precursor
(C-terminal
part)
gbs1925 similar 6-29,37-43,51-56,70-77,82-102,110-119,127-143,178-:2, 1-
314 144,
to B:S, 361
pneumococcal190,201-209,216-243,261-269,281-292,305-313,327-C:12,
D:57
istidine 39,341-354,356-373,391-397,423-429,438-445,450-478
triad
protein
B precursor
(N-terminal
part)
gbs1962 conserved -12,15-21,32-41,59-76,80-89,96-104:3 90-103 145,
362
ypothetical
protein
gbs2008 imilar to 9-28,30-41,44-54,69-74,77-82,90-97,104-123,125-135,149-
:253, -82, 146,
C5A 8:2, 509-576363
peptidase, 155,164-173,177-184,217-226,230-235,238-244,258-C:3,
putative D:6,
H:2
peptidoglycan72,282-297,300-305,309-315,317-322,327-336,348-
linked
protein 62,368-374,380-387,400-411,414-424,451-458,460-
(LPXTG
motif) 66,483-494,497-503,506-511,521-528,540-553,569-
87,598-606,628-642,661-681,688-700,718-733,740-
749,752-764,769-783,823-834,848-854,862-872,878-
884,886-898,915-920,938-951,954-961,963-972,982-
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
_77_
S. agalactiaePutative predicted immunogeruc as** No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clones immunogeni(DNA,
per
~RF c regionProt.)
and (aa)
screen
989,996-1003,1010-1016,1021-1032,1038-1044,1047-
1057,1060-1070,1079-1088,1094-1102,1117-1127,1129-
1135,1142-1153,1158-1204,1212-1229,1234-1263,1269-
1277,1308-1313,1327-1338,1344-1376,1400-1415,1436-
1443,1448-1458,1497-1504,1511-1522,1544-1566
gbs2018utative 8-36,40-64,71-79,88-94,102-109,118-127,138-148,151-:132, 1-
60, 147,
B:6, 55-139,364
peptidoglycan159,163-174,192-198,200-206,220-233,268-273,290-C:13, 12-308,
linked D63, 386-
protein 01,304-309,316-323,331-349,378-391,414-420,427-E:15, 58,
(LPXTG H:2, 458-624
J:9,
motif) 37,455-475,494-510,541-547,549-555,616-640:13
gbs2029ypothetical16-31,35-42,70-77,91-101,120-130,132-140,143-153,185-G:8
73-281148,365
protein
190,195-202,215-222,228-238,241-251,257-264,268-
77,288-302,312-324,326-333,341-348,364-382,415-
29,438-454,458-466,491-499,501-521
gbs2042ypothetical8-14,32-57,74-149,155-177,179-212,221-266,271-296,304-:11
66-490149,366
protein
24,329-346,349-359,365-401,413-419,426-454,465-
78,493-510
gbs2054NA mismatch2-28,33-51,64-89,96-119,126-132,138-146,152-159,161-E:8
102-113150,
367
repair protein169,172-179,193-198,205-211,221-231,235-254,273-
HexA
80,297-303,312-320,328-346,351-373,378-384,391-
98,448-454,460-468,470-481,516-558,574-593,597-
602,613-623,626-646,649-656,668-673,675-683,696-
708,715-722,724-739,745-751,759-777,780-804,816-822
gbs2058ypothetical12-28,41-91,98-107,112-120,125-131,151-193,215-:3 128-
138151,368
protein
21,240-250,263-280
gbs2060aspartyl-tRNA16-24,32-38,46-62,68-81,90-105,127-133,144-150,160-:3,
96-109,127-152,
L:12 369
ynthetase(aspS)166,178-184,186-202,210-219,232-240,252-258,264- 139
73,293-324,337-344,349-357,360-369,385-398,410-
16,419-427,441-449,458-476,508-515,523-539,544-
49,562-569,571-579
gbs2075ypothetical19-25,28-34,56-61,85-97,110-116:2 9-53 153,
protein 370
gbs2106protein -37,41-50,62-72,91-97,99-109,114-125,136-141,149-:5, 7-
225 154,
of unknown B:6, 371
C:4,
function/lipoprotein,158,160-166,201-215 :14,
E:11,
utative :8,
IC:23
gbs2118similar 15-31,44-51,96-105,122-130,149-157,162-168,178-:17 63-
481155,
to inosine 372
monophosphate183,185-192,198-204,206-213,221-234,239-245,248-
dehydrogenase55,257-266,289-335,349-357,415-422,425-441,448-
54,462-468
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
_7g_
S. agaiactiaePutative predicted immunogeruc as*~'No. LocationSeq.
antigenicfunction of of ID
protein(by homology) selectedidentified(DNA,
clones immunogeniProt.)
per c region
~RF (aa)
and
screen
gbs2131BC transporter,-31,39-55,63-72,76-99,106-155,160-177,179-199,207-:2
05-525 156,
permease 17,223-240,245-255,261-267,294-316,321-343,354- 373
protein, 78,382-452,477-488,529-536,555-569,584-591,593-
putative 612,620-627,632-640,647-654,671-680,698-704,723-
730,732-750,769-775,781-788,822-852
0112 ypotheticalone :6 -18 157,
protein 374
0147 ypothetical-14 E:3, 12-24 158,
protein I:3 375
0532 ypothetical-11,22-30 :10 12-25 159,
protein 376
0534 ypothetical-12 :2, -18 160,
protein G:2 377
0557 ypothetical-28 :2, 7-14 161,
protein G:6, 378
H:4
0862 ypothetical6-16 G:7, 8-16 162,
protein H:4 379
0891' ypothetical-15,18-33 :6 4-36 163,
protein 380
IZF0895ypothetical-10,16-21 :21 0-31 164,
protein 381
0943 ypotheticalone C:2, 6-19 165,
protein IC:9 382
0973 ypothetical11-18 :2, -10 166,
protein G:3, 383
H:B,
:2,
IC:2
0999 ypothetical13-24 :4, -15 167,
protein IC:3 384
ARF1010ypothetical15-27 :2 7-16 168,
protein 385
ARF1230ypothetical11-16 :11 1-15 169,
protein 386
1503 ypothetical-16 E:13 9-21 170,
protein 387
1556 ypothetical-24,40-48,54-67 :2 2-39 171,
protein 388
1585 ypothetical6-30,34-55,62-68,78-106 :5,J:4 68-74 172,
protein 389
1588 ypotheticalone :2 -14 173,
protein 390
1735 ypothetical9-19 :13 6-21 174,
protein 391
1809 ypothetical-17 :2, 1-9 175,
protein L:17 392
1826 ypothetical-30 :6 1-8 176,
protein 393
RF1882 ypothetical-16,23-46,51-56 :23 5-55 177,
protein 394
1996 ypotheticalone :3 7-16 178,
protein 395
CRF0123ypotheticalnone :32 -14 179,
protein 396
CRF0180ypothetical-36,43-65 E:6, 0-62 180,
protein G:6, 397
H:12
CRF0208ypothetical10-30 :2 14-21 181,
protein 398
CRF0258ypothetical9-17 :2 1-10 182,
protein 399
CRF0285ypothetical-12 :2 -16 183,
proteui 400
CRF0311ypothetical-15 :4 -23 184,
protein 401
CRF0446ypotheticalone :20 10-21 185,
protein 402
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-79-
S. agalactiaePutative predicted immunogeruc as** No. LocationSeq.
antigenicfunction of of ID
protein(by homology) selectedidentified(DNA,
clonesimmunogeruProt.)
per a region
~RF (aa)
and
screen
CRF0455ypotheticalone :5 6-16 186,
protein 403
CRF0491ypothetical-29,31-38 G:4 -14 187,
protein 404
CRF0520ypothetical-35 :4 3-42 188,
protein 405
CRF0530ypotheticalone G:13, -17 189,
protein H:8, 406
IC:3
CRF0570ypothetical9-18,30-35 :2 15-33 190,
protein 407
C12F0649ypothetical-9 G:B, 6-12 191,
protein H:6 408
CRF0853ypotheticalone :6 -17 192,
protein 409
CRF0955ypothetical12-21,37-44,52-61,72-80 E:7, 8-48 193,
protein L:44 410
CI2F0983.1ypothetical-10,29-44,54-61,69-78 :59 13-27 194,
protein 411
CRF0983.2ypothetical13-23,36-53 :33 -15 195,
protein 412
C12F1083ypothetical-25,28-46,56-72,81-99,120-132,134-142,154-160:18 129-
141196,
protein 413
CRF1095ypothetical-15,24-33,35-41,64-86 :15 1-33 197,
protein 414
C1ZF1212.1ypothetical9-15 :5 -13 198,
protein 415
CRF1212.2ypothetical-11,13-19,34-48 :30 15-32 199,
protein 416
CIZF1290ypothetical-21 :7 11-31 200,
protein 417
CRF1383ypothetical3-57 :13 8-50 201,
protein 418
CRF1416ypothetical-32 E:16, -13 202,
protein J:7 419
CRF1500ypothetical-10,13-25,32-42,56-68,72-84 :16 6-38 203,
protein 420
CRF1513ypothetical-20,31-48,52-58,65-71,80-93,99-108,114-123:2 7-49 204,
protein 421
CItF1518ypothetical6-12,14-20 :28 -25 205,
protein 422
C1ZF1663ypothetical14-25,27-38 :10 -14 206,
protein 423
C12F1667ypothetical-41,57-105,109-118,123-136,144-152G:4 86-99 207,
protein 424
CRF1832ypotheticalNone E:5, 6-19 208,
protein L:8 425
C1ZF1866ypotheticalone G:3, -19 209,
protein H: 426
18
C12F1892ypothetical14-47 :11 1-14 210,
protein 427
C12F1942ypothetical-21,29-44 :14 -18 211,
protein 428
CRF1992ypothetical3-29 :10 10-28 212,
protein 429
CRF2047ypothetical6-16,22-36 :9 11-22 213,
protein 430
CI2F2050ypothetical-19,30-44 :2 18-27 214,
protein 431
CI~E2096ypothetical-15,37-45,58-65 G:2 8-47 215,
protein 432
C12F2113ypothetical-15,23-34 :5 -15 216,
protein 433
N1tF1311transposase,0-36,44-54,79-85,101-114,138-152,154-164,170-175,179-:3
10-28 217,
C- 00,213-220,223-240,243-255,258-264,268-284 434
terminal
part
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-80-
Table 1B: Immunogenic proteins identified by amino acid sequence identity with
peptides identified by bacterial
surface display.
S. IdenticalPeptide sequence Peptide ProteinImmunogeniSequenc
name
a~alactiaeregion identifiedc regiona
by (aa) ID
antigenic BSD (DNA,
protein protein)
(new)
gbs0384210-226EYKGNFSQKTINItFKS gbs0995.1gbs0995210-226435,449
738-753QTQRSGKINT'DFMPQL bs0995.2bs0995 738
-753
gbs0393326 TIGYGKLTGKVNHI3YVA gbs0986.2gbs0986326 436,
- - 344 450
344
326 TIGYGKLTGKVNIKHYVANKDG gbs1143.1gbs1143327
- - 349
348
338 ANKDGSVTAFV gbs0986.3gbs0986338
- - 354
354
371- VNQNIVFRVLTKDGRPIFEK gbs1143.2gbs1143372
392 - 393
801- GTNL gbs0986.4gbs0986801-
809 809
877 EKSKPVEPQKATPKAPAKGL bs0986.5bs0986 877
- - 901
901
bs0396893 QELLTPTQLSKLQ bs0983.1bs0983 893 437,
- - 906 451
906
gbs040751- YDKLEALVAYHGAKSAS bs0972.1gbs097251- 438,
69 69 452
bs0408110 QPNRTYLTDKLVPYI bs0971.1bs0971 110 439,
-125 -125 453
bs0410291- QS1KQHDKEKLRTVL bs0969.1bs0969 291- 440,
305 305 454
gbs0714210 EYKGNFSQKTINRFKS gbs0995.1gbs0995210 441,
- - 226 455
226
738 QTQRSGKINTDFMRQL bs0995.2bs0995 738
-753 -753
gbs0723326 TIGYGKLTGKVNHHYVA gbs0986.2gbs0986326 442,
- - 344 456
344
326 TIGYGKLTGKVNIiHYVANKDG gbs1143.1gbs1143327
- - 349
348
338-354NHHYVANKDGSVTAFV gbs0986.3gbs0986338-354
371-392VNQNIVFRVLTKDGRPIFEK gbs1143.2gbs1143372
- 393
801- GTNL gbs0986.4gbs0986801-
809 809
877 EKSKPVEPQKATPKAPAKGL bs0986.5bs0986 877
- - 901
901
gbs0726893 QELLTPTQLSKLQ gbs0983.1gbs0983893 443,
- - 906 457
906
bs073751- YDKLEALVAYHGAKSAS bs0972.1bs0972 51- 444,
69 69 458
bs0738110 QPNRIYLTDKLVPYI bs0971.1bs0971 110 445,
-125 -125 459
bs0740291- QSIKQHDKEKLRTVL bs0969.1bs0969 291- 446,
305 305 460
gbs089732 EGDVLLEIMSDKT gbs0898.1gbs089832 - 447,
- 44 461
44
bs0966399 GLTVEEKFVTF bs0144.1bs0144 420 448,
-410 - 431 462
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-~1-
Table 2. Epitope serology with human sera
Peptides positivityas fromas to Seq
ID
gbs0012.1++ 120 143 218
bs0012.2 + 138 161 218
gbs0012.3+ 156 179 218
bs0016.2 +++ 110 129 219
gbs0016.3+ 168 184 219
bs0048.1 + 74~ 90 222
bs0053.1 +++ 759 773 223
gbs0061.1+++ 237 260 224
bs0084.1 + 265 284 225
bs0107.1 ++ 65 74 226
bs0108.1 ++ 41 50 227
bs0123.1 + 163 174 229
gbs0127.1++ 26 37 230
bs0183.1 + 174 189 232
bs0235.1 ++ 240 256 234
bs0260.1 + 285 297 236
gbs0286.1+ 238 247 238
gbs0288.1+ 491 519 239
bs0437.1 ++ 114 140 243
gbs0539.1+ 267 284 250
bs0579.1 + 439 453 252
bs0580.1 ++ 162 178 253
gbs0628.1++ 347 364 254
bs0632.1 +++ 699 715 255
bs0634.1 + 60 71 256
bs0667.1 ++ 244 257 257
gbs0672.1+ 44 63 258
bs0672.2 + 57 76 258
bs0785.1 + 185 196 260
gbs0851.1+ 119 129 263
bs0896.1 ++ 182 195 266
gbs0898.1++ 32 44 267
bs0898.2 + 424 442 267
bs0904.1 + 247 256 268
gbs0918.1++ 678 694 269
bs0918.2 + 785 805 269
gbs0918.4+ 55 77 269
bs0918.5 +++ 72 94 269
bs0995.1 + 210 226 281
bs1087.3 + 37 59 289
bs1165.1 + 13 29 296
gbs1816.1+ 136 159 348
bs1821.1 + 205 222 349
bs1823.1 + 99 110 350
bs1834.1 + 160 176 351
bs1875.1 + 457 470 355
gbs1879.1+ 221 237 356
bs1893.1 + 167 190 357
bs1925.1 + 96 120 361
bs2018.3 +++ 399 417 364
gbs2018.4+++ 503 519 364
bs2018.5 +++ 544 563 364
bs2106.2 + 46 68 371
bs2106.7 + 159 183 371
bs2106.8 + 184 198 371
~gbs2118.1++ 463 481 372
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
_8~_
Table 3: Gene distribution in S. agalactiae strains.
~RF Common name Gene distributionAmino acid Seq.
(presenfi subtitutionsID
of 50) (in (DNA,
serotype Prot.)
II=~ strain)*
gbs0012eakly similar to beta-lactamase44/44 ----- -- 1,
------ 218
--
n.d.
gbs0016glucan-binding protein40/44 .......-........0/~4.................2,
B (S.mutans) . 219
gbs0024Phosphoribosylformylglycinamidine46/46 1~~2~8 -- 3,
220
gbs0031surface immunogeruc 46/46 1/225 4,
protein 221
gbs0048nknown 30/46 0/61 5,
222
gbs0053aldehyde-alcohol dehydrogenase45/45 0/224 6,
(adhE) 223
gbs0061rplB ribosomal protein46/46 0/218 7,
L2 224
gbs0084NA-directed RNA polymerase,45/45 0/207 8,
alpha 225
subunit (rpoA)
gbs0107conserved hypothetical46/46 0/235 9,
protein 226
gbs0108deoxyuridine 5~-triphosphate44/44 0/125 10,
ucleotidohydrolase 227
gbs0113ribose ABC transporter44/45 0/227 11,
228
gbs0123similar to argininosuccinate44/44 0/184 12,
synthase 229
gbs0127rpmV 50S ribosomal 46/46 0/40 13,
protein L28 230
gbs0144oligopeptide ABC transporter,45/45 0/282 14,
substrate- 231
finding
gbs0183membrane protein, putative44/44 0/223 15,
232
gbs0184oligopeptide ABC transporter,46/46 1/203 16,
oligopeptide-binding 233
gbs0235glycine betaine/carnitine/choline46/46 0/219 17,
ABC 234
transporter
gbs0255conserved hypothetical46/46 0/180 18,
protein 235
gbs0260glycyl-tRNA synthetase46/46 0/209 19,
(beta subunit 236
gbs0268transketolase (tkt) 46/46 0/208 20,
237
gbs0286NH3-dependent NAD+ 45/45 0/191 21,
synthetase 238
gbs0288similar to penicillin-binding45/45 0/212 22,
protein lA 239
gbs0343seryl-tRNA synthetase 46/46 0/228 23,
(serS) 240
gbs0428similar to fibrinogen 45/46 1/126 25,
binding protein, 242
putative peptidoglycan
linleed protein
(LPXTG motif)
gbs0437glucose-6-phosphate 45/45 0/232 26,
isomerase (pgi) 243
gbs0460decarboxylase 46/46 1/81 27,
244
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-~3-
ORF Common name Gene distributionAmino acid Seq.
(present substitutionsID
of 50) (in (DNA,
serotype Prot.)
IA strain)*
gbs0465oxydoreductase 46/46 0/126 28,
245
gbs0489acetyltranserase, GNAT45/45 3/144 30,
family 247
gbs0492gbs0492 valyl-tRNA 44/44 3/125 31,
synthetase 248
gbs0538amino acid ABC transporter46/46 0/214 32,
(ATP-binding 249
protein)
gbs0539similar to phosphomannomutase46/46 0/244 33,
250
gbs0555eta-lactam resistance 46/46 0/218 34,
factor (fibA) 251
gbs0579dipeptidase 46/46 0/218 35,252
gbs0580inc ABC transporter, 45/45 2/235 36,
zinc-binding 253
adhesion liprot
gbs0628cell wall surface anchor42/44 0/219 37,
family protein - 254
(Il'xTG)
gbs0632cell wall surface anchor44/45 0/238 38,
family protein, 255
putative (FPKTG motive)
gbs0667regulatory protein, 44/44 0/229 40,
putative, truncation 257
gbs0672transcriptional regulator43/43 0/203 41,
(GntR family) 258
gbs0687nknown proteins 45/45 0/149 42,
259
gbs0785imilar to penicillin 45/45 0/218 43,
binding protein 2B 260
gbs0828nknown proteins -.........-..-............45,
4646_-v...~~~2p......................262
...
gbs0851ypothetical protein 46/46 0/140 46,
263
gbs0865gbs0865 Unknown 44/44 0/241 47,
264
gbs0890exonuclease RexB (rexB)46/46 0/232 48,
265
gbs0896similar to acetoin 46/46 0/239 49,
dehydrogenase 266
gbs0898acetoin dehydrogenase,45/45 0/180 50,
thymine PPi 267
dependent
gbs0904phosphoglucomutase/phosphomannomuta46/46 0/169 51,
se family prote 268
gbs0918weakly similar to histidine45/45 1/209 52,
triad protein, 269
putative lipoprotein
gbs0931pyruvate kinase 46/46 0/185 53,
270
gbs0947similar to L-Lactate 46/46 0/233 54,
Dehydrogenase 271
gbs0948DNA gyrase, A subunit 44/44 0/172 55,
(gyrA) 272
gbs1035conserved hypothetical46/46 - 0/210 - 69,
protein ~- ~ 286
gbs1066gbs1066 Unknown 17/46 - a~92 - 71,
- 288
gbs1087ighly repetitive pep6doglycan42/45 --------w- 72,
bound -----------289
n.d.
protein (LPXTG motif) ...... ..----.._.
...........,~............
..
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-84-
ORF Common name Gene distributionAmino acid Seq.
(present substitutionsID
of 50) (in (DNA,
serotype Prot.)
IA strain)*
gbs1103BC transporter (ATP-binding46/46 1/165 73,
protein) 290
gbs1116anthine permease (pbuX)~ ~45/45 1/170 74,
- - 291
gbs1158imilar to oxidoreductase44/44 1/170 78,
295
gbs1165cysteine desulphurase 43/43 0/148# 79,
(iscS-1) 296
gbs1195staphylokinase and 45/45 60/142 80,
streptokinase 297
gbs1209ATP-dependent DNA helicase43/44 1/94# 81,
PcrA 298
gbs1214conserved hypothetical43/46 0/97 82,
protein 299
gbs1260BC transporter, ATP-bindingm~~~44/46 11198 84,
protein ~ ~~ 301
gbs1306aminin binding protein- 45/46 ~ 0/215 87,
(Spellerberg,B et ~ ~ ~ 304
a11999) _ .. _._.__ ._. ,
_ _. .._. .. _ ....-.
gbs1307lmb lamirun-binding 'm' ' 45/45n.d. ~-- 88,
surface protein 305
gbs1308C5a peptidase, authentic-- -- ~4646-0/205 89,
frameshift ~----- 306
gbs1309ypothetical protein m ~~~~~~~~~44/46~0/214 90,
~~W ~ 307
gbs1356utative peptidoglycan 20/46 50/211# 94,
linked protein 311
(LPXTG motif) - Agglutinin
receptor
gbs1376similar to ATP-dependent45/45 0/197 95,
Clp proteinase 312
(ATP-binding subunit),
CIpL
gbs1377similar to homocysteine45/45 0/55 96,
S- 313
methyltransferase
gbs1386-hydroxy-3-methylglutaryl-coenzyme44/44 0/219 97,
A 314
synthase
gbs1390gbs1390 Unknown 43/43 0/198 98,
315
gbs1391gbs1391 Unknown 44/44 0/214 99,
316
gbs1403similar to 5'-nucleotidase,45/45 3/189 100,
putative 317
peptidoglycan bound
protein (LPXTN)
gbs1408imilar to ABC transporter45/45 0/205 101,
(ATP-binding 318
protein)
gbs1429unknown proteins 46/46 1/193 103,
320
gbs1452rplT 50S ribosomal 46/46 0/101 105,
protein L20 322
gbs1464ferrichrome ABC transporter44/44 2/232 106,
(permease 323
gbs1470conserved hypothetical46/46 2/164 107,324
protein
gbs1528conserved hypothetical45/45 0/213 108,
protein 325
gbs1531vrB excinuclease ABC 45/45 0/108 110,
chain B 327
gbs1533glutamine ABC transporter,44/44 0/166 111,
glutamine- 328
finding prote
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-85-
ORF Common name Gene distributionAmino acid Seq.
(present substitutionsID
of 50) (in (DNA,
serotype Prot.)
IA strain)"'
gbs1542oxidoreductase, aldo/keto45/45 1/219 113,
reductase family 330
gbs1565ypothetical protein 43/43 1/218 115,332
gbs1586peptidyl-prolyl cis-trans45/45 1/227 116,
isomerase, 333
cyclophilin-type
gbs1591-methylthioadenosine 45/45 0/203 117,
nucleosidase/S- 334
adenosylhomoc
gbs1632similar to branched-chain45/45 0/223 118,
amino acid ABC 335
transporter, amino
acid-binding protein
gbs1638amino acid permease 45/45 0/100 119,
336
gbs1662conserved hypothetical45/45 0/213 120,337
protein
gbs1666WI/SNF family helicase45/45 0/200 121,
338
gbs1673conserved hypothetical45/45 0/147 122,339
protein
gbs1695dihydroxyacetone kinase43/43 1/165 123,
family protein 340
gbs1754excinuclease ABC, A 43/43 0/224 124,
subunit (uvrA) 341
gbs1760Similar to A/G-specific46/46 0/181 125,
adenine glycosylase 342
gbs1777glycerol uptake facilitator43/43 0/199 126,
protein, putative 343
gbs1783polyprenyl synthetase 45/45 0/217 127,
family protein 344
gbs1784BC transporter, ATP-binding45/45 1/220 128,
protein 345
CydC
gbs1790nknown proteins 41/43 3/75# 129,
346
gbs1805imilar to secreted 45/45 0/66 130,
unknown proteins 347
gbs1816domain protein 43/43 1/176 131,
348
gbs1821imilar to 23S ribosomal43/43 2/155# 132,
RNA 349
methyltransferase
gbs1834two-component sensor 44/44 0/213 134,
histidine kinase 351
gbs1842transcriptional antiterminator,43/43 0/208 135,
BgIG family 352
gbs1850ypothetical transaldolase44/44 0/194 136,
353
gbs1875alkyl hydroperoxide 46/46 0/192 138,
reductase (large 355
subunit) and NADH dehydrogenase
gbs1879endopeptidase O (pepO)43/43 0/135 139,
356
gbs18932-keto-3-deoxygluconate36/46 0/228 140,357
kinase
gbs1899N-acetylmuramoyl-L-alanine43/43 0/149 141,
amidase, 358
family 4 prote
gbs1907citrate carrier protein,43/43 0/219 142,
CCS family 359
gbs1925similar to pneumococcal43/43 0/103 144,
histidine triad 361
rotein B precursor
(N-terminal part)
gbs1962conserved hypothetical28/46 0/136 145,362
protein
gbs2008similar to C5A peptidase,43/43 n.d. 146,
putative 363
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-86-
ORF Common name Gene distributionAmino acid Seq.
(present substitutionsID
of 50) (in (DNA,
serotype Prot.)
IA strain)*
peptidoglycan linked
protein (LPXTG
motif)
gbs2018putative peptidoglycan43/45 0/104 147,
linked protein 364
(LPXTG motif)
gbs2029nknown proteins 44/44 1/238 148,
365
gbs2054NA mismatch repair 46/46 0/206 150,
protein HexA 367
gbs2060aspartyl-tltNA synthetase46/46 2/211 152,
(asps) 369
gbs2106protein of unknown 44/44 0/160 154,
function/lipoprotein, 371
putative
gbs2118similar to inosine 43/43 0/113 155,
monophosphate 372
dehydrogenase
gbs2131BC transporter, permease45/45 0/237 156,
protein, 373
putative
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
_87_
Table 4. Immunogenicity of epitopes in mice
ORF as as IB PeptideSeq
from to ELISA ID
gbs0016110 129 + 219
168 184 +
gbs0986877 901 + 277
333 354 +
326 344 +
801 809 +
gbs18051 54 +++++ 347
gbs2018544 563 ++ +++++ 364
31 51 + +++
107 119 +
399 417 ++ ++++
503 519 + ++++
gbs0012120 198 ++ + 218
gbs001620 35 + ++ 219
gbs0031118 201 ++++ 221
gbs042848 132 + +++++ 242
gbs0538118 136 + ++++ 249
gbs0580162 178 + + 253
gbs0628347 364 + +++++ 254
gbs0632699 715 + +++++ 255
gbs067250 76 + 258
gbs0918785 819 + +++++ 269
44 128 ++
gbs097190 128 +++++ 274
gbs1087314 384 + 289
gbs1143327 349 +++ 293
gbs1306242 314 ++ ++++ 304
405 478 ++
23 100 +
gbs1307129 210 ++ 305
gbs1309162 188 ++ 307
gbs1352750 772 ++ +++++ 310
gbs16321 56 ++ 335
gbs1662322 337 + +++++ 337
gbs167372 90 + +++++ 339
gbs1784374 395 + 345
gbs1816136 159 + ++++ 348
gbs1899141 164 + 358
gbs192596 157 ++ + 361
gbs20081 82 + 363
gbs2018489 556 + +++++ 364
gbs2106159 183 ++ 371
49 133 + +++++
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
_$8_
Table 5: Immunogeruc proteins identified by bacterial surface display.
S. agalactiaePutative predicted immunogeruc as**No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clonesimmunogenic(DNA,
per
~13k' region Trot.)
and (aa)
screen
gbs0233 similar -26, 35-41, 53-61, 73-84,103-108,114-120,140-146,:5, 1-
48, 463,
to glycine B:9, 113-133 475
etaine/carnitine/choli156-162,192-208, 214-219, :3
227-233, 239-252, 260-268,
a ABC transporter84-297
(osmoprotectant-
inding protein)
gbs0419 protein -27, 38-44, 50-56, 59-64, C:3, 1-79, 464,
of unknown 72-79, 83-89, 92-97, 108-116,D:4, 231-302 476
function/lipoprotein123-148,152-167,183-196, :2,
200-220, 232-244, 255-261,K:4
65-274, 282-302, 309-317
gbs0456 cell wall 6-28, 66-72, 85-105,115-121,144-151,:9, 1-80, 465,
surface 160-170,176- B:125,808-821 477
anchor family185, 223-230, 252-288, :9
protein 296-310, 319-333, 367-374,
458-
64, 471-480, 483-488, 520-528,
530-549, 559-564, 593-
601, 606-616, 636-643,
655-662, 676-682, 684-699,
719-
726, 735-750, 757-764,
777-785, 799-810, 812-843,
846-
853, 868-873, 880-889,
891-899, 909-929, 934-940,
963-
969, 998-1004,1007-1014,1016-1022,1030-1046
gbs0942 protein 7-24, 35-41, 75-81, 91-114,122-132,137-144,148-156,:3, 1-
79, 466,
of unknown B:9, 305-321 478
function/lipoprotein183-192,194-200, 212-228, C:2,
233-238, 251-258, 275-295,J:3
26-332, 337-346
gbs0973 gid protein1-38, 42-52, 66-72, 86-92,:2, 13-92,135-142467,
(gid) 98-104,115-122,127-146, G:3, 479
154-164, 169-187,198-212, :8,
225-237, 255-269 I:2,
:2
gbs0975 nknown protein-36, 39-49, 63-69, 71-77, A:3, 1-68, 468,
81-88, 123-131,133-139,160-B:S, 212-270,480
169, 174-180, 188-194, C:S, 02-446
210-217, 273-278, 289-300,D:2,
317-
34, 336-341, 383-401, 425-438:2
gbs1038 permease, 1-29, 31-42, 49-63, 72-79,:2, 1-57, 469,
putative 81-93,112-132, 159-165, C:3, 84-106 481
188-195,197-232, 262-267, E:3,
279-286, 294-301, 318-326,J:2
48-366, 381-405, 409-426,
436-465, 471-480, 484-492,
97-505, 521-544, 554-561,
567-577, 581-589, 601-609,
611-622, 636-651, 653-667,
669-685, 700-708, 716-722,
729-744, 749-766, 780-786,
789-811, 814-864
gbs1144 nknown protein-24, 35-48, 57-63, 72-78, :30 1-124 470,
87-92,113-119, 123-137,147- 482
153,173-181, 212-233
gbs1279 conserved 13-34, 62-69, 78-83, 86-91,:44, 1-84 471,
domain 98-104, 107-115,146-159, B:2, 483
protein 179-188,195-205, 209-221, C:4
226-233, 239-253, 276-282,
84-294, 297-308, 331-354,
375-382, 388-399, 421-433,
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-89-
S. agalactiaePutative predicted immunogenic as**No. LocationSeq.
function of of
antigenic(by homology) selectedidentifiedID
protein clonesimmunogeruc(DNA,
per
~RF region Prot.)
and (aa)
creen
1119-458, 464-469, 472-491,
508-513, 525-531, 534-550,
75-593, 601-618, 629-635,
654-661, 666-680, 706-721,
723-740, 771-805, 810-830,
845-851
gbs1441conserved -32, 45-64, 73-83, 86-92,100-111,125-147,:2, 1-71 472,
157-163, B:B, 484
ypothetical 170-175,177-188, 226-232, C:2
protein 245-252, 258-274, 320-335,
48-359
gbs1677sodium transport13-40, 43-71, 76-83, 87-101,:3, 1-51 473,
109-119, 125-156,162-175, C:2, 485
family protein182-219, 226-232, 240-262,:5
270-287, 306-318, 326-342,
44-408, 414-444, 449-456
gbs2093embrane protein,-16,18-34, 45-54, 99-108, :5, 1-87, 474,
134-140, 203-212, 241-257,C 342-480 486
:8,
utative 66-274, 279-291, 308-315, :2
330-336, 355-370, 374-382,
02-410, 428-455, 466-472,
474-480, 531-554, 560-566,
72-580, 597-618, 632-660,
664-674, 676-685, 691-705,
708-735, 750-768
Table 6. Immune reactivity of epitopes within identified antigens with human
sera
Peptides Positivityas from as to Seq
ID
bs0233.1 + 115 132 475
gbs0233.2+ 1 26 475
gbsU419.1++ 33 55 476
gbs0942.2+++ 1 25 478
gbs0973.1+ 37 61 479
gbs0975.1+ 1 24 480
gbs1038.1+ 1 23 481
gbs1144.3++ 46 60 482
gbs1279.1+++ 1 28 483
gbs1279.2+ 23 50 483
gbs1279.3++ 45 71 483
gbs1441.1+ 1 22 484
gbs1441.2++ 17 38 484
gbs1677.1+ 1 22 485
gbs1677.2+ 17 38 485
gbs2093.1+ 1 27 486
gbs2093.2++ 22 47 486
gbs2U93.4+ 422 447 486
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-90-
Table '7. Immunogenicity of epitopes in mice
~RF a~ ~a Peptide~eq
from go ELI~~ I~
gbs0233115 132 ++++ 475
1 47 ++
gbs04191 55 ++++ 476
gbs045822 85 ++ 477
gbs0942307 320 + 478
1 44 ++
gbs097315 76 ++ 47g
40 92 +++
gbs09751 59 ++ 480
213 269 +
403 445 +
gbs10381 56 ++++ 481
85 105 +
gbs114437 121 +++++ 482
gbs12791 71 +++++ 483
gbs14411 38 +++ 484
gbs16771 38 +++ 485
gbs20931 47 +++ 486
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
-91-
References
Altschul, S., et al. (1990). Journal of Molecular Biology 215: 403-10.
Balter, S. et al. Tn Gram positive pathogens ed. by Fischetti V.A. et al. AMS
Press 2000,154-160.
Bennett, D., et al. (1995).-T Mol Reco ng-it 8: 52-8.
Brodeur, B., et al. (2000). Infect Immun 68: 5610-8.
Burnie, J., et al. (1998). ]f Antimicrob Chemother 41: 319-22.
Campbell, J., et al. (2000). ~bstet G.~ 96: 498-503.
Cheng, Q., et al. (2002). Infect Immun 90: 6409-15.
Clackson, T., et al. (1991). Nature 352: 624-8.
Devereux, J., et al. (1984). Nucleic acids research 12: 387-95.
Doherty, E., et al. (2001). Annu Rev Biophys Biomol Struct 30: 457-4~5.
Eisenbraun, M., et al. (1993). DNA Cell Biol 12: 791-7.
Etz, H., et al. (2001). J Bacteriol 183: 6924-35.
Farley, M. (2001). Clin Infect Dis 33: 556-61.
Ganz, T. (1999). Science 286: 420-421.
Georgiou, G. (1997). Nature Biotechnolo~v 15: 29-34.
Glaser, P., et al. (2002). Mol Microbiol 45:1499-513.
Hashemzadeh-Bonehi, L., et al. (1998). Mol Microbiol 30: 676-678.
Heinje, von G (1980 e.g. Sequence Analysis in Molecular Biology, Academic
Press.
Hemmer, B., et al. (1999). Nat Med 5: 1375-82.
Hoe, N., et al. (2001). J Infect Dis 183: 633-9.
Hornef, M., et al. (2002). Nat Immunol 3: 1033-40.
Jackson, L., et al. (1995). Ann Intern Med 123: 415-20.
Johanson, K., et al. (1995). J Biol Chem 270: 9459-71.
Jones, P., et al. (1986). Nature 321: 522-5.
Kajava, A., et al. (2000). Bacteriol 182: 2163-9.
Kohler, G., et al. (1975). Nature 256: 495-~.
Larsson, C., et al. (1999). Vaccine 17: 454-8.
Lewin, A., et al. (2001). Trends Mol Med 7: 221-8.
Marks, J., et al. (1992). Biotechnolog,~(N Y) 10: X79-83.
McCafferty, J., et al. (1990). Nature 348: 552-4.
Michel, J., et al. (1991). Infect Immun 59: 2023-8.
Navarre, W., et al. (1999). Microbiol Mol Biol Rev 63:14-229.
Nizet, V. & Rubens, C.E. in Gram positive pathogens ed. by Fischetti V.A. et
al. ASM Press 2000,
pp 125-136.
Okano, H., et al. (1991). if Neurochem 56: 560-9.
Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression; CRC Press,
Boca Ration, FL (1988).
Paoletti, L., et al. (2002). Semin Neonatol 7: 315-23.
Paoletti, L., et al. In Gram positive pathogens ed. by Fischetti V.A. et al.
ASM Press 2000, pp 13~-153.
Phillips-Quagliata, J., et al. (2000). j Immunol 165: 2544-55.
Rammensee, H., et al. (1999). Immunogenetics 50: 213-9.
Seeger, C., et al. (1984). Proc Natl Acad Sci U S A 81: 5849-52.
Shibuya, A., et al. (2000). Nature Immunoloay 1: 441-6.
Skerra, A. (1994). Gene 151: 131-5.
Tang, D., et al. (1992). Nature 356:152-4.
Tempest, P., et al. (1991). Biotechnolog,~~N Y) 9: 266-71.
Tettelin, H., et al. (2002). Proc Natl Acad Sci U S A 99:12391-6.
Tourdot, S., et al. (2000). Eur T Immunol 30: 3411-21.
Wiley, J., et al. (1987) Current Protocols in Molecular Biology.
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
1/109
SEQUENCE LISTING
SeqID
1
atgaagaaagttttaaccttCttattatgtagcttatattttgtatcaatcccagctata60
agtaccgaggagccattaacgctttetcaaaatagacgatacgecttaactcagacagtt120
gtggataaggaaatgtattttgatgctattccagagagaccaactacaaaaattgaaata180
agcagttttcaagatgaagctttaaccataacaggagagactttagttccaaatacttta240
ttgtcgattgtttetcttacaattaattcaaatggaattccagtatttactttgtccaat300
ggacagtteataaaggctagtcgtgaagctatttttaatgatttagtttctaagcagcaa360
tCtgtCtCattggattattggttaaaaCCttCttttgtgaCttatgaagCaCCttaCaCa420
a.atggtgttagtgaagttaaaaataatttaaaaecttattccagagtgcatttagtagaa480
caagcagaaacagaacatggtatttattataaaaCggacagtggtttttggatatcagta540
gaagatctatCggttgctgataatcgtatggctaaggttcaagaagtattattggaaaaa600
tataataaagataaatatggtatatacatcaaacaa.ttaaatacacagacagtagctggt660
attaatattgataggtcaatgtactctgcaagtattgcaaaattagcaacactttatgct720
agccaagagcaagtaaaattaggaaaactgtcattggacagcaaatttgaatacaaagat780
aatgttaatcaatttcctaatagctatgatcCaagtggtagtgggaaattagagaaaaaa840
getgateataaattatataccgttaaggagttacttgaagcaactgccaaggaatcagat900
aatgttgcaacaaatatgctaggttattatgtcaataatcaatatgattcaatgtttcaa960
acacaagtagacacaatttctggtatgcactgggatatgaaaaaacgccagatttctcca1020
caagctgcgggtaaaatgatggaagcaatttattatcaaaatggagatattgttaattac1080
ctatcaaagactgattttgataatacaagaatccctaaaaatataccagttaaagtagca1140
cataaaattggagatgcttatgactacaaacatgatgcggctattgtttatgcagaacaa1200
ccttttattatgattatctttacggataaatcatcttacgatgatatcactaagattgct1260
gacgacgtttaccaggttttaaaataa 1287
SeqID
2
atgaaaaaaagaatattatcagcagtccttgtgagtggagtaactcttggaactgetgcc60
gtaacagtaaacgctgatgaetttgactcgaaaattgctgctactgattcagtaatcaat120
actttatcagggcaacaagcagcagcacaaaaccaggtgactgetattaaaggacaagtt180
ggtgctttagagtctcaacaatcagaattagaagegcaaaatgctcaacttgaggctgta240
tctcagcagttaggtcaagagattcaaactctttctaataaaattgttgcacgtaacgaa300
tctttgaaaaagcaagttcgtagtgctcaaaagggtaacttgactaactatattaatact360
attttaaattcgaaatcagtatctgatgetgttaatcgtgttgttgctattcgtgaggtt420
gtttcagctaatgaaaagatgttagcacaacaagaggctgacaaagcggccttagaagct480
aaacaaattgaaaatcaaaatgctataaatactgtagcagctaacaagcaagctatcgaa540
aataataaagcagccttagcaacacaaagagcacaattagaagcagCtcaattagagtta600
tctgctcaattgactacagteCaaaatgaaaaagcatctttaattcaggcaaaagcacaa660
gctgaggaagctgcgcgtaaggcagctgaagcacaagcagcagctgaagcgaaagcacaa720
gctgaagcgaaageacaagctgagtctgtagcaaaagcacaggcagcagcacaagttgag780
tctgccacagctcctactgaaacagttcaaacacaacegagaactgaaataaagccttet840
aatcttacggctacttcttcggcaactactgttgctacaactacagetacagctactaat900
gagccaaaagttactcaaccttctgtagtaactaaagcagttgaagcacctaaagcagtt960
gtttcttcaacacctagagcggtatcaaaacctgttgtcagaagttatgattcaagtaac1020
acatacccaatgggacaatgtacttggggagctaagtcaatggcttettgggttggtaac1080
tattggggaaatgctaatcagtggggtgctagtgcacgtgcagctggttattctgtagga1140
actacccctcgtgttggtgcagtagctgtttggccatatgatggtggtggttacgggeac1200
gttgcagtagtaacgtcagtggctaacaattcatctatccaagttatggaatcaaactat1260
gctggaaatatgagtattggcaattaccgtggttcatttaaacctagtgcttctggctct1320
gtttactatatttacccaaattaa 1344
SeqID
3
atgaataaacgtatttttgttgagaaaaaggctgactttgacattaaatcggctagtctt60
gtgaaagagttgacgcataatetacaactgacttctttgaaggatttgegtattgtgeag120
gtctatgatgtcttcaatttggctgaggatttgctggcgcgtgctgagaagcatattttc180
tctgagcaggtgacagactgtcttttgacggaaactgaaatcactgeggagcttgataag240
gttgCCttCtttgCCattgaggCgCttCCtggtCaatttgaCC2aCgtgCtgCtagttCg300
caagaatctttgctattgettggaagtgacagtcaggttaaggtcaatacagcccagctt360
tacttggtcaataaggatattgcagaagcagagcttgaagccgttaagaactatcttttg420
aatcctgttgattcacgtttcaaggacattaccttgccgcttgaagagcaggetttctct480
gtgtctgataagacaatccctagtcttgatttctttgaaacttataaggctgacgatttt540
gcggcctataaggcagagcagggcttggctatggaggtcgatgatcttctcttcatccaa600
gattatttcaaatcaategggcgtgtgccaactgagactgagttgaaagttttggatact660
tactggtcagaccactgccgtcacacaacctttgaaactgagttgaaaaaCatcgacttt720
tcagcttetaaattccaaaaacaattgcaggcgacttatgacaaatatatcgccatgcgt780
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
2/109
gatgaacttg gtcgttctga aaagccgcag acacttatgg atatggcgac tatetttggt 840
cgttatgaac gtgccaatgg acgactggat gatatggaag tctcagatga aataaatgcc 900
tgctcagttg aaattgaagt agatgttgat ggtgtaaaag agccttggct cctcatgttt 960
aagaatgaga ctcacaatca cccaacagaa attgagccat ttggtggcgc agcaacttgt 1020
atcggtggtg ccattcgtga cccgttgtca ggacgttcat acgtttatca ggctatgcgt 1080
atttcaggcg caggcgatat tacgactccg attgcggaaa cacgtgctgg taaattgccg 1140
caacaggtta tttctaaaac tgcggcgcac ggetattctt catatggtaa ccagattggg 1200
CttgCgaCaa CttatgtgCg tgagtaCttt Ca.CCCtggCt ttgtagCCaa aCg'Catggag 1260
cttggagctg tggttggtgc tgcacctaag gaaaatgtgg ttcgtgaaaa accagaagca 132D
ggcgatgtgg tcatettgct cggtggtaaa acaggtcgtg acggtgtcgg cggtgcgaca 1380
ggttcateta aggttcaaac ggttgaatct gtggaaacag ctggcgcaga ggt~.Caaaaa 1440
gggaatgcca tcgaagaacg taagattcaa cgecttttcc gtaatggtaa tgtcactcgc 150D
ctaatcaaga aatcaaatga ctteggtgca ggtggtgtct gtgttgccat cggtgaattg 1560
gctgacggtc ttgaaatcga tttggacaag gtaccgctta aataccaagg tcttaatggt 162D
actgaaattg caatctcaga atcacaagag cgtatgtcag tcgttgttcg tcctagtgac 168D
gtggatacct tcatcgcagc ctgcaacaag gaaaatatcg atgccgttgt ggttgetact 174D
attactgcaa aaccaaacct tgtcatgact tgggatggtg aaacaattgt tgaettggaa 1800
cgccgtttcc ttgataccaa cggtgtccgt gtcgttgttg atgetaaagt cgttg2caaa 1860
gacttgacag ttccagaggt acgcacaaca tcagcagaga cacttgaagc ggatacgctt 1920
aaggtcttgt ctgacctcaa ccacgctagt caaaaaggtc tccaaactat etttgactca 1980
tctgttggtc gctcaaccgt taaccaccca atcggtggcc gttaccaaat cacaccaaca 204D
gaaagctctg ttcaaaaatt gccagttcaa cacggtgtca caacaactgc atctgttatg 2100
gctcaaggtt acaatcctta tattgcagaa tggtcacctt accacggtgc tgcotatgct 2160
gtcattgaag cgacagctcg cttggtagca acgggtgctg actggtetcg tgcacgtttc 2220
tcttaccaag agtatttcga gcgtatggat aaacaggcag agcgttttgg tcagccagta 228D
tcagctcttc ttggttctat tgaggctcag attcaacttg gattgccatc aatcggcggt 2340
aaggactcta tgtctggtac tttcgaagaa ttgacagtac cgccaacctt ggtagctttc 24D0
ggtgtgacaa cagcggacag ccgcaaggtt etctctectg agtttaaagc ggctggtgag 2460
aatatctact acattccagg tcaagctatt tcagaagata ttgattttga ccttatcaag 2520
gctaacttta gceagttcga gactattcaa gctcaacata agattaetgc tgettcagct 2580
gttaaatacg gtggtgtcet agaaagtctt gctctcatga cttttggtaa ccgtatcggg 2640
gcctctgttg aaattgcaga gcttgacagt agcttgacag ctcaactcgg aggetttgtc 2700
tttacatcag ctgaggaaat tgctgactcg gtgaaaatcg gtcaaactea ggcagccttt 2760
acacttactg tcaatggaaa tgaccttgct ggggcaagcc ttctatcagt cttcgaaggc 2820
aaattggaag aggtttaccc aacagagttt gaacaggcag acgctcttga agaagttcct 2880
gctgtggtat cagatactgt tatcaaggct aaggaaacaa ttgaaaaacc agtggtttac 2940
attccagtct tccctggtac caactcagaa tatgattcag ctaaggcctt tgaacaggtt 3000
ggagctagtg tcaacttggt agcatttgta accttgaatg aggctgctat tgctgactca 3060
gttgacacaa tggtcgctaa tattgetaag gcaaatatca tcttctttgc tggaggattc 3120
tcagcagcgg atgaaccaga tgggtetgct aagtttatcg tcaatatctt gcttaacaag 3180
aaggttcgeg cagctattga cagcttcatc gaaaaaggtg gccttatcat cggtatetgt 3240
aatggtttcc aagcccttgt taaatcaggt cttcttccat acggaaactt cgaggaagct 3300
ggtgagacaa gtccaaccct cttctataac gatgccaacc agcacgttgc caagatggtt 3360
gagactcgta tcgcaaatac caactcacct tggttggtag gagttgaggt cggcgatatt 3420
catgccatcc cagtttcaca cggtgaaggt aaatttgttg tcagcgcttc tgaatttgca 3480
gagctaagag acaatggtca aatctggagc caatatgtgg actttgacgg acaaccatct 3540
atggattcta aatacaatcc aaatggctct gtcaatgcca tcgaagggat taccagcaag 3600
aatggtcaaa tcatcggtaa gatggggcac tcagaacgct gggaagacgg cctcttccaa 3660
aatatccctg gtaacaaaga ccaagcettg tttgctagtg cagtaaaata ttttacagga 3720
aaataa 3726
SeqID
4
atgaaaatgaataaaaaggtactattgacatcgacaatggcagcttcgctattatcagtc60
gcaagtgttcaagcacaagaaacagatacgacgtggacagcacgtactgtttcagaggta120
aaggctgatttggtaaagcaagacaataaatcatcatatactgtgaaatatggtgataca180
ctaagcgttatttcagaagcaatgtcaattgatatgaatgtcttagcaaaaataaataac240
attgcagatatcaatcttatttatcctgagacaacactgacagtaacttacgatcagaag300
agtcatactgccacttcaatgaaaatagaaacaccagcaacaaatgctgctggtcaaaca360
acagctactgtggatttgaaaaccaatcaagtttctgttgcagaccaaaaagtttctetc420
aatacaatttcggaaggtatgacaccagaagcageaacaacgattgtttcgecaatgaag480
acatattcttctgcgccagctttgaaatcaaaagaagtattagcacaagagcaagctgtt540
agtcaagcagcagctaatgaacaggtatcaccagctcctgtgaagtcgattacttcagaa600
gttccagcagctaaagaggaagttaaaccaactcagacgtcagtcagtcagtcaacaaca660
gtatcaccagcttctgttgccgctgaaacaccagctccagtagctaaagtagcaccggta720
agaactgtagcagcccctagagtggcaagtgttaaagtagtcactcctaaagtagaaact780
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
3/109
ggtgcatcaccagagcatgtatcagctccagcagttcctgtgactacgacttcaccagct840
acagacagtaagttacaagcgactgaagttaagagcgttccggtagcacaaaaagctcca900
acagcaacaccggtagcacaaccagcttcaacaacaaatgcagtagctgcacatectgaa960
aatgcagggctccaacctcatgttgcagcttataaagaaaaagtagcgtcaacttatgga1020
gttaatgaattcagtacataccgtgegggagatccaggtgatcatggtaaaggtttagca1080
gttgactttattgtaggtactaatcaagcacttggtaataaagttgcacagtactctaca1140
caaaatatggcagcaaataacatttcatatgttatctggcaacaaaagttttactcaaat1200
acaaacagtatttatggacctgctaatacttggaatgcaatgccagatcgtggtggcgtt1260
actgccaaccactatgaccacgttcacgtatcatttaacaaataa 1305
SeqID
atgttaaaacattttggtagtaaagtaagaaatttgagagtaactagaaatattactcgc60
gaagatttttgtggtgatgaaactgagttatctgtaagacaattagctaggattgaaagt120
ggacagtcaattccaaacttgactaaagctcactacatagctaaacaattgaatgtaaaa180
ttggatattttaacaggaggagagagcttagaattacctaaacggtataaagagttgaag240
tacaaattgttgcgtaccccgacttacggagatgctaatagacttgcagttagagaagca300
tattttgatgaaatctatgaagtattttatgaggagctcccagaagatgaaagactaatt360
attgattgtatgcaatcaaaattagatgttcatttttctgttaatgataattttggaatc420
actattttacatgactactttgatcaaattaagaaaaaaaaggaatataccacaaatgat480
tttgttatgatagatttatatttactttgcttttctattaactatggaatgaagagcttg540
tattctttagagaactatcattttattatgtcaaaattgttagagcaagataatttactt600
cctgaggataattttcaattgaacaacgttttattaaatcatgtcgaattagcttttcaa660
tttaagcagaaaaaatatgtacagcaaattattcatagaagtaatgctattatgacagaa720
atccatgattttcaaaaaagaccaatactaagcttaatagagtggaaatatttattaatt780
attgaaaaagatagaacaaaagcagaaacatgttttaaacaatcaattctatttgcagag840
ttaataggtgatctatatttaaaaggaaaattaatagaggagtggaataaagatttaaca900
tga 903
SeqID
6
atgactgaaaaaactaaagcggtagaaactacagatgttgctcttgcaattgatacattg60
gttcaaaacggtttaaaagcacttgatgagatgcgtcaacttaatcaagaacaagttgat120
tatattgtagctaaagcttctgttgcagccttggatgcccatggagaacttgctcttcat180
gcagtagaagaaactggtcgtggtgtctttgaagataaagcgacaaaaaatttatttgca240
tgtgaacacgtcgttaacaacatgcgtcatacaaagacagtgggagttattgaagaagac300
gatgtcacaggcttgacattaattgctgaaccagtgggagttgtctgtggtattacgcca360
acaaccaacccgacttcaactgctattttcaagtcattaatetctcttaaaacacgtaat420
ccaattatttttgccttccacccatcagcacaagaatcatcagcacatgcagcacgtatt480
gttcgtgatgctgctattgctgctggagctcctgaaaattgtgtccaatggattgaacaa540
ccatcgattgatgcaactaatgctttgatgaaccatgatggtattgccactatccttgcg600
acaggtggtaatgcgatggttaaagctgcctactcatgtgggaaacctgcccttggtgta660
ggtgctgggaatgttccagcttatgttgaaaaatcagctaatatccgacaagccgetcac720
gatattgttatgtctaaatcatttgataacggtatggtatgtgcatcagaacaggctgtt780
attattgataaagaaatttataaagaatttgttgaagaatttaaatcttatcatacttat840
ttcgttaataagaaagaaaaagetcttcttgaagaattctgttttggtgcaaaagcaaat900
agcaaaaactgtgctggtgcaaaattaaatccaaatattgttggaaaatcagcagtttgg960
attgctgaacaagctggatttactgttccagaaggaacaaatattcttgccgcagaatgt1020
actgaagttagtgaaaaagaacctttgacacgtgaaaaactatcacctgttattgccgta1080
ttgaaagctgaatctacagaagatggtgttgaaaaagctcgtcaaatggttgagtttaat1140
ggtctaggacactcagctgctattcatacaaaagatgcagacttagctcgtgaatttgga1200
actagaattcgtgctatccgtgttatttggaattcteettctaettttggtggtattggg1260
gatgtttacaatgctttcttgccatcattgactcttggttgtggttcgtatggacgtaac1320
tcagttggtgataacgttagtgctataaatctcttgaatatcaaaaaagtaggaagacgt1380
agaaataatatgcaatggtttaaagtcccttcaaaaacatacttcgaacgtgattctatt1440
aaatatttgcaaaaatgtcgcgatgttgaacgtgtcatgattgttacagatcacgccatg1500
gttgagcttggtttettggatcgtatcattgaacaacttgatcttcgtcgcaataaagtt1560
gtttatcagatttttgctgaagtagaaccagatccagacattacaacagtaatgaaagga1620
acagatttgatgcgtaccttcaaaccagacactattattgcattaggtggtggttctcct1680
atggatgctgcgaaagttatgtggctcttctatgaacaaccagaagttgatttccatgac1740
ctcgttcaaaaattcatggatatccgtaaacgtgcgttcaaattcccagaacttggtaag1800
aaaacaaaatttgttgctattccaacaacttctggaacaggttctgaagtgacaccattt1860
gccgttatctctgacaaagcaaataatcgtaaatatccaatcgctgattattcattaaca1920
ccaactgtagctatcgttgatccggcccttgttatgactgttcctggttttattgcggct1980
gatacgggtatggatgtattgacacatgcaacagaggcttatgtttcacagatggcaaat2040
gattatacagacggacttgcccttcaagcaattaaaattgtgtttgactacttagaacgc2100
tcagtaaaagatgctgattttgaagcacgtgaaaagatgcacaatgcgtcaactatggca2160
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
4/109
ggtatggctttcgecaatgcattcttaggtatttetcactcaatggcgcataaaattggc2220
gcacaattccataccgtacacggacgtacaaatgcaattcttttgccgtatgttatccgc2280
tataatggaactcgtccagctaaaacagcaacatggcctaagtacaattactatcgtgct2340
gatgaaaaatatcaagatatcgctaaattactcggettaccagcagcaacaccagaagaa2400
gctgtcgaatcatatgcaaaagctgtgtatgaccttggaacacgtttaggtattaagatg2460
aatttccgcgaccaaggcattgatgaaaaagaatggaaagaaaaatctcgtgaactagct2520
ttcttagcatatgaagatcaatgttcaccagcaaatccacgccttccgatggtagatcac2580
atgcaagaaatcatcgaagatgcttattatggttatgaggaaCgtCCaggacgtegtaag2640
taa 2643
SeqID
7
gtgggtattaaagtttataaaccaacgacaaatggccgtcgtaatatgacttctttggat60
tttgcagaaatcactacaaacactcctgagaaatcattgcttgtttcactaaagaataaa120
gcaggacgtaacaacaacggacgtattactgttcgtcaccaaggtggtggacacaaacgt180
cattacegtttgattgacttcaaacgtaataaagatggtgttgaagcagttgttaaaaca240
attgaatacgatccaaategtactgcaaatattgctcttgtacactatactgatggtgtt300
aaagcttacattcttgcgcctaaaggccttgaagtaggtcaacgcattatttctggtcca360
gaagcagatatcaaagttggtaacgcacttccacttgctaacattccagtcggtacagtt420
atccataatattgaattgcaaccaggtaaaggtgctgaattgattcgtgccgcgggtgcta.80
tctgctcaagtacttggtcaagaaggtaaatatgttcttgttcgccttcaatcaggtgaa540
gtacgtatgatccttggtacttgccgtgcaacaattggtactgttggtaatgaacaacaa600
tcacttgttaacattggtaaagcaggacgtaatcgttggaaaggtgttcgccctacagtt660
cgtggttetgtaatgaacectaatgatcacccacacggtggtggtgaaggtaaagcacca720
gttggtcgtaaagcaccatctactccatggggtaaacctgcacttggacttaaaactcgt780
aataagaaagctaaatcagacaaacttattgttcgtcgtcgtaaccaaaaataa 834
SeqID
8
atgattgagtttgaaaaaccaataataacaaaaattgatgaaaataaagattacggcaga60
tttgtcatcgaaccactagaacgtggetacggtacaactctaggaaactetettcgtcgt120
gtgcttctgtcttcacttccaggtgcagcagtcacatcaatcaaaattgatggagtatta180
cacgaatttgatactatcccaggtgtacgtgaagatgtgatgcaaatcatccttaatgta240
aaaggacttgctgtgaaatcttacgtcgaagacgaaaagattatcgaactagacgttgaa300
ggtcctgcagaaattactgccggagatattttaacagatagtgatategaaattgtaaac360
cctgaccattatettttcacaattgctgaaggtcacagtttgaaagcaacaatgacagtt420
getaaaaaccgaggttatgttccagcagaaggaaataaaaaagatgatgcaccagtggga480
acattggctgtagattcaatetatacaccagtgaaaaaagttaattatcaagttgaacct540
gctcgtgtaggtagtaacgatggctttgataaattaactattgaaatcatgacaaatggc600
acaatcattcctgaggatgctcttggtctttcagctcgcgtcttaattgaacacttaaac660
ttgtttactgatttaacagaggttgctaaagcaactgaagtaatgaaggaaacagagaaa720
gtgaacgatgagaaagtgcttgaccgcacaattgaggaacttgatttgtcagtgcgctca780
tataactgtttaaaacgtgctggaattaatacagtatttgatttaacagaaaaaactgag840
cctgaaatgatgaaagtccgaaacttaggacgtaagagtcttgaagaagttaaaatcaaa900
cttgccgatctaggtcttggattaaaaaacgataaataa 939
SeqID
9
atgaaaaagattcgattatcaaagtttattaaaatgattgttgttattttgtttttaatt60
agtgtagcagctagtttttattttttccacgttgeccaagttcgagatgataaatccttt120
atttcaaatggtcaacgtaagcctggaaactctttatatgcttatgataaatcetttgatl80
aagctattaaagcaaaaaatagaaatgacaaaccaaaatataaagcaagttgcttggtat240
gttcctgctgctaagaaaactcataagacagctgttgtcgttcatggttttgcgaatagc300
aaagagaatatgaaggcatatggttggctgtttcataagttaggatacaatgttcttatg360
ectgacaatattgcacatggtgaaagtcatgggcagttgataggctatggctggaacgac420
cgcgagaacattatcaaatggacagaaatgatagttgataagaatccatcaagccaaatt480
actttatttggtgtttcaatgggtggagcaacagtcatgatggctagtggtgaaaaatta540
cctagtcaggttgttaatatcattgaagattgcggttattctagtgtttgggatgaatta600
aaatttcaggctaaagagatgtatggtttaccagccttcccactcttatatgaagtttca660
acaatttctaaaatcagagcaggtttttegtatggacaagcaagtagtgtcgaacaattg720
aaaaagaataatttaccagccctctttattcatggtgataaggataattttgttccaaca780
agtatggtttatgacaactataaagctacagcaggtaagaaagagctttatattgtaaaa840
ggggcaaaacatgcgaaatcttttgaaacagagccagaaaaatatgagaaacgtatctct900
agttttttgaaaaaatatgaaaaataa 927
SeqID
atgtcaaaagtacgtggctttgaattagttagccaatttagcaataaagagttattacca60
aaacgagaaacagctcacgcagctggetatgatttaaaagtagctaaaaaaacggttatt120
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
5/109
gaacctggtgaaattacattggtcccgaccggtattaaagcacacatgcaaccaggggag180
gtcctgtacctttatgatcgttcatcgaatccacgtaaaaaagggattgtcctaataaat240
tcagttggtgttattgatggtgactactataataaccaagtcaatgaaggacatattttt300
gcacagatgcaaaatattactgatcaggctgttattttagaagaaggggaacggattgtt360
caggctgtttttgccccattcttattggcagatgacgatcaggctacaggaatgcgtaca420
ggtggttttggtagtactggaaaataa 447
SeqID
11
atgaaatttggaaaaaaacttggctttctagccttattgatgtctattgtCCtCattCta60
ggtgcatgtggtaaaactggaettgga.a~.ttctactggga.attctacaaaaaatgtaacc120
aaaaaa.tctgctaaaaa.cttga.aactaggtgt~.tct~.tttca.acaactaacaatccctac180
tttgttgcgatgaaagacggtattgacaaatatgctagcaataaaaaaataagcattaag240
gtagctgatgctcaagatgacgccgcacgtcaagcagatgatgtcca.aaactttattagt300
caaa.acgtagatgctattttgattaatcccgttgactcaaaagctattgtaacagctatt360
aagtctgcaaacaacgctaatattcctgttattetaatggaccgtggtagtgagggaggc420
aaagtattaactactgtcgcttcagataacgttgctgctggtaagatggctgcggattat480
gctgttaaaaaactaggcaaaaaagcaaaagcctttgaattatctggagtaecaggtgcc540
tCtgCta.CtgtagaCCgtggtaalggatttClttCagttgC~ac'iatCtc'ia.aCttgaCatt600
ctttcaagccaatctgccaattttgaccgcgccaaagctttgaatactacacaaaatatg660
attcaaggacataaagatgtccaaattattttcgcacaaaatgatgaaatggcacttggg720
gctgcacaggctgtcaaatctgctggettgcaaaatgttcttatcgtaggaattgatggt780
cagccagatgcccatgatgccattaaaaaaggagatatttcagccactattgcacaacaa840
ccagctaagatgggagaaatagcaattcaagcagcaattgatcattataaaggcaaaaaa900
gtagagaaagaaacaatttctccaatttaccttgttaccaaagacaatgttgaaaaatac960
aattggtaa
969
SeqID
12
atgggaaaagaaaaattaattttagcttattctggtggtttagatacctctgttgctata60
gcttggttaaaaaaagattatgacgttattgctgtctgtatggatgttggcgaaggtaaa120
gatcttgattttattcacgataaggctttaacaataggtgccatagaatcttatatttta180
gatgttaaagatgagttcgctgagcattttgtgttaccagctttacaggcacatgcgatg240
tatgaacaaaaatacccgcttgtttcagcgcttagtcgtccaattattgctcaaaaatta300
gttgaaatggcacatcaaacaggtgcgaccacaattgcccatggatgtacaggtaaagga360
aatgaccaagtgcgttttgaagttgcaattgcagcactagatcctgaattaaaagtaatt420
gcccctgttcgtgagtggaagtggcatcgtgaagaggaaattacttttgcaaaagctaac480
ggcgtacctattccagcagatttagataacccttattctatagaccaaaatttatgggga540
cgtgccaatgaatgtggtgtgcttgagaatccttggaatcaagcgccagaagaagctttt600
ggtattacaaaatcaccagaagaagctcctgattgtgcagaatatattgatattacgttc660
caaaatgggaagcctatagctataaacaatcaagaaatgacactagcagatttgatttta720
tcgctaaatgaaattgcaggaaaacatggtattggacgcattgatcatgttgaaaatcgt780
ttagtcggtatcaaatcacgtgaaatttatgaatgtcctgcggcaatggtactgttagct840
gctcataaagaaattgaagatttaacattagtccgtgaagtgtctcattttaaacctatc900
cttgaaaatgaactatcaaatcttatttataatgctttatggtttagtccagctacaaaa960
gctatcattgcctatgtcaaagaaacacaaaaagtggttaatggtactacaaaagttaag1020
ttatataaaggttctgccaaagtcgttgctegccactcgtctaattcattatatgatgag1080
aacttagcaacttatacagctgctgataactttgatcaagatgcagcagttggttttatc1140
aaactctggggacttccaacecaagttaatgcacaagtaaacaaaggataa 1191
SeqID
13
atggctaaagtatgttatttcacaggacgtaaaacagtttetggtaacaaccgttcacac60
gcgatgaaccaaacaaaacgtactgttaaaccaaaccttcaaaaagttactgttcttatc120
gacggtaaaccaaaaaaagtttgggtttcagctcgtgcgcttaaatctggtaaagtagaa180
cgcgtttaa
189
SeqID
14
atggcaaaacagaaaaataactggcgccgtgttggagttggtgtccttacacttgcttca60
gttgcgactcttgctgcatgtggaagtaaatcagcttcccaggattctaatggagcgatt120
aattgggctattccaacagaaatcaatacactagatttatctaaagttacagacacttac180
tcaaatctagctattggtaactctagtagtaatttccttcgcttagataaggatggaaag240
acgagaccagatttggctactaaagttgatgtttcaaaagatggtttaacttatacagct300
acattacgtaaaggcttgaagtggtcagatggcagtaaacttactgcaaaggattttgtt360
tattcatggcaacgtttagttgatcctaagacagcttcacaatatgcttaecttgctgtt420
gaagggcatgtgcttaatgccgataaaatcaacgaaggacaagagaaagacttgaataag480
ctaggtgttaaggcagaaggcgatgacaaagttgttattactttatctagtccgtctcca540
caattcatctactaccttgcattcactaatttcatgccacaaaaacaagaagttgttgaa600
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
6/109
aaatatggaaaagattacgcaactacttcaaaaaatacagtttactcaggaccatatact660
gttgaaggttggaatggttcaaatggtactttcaccctgaagaaaaacaaaaattattgg720
gacgctaaaaatgtaaaaacaaaagaagttcgcatccagactgttaaaaaaccagatacc780
gccgttcaaatgtataaacgtggtgaattagatgcagctaatatctcaaatacttctgct840
atttatcaagctaataaaaataataaagatgtcacagatgttctagaagcgaccactgec900
tatatgcaatataatactactggttctgtgaaagggcttgataatgttaagattcgtcgc960
gccttaaacttagcaactaaccgtaaaggagttgttcaagcagccgttgatacaggctca1020
aaaceggcaattgcttttgcaccgactggtttagccaaaacaccagatggaactgatttg1080
gcaaaatatgttgccccaggttatgaatataataaaactgaagcagcaaaactctttaaa1140
gaaggtttggctgaatcaggcttgactaagctaaaattaacaattacagcagatgctgat1200
gttcctgctgccaaaaactctgttgactatatcaagtctacttgggaagctgctcttcca1260
ggacttactgttgaagaaaaatttgtaacctttaaacaacgcttagaagacagtagaaaa1320
caaaactttgatatcgtagtttctgtttggggtggggattatccagaagggtcaactttc1380
tacggcctctttaagtcagattcacaaaataacgatggaaaatttgctaacaaggactat1440
gacgctgcttataacaaggcaatttccgaagatgccttaaaaccagaagaatcagcaaag1500
gactataaagaagcagagaaaattctatttgagcaaggcgcttataacccactctacttc1560
cgtagtggtaaaggtttacaaaatccaaaattaaaaggtgttattcgtaatactacaggt1620
ttgtcaatagactttacacatgcttataaaaaataa 1656
SeqID
15
atggaactcttaaaaacacccatctttggtatttgcttttctttaatactctatacgata60
ggacaacatttatttaagaagagtaaaggtttcttccttttgcagcctcttttctttgca120
atggttagtggtattgtcattctttggcttatgtcaaaaggtttaggaaccgatgttaag180
acattttatacacaagcttataaaccaggtggcgatttaatattttggtttttaaatcca240
gcaacaattgcttttgcagttcctctctataagaaaaatgacgttgttaaaaaatattgg300
gtagaaattctcagcagtttagtaatcggtatgattgtttcccttatgcttatcgtcgct360
atttctaaaatggttgggcttagtcaagtcggaattgcttcaatgttgccacaagcagca420
acaacagcaattgctcttccaataacagcagcaattggagggaacacagctgtgacagca480
atggcgtgtatcttaaatgcagttattatttatgcattaggtaaaaaattagtgtcattt540
ttccatttgaatgatagtaagattggtgcaggattaggtctagggacctctggtcataca600
gtcggagcagcctttgcattggaattgggagaactgcaaggtgcgatggcagctatagcg660
gtggtggttatcggtttggtagttgatttggttattcctatctttagtcatttgattggt720
ttgctataa 729
SeqID
16
gtgactaaatatttgaagtacatctcttttgttgctttgtttctggcgagtatcttttta60
gtagcttgtcaaaatcaaaattcacaaacaaaggagcgaacacgaaaacaacgacccaaa120
gatgaattggttgtttctatgggggcaaagcttectcatgaattcgatccaaaggaccgt180
tatggaatccataatgaaggtaatattactcatagtaccctattgaaacgttctcctgaa240
ctagatataaaaggagagcttgctaaaaaatataaaatctctaaggatggcttaacgtgg300
tcgttcgacttaaatgatgattttaaattctccaatggtgagcctgttactgctgacgat360
gttaagtttacttatgatatgttgaaagcagatggaaaagcttgggatttgacctttatt420
aagaatgttgaagtagttgggaaaaaccaggtaaatattcatttgactgaggcgcattcg480
acatttacagcacagttgacagaaatcccaatcgtccctaaaaaacattacaatgataag540
tataagagcaatcctatcggttcaggaccttacatggtaaaagaatataaggctggagaa600
caagcaatcttegttcgaaatccatattggcacggtaaaaagccttattttaaaaagtgg660
acttgggtattacttgatgaaaatacagcactagctgctttagaatctggtgatgttgac720
atgatttacgcaacgccagagcttgctagcaagaaagtcaaaggaacacgtcttctagat780
attgcttcaaatgatgttcgtgggttatcgctaccttatgtgaagaaaggtgttgtgaaa840
aattcaccagacggttatccagtaggaaatgatgtcactagtgatccagcaatcagaaaa900
gccttgactattggtttaaatagacaaaaagttctggatactgttttaaatggttatggt960
aaaccagcttattcaattattgatagaacaceattctggaatccaaaaacagcaattaaa1020
gataataaagtagctaaagctaagcaacttttgacaaaagctggatggaaagaacaagca1080
gacggtagccgcaaaaaaggaaatettaaagcggaatttgacctttactaccctactaat1140
gatcaattacgagcaaacttagccgttgaagtagcggagcaagctaaagccttaggtatt1200
actattaaactcaaggctagtaactgggatgaaatggcaactaagtcacatgattcagcc1260
ttactttatgcgggaggacgtcatcatgcgcagcaattttatgaatcacattacccaagt1320
ttagctggtaaaggttggaccaatattactttttataacaatcctactgtgactaagtac1380
cttgacaaagcaatgacatctcccgaccttgataaagctaacaaatattggaagttagct1440
cagtgggatggcaaaacaggtgcttccactcttggagatttaccaaatgtatggttggtg1500
agtcttaaccatacttatat.tggtgataaacgtatcaatgtaggtaaacaaggtgtccat1560
agtcatggtcatgattggtcattattgactaacattgctgaatggacttgggatgaatct1620
gctaagtaa 1629
SeqID 17
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
7/109
atgggccaagaaectatcategaatatcaaaatatcaataaagtgtatggggaaaatgtt60
gcggttgaagatattaaccttaaaatttaccctggtgatttcgtttgtttcateggtacg120
agtggatcaggtaaaacaacattaatgcgtatggttaaccatatgttaaaaccaacaaat180
ggtactctattatttaagggaaaagatatttetactattaaccccattgaattaagacgc240
agaattggatatgttatccaaaacattggtttaatgcctcatatgaccatttacgaaaat300
atagttcttgtaccaaaattattgaaatggtcagaagaagctaaaagagctaaagcaagg360
gaacttattaaattagttgaattacccgaagaatatttggatcgctaccctagtgagttg420
tctggcggtcagcaacaacgtatcggtgtcattcgcgctcttgcagcagaccaagata.tt480
attttaatggatgagccttttggagctctggatcetattactagagaaggtattcaagac540
ttagtcaagtctcttcaggaagaaatggggaaaactatcatctt~.gttactcatgatatg600
gatgaagf~C:4.tCaagttagC~aCaaaaattattgttatggaCaatggtaa~7latggtCC'ac'7660
gaagggacacccaatgatctettacatcatectgctaccagtttcgttgaacaaatgatt720
ggggaagagcgtcttcttcatgcgc~.ggctgat~.ttacccctgttaaacagataatgtta780
aataatcctgtttcaataactgctgaaaaaacactaactgaagctattacactaatgcgcs40
caaaaacgcgttgactcacttctagtaaccgataacggtaaattaattggttttattgac900
ttagaatctctaa.gcagtaaatataagaaagaccgacttgtttctgatatcttaaaacat960
actgatttttatgttatggaagacgacttacttagaaatactgctgagegtattttaaaa1020
cgtggtttaaaatacgctccagttgttgaccatgaga~.taacctaaagggcattgttact1080
cgtgcatccctagttgatatgttatacgatattatttggggcgatactgaaacggaggat1140
caataa 1146
SeqID
18
atgaaaatagataaaaaagaatttttagcacttattgctagtattattttattaattttt60
gcttctgttacgtttttcttatttaaagatcatggcactactcaaatggatactgtagaa120
agcagtgttaaccatgtcagtgattctcaattaactgaggcacaagatatgttagataaa180
tttgagaagaaaccttcagaaaaattattgaaggatgtcgaacttgctttaaataaattg240
tccaattcttctaaaaaagaagctttgcaaaaacgttttaagaaagcaaaagataagtat300
cttaaagacgaagcagataagaaagctaccaaagatgctacagatttagtagaaattcta360
gaacaagccccttcagaagaaaatgtgttaaaagctgaagcagcagtcaataagttaact420
gtcaaagaatctaaagaagctttacaaaaacgtattgatactgttaagacacaatatggt480
ttgattgggaatcaaactccctctagttcagtagctgaaactacagaacaagggacagct540
aatcctgctagtcaggatacttctagttacgttaatcagaatgtagcaccaacttatgag600
caaccgcaaaegaataatacaccagttactccaggggttaacaatactgttccgactcca660
ggaactggtactgcacctgctactaatgggacgggtgttgctcagtaa 708
SeqID
Z9
atgactaaagatttattattggagcttggccttgaagagttgccagcttatgttgtgaca60
ccgagtgagaagcaattgggccaaaaaatggtcaagtttttagaggatcatcgtttatca120
tttgaaactgttcaaactttttcaactccacgtcgtttggctgttcgtgttaaaggattg180
gcagaccagcagacagatttaacagaagatttcaagggtccttctaagaaaattgctttg240
gatgcagaagggaatttttctaaagcagcccaaggttttgttcgcggaaaaggtttaagt300
gttgatgatatcgaatttcgtgaagttaagggagaagaatatgtttatgtcactaagcat360
gaaactggaaaaagtgcgattgatgttttagcaagtgtgacagaggtattaacagaattg420
actttcccagtgaacatgcattgggcaaataatagttttgaatatattcgtccagttcac480
actttagtggtattattagatgatcaagccttagagctagacttccttgatattcattca540
gggcgtattagtcgagggcaccgtttcttgggttctgacaatgaaattttatctgctagt600
tcgtatgaagatgacttgcgacaacaatttgttattgctgatgcaaaagaacgccagcaa660
atgatcgttgatcaaattcatgctatcgaagaaaaggaaaatatttcagttgaaattgac720
gaagatttactaaatgaagtgcttaatttagttgagtatccgacagcattcttgggttct780
tttgacgagaaataccttgatgtacctgaagaagttttagtcacttcaatgaaaaatcat840
caacgctattttgttgttcgcgacagggatggaaaattgttaccaaactttatttctgtg900
cgtaatggaaatgetgagcatatcgaaaatgttataaaaggtaatgaaaaagttttagtg960
gctcgtctcgaagatggtgaattcttctggcaagaagatcagaaacttaatattgcagat1020
ttagttgagaaattaaaacaagtaactttccatgaaaaaattggttcactttatgaacat1080
atggatcgtgtaaaagttatttcacaatatttggctgagaaggcagatctttetgatgaa1140
gaaaaattagctgtgcttegagctgcaagtatttataaatttgacctettaactggaatg1200
gttgatgagtttgatgaattacaaggtattatgggtgagaaatatgccttacttgcaggg1260
gaacagcccgcagtagcagcagcgatacgtgaacattatatgccgacatcggcegatgga1320
gagcttccagaaaccagagttggtgcaattctagcgttagctgataaatttgacacctta1380
CtttCattCttCtCagttggtttgattCCo'l.agCggttCa.~~.tgatCCc.ta.tgCtCttCgt1440
cgagctactcaggggattgtccgtattttggaagcttttggttgggatatcccacttgat1500
gaattagtaactaacctttatggtctatcgtttgctagtttagattatgctaatcaaaaa1560
gaggtcatggcctttatttcagctcgtattgaaaagatgattggctctaaggtccctaaa1620
gatattcgagaagccgttttagaatcagacacttatattgttagccttattctagaagct1680
agccaagcattggtgcaaaagagcaaggatgctcaatataaagtttccattgaaagtttg1740
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
8/109
tcacgtgcatttaatttagctgaaaaagttactcattctgtatcggtggactattcattg1800
tttgaaaataatcaggagaaggcgctatatcaagctattttgtcacttgaactgactgag1860
gatatgcatgacaacttagataagcttttcgcacttagtccaattattaatgatttettt1920
gataatacaatggtaatgacagatgatgaaaaaatgaaacaaaatcgtctggctttactc1980
aatagccttgttgcaaaagcaagaacagtcgctgcttttaacttattaaacacaaaataa2040
SeqID
20
atgacatttgacaecattgatcaattagcggttaatacagtcegcacgctttctattgat60
gctatccaagcagcaaattctgggcacccaggtcttcctatgggagctgcgcctatggct120
tatgtgctttggaataaattcttaaatgtaaacccaaaaacaagtCgcaattggacaaac180
CgtgaCCgttttgtgCtatCagCtgggCatggttCdgCtCttCttt~.t~.gCCta.CttC~.t240
ttagCtggCtatgatttatcaattgatgatttaaaacaattccgccaatggggatcaaaa300
dcacctggacatccaga.agttaaccatactgatggtgtagaagcaacaactggaccttta360
gggcaaggtattgctaatgctgttggtatggcaatggctgaagctcatttggctgctaaa420
tttaataaaccaggctttgatttagttgatcattacacttatacacttcatggtgatggt480
tgtttgatggagggtgttagecaagaagctgccagtcttgctggacacttaaaacttggt540
aaattggtccttctttatgattcaaatgatatctcacttgatggtccaacgtctcaatca600
tttacagaagatgtta.aa.gggcgttttgaatcatatggttggcaacatatcttagttaaa660
gatggtaatgatttagaagcgattgetgcagcaattgaagctgctaaagctgaaactgat720
aaaccaaccattattgaagttaaaactattattggatttggcgeagagaaacagggaaca780
tcttcagttcatggagcgccacttggtgcagaaggtattacttttgccaagaaggcttats40
ggatgggaatatccagactttactgttcctgctgaagttgtagctcgatttgcctcagat900
cttcaagegcgtggtgcgaaggcagaagaggcatggaatgatctttttgctaaatatgaa960
gttgagtatccagaattagcagctgaatacaaagaagcttttgctggccaagctgagaca1020
gttgaattgaaagctcatgacctaggttcatcagtggctagtcgtgtttcaagccaacaa1080
gcta.ttcaacaattatcgactcaa.ttaccgaacctctggggagggtcagcagacetctea1140
gcttctaataacacaatggtagcagcagaaacagatttccaagcaagtaattacgctggg1200
cgtaacatttggtttggtgtacgtgaatttgcaatggctgctgcaatgaatggaattgcg1260
ettcacggtgggactcgtgtttatgggggtacattctttgtcttctcaaactacttgtta1320
ccagcagtacgtatggctgcacttcaaaacttgccaactgtctatgttatgacacatgat1380
tctattgctgttggagaagatgggccaactcatgagccaatagaacaattagcatcagtg1440
cgctcaatgcctaatttgaacgttatccgtcccgcagacggtaatgaaacaaacgctgca1500
tggcaacgagctgtatcagagacagatcgaccaacgatgcttgttttaacacgtcaaaac1560
ttaccagttcttgaaggaacatcagaattagcccaagaaggggttaataaaggtgcttat1620
attttatcagaagctaaaggtgaacttgatggtatcatcattgcaacaggttcagaagtt1680
aaattagctttagatactcaagacaaacttgagtcagagggcatccatgttcgcgtcgta1740
tctatgccagcacaaaacatttttgatgaacaagaggcttcatatcaagagcaagtgctt1800
ccatcagctgttacaaaacgtcttgctattgaggcaggatcaagcttcggttggggtaaa1860
tatgttggtttaaatgggctaacacttactattgatacttggggagcatcagcaccaggt1920
aacagaattttcgaagagtatggctttacagttgagaatgctgtatcgctatataaagaa1980
ctttaa 1986
SeqID
21
atgactttgcaagatcaaattatcaaagaactcggtgtaaaacetgttattaatccaagt60
caagaaatccgtcgttccgtagaatttttaaaagactatctattaaaacatagttttcta120
aagacctatgtactgggtatttcaggggggcaagattcaactttagcaggacgtctagct180
caactagcagttgaagagttgcgtgctgatacaggggaaaactatcaatttatagctatt240
cgtttaccatatggtattcaggccgatgaagaagatgcacaaaaagcattagattttatc300
aagccagatattgctttgaccattaatattaaagaagctgttgatggccaagttagagct360
cttaatgcagcaggagtagagattacagactttaataaaggaaatattaaagctcgtcaa420
agaatgattagtcaatatgcagttgcaggtcaatatgctggagcggttattggtactgat480
catgctgcagaaaatattacaggttttttcaccaaatttggtgatggaggtgctgactta540
ttacctctctttagacttaataaaagtcaggggaaacagttattagctgaacttggtgct600
gataaagccttgtacgaaaagattccaaccgcagatttagaagaaaataaaccaggaatc660
gctgatgaaatagcccttggagtaacctaccaagaaattgatgcttatcttgaagggaag720
gtggtttcggacaagtctcgaggtatcattgaaaattggtggtataagggtcaacataaa780
cgtcatcttccaatcacaatttttgatgatttetggaaatas 822
SeqID
22
attaaaaaggaatctgttatcaaactattgaagtatgcttttggcattataatgggattt60
attatcttagctattgtaataggtgggctcetatttgcatactacgttagtegttctccg120
aaattaaccgatcaagetttaaaatccgttaactctagtttggtttatgatggtaataat180
aaacttattgccgatttaggctcagaaaagcgtgaaagtgttagtgeggatagcattcca240
ctaaatttggttaacgctatcacttctatcgaagataaacgtttctttaaacatagaggt300
gtcgatatttatcgtattttaggtgcagcttggcataatcttgttagtagtaatacgcaa360
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
9/109
ggtggttcaaeccttgatcaacagttgattaaactggcttacttttctaccaataaatct420
gaccaaacgttaaaacgtaaatcacaggaagtttggcttgcgcttcaaatggagcgtaaa480
tacaccaaagaagaaattcttactttetatattaataaagtttatatgggaaatgggaat540
tatggtatgagaacaacagctaaatcatactttggtaaagacctaaaggaattatctatt600
gcacaacttgctttgctcgctggtattcctcaagcacctacacaatatgacccttataaa660
aacccagaatctgctcaaacaagacgtaataccgttcttcagcagatgtatcaagataaa720
aacatttctaaaaaggaatacgaccaagctgttgcaactccagtaactgatggcttaaaa780
gaattaaagcaaaaatctacttatccaaaatatatggataactacttaaaacaagttatt840
agtgaagttaaacaaaaaactggtaaagatatctttactgctgggctaaaagtgtatact900
aatatcaacactgatgcacaaaaacaactatatgaeatctaCaaeagtgacacttaCatc960
gettatceaaaeaatgaattacaaatagcatetaccatcatggatgcgactaatggtaaa1020
gtcattgeacaattaggcgggcgtcatcagaatgaaaatatttcatttgggacaaateaa1080
tetgtcttaacagaecgcgattggggttctacaatgaaacctatctcagcttatgcacct1140
gctattgatagtggtgtctataattcaacaggtcaatcattaaacgactcagtttactac1200
tggcctggtacttctactcaactatatgactgggatcgtcaatatatgggttggatgagt1260
atgeagaecgctattcaacaatcacgtaacgtccctgctgtcagagcacttgaagccgct1320
ggattagacgaagcaaaatctttccttgaaaaattaggcatatactatccagaaatgaac1380
tattcaaatgctatttcaagtaacaacagtagcagtgatgcaaaatatggtgcaagtagt1440
gagaaaatggcagcggcttactcggcttttgcaaacggcggaacttactataaaccgcaa1500
tatgttaataaaattgaatttagcgatggaaccaatgatacttatgcagcgtctggtage1560
cgtgcgatgaaagagactactgcctacatgatgacggatatgctgaaaacagtactaaca1620
tttggtactggtactaaagcagctatccctggtgttgcacaagctggtaagactggtact1680
tccaactatacggaagatgagttagctaaaattgaagcaactactggtatctacaatagc1740
gcegttggtacaatggctcctgatgaaaactttgtcggctatacttctaagtacacaatg1800
gcaatttggactggttataaaaatcgcettacaccactttatggtagccaactggatatt1860
gctactgaggtttatcgtgcaatgatgtcctacctaactggeggatacagtgcagattgg1920
acaatgccagaagggctctatcgaagcggaagctacttgtatatcaatgggacaactaca1980
accggcacttactcttcttctgtctataagaatatctatcaaaattctggacagtcaagt2040
caaagcagtagttcaacatcctctgagaaacaaaaagaggataagaatacagcaaatgat2100
gccaattcatcatccccacaagtcgaaacacctaataatggtaatgctactacccctaat2160
aattccaatcaaactgtgccaggaactggacatggtaatggtaatggtaacaacaataca2220
gtacetaacggtaattaa
2238
SeqID
23
atgttagacttaaaacgtattcgtacagattttgatgttgtcgctaaaaaattggccacg60
cgtggtgttgaccaagaaacattaacaacccttaaagaacttgatataaaacgccgtgaa120
ctacttatcaaagctgaagaggcgaaagcgcaacgtaatgttgcttctgctgccattgct180
caagcaaaacgaaataaagagaatgcagacgagcaaatcgcagctatgcaaacactttcc240
gctgatatcaaagcaattgatgcggaattggcagatgtggatgctaatttacaatcaatg300
gtgaccgtacttcctaatacaccagetgatgatgtgccgcttggagcagacgaggatgaa360
aatgttgaagttcgtcgctggggaactcctcgtgaatttgattttgagaccaaagctcac420
tgggatttaggtgaaagccttggaattctcgattgggaacgtggtgcaaaagttactggc480
tctcgcttcctcttctacaaaggtctaggtgctcgtttagagcgtgctatctacagcttc540
atgctggatgaacacgctaaggaggggtacactgaagtgatccctccttatatggttaac600
cacgattcaatgttcggtacgggacaatatccaaagttcaaggaagatactttcgaatta660
gcagatagcccattegtacttatcccaacagctgaagttcctttaacaaactattatcgt720
gatgaaattatcgatgggaaagaattacctatatactttactgccatgagtccatcattc780
cgttcagaagcaggctctgcaggacgtgacacacgtggattaattcgccttcatcaattc840
cataaagtagaaatggtgaaatttgccaagcctgaggaatcataccaagaattagaaaaa900
atgacagcaaatgctgaaaatattcttcaaaaacttaatctcecataccgtgtcattacc960
ttgtgtacaggagatatgggattctcagcagctaaaacgtatgacttagaggtatggatt1020
cccgctcaaaatacttatcgagaaatttcttcatgttctaatactgaagatttccaagca1080
cgtcgtgctcaaattcgttaccgtgacgaagttgatggcaaagttaggttgcttcatact1140
ttaaatggttcaggacttgcagttggacgtactgtagcagcaatcctcgaaaattatcaa1200
aatgaagatggttctgtgactatcccagaagttcttcgtccatatatgggtaatatcgat1260
attattaaaccaaattag 1278
SeqID 24
gtgacaatatcaaatcaagaattgacgcttaetcccttaagaggaaaaagtggcaaagcc60
tatattggtacttatccaaatggtgaacgtgtctttgtcaaatataatacg~.caCCtatt120
ttgccagccttagctaaggaacagattgcgccacaactactgtgggcacgccgtacaagt180
aatggcgatatgatgagtgctcaagaatggttagatggtcgaacattgactaaagaagat240
atgggtagtaaacagattattcatattttattgegcctgcacaagtctcgtcccttagta300
aatcagctgttacaattagggtataaaattgaaaacccttatgatttgttgatggattgg360
gaaaaacaaaetcctattcaaatccgggaaaacacttatttgcaatetattgtgactgag420
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
10/109
ttaaagcgtagtttacctgagtttcgaacagaggttgcaacaatcgttcacggagatatc480
aaacatagcaactgggttattacaacaagtggtttaatttatttggttgattgggattct540
gttcgtttaacagatcgcatgtatgacgttgcatatattttaagtcattatattccacaa600
aaacactggaaagattggctgtcttactacggttataaagataatgagaaagtctggagc660
aaaattatctggtatgggcaattttcatatttatcacagataatcaaatgttttgataaa720
cgagatatggagcatgtcaatcaagaaatttatgaattacgaaagtttagagagttaatt780
aaaaagcataatgcgagttag 801
SeqID
25
atgaaaatatCaCaataCaat~aatggtC~attCgcCgattgaaagttggagctgCcltct60
gtaatgattgctagtggaagcattgttgctttagggcaatctcatattgtttcagcagat120
gagatgtcccaacctaaaacaaccattacagctccaacagctaacacttctacaaatgta180
gaaagtagtactgataaggcattatcaaaagttactacgatggagacaagttcagaaatg240
cctaaaatgcaaaatatggcaaaagttgaaaaaacgagtgacaaacctatgatggtggct300
acctctgttagaaaaatgatggcaacgccgacacctgtagcgatgaccaaaacgactagt360
gtagatgaggtaaagaaatcaactgatactgcttttaaacagacagtagacgttccgget420
cattatgttaatgcagcaaaagggaatggcccatttctagcaggtgtaaatcaaacgatt480
ccatatgaagcgtttggtggagatggcatgttaacgcgtttaatccttaaatcttctgaa540
ggagcaaaatggtcagataatggtgttgataaaaatagtccattattaccattgaaaggc600
ttaactaaaggtaaatatttctatcaagtttctttaaatggtaatacgacaggtaaagag660
ggacaagctctcttagatcaaattaaagctaatgataaacatagctaccaagccacaatt720
agagtttatggtgctaaagatggtaaagttgatttaaaaaacatgattagccaaaaaatg780
gtaaccattaacattcctcacattacaactgatatggaagtaaaaaattetctaaagatg840
gcctttaaagaaaaagtagaegtcccagcaaaatatgttagtgctgcaaaagetaaaggt900
ccatttttagcaggtgttaacgaaacgattccatatgaagcgtttggtggggatggcatg960
ttaacgcgtttaatcettaaagettcagagggagcaaaatggtcagacaatggtgttgat1020
aaaaatagtccattattaccgttaaaagatttaactaagggtaaatacttctaccaagtc1080
tctcttaatggcaatacagccggtaaaaaaggccaagctctcttagatcaaattaaggca1140
aatggaagccatacttatcaagcaactatcactatttatggtacgaaagatggcaaagtt1200
gatatgaatactattttaggacaaaagacagtgatgattcatattaatgtcgctaaaaaa1260
gatatgaatagcacatcaatgatgatgaaaaaagataagatgacaatgcctatgaagaaa1320
gaaatgacttcatctaaaataaataccggtatgatgatgtctaacaacaagatgtcagct1380
aatatgcaaatgtcatcacaagccaaatcaaatgataaagctggtaaaaaaatgtctatg1440
atgtctaaaaatttacctaatacaggtgaaacaaagcaacaaaatgtaggtgtgctaggt1500
atgcttagtctagcctttgcgacaggtctaactgcgctaggccttaaaaaatctaaacaa1560
agatag 1566
SeqID
26
atgacacatattacatttgactattcaaaagtcttgggtcaatttgtaggcgaacacgag60
ttagactacctacaaccacaagtaagtgcagcagatgctttccttcgtcaagggactggt120
cctggctcagattttctcggatggatggacctcccagaaaactatgacaaagaagaattt180
tctcgcattcaaaaagccgctgaaaagattaaatcagatagcgaagtactcgtggttatt240
ggtattggtggttcgtaccttggcgcaaaagcagcaattgactttttgaataatcatttt300
gctaatttgcaaaccgcagaagaacgtaaagcgcctcagattctttatgctggaaattct360
atttcatctacttaccttgccgatttagttgaatacgtccaagataaagaattctcagta420
aatgtcatttcaaaatcaggtacaacaactgaaccagcgattgctttccgtgtatttaaa480
gaacttctagttaaaaagtacggtcaagaagaagctaataaacgtatctacgctacaact540
gataaagttaaaggtgcegtaaaagttgaagcagatgctaacaattgggaaacatttgta600
gttcctgataatgttggtggtcgtttctcagtactgacagccgtaggtcttcttccaatt660
gctgcttcaggagcagatattactgctcttatggaaggcgeaaatgctgctcgtaaagat720
ttatcttcagataaaatctctgaaaacattgcttatcagtacgctgcagttcgtaatgtt780
ctttatcgcaaaggttatatcacagagattttagctaactacgaaccatcattacaatac840
tttggtgaatggtggaaacaattagcaggtgaatcagaaggtaaagatcaaaaaggtatc900
tatcctacatcagcaaacttctcaactgatcttcactcacttggtcaatttattcaagaa960
ggttaccgtaacctctttgagacagttgttcgcgttgagaaacctcgtaaaaatgtgact1020
attcctgaattaaccgaagatttagatggtcttggttatcttcaaggaaaagatgtagat1080
tttgttaataaaaaagcaacagatggtgtactccttgctcatacagatggtggggttcca1140
aatatgtttgtaacgcttectacacaagacgcttacacccttggttacactatttacttc1200
tttgagttagcaattggcctttcaggttatcttaactcagtaaatccatttgatcaacca1260
ggggtagaagcatataaacgtaatatgtttgctcttctaggtaaacctggattcgaagag1320
cttagcgctgaattgaatgcacgtctttaa 1350
SeqID 27
atgaaagaaa aacaaacagc cggacgtcgt caattagaag aatttgcacc tgaatttgcc 60
agatataatg atgatatttt atttggtgag gtttgggcaa aagaggatca tttaacagat 120
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
11/109
aaaacacgtt ctattattac tatatctgcc ttaattagcg gaggaaatct tgaacagtta 180
gagcatcatc ttcaatttgc caaacaaaac ggagttacta aagaagaaat tgetgacatt 240
atcactcacc ttgcttttta tgttggatgg ccaaaagctt ggtcagcctt taataaaget 300
318
aaggaaattt ggatataa
SeqID
28
gcttggagagctttagaggatgctcaaaaatctggtaaggtaaaatccatcggtgtctca60
aactttttagaaaaagacttagaaaatatcttaaaaaatggtcatgttaaacctgctgtc120
aatcaaatcttagctcacatcggaaatacacctttcgacttgattgattactgtcaaagt180
aaaggtattcaagttgaagcttattcaccaattgcacatggacaagcattgaaatctgat240
ggtattcaaaaaatggctgaaaaatatggggttagtgttgctcaattatgtattca~.tat300
ttactacaattaaacctgatcgttttaccaaaggcttctagtaaagaacatttacagtct360
aatctagactttgactttgtaattagtgacgaagatatgtcg~.tattaaaatcacttatg420
tttgacgattatggggaattttctaacttccctgtttttagtgaaaaatga 471
SeqID 29
atgtttagaa ggtctaaaaa taacagttat gatacttcac agacgaaaca acggttttca 60
attaagaagt tcaagtttgg tgcagcttct gtactaattg gtcttagttt tttgggtggg 120
gttacacaag gtaatcttaa tatttttgaa gagtcaatag ttgctgcatc tacaattcca 180
gggagtgcag cgaccttaaa tacaagcatc actaaaaata tacaaaacgg aaacgcttac 240
atagatttat atgatgtaaa gaatggattg attgatcctc aaaacctcat tgtattaaat 300
ccatcaagct attcagcaaa ttattatatc aaacaaggtg ctaaatatta tagtaatccg 360
agtgaaatta caacaactgg ttcagcaact attactttta atatacttga tgaaactgga 420
aatccacata aaaaagctga tggacaaatt gatatagtta gtgtgaattt aactatatat 480
gattctacag ctttaagaaa taggatagat gaagtaataa ataatgcaaa tgatcetaag 540
tggagtgatg ggagtcgtga tgaagtctta actggattag aaaaaataaa aaaagatatt 600
gataataate caaaaacaca aatagatatt gataataaaa ttaatgaagt caatgaaata 660
gagaaattgt tagttgtatc gctaccagat aaaattaagt attcaccaga ggctaagcat 720
aggactgttg aacaacacgc ggaattagat gcaaaagata gcattgcaaa tacagatgaa 780
ttgccatcaa attcaacgta taactggaaa aatggtcata aaccagacac ctcaacatca 840
ggtgaaaaag acggaattgt tgaagttcac tatccagatg gtactgttga tgatgtgaat 900
gttaaagtaa ccgttacatc gaaaaaaact gataatacag ctccaacatt aaccgtcact 960
ccagagcaac agactgttaa agtggatgaa gatattacct ttacggttac agctgaagac 1020
gaaaatgaag ttgaaetagg tttagatgat cttaaagcta agtatgaaaa tgatatcatt 1080
ggagctcgtg ttaaaattaa gtatettact aaagaaccta ataagaaagt catggaagtg 1140
acaattatga aagctacttt agcagataag ggcgcaatta cctttactgc aaaagataaa 1200
gcaggtaatc aagcagaacc taagacagtt accatcaatg ttcttccgcc agataaaatt 1260
aagtattcae cagaggctaa gcataggact gttgaacaac acgcggaatt agatgcaaaa 1320
gatagcattg caaatacaga tgaattgcca tcaaattcaa cgtataactg gaaaaatggt 1380
cataaaccag acacetcaac atcaggtgaa aaagacggaa ttgttgaagt tcactatcca 1440
gatggtactg ttgatgatgt gaatgttaaa gtaaccgtta catcgaaaaa aactgataat 1500
acagctccaa cattaaccgt cactccagag caacagactg ttaaagtgga tgaagatatt 1560
acctttacgg ttacagctga agacgaaaat gaagttgaac taggtttaga tgatcttaaa 1620
gctaagtatg aaaatgatat cattggagct cgtgttaaaa ttaagtatct tactaaagaa 1680
cctaataaga aagtcatgga agtgacaatt atgaaagcta ctttagcaga taagggcgca 1740
attaccttta ctgcaaaaga taaagcaggt aatcaagcag aacctaagac agttaccatc 1800
aatgttcttc cgccagataa aattaagtat tcaccagagg ctaagcatag gactgttgaa 1860
caacacgcgg aattagatgc aaaagatagc attgcaaata cagatgaatt gccatcaaat 1920
tcaacgtata actggaaaaa tggtcataaa ccagatacct caacaccagg agagaaaaac 1980
gctgttgttg ttgtgaccta tecagataag tcaacagatg aagttcctgt aaaagttaca 2040
gtggttgacc cacgtacaga cgcagagaaa aatgatccag caggtaaaga tcaaactgtc 2100
aaagtgggtg aacaaccaga tccgacaaaa tctcttgaag cagtaccagc tggaagtaca 2160
gtagcgtaca aagaaccagt tgatactaag acaccaggag agaaaaacgc tattgttgtt 2220
gtgacctatc cagataagtc aacagatgaa gttcctgtaa aagttacagt ggttgaccca 2280
cgtacagacg cagagaaaaa tgatccagca ggtaaagatc aaactgtcaa agtgggtgaa 2340
caaccagatc cgacaaaatc tcttgaagca gtaccagctg gaagtacagt agcgtacaaa 2400
gaaccagttg atactaagac accaggagag aaaaacgcta ttgttgttgt gacctatcca 2460
gataagtcaa cagatgaagt tcctgtaaaa gttacagtgg ttgacccacg tacagacgca 2520
gagaaaaatg atccagcagg taaagatcaa actgtcaaag tgggtgaaca accagatccg 2580
acaaaatctc ttgaagcagt accagctgga agtacagtag cgtacaaaga accagttgat 2640
actaagacac caggagagaa aaacgctgtt gttgttgtga cctatccaga taagtcaaca 2700
gatgaagttc ctgtaaaagt tacagtggtt gacccacgta cagacgcaga gaaaaatgat 2760
ccagcaggta aagatcaaac tgtcaaagtg ggtgaacaac cagatccgac aaaatctctt 2820
gaagcagtac cagctggaag tacagtagcg tacaaagaac cagttgatac taagacacca 2880
ggagagaaaa acgctgttgt tgttgtgacc tatccagata agtcaacaga tgaagttcct 2940
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
12/109
gtaaaagttacagtggttgacccacgtacagacgcagagaaaaatgatccagcaggtggg3000
gaaacaacagtaccacaaggcacaccgatcagtgatgaagaaattacaggattagtgaag3060
attccagaaggatcaaacggcgtaccgaaagtagtaggagaccgtccgaatacagacgta3120
ccaggagattataaagtaacggtagaagtaacgtatccagatggaacaaaggatacagta3180
gcagtaacggttcatgtgacaccaaaaccagtaccggataaagataaatatgatccaaca3240
ggtaaatctcagcaagtcaacggtaaaggaaataaactaccagcaacaggtgagagtgca3300
actccattctttaatgttgcagctttgacaattatatcatcagttggtttattatctgtt3360
tctaagaaaaaagaggattaa 3381
SeqID
30
atgcagattctegaagactatgatggtagagcattacccaagctagaaacggatcgactt60
atcttgcgtcagcgaacggtgggggatgtcccagccatgtttgattacgtttgcttggaa120
gaggttgcctatccagcagggctcagcccaatagcatctttagaagatgagtatgattat180
tttgaaaatcgctactatcaaaatctggaaaaggcaaaattaccatctggttatggtatt240
acggttaaaggaagtgaccggattatcggatcctgcgcctttaaccatcgccgtgaagac300
gatgttttcgagattggctatctgcttcatcctgactactggggtcatggctatatgaca360
gaagctgtegecgctttgattgaagtcggttttacccttctcaatctccacaaaatcgaa420
atccgctgctatgactacaataagcaaagccagcgcgtggcagaaaaactaggattcacc480
cttgaagcaaccatccgtgategtaaggataatcaaggcaatcgctgtgtcaatttgata540
tatggtttgctgaggagtgagtgggagtaa 570
SeqID
31
atgtcaaaagaactatcaccaaaatacaatcctgccgaggttgaggaaggccgttatcaa60
acttggcttgaccaagatgttttcaagccatcaggggatactgaggctaagccctattct120
atcgtgattccaccaccaaacgttacgggtaaattacacttgggtcacgcttgggataca180
actctacaagatatcattattcgtcaaaagcgtatgcagggctttgatacactctggctt240
ccaggtatggaccacgctggtatagccactcaagctaaggttgaggagcgccttegtgag300
caaggtatttcacgttatgatcttggtcgtgaaaaattcctagataaagtttgggaatgg360
aaagacgagtatgcagcaactattaaatctcagtgggggaaaatgggtctttcggttgat420
tatagccgtgagcgttttaccettgatgagggactttcaaaagcggtaagaaaagtcttt480
gttgatttgtacaataaaggttggatetatcgtggggaattcatcattaactgggatcca540
gcagctcgtacagecetttcagatattgaagttattcacaaggatgttgagggtgctttc600
tatcatatgaattatatgctggaagatggctcacgcgccctagaagtagcaacaactcgt660
cctgagactatgtttggagatgtggctgtagcggtaaatccagaagatccacgttacaaa720
gatttgattggtcaaaatgttatccttcctatcatcaataaacctattccaatcatcgct780
gatgaacacgctgatccagaatttggaacaggtgtggttaagattacgccggctcacgac840
cctaatgacttcgctgtaggtcaacgccacaacttaccacaagttaacgttatgaacgat900
gatggtactatgaatgaacttgcggatgaatttaatggtatggatcgtttegaagctcgt960
aaggcagtagtcgctaaattagaatcgttaggaaacttagtaaaaattgaaaaaatgact1020
cattetgttggtcattcagaacgaacaggcgttgtggttgaaccacgtttatctactcaa1080
tggttcgtcaagatggatcaattggctaagaatgccattgccaaccaagatacagaagac1140
aaggtagagttttatccaccacgatttaacgatacttttatgagctggatggaaaatgtc1200
catgactgggttatctctcgtcaattatggtggggacaccaaattcctgcatggtacaac1260
gtcaatggtgagatgtatgttggagaagatgccccagagggtgacggatggacacaggat1320
gaagacgttctagacacatggtttagttctgctttatggccgttttcaacaatgggatgg1380
ccagacaccgaagcagctgacttcaaacgctacttcccaacatcaaccttggtaactgga1440
tacgatatcatcttcttctgggtategcgcatgattttccaatctcttgaatttacagga1500
cgecaaccattctcaaatgttettattcatggactcatccgtgatgaagaaggacgtaaa1560
atgtctaaatcacttggcaacgggattgatccgatggatgtcattgagaaatatggtgcg1620
gatgcccttcgttggttcctctcaaatggttcagcccctggtcaagatgtgcgtttttca1680
tacgaaaaaatggatgcttcgtggaatttcattaataagatttggaacatttcacgctat1740
atccttatgaataacgaaggtttaacgttggatcaagccagagaaaatgtggaaaaagtt1800
gttaatagtcaagttggaaatgtaacagaccgttggattctccacaatttaaatgagact1860
gtgggtaaagttactgaaagctttgacaagtttgaatttggtgttgctggtcacatcctt1920
tacaactttatctgggaagaatttgctaattggtacgttgagttaacaaaagaggttctt1980
tatagtgacaatgaagatgagaaagttgttacacgttctgttcttctttataccttagat2040
caaatcttgcgtcttcttcatccaatcatgecatttgtgacagaagaaatttttggacaa2100
tacgcagaaggatcaattgtccttgcaagttatccacaagttaacgcgacatttgaaaat2160
cagacagctcacaaaggegttgaaagcttgaaagatttgattcgttcagtgcgaaatagc2220
agagcagaggtcaatgttgctCCatCtaaaCCaatC~.Ctatcttggttaagacaagtgac2280
agcgaactcgaaagcttcttcaaagacaatagtaactacatcaaacgcttcacaaaccca2340
gagacgcttgaaatcagetcagcgattactgccccagaacttgccatgactagcattatc2400
acaggtgcagaaattttcctcccacttgctgacctccttaacgttgaagaagagttggca2460
cgacttgaaaaagaacttgctaaatggcaaaaagaactaaatatggtcggcaaaaaactc2520
agcaacgagcgctttgtagctaacgctaaaccagaagtcgtccaaaaagaaaaagacaaa2580
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
13/109
cagaccgact accaaactaa atacgacgca actatagcac gtattgaaga gatgaaaaaa 2640
ttaaataatg attga 2655
SeqID
32
atggttgagccaattatttcaatacaaggacttcataaaagttttgggaaaaatgaggtt60
ttaaaaggcattgacttggatattcatcaaggagaagtggtggttattattggcccttct120
ggctctggtaagtcaacatttttaagaacaatgaatctcttggaagtaccaacaaaggga180
acagtgacttttgaagggattgatataacagacaaaaagaatgatatttttaaaatgcgc240
gaaaaaatgggcatggtttttcaacagttcaatctatttcccaatatgactgtactagaa300
aatattactttatcacctattaagacaaaggga.ctttetaagcttgatgctcagacaaaa360
gcatacgagetacttgaaaaagttggactcaaagagaaggctaatgcttatccagcta.gc420
ttatctggagggcaacaacaacgaattgctattgcaagaggtcttgeaatgaatcctgat480
gtccttctttttgatgaacctacttcagctcttgatcctgaaatggtaggtgaagtcttg540
actgttatgcaagatttagctaaatctggtatgacgatggttattgtcactcatgaaatg600
ggttttgcacgtgaagtagcggatcgtgtcatttttatggatgcaggcattattgttgag660
caagggacccctaaggaagtatttgagcagacaaaagaaatccgcacaagagatttctta720
agtaaagtattataa 735
SeqID
33
atgaattataaagagatttatcaagagtggttagaaaacgactcactcggtaaagatatt60
aagtcagatttagaagctattaaaggcgatgaatctgaaattcaggatcgtttttacaaa120
acattagaatttggaacggcgggattgagaggtaaacttggagcaggaaccaatcgtatg180
aatacttatatggtggggaaagcagcacaagcattagctaatacgattattgatcatggc240
ectgaagctattgcacgtggaattgcagttagttatgatgtccgttatcaatctaaggaa300
tttgcagaattaacttgttccattatggcagcaaatggtattaagtcttatatttataaa360
gggattcgcccaacaccaatgtgctcatatgctattcgtgatctaggatgtgtttcgggt420
gtgatggttactgctagtcataatcctcaagcttataatggttataaggcatattggaaa480
gaaggatctcagattttagatgatattgctgatcaaattgccaatcatatggatgctata540
accgattatcagcaaattaggcaaataacatttgaagaggctctggcaagtggtttggca600
agttatattgatgagagtattgaagaagcatataaaaaagaagtgcttggtttaaccatt660
aatgatactaacattgataagtcagtecgagtagtttataetcctttaaatggcgtagga720
aatttacctgtgcgcgaagttttaagacgccgtggttttgaaaatgtttatgtggtacct780
gagcaggaaatgcccgatcctgattttacaacggttggctatccaaaccctgaagttcct840
aaagcatttgcctattcagaatctetaggaaagtcagttgatgcagatatcttacttgcc900
acagatccagattgtgaccgagtagcattggaagtcaaagatagtaagggagaatatatt960
ttcttaaatggtaataagataggggcacttctttcctattatattttttcacaacgatgt1020
gccttagggaatttgccacatcatcctgtattggtaaaatccattgtaactggtgatcta1080
tcaaaagttattgcagataaatataatattgaaactgttgaaactttaaccggatttaaa1140
aatatttgtggaaaagctaatgaatatgatatctcaaaggataaaacttatctctttggc1200
tatgaagaaagtattggtttttgctatggcacttttgtacgtgataaagatgctgtgagt1260
gcttcaatgatggtagtagaaatgactgcctattataaagaacgagggcaaacactttta1320
gacgttttgcaaaccatttacgatgaatttggctattacaacgagcgccaattttctctt1380
gagttagagggtgctgaggggcaagaacgtattagtcgtattatggaggattttagacag1440
gacccaatattacaagtaggtgagatgagattggagaattctattgatttcaaggatggt1500
tataaggattttccaaagcaaaattgtttaaaatattattttaatgagggttcatggtat1560
gctttaaggccgtcagggacggaacctaagataaaatgttacctttatacgattggttgt1620
acagaagcagatagtttatcgaaacttaatgcaattgagtcggcttgtcgtgctaaaatg1680
aatagtactaaataa 1695
SeqID
34
atgtatagagaaattaccgctgtcgaacacgatcgctttgtgagcgaatccaaccaaaca60
aacctacttcaatcttctaattggeccaaagtaaaagacaactggggtagtcaattactt120
ggcttttttgacggtgaaacccaaattgccagcgctagtattctcatcaaatcacttcct180
cttggcttctccatgctatatattccgcgtggaccaatcatggattactccaatctagat240
attgtaactaaggtccttaaggaccttaaagcttttggcaaaaaacaaagagctctcttt300
atcaagtgtgatcctctcatctatttaaaaatggtcaatgccaaagattttgaaaattcg360
cccgatgaaaaagaagggttaatcgccattgatcatttacagcgtgcaggtgctgattgg420
aetggtcggacaacagatttagctcatactatccaaccacgttttcaggcaaacctatat480
gctaatcaatttggacttgataaaatgtctaaaaaaactcgtcaagctattcgaacttcc540
aaaaataagggagtagatatacaatttggtagccatgaactacttgaagattttgcagag600
ttgatgaaaaaaacggaagaccgtaaagggataaatcttagaggaattgactactaccaa660
aaactccttgatacgtatcctaataactcatacatcacaatggcttcgctagatgttgca720
aaacgattagaaaaaatagaaaaagaatgtcagatagcccaatctgaaagaataaaatca780
cttgaacttaatcgtgagaaaaaagt,taaacaacaccaaggtacgattgatcgattaaat840
aaagaaattgattttctcaaagaagctcaaaaagcctatgaccgagacattattccattg900
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
14/109
gctgcaaccctcactctagaatttggtaatacatcagaaaatatttatgctggtatggac960
gattactttaaatettattctgctcctatttacacttggtttgaaacagctcaaagggct1020
tttgaacgtggaaatatttggcaaaatatgggggggattgagaatgacttatctggtggt1080
ttatatcattttaagtctaagttcgaaccaatcattgaggaatttattggagaatttaac1140
attccagtgaacagattgctttataaagcctctaattatgtctatgccttacgcaaaaaa1200
cgtaatagctag 1212
SeqID
35
atggcttgtacaacaatattggttggtaaaaaggcttcttatgatggttcgactatgatc60
gctagaaeggaagactctgttaatggcgatttcacacccaaaaaattaa~.ggtaatgaca120
tctaaagatcaaccgcgtcattacaaatcagttttatcaaattttgaagtagatttacca180
gataacccacttccttatacttcagtaccggacgcattgggaaaagatggtatatggggt240
gaagccggtattaacagtaaaaatgtagcgatgagtgctacagaaactattacaacgaat300
tcccgcgttttgggtgcagatcctttggtttcagatggtataggggaagaggatatactc360
actttagtgcttccctatattcagtcagcgcgagaaggtgtggagcgtttaggtgctatt420
ttggaaaaatatggaacctatgaatcaaatggtattgetttttcagataecgaagaaata480
tggtggttagaaacaattggtgggcatcattggattgctcgtcgcgtacctgatgatgtt540
tatgttactaatcctaaccaactaggaattgatcattttgaatttaataactgtgatgac600
tacatgtgctetagtgatttgaaagagtttatcgaacaataccatttagatttgacctat660
tctaatgagcatttcaatcctcgatatgcttttggtagccaacgtgataaagatcgtcat720
tacaacacaccaagaagttgggcaatgcagcgttttttaaatcctgaaattgaacaggat780
ccacgtagcttgtttattccctggtgtcaaaagccttaccgaaaaattactgttgaggat840
attaaatatgtgttgagtgatcattatcaagacagtgtgtatgacccatatggaccagaa900
ggggatgcggtaagtaggagagcttttcgttcagttggtatcaaccgaactagtcaaacg960
tctattctacaattacgaccaaataaatcacttgaaacgacaggtgttcaatggttatct1020
tatggctctatgccatttgcaaccatggtgccgttgtttacacaagttgagactgtacca1080
aactatttttcgaatacaaccaaggatgcttcaacagataatttttattggaccaatcgt1140
ttaattgcagctctagcagatccacacttttatcaacatgaagctgatattgaaagctat1200
atcgagagaacgatggctcaaggacatgcacatattaacggtgttgatagagaagttgct1260
gagaataaagagattgattttcaacagaaaaatcaagaaatgagtgactatatccaaaaa1320
gaaagccaagaattgttaaatcgtattctatttgatgcaagtaatttaatgacaaatcgc1380
ttttcaatgggagattaa 1398
SeqID
36
atgagaaagaaatttcttttattgatgagctttgtagctatgtttgcagcttggcaactt60
gttcaagttaaacaagtttgggctgatagtaaacttaaagtggtaacaactttttaccca120
gtttatgagtttacaaaaaatgtcgttggtgataaagctgatgtatctatgttaattaaa180
gcaggtacagaaccgcatgattttgaaccatcaactaaaaacatcgctgccatccaagat240
tcaaatgcttttgtttacatggatgataacatggaaacttgggctccaaaagtagctaag300
tcagttaaatccaaaaaagtaacaactattaaaggtactggcgatatgttacttactaaa360
ggcgtcgaagaagaaggtgaagaacatgaaggacatggtcatgaagggcatcatcatgaa420
cttgacccacacgtatggttgtctccagaacgtgcgatttctgttgtagaaaacatccgt480
aataaatttgtcaaagettatccaaaagatgcagcttcatttaacaaaaatgcagatgct540
tacattgcaaaattaaaagagcttgacaaagaatacaaaaatggtttgtcaaatgetaaa600
caaaagagttttgtgactcaacacgcagcgtttggttacatggcgcttgattacggttta660
aatcaagttccaattgctggtcttactccagatgcagaaccttcatcaaaacgtttaggc720
gaattagctaaatacatcaagaaatataacatcaactacatttattttgaagaaaatgct780
tcaaataaagttgctaaaactttagcagatgaagttggcgtgaaaacagctgtgcttagt840
ccacttgaaggactttctaaaaaagaaatggcagctggcgaagattacttetcagttatg900
agacgtaatttgaaagttcttaaaaagacaacagatgttgcaggtaaagaagtagctcct960
gaagaagataaaactaaaacagttgaaacaggttactttaaaactaaagatgttaaagac1020
cgtaaattgacagattactctggtaattggcaatcagtatatcctettcttcaagatggg1080
acacttgatccagtttgggattacaaagctaaatctaaaaaagatatgactgctgcagag1140
tacaaaaaatattatacagcaggttacaagactgacgtagaatcaatcaagattgatggt1200
aaaaaacatcaaatgacctttgtacgtaatggtaaatcacaaacatttacatacaaatat1260
gcaggttacaaaatcttaacttataaaaaaggtaatcgtggagtacgttatctctttgaa1320
gctaaagaaaaagatgctggtcaattcaaatatatecaatttagtgacCatggtattaaa1380
ccgaataaagctgaacacttccatatcttctggggttcagaaagccaagaaaaattattt1440
gaggaaatggaaaactggccaacatacttcccagctaaaatgtctggacgtgaagttgcc1500
caagaccttatgtctcattaa 1521
SeqID 37
atgaaattat cgaagaagtt attgttttcg gctgctgttt taacaatggt ggcggggtca 60
actgttgaac cagtagctca gtttgcgact ggaatgagta ttgtaagagc tgcagaagtg 120
tcacaagaac gcccagcgaa aacaacagta aatatctata aattacaagc tgatagttat 180
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
15/109
aaatcggaaattacttctaatggtggtatcgagaataaagacggcgaagtaatatctaac240
tatgctaaacttggtgacaatgtaaaaggtttgcaaggtgtacagtttaaacgttataaa300
gtcaagacggatatttctgttgatgaattgaaaaaattgacaacagttgaagcagcagat360
gcaaaagttggaacgattcttgaagaaggtgtcagtctacctcaaaaaactaatgctcaa420
ggtttggtcgtcgatgctetggattcaaaaagtaatgtgagatacttgtatgtagaagat480
ttaaagaattcaccttcaaacattaccaaagcttatgctgtaccgtttgtgttggaatta540
ccagttgctaactctacaggtacaggtttcctttctgaaattaatatttaccctaaaaac600
gttgtaactgatgaaccaaaaacagataaagatgttaaaaaattaggtcaggacgatgea660
ggttatacgattggtgaagaattcaaatggttcttgaaatctacaatccctgccaattta720
ggtgactatgaaaaatttgaaattactgataaatttgcagatggcttgacttataaatet780
qttggaaaaatcaagattggttcgaaaacactga~.tagagatgagcactacactattga.t840
gaaccaacagttgataaccaaaatacattaaaaattacgtttaaaccagagaaatttaaa900
gaaattgctgagctacttaaaggaatgacccttgttaaaaatcaagatgctcttgataaa960
gCtaCtgCaaataCagatgatgCggCatttttggaaattCCagttgCatCaaCtattaat1020
gaaaaagcagttttaggaaaagcaattgaaaatacttttgaacttcaatatgaccatact1080
cctgataaagctgacaatecaaaaccatctaatcctccaagaaaaccagaagttcatact1140
ggtgggaaacgatttgtaaagaaagactcaacagaaacacaaacactaggtggtgctgag1200
tttgatttgttggcttctgatgggacagcagtaaaatggacagatgctcttattaaagcg1260
aatactaataaaaactatattgctggagaagctgttactgggcaaccaatcaaattgaaa1320
tcacatacagacggtacgtttgagattaaaggtttggcttatgcagttgatgcgaatgca1380
gagggtacagcagtaacttacaaattaaaagaaacaaaagcaccagaaggttatgtaatc1440
cctgataaagaaatcgagtttacagtatcacaaacatcttataatacaaaaccaactgac1500
atcacggttgatagtgctgatgcaacacctgatacaattaaaaacaacaaacgtccttca1560
atccctaatactggtggtattggtacggctatctttgtcgctatcggtgctgcggtgatg1620
gcttttgctgttaaggggatgaagcgtcgtacaaaagataactaa 1665
SeqID
38
atgaaaaagagacaaaaaatatggagagggttatcagttactttactaatcctgtcccaa60
attccatttggtatattggtacaaggtgaaacccaagataecaatcaagcacttggaaaa120
gtaattgttaaaaaaacgggagacaatgctacaccattaggcaaagcgacttttgtgtta180
aaaaatgacaatgataagtcagaaacaagtcacgaaacggtagagggttctggagaagca240
acctttgaaaacataaaacctggagactacacattaagagaagaaacagcaccaattggt300
tataaaaaaactgataaaacctggaaagttaaagttgcagataacggagcaacaataatc360
gagggtatggatgcagataaagcagagaaacgaaaagaagttttgaatgcccaatatcca420
aaatcagctatttatgaggatacaaaagaaaattacccattagttaatgtagagggttcc480
aaagttggtgaacaatacaaagcattgaatccaataaatggaaaagatggtcgaagagag540
attgatgaaggttggttatcaaaaaaaattacaggggtcaatgatctcgataagaataaa600
tataaaattgaattaactgttgagggtaaaaccactgttgaaacgaaagaacttaatcaa660
ccactagatgtcgttgtgctattagataattcaaatagtatgaataatgaaagagccaat720
aattctcaaagagcattaaaagctggggaagcagttgaaaagctgattgataaaattaca780
tcaaataaagacaatagagtagctcttgtgacatatgcctcaaccatttttgatggtact840
gaagegaccgtatcaaagggagttgccgatcaaaatggtaaagegctgaatgatagtgta900
tcatgggattatcataaaactacttttacagcaactacacataattacagttatttaaat960
ttaacaaatgatgctaacgaagttaatattctaaagtcaagaattccaaaggaagcggag1020
catataaatggggatcgcacgctctatcaatttggtgcgacatttactcaaaaagctcta1080
atgaaagcaaatgaaattttagagacacaaagttctaatgctagaaaaaaacttattttt1140
cacgtaactgatggtgtccctacgatgtcttatgccataaattttaatccttatatatca1200
acatcttaccaaaaCCagtttaattcttttttaaataaaataccagatagaagtggtatt1260
ctccaagaggattttataatcaatggtgatgattatcaaatagtaaaaggagatggagag1320
agttttaaactgttttcggatagaaaagttcctgttactggaggaacgacacaagcaget1380
tatcgagtaccgcaaaatcaactctctgtaatgagtaatgagggatatgcaattaatagt1440
ggatatatttatetCtattggagagattacaactgggtctatccatttgatcctaagaca1500
aagaaagtttctgcaacgaaacaaatcaaaactcatggtgagccaacaacattatacttt1560
aatggaaatataagacctaaaggttatgacatttttactgttgggattggtgtaaacgga1620
gatcctggtgcaactcctcttgaagctgagaaatttatgcaatcaatatcaagtaaaaca1680
gaaaattatactaatgttgatgatacaaataaaatttatgatgagctaaataaatacttt1740
aaaacaattgttgaggaaaaacattctattgttgatggaaatgtgactgatcctatggga1800
gagatgattgaattecaattaaaaaatggtcaaagttttacacatgatgattacgttttg1860
gttggaaatgatggcagtcaattaaaaaatggtgtggctcttggtggaccaaacagtgat1920
gggggaattttaaaagatgttacagtgacttatgataagacatctcaaaccatcaaaatc1980
aatcatttgaacttaggaagtggacaaaaagtagttcttacctatgatgtacgtttaaaa2040
gataactatataagtaacaaattttacaatacaaataatcgtacaacgetaagtccgaag2100
agtgaaaaagaaccaaatactattcgtgatttcccaattcccaaaattcgtgatgttcgt2160
gagtttccggtactaaccatcagtaatcagaagaaaatgggtgaggttgaatttattaaa2220
gttaataaagacaaacattcagaatcgcttttgggagctaagtttcaacttcagatagaa2280
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
16/109
aaagatttttctgggtataagcaatttgttccagagggaagtgatgttacaacaaagaat2340
gatggtaaaatttattttaaagcacttcaagatggtaactataaattatatgaaatttca2400
agtccagatggctatatagaggttaaaacgaaacctgttgtgacatttacaattcaaaat2460
ggagaagttacgaacctgaaagcagatecaaatgctaataaaaatcaaatcgggtatctt2520
gaaggaaatggtaaacatcttattaccaacactcccaaacgcccaccaggtgtttttcct2580
aaaacagggggaattggtacaattgtctatatattagttggttctacttttatgatactt2640
accatttgttctttccgtcgtaaacaattgtaa 2673
SeqID
39
ggagcaaaaaaggcagggtggaetgaatacgctaggatgttagaagtcagagagcaggtt60
gaeca.tgtgatgattccaaaaa-tcaatca.ggattta.ceaatctacgctggtccagaagag120
gacaatctgcaacggggagttggtcatctagaagggataagtttgccgattggaggggct180
tctacacatgcggtcttgagcggtcaaagaggtatgccagctgctcggttgtttgcggat240
ttggataagatgaaaaaaggtgattatttttatgttaccaatctga~.agaaaccttggct300
tatcaagtggatcgtatcatggtgattgaacetagccaattggatgccgtgagcattgaa360
gaggataaagattatgttacccttctgacctgtacaccttatatgggctctttgtcaact420
gtaatgggtgacttatcattaacaacgagagagaatcagcttggttctctctctttttgg480
atgttcaaagcgatgagaattttgcttttaaaatttttaaagttgcgaaagccaaaggct540
tgtcgcttgatgtctttgataagcttgttggtcgcttctaatttggcattggaaagggat600
agctga 606
SeqID
40
atgtcggatgttgtcgaaaaacaaacagctaaatcgtttataatgaacgtattaaatggt60
ttagctttagggactgttattgtcttgataccaggagcaatccttggagaattaatgaaa120
gctttactgccaatgtggagcggatttgcaactttaatcgctgcaacagcagttgcaaca180
agtatgatggggcttgttattggtattatggttggtctcaattttaaatttaatcccatt240
caatcagcatcactaggattagcggttatgtttgcaggtggagctgcaaccttccttaaa300
ggcgctattatgctaaaaggaacaggcgatatcattaatatgggaattactgctgcctta360
ggtgtccttttgatccaatttttatctgacaagacgaaatcattcactttgattgtcatt420
ccaacagtaacactcttactagttggaggagtaggtcatgtgttattaccttatgtcaaa480
atgattaccaecatgattggacaagggattgcttcattacttggtttacaacctgttttg540
atgtcaattttaattgcgatgattttctgtttcttgatcgtatctccaatcacaacagtt600
gggattgctttggcaattagtttgtccggaattggttctggtgctgctaatttaggtatc660
tgtgctgctagttttgggctttgtatggctgggtggtcagtcaattctaaggggacagcc720
ttagcgcatgttttagggtctcctaagatttcgatggctaatgtattagcaaaaccgaag780
attatgctacctatgatatcttcagcagcaatactaggaattctcggagctctctttaat840
attcaaggaacaccagctagtgcaggttttggtatcagtggtttgattggaccgattaat900
gctcttaatttagcaaaaggtggatggtcagttatgaatatgttattgataattataata960
tttgttgctgcaccaattatattgaattttatttttaattacctctttataaaagtactt1020
aaaattattgatccaatggactataaattagatatttaa 1059
SeqID
41
atggctagacccttagtagaacaaacagcagatcgtctattgcatttaattttagaaaga60
gaataccctgttggtgctaagctccccaatgaatatgaattagcggaagatctagatgtt120
ggtcgcagcacaatccgagaagcagtcagaagtttagcaacgcgtaatattttagaagtc180
agacagggctctggaacatatattagttctaaaaagggtgtttctgaggatccattaggg240
ttctctctaataaaggacacagataggttgacatcagatctctttgaactacgcctttta300
ttggaacctcgaatagcggagctggtagcttatagaattacagatgatcagttacaatta360
ctcgaaaagcttgttggagatattgaagatgctgttcacgcaggcgatccgaaacattta420
cttttagatgtggaatttcattccatgctagctaaatacagtggtaatattgcaatggat480
agccttttgccagtcatcaaccagtcaattcatctgataaatgcgaattatacaaatcgt540
cagatgaagtcggatagtttagaagcacatagagaaattatcaaagcaatccgagaaaaa600
aatccagtagctgcacatgatgctatgcttatgcatatcatgagtgttagacgttcagca660
ttgaaagcttas 672
SeqID
42
atgattaagaaaaataaagtttttttaggagttcttttagtcettgttgttatccttgga60
ggtggtgtattattttaccaatcacaattccaaaagacaactaatcaagcgttagctatt120
gcttataaagatgctaaagtggctaagaaggatgtcatacatcaaaaaattgacaaagaa180
tttgaaaactttagagggagctacgaaattgagttcaataccaaaagcgcagaatacagc240
tatcatgtagatgctaagactggacaaatccttgagcgggacatggataataatggcttt300
tcaaaatcgacttctcagtcaagttcatcgtcaagtcaaaaatctcataaaataagtcaa360
gaagaagccaaaaagattgcatttaaagatgctaatatagaggaatcagaagtcagtaat420
cttaagatcaaagaagaaattgaaaatggaaaatcagtttatgatattgactttgtggac480
ctgaaaaataaaaatgaagttgattatcaaattgatgcagaaactggaaaaatcattgaa540
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
17/109
cgttctagag atcatatgaa tgattaa 567
SeqID
43
ttgaatcgtaaaaaaaggtatcgtctcactgtaaaaaagcaaaatgetagcatacctaga60
cgattaaatcttctattttttattattgttttattatttactgttctaattcttcgttta120
gagcaaatgcagattgggcaacaatcattttacatgaaaaaactgacagctcttacgagt180
tatacagtgaaagaatcaaaagcgagaggtcagatttttgatgctaagggagtagtctta240
gttgaaaatgatgaacgtcctactgtggcgttttctagaggaaacaatatttcatctcag300
tctatcaaagagttagcgaataaattatcacattacattaccttaaccgaagttgcttca360
agcgatagagcaaagagaga.ttattatttagcagataaagccaactacaaaaaagttgtt420
gaaagtttaccagattctaaacgttacgataaatttggtaaccatctagccgaatcaaCC480
gtatatgcaaatgcagttgctgcagttccagtgagcgctattaactattctgaagatgag540
ttaaaagtggttgccttatttaaccaaatgaatgcgacaccaacgtttggttcagtgaaa600
ttaagtacaggcgaattaagtgatgatcaaatcaagaaactggatgctgataagaaggaa660
ctgttaggaatttctgtaacaagtaattggcatcgtcgtaaaaaaggaacttctttatcg.720
gatatattaggtactatttctacagaaaaggcaggtttaccaagagaagaagttaaaaaa780
tatttgaaaaaaggctattcactgaatgaccgagtgggaacttcttaccttgaaaaacaa840
tatgaagatgacttacaaggaatcagacaaattcgcaaagtagttgttaataaaaaaggt900
aaagttgtttcagataatattacgcaagaaggtaagtcaggaagaaatcttaaattaacg960
attgatcttaattaccaaaacaaagtagaaagtatcttgaaacaatactatggcagtgaa1020
ttatetagtggacgcgctagtttttccgaagggatgtatgcagttgctatagaaccttca1080
actggtaaagtgttagcaatggctggtctgaaaaatgatcatgggaatttagttgatgac1140
agcctaggcactattgctaagaatttcacgccaggatctgttgtgaaaggtgcgacgcta1200
tcatcaggatgggaaaataaagttcttagaggaaatgaagtgctttatgaccaagaaatt1260
gctaatatacggtcatggtttacacgaggtttgactccaatatctgcggcacaagcgcta1320
gagtattcatctaatacttatatggttcaagtagcacttcgtttaatgggacaagactat1380
aatacaggagatgctttaactgatcgaggctatcaagaagcaatggctaaactaaggaaa1440
acttacggcgaatatggtttaggggtttctacaggattagatttacctgaatcagaaggt1500
tatgtacctggaaaatacagcttaggaacaactctaatggaatcgttcggtcagtatgat1560
gcctatacaccaatgcaacttggtcagtatatctcaactattgcgaataatgggaatcgt1620
ttagcacctcacgtggtttcagatatctatgaagggaatgattctaataagttcgctcaa1680
ttggttcgttcaatcactcctaaaacactaaataagatagctatctcagatcaagagtta1740
gccattattcaagaaggtttttataacgttgtcaatagtggaagtggctatgcaactggt1800
acgtcaatgagggggaatgtgacaaccattagtggtaaaactggtaccgctgaaacattt1860
gctaaaaatgtaaatggacaaacagtttctacctacaacttaaacgctattgcctacgat1920
actaatcgtaaaatagcagtagcggtaatgtatccgcatgttacaactgatacaacaaaa1980
tcccatcaattagttgcacgagatatgattgatcaatatatttcacagttcacaggacaa2040
taa
2043
SeqID
44
atgacggtttttcctaaacattttctatggggaggtgcagttgctgccaatcaggtagag60
ggtgcatttagaacagatggcaaaggtttatctgtacaagatgtacttccaaatggtggt120
ttaggcgatttcaccgccaaacctactccagacaatttgaagctagaagcaattgatttt180
tatcataactataaaaatgatataaaactgtttgcagagatgggctttaaagtttttaga240
acctctattgcctggtctcgaatttttccaaatggtgatgatagtgctccaaacgaagct300
ggcttacaattttatgataatttatttgatgagttgcttaaatataatatcgagcccttg360
gttaccttatctcattatgaaacaccgcttcatcttgcaaaaacttataatggttgggct420
gatagacgtttgatagcattttttgagaaatttgctcaaacagtcatggagcgttataaa480
gataaggtgaaatattggttgacttttaatgaagtgaattctattttacatatgcctttc540
accagtggtgctattatgaccgacaaatcacaactaagtcctcaggagctttatcaagct600
attcatcatgaattagtagcatcggctagagtgacaaaattagggcgttctatcaatcct660
aattttaaaattggctgtatgattctggctatgccagcttatcctatgacatctgatcca720
agagatgtcctggctgcaagacaatttgaacaacataatctgctattttcagatatacat780
gtcagaggtaaatatcccacttatattcagtcetatttcaaaaataatggtattaaaatt840
aaatttgaagaaggagatgaggaagtattggcacaaaatacagtagattttctatcgttt900
agttactatatgagcgtgacacaagcttatgactttgaaaattatcaaagtggtcaggga960
aatatccttggaggcetaactaatcctcatttaacaacttcagaatggggatggcaaatc1020
gatcccatcgggctacgcctagtcttaaatcagtattatgaacgttatcagattccgttg1080
tttattgtagaaaatggattgggagcaaaagatcaattgatagaaacactagacggtgat1140
tatactgtcgaagatgattatcgtattgattatatgaatcaacatttagttcaagttgct1200
aaagctattgaagatggtgttgaaataatgggatatacatcttgggggtgtattgattgt1260
gtatccatgtctacagctcaactaagtaaacgttatggtctaatatatgttgatcgaaat1320
gatgatggaacagggagtctacaacgttacaagaagaagtcatttggttggtaccaaaaa1380
gtgattaagacaaatggccaatcattgtttgaacatcataacagataa 1428
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
18/109
SeqID
45
atggctacttttcaaattaaagaaaaaatgttttctctaggcggtaaatttactattaca60
gaccagactgggcttccctgttatcacgttgaaggaagtttgttccctctacctaagact120
tttaaagtctttgacgaagaggggcatctgattagtcagattgagaagaaggttttaagt180
tttttaccaaagtttaatgtgacattagccaatgggaatcatttcacgattaagaaagat240
ttctcatttttgaaacctcattacaccattgaagaccttgatatggaagttaagggaaat300
ttttgggatatagatttccaactcttaaaagacaatcaagttatagcaaacatatctcaa360
cagtggtttcgtatgacttcaacttatcaggtagaagtttacaatgaaacttacaacgat420
ttgacaatttcgcttgtcatagcgatcgactatgtcaaagagttagaaaaaaatgcatca480
aactaa 486
SeqID
46
atgaaaaaaataacaactttaatcttagctagtagcttattactagttgcaacgacatcg60
gttaaagctgatgataactttgaaatgccaacgcgttatgttaaaatgagtgaaaaatca120
aaagcattttatcaaagactacaagaaaaacaacgtaaggcacatactactgtgaagact180
tttaataattcagaaataaggcatcaactacctcttaaacaagaaaaggctagaaatgat240
atctacaatttaggcattcttatttctcaggagtctaaagggttcatccaacgtattgat300
aatgcctattctttggaaaatgtctcagatattgttaatgaagctcaggctttgtataaa360
cgtaactatgatttatttgaaaaaatcaaatctacacgtgataaggttcaagtcttactt420
gcatcgcatcaagataatacagacttaaaaaacttttatgctgagttagatgatatgtat480
gaacatgtttatctcaatgaaagtagagtggaggcgataaacagaaatatccaaaaatat540
aattag 546
SeqID
47
atgaaattaaaaaaattctttgaggatttgctggctaaactagaatatagacccattcaa60
gtttttatgcgtcattttcaaagtgcagagatggacttatcagccatagcagttgcttat120
tatctattagtgacagcttttccattactagttattgctgctaatatttttccttatttt180
catattaatgtgtcggatttattgtcacttatgcaaaaaaatcttccgaaaaatatttat240
gaacctgcctcacgcttagcagtagatgctttttcgaaaccgtctaccggcattttggga300
ttcgcttcattaacagctttttggacaatgtctaaaagtttgacctetcttcaaaaagcc360
attaataaagcatacggtgttgaccaacacagagactttgtgattagtcgtttagtgggt420
gtggggactgggctgatcatcctatttttactgacttttgttttaattttttcaactttt480
tcaaaaccagttttacagataattgtaaacatgtatgatttgggagatactctaacggcg540
tggcttttaaatcttgcacaaccagttacatttttgactatatttttaggtattggaatt600
ttatactttattttacctaacgcacgaattagaaaagtacgttatgtcattccagggaca660
ttattttcaacgtttgttattggtttttttagtaatttaattagccaatacgtcttaaat720
agggttgagaaaatggtagatattaaaacgtttggttcggtcgttatctttatcttaatg780
ctatggtttattttcttagcccacattatgattttaggtgcaatactgaatgccagcgtt840
caagaaattgcgacaggaaaaattgaatcaaggcgtggagatattatgtctcttatccaa900
aaatccaaagaagaaaaataa 92i
SeqID
48
atgaaattactttatactgatattaatcatgatatgacagaaatcttagtcaateaggcc60
gcgcatgctgctgaagctggatggcgtattttttatattgctccaaactctttatctttt120
gaaaaagagcgtgcagtattagagaaccttcctcaagaagcctcttttgctattacaatt180
actcgctttgctcaattggcacgttattttactttaaaccagcctaatcaaaaagaaagt240
ttaaacgatattggattagcaatgatcttttatcgtgctttagcaagttttgaagatgga300
caattaaaagtttttggacgattgaagcaagatgcttcctttatcagtcaattggtagac360
ctatacaaagaattgcagacagcaaatctgagtattttagatttaaaatatttacattct420
cctgaaaaatttgaagatttattagctatttttctagtggtttcagatcttttaagagaa480
ggagaatacgacaatcaatctaaaattgccttttttacagaacaagtaaggtcaggccag540
ctagatgtggatttaaagaacactatccttatagtcgatggttttacccgtttctcagct600
gaagaagaagctttaattaaaagtctgagttcacgttgtcaagagattatcatcggagct660
tatgctagccaaaaagcgtataaggctaactttactaatggaaatatttattctgcaggg720
gttgattttttaagatatctagcaacgacatttcaaacaaaaccagaatttatcttgtct780
aagtgggaaagtaagtctggttttgaaatgatttcgaaaaatatcgaaggtaaacatgat840
tttacaaatagtagtcacattttagacgacactgctaaagattgtataacaatttgggag900
tgcattaatcaaaaagatgaagtggaacatgtggctagagctatacgtcagaaactttat960
cagggatatcgctacaaagatattttagttttactaggagatgtagatagttataaacta1020
caattaagcaagatttttgagcagtatgatattccttattatttcggtaaagctgaaaca1080
atggctgcgcaccctttagttcattttatggattccttgtctcgaataaaacgttatcga1140
tttagagctgaagatgttttaaatctttttaagacaggtatttatggagagattagtcaa1200
gatgatttagattattttgaggcttatatctcatatgcagacattaaaggtcctaagaag1260
ttctttacagattttgttgtgggggctaaaaaatttgatttagggcgtcttaacactatt1320
cgtcagtccctcettgctccactggaaagttttgttaaaacgaaaaaacaagacggtata1380
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
19/109
aaaacactcaaceaattcatgtttttccttactcaggtaggtttgagtgacaatttatcg1440
cgattagttggtcaaatgtctgaaaatgaacaagaaaaacatcaagaagtttggaaaaca1500
tttacagatattttagagcagtttcaaacaatatttggtcaagaaaaattaaatttagat1560
gaatttttatcgttattaaattcaggtatgatgcaagccgagtatcgtatggtccctgct1620
actgttgatgtggttactgttaagtcttacgacttggtagaaccacatagtaatcaattt1680
gtctatgccctaggcatgacacaatcacattttccaaagattgctcaaaacaaatcttta1740
atatctgatattgaacgtcagcttataaatgatgccaatgacactgatggtcattttgac1800
attatgacgcgagaaaatttgaagaaaaaccattttgctgctctctctctttttaatgct1860
gctaaacaagcattagtgttgactataccacaattattgaatgagtctgaagatcagatg1920
tcaccatatcttatcgaactaagagatataggtgttccttttaatcataaaggacgccaa1980
tcgttaaaagaagaag~ctgataatattgggaattaca~.agctttattatcgcgtgttgtt2040
gacttgtatcgctctgctattgacaaagagatgactaaagaagaacaaactttttggtca2100
gttgctgttcgttatttgcgtcgtcaattaacttctaaagggattgagataccaataatt2160
aCagatagtCttgataCtgtgaCagtttCatCagatgtgatgaCCagaCgCttCGC:agaa2220
gatgaCCCaCttaaattatcctcatctgctttgacaactttttataataatcaatataag2280
tattttttacaatatgtgttaggtttggaagaacaagactcaattcatccagatatgcgg2340
caccatggaacgtaccttcatcgtgtttttgaaattctgatgaaaaaccaagggatagaa2400
tCttttgaagcgaaaCtCaaCtCtgCaattaataaaaccaatcaagaagatgttttcaaa2460
tccttgtattcagaagatgcagaaagtcgttattctttagaaattttagaagatatcgcg2520
cgtgcaactgcaaccatattacgacaagatagtcagatgactgttgaaagtgaagaagaa2580
cgatttgaactaatgattgataatactataaaaattaacggtattattgaecgtatcgat2640
cgtttatctgatggttctttgggtgtcgtggactataaatcaagcgctcaaaaattcgat2700
atccaaaaattttataacggtctaagtccacaattagttacctacattgatgctatcagt2760
cgtgacaaggaggttgaacaaaaaccaccgatttttggagctatgtatttacatatgcaa2820
gaacctaaacaagacttgtctaaaattaaaaatttagatgatttagtaacaaaaaatcat2880
caagctttaacttataaaggattattttcagaagctgaaaaagaatttttagcaaatggg2940
aaataccatctcaaagattccctttattcagaggctgaaattgctattttacaagcacat3000
aaccaattgctttacaaaaaagcatetgagactattaagtcaggtaagtttttgatcaat3060
ccatatacagaagatgctaaaacagttgacggtgatcagtttaagagtattacggggttc3220
gaggcggataggcatatggcgcgtgccagagcgctttataaattacctgctaaggaaaaa3180
cgtcaaggtttcttaacattaatgcagcaagaggaggaaaatgatgacctttaa 3234
SeqID
49
atgagcgaaactaaagttatggctttgcgcgaagcgattaatgtcgctatgagcgaagaa60
atgcgcaaagatgaaaaagtatttttaatgggtgaagatgtaggtgtatatggaggagac120
ttcggtacatcagttggtatgttagaagagtttggtgetaagcgcgttcgcgacacaccal80
atctcagaggctgcgattgcaggttcagctatcggtgctgcacaaacaggtttgcgtect240
atcgttgatttgacattcatggatttcgtaacaatcgcaatggatgctatcgttaaccaa300
ggtgctaaaacgaattatatgtttggtggaggtetatcaactccagttactttccgtgtg360
gcatcagggt caggtattggttcggctgcacaacactcacaatcattagaagcttggtta420
acacacattccaggtctaaaagttgttgcacctggtactgttaatgagtcaaaagcactt480
ttgaaatcttctattcttgacaataacccagttatcttcttagagccaaaagctctctat540
ggtaagaaagaagaagttaacatggatcctgatttctatattccacttggtaaaggggat600
attaagcgtgagggtactgacttaacaattgtttcttatggccgtatgcttgagcgtgtt660
atgcaagctgctgaagaagttgctgaggaaggtattaacgttgaggttgttgatccacgt720
acacttattccgcttgataaagaattaattatcgattctgttaagaaaactggtaaattg780
attttggttaacgatgcttataaaactggtggtttcactggtgaaattgcaactatggtt840
gctgaaagtgaagcatttgattaccttgatcatcctatcgtgcgtcttgcaagtgaagat900
gttccagtaccgtattcacgtgtacttgaacaaggaatcttacctgatgtagcaaaaatt960
aaagatgctatctacaaagtagttaacaaaggtaaataa 999
SeqID
50
atggcttttgatgtaattatgccaaaacttggggttgacatgcaagaaggcgaaatcctt60
gagtggaaaaaaaatgaaggtgacaccgttaatgaaggtgatgtccttcttgaaatcatg120
tctgataaaaccaatatggaaattgaagcagaagacactggtgtacttttaaaaattgta180
catcaggcaggagatgttgttcccgtcactgaagtgattgcctatatcggagaagaaggt240
gaagaagtaggtacgtcatcaccttcagctgatgcaactatcacagctgaagatggtcaa300
tcagtttctggacctgctgctccttcacaagagacagttgcagcagcaactcctaaagaa360
gaacttgcagctgatgagtacgatatcgtagtcgtaggtggtggacctgcaggttattac420
gcagcaatccgcggtgctcaacttggaggaaaaattgccattgttgagaaaactgaattt480
ggtggtacgtgtttgaatgttggttgtatccctacaaaaacatatcttaaaaatgctgaa540
atcctagatggtttgaaagtagcagctggacgtggtatcaaccttgcttcaactaactat600
gcaattgatatggataagactgttgcctttaaaaattctgtagttaagacactgactggc660
ggtgtacgtggtctcttgaaagcgaacaaagttgaaattttcaatggacttggacaagta720
aacectgataagtctgttgttattggcgataaagttatcaaaggtcgtaacgtcgttctt780
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
20/109
gcgactggttctaaggtatctcgtattaatattccaggtattgaatcaccattagtatta840
acatcagatgatattcttgatttacgtgaaattcctaagtcacttgctgttatgggtggt900
ggtgtcgtaggtattgagcttggtcttgtatgggcttcatatggtgttgacgtaactgtt960
attgaaatggctgatcgcatcattccagcaatggataaagaagtatcgctagaacttcaa1020
aaaatccttgctaagaagggaatgaagattaaaacatcagttggtgtttctgaaattgtt1080
gaagccaataatcaattaacgcttaaattaaacaacggcgaagaagttgttgctgataaa1140
gctcttctttcaattggacgtgttccacaaatgaatggtcttgaaaatcttgagcctgaa1200
cttgagatggaacgtggacgtattaaagttaatgcttatcaagaaacttcaattccaggt1260
atctatgcaccaggtgatgttaatggaactcgtatgttagctcatgctgcataccgtatg1320
ggtgaagtagctgctgaaaacgcactcggcggtaataagcgtaaagcacatctagatttc1380
actccagcagctgtttatactc~.tcctgaa~gtagcaatggtggggatgacag~tagag'caa1440
gcacgtgaacaatatggtgacatattagttggtaaaaatagctttacaggcaatggtcgt1500
gctatcgcttcaaacgaagcacatggttttgtaaaagtaattgctgaacctaagtataaa1560
gagattcttggtgttcacattattggtccagctgcagcggaattgattaatgaagcttct1620
acgattatggaaaatgagttgactgtctatgatgtagcacaatctatccatggtCaCCCa1680
acattctctgaagttatgtacgaagctttcttagatgttctcggtgaagctattcacaac1740
cctccaaaacgcaaataa 1758
SeqID
51
atgggaaaatattttggtacagatggtgttcgcggtgaagctaatgttgaactgaegcca60
gaattggcttttaaattaggacgttttggaggatatgttctaagtcaacacgaaactgat120
egtccgagagtttttgtagctcgtgatactcgtatttctggtgaaatgctggaatctget180
ttgattgctggtctactttcagtaggtattgaggtttataaacttggtgttttagccact240
cctggagtgtcttaccttgtccgtacagaaaaagctagtgcaggggttatgatttcagca300
agccacaatccagcacttgataatggtattaagttctttggtagtgatggttttaaactt360
gatgatgatcgtgaattagaaattgaagctttacttgatgcgaaggaagacactttacca420
cgtccatcagcacaaggtttaggtactttagtagattatcctgaaggacttcggaaatat480
gagaagtttatggaatcaactggtattgatttagaaggtatgaaggttgcgttggataca540
gcaaatggagcagcaacagcctcagctcggaatatctttttagacttgaatgctgatata600
agtgttattggtgatcaaccagatggtttgaatatcaatgatggtgttggttcgacacat660
cctgagcaattacaaagtttagttagagaaaatggttccgatatcggtctagcttttgat720
ggtgatagtgatcgtttgatcgctgttgatgaaaatggagagattgtagatggtgataaa780
attatgtttatcattgggaaatatctttctgataaagggcagcttgctcagaatacaatc840
gtaacaacggttatgtcaaatctcggctttcataaagcgctcgaccgtgaaggtattcat900
aaagcgattaccgctgtaggagaccgctacgtggttgaagaaatgcgtaaatcaggatat960
aatcttggcggggagcaatcaggccacgttattatcatggattacaatactacaggggat1020
ggacaattaacagccatccaattgactaaggtcatgaaagaaactggtaagaaattatca1080
gagttagctagtgaagtgacgatttatcctcaaaaattagtaaatattcgtgttgaaaat1140
aacatgaaagataaagcgatggaagttcctgcaattgcggaaattattgctaaaatggaa1200
gaagagatggatggcaatggtcgtattctagtacgtcctagtggtactgagcctcttctt1260
agagttatggcagaagcgccaacaaatgaagcagttgattattatgttgatactatcgca1320
gatgtcgttcgtacagaaattggtttagattaa 1353
SeqID
52
atgaaaggtcaaaaaattattgctctagctggtcttgtcctgtcatgccattttgctctt60
acggcatgtcatactcaagaacacaaaaattctcatcatattaaaacaaagcaggttgct120
aagaaaaaagetaataaaaagaaagtctctgttaaggaaagtcataaaaaacgcaagggt180
gttgcaggggttgactttccaactgatgatggctttttactgactaaagattcgaagatt240
ttatctcatcccgattctggaatcgttgtagcacatggaaatcattctcattttattttt300
tactctgatttaaaaggttcaaaatttagctatttaattcctaatgcaaatgcaaaaact360
aataaaaagcaagcggtaagaaactttaaagcaggggcggtagctgttaatacattaaat420
gatggctatgtttttaatcccgcagatattgtttcagaagatgctaatggctacgtggtc480
agacatggtgatcatttccactatattccaaaagcaagtttatctcagcaaaagcaagta540
caagcaagtagagctgtttcacgtttaggaaatcaaaataatagccattacagagttaat600
agttctaaaattgcagggcttcaccacccaacaagtgatggtttcttattcaatggacaa660
ggaataaaaggcactaccccaacaggtattttagtagaacatcataatcatctgcatttt720
attagttttgctgatttaagaaaagggggatggggatcaattgctgaccgttaccaacca780
caaaagaaagttgattctaaaaaacagtcaccatcaagtaaaaagecaagaactgaaaat840
actttacetaaggacatcaaagataagctagcttaccttgctcgtgaattacatttagat900
atttcacgtatcagagtccttaaaacactaaatggtgaaattggatttgaatacccacat960
gatgatcatacacatgttattatggccaaagatattgatctaagtaagccaattccaaat1020
ccacatcatgatgacgaagatcatcacaaaggtcatcaccatgatgagtccgaccataag1080
catgaagaacacgagcacactaagtcaaataaattatctgatgaagatcaaaagaaatta1240
atttatttagcagagaagcttggtttaaatcctaatcaaattgaagtattaacgtcagag1200
gatgggagtatcatctttaaatatccacatgatgaccactcacacactatagcaagtaag1260
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
21/109
gatattgaaattgggaagcctatcccagatggacaccacgatcactctcatgcaaaagat1320
aaagttggtatggcaactctaaaacaaattggttttgatgatgagattattcaggatatt1380
ctgcatgcagatgctccaacaccattcccatccaatgaaactaatcctgaaaaaatgcgt1440
cagtggcttgcaactgttactaagattaacattggacaaagaaccaatccattccagcgt1500
tttggtctatcattgatgcctaatattgaagttctaggaattgggtttactccgattaat1560
gatatgacgccagttttgcaattcaaaaaacttaaacagctttggatgacaaatactggt1620
attacagattattctttccttgataagatgccactattagaaggattggatatttcacaa1680
aacggtattaaggatttatctttccttacaaaatataaacaattaagtcttattgctgca1740
gctaataatggcattacttcgctaaaaccattggctgaattaccaaaccttcaattctta1800
gttttgagtcataacaatatctctgacttgacaecgttatcaaacttgacaaaactccaa1860
gaattgcaccttgatcataataatgtgaagaatttaagtgcactttctggtaaaaaagat1920
ttgaaagttctagatttatcaaacaataaatcegcagacttatcgactetaaaaacaact1980
agtcttg~.ga.egcttcttttaaatgagacgaatacaagcaatctaagtttcttaaagcaa2040
aatcctaaggtatctaatttaacaattaataatgcgaaattagcatcattagatggtatt2100
gaagagagcgatgaaattgttaaagtagaagctgaagggaaccaaattaagtcactagta2160
ttgaaaaataaacaaggttcgttaaaattcttgaatgtgaCtaataatcagttaacatca2220
cttgaaggtgttaataattatacttcacttgagaccttaagtgtttctaaaaataaactt2280
gaatctttagatattaaaacacctaacaa.aacagttacaaatcttgattttagccataac2340
aatgttccaacatcacaattgaaattgaatgaaaaaaatattcctgaagcagtagctaag2400
aattttccagcagttgtagaaggttcaatggttggaaatggtagtcttgctgaaaaagca2460
gctatggcttctaaagaggacaaacaagtttcagataatactaatcaccaaaaaaacact2520
gaaaaatctgctcaagcgaatgetgatagtaaaaaagaaaaccctaaaacacatgatgaa2580
catcatgaccatgaagaaacagatcatgcacatgtaggtcatcatcaccattaa 2634
SeqID
53
atgaataaacgcgtaaaaatcgttgcaacacttggtcctgcggtagaattccgtggtggt60
aagaagtttggtgagtctggatactggggtgaaagccttgacgtagaagcttcagcagaa120
aaaattgctcaattgattaaagaaggtgctaacgttttccgtttcaacttctcacatgga180
gatcatgctgagcaaggagctcgtatggctactgttcgtaaagcagaagagattgcagga240
caaaaagttggcttcetcettgatactaaaggacctgaaattcgtacagaactttttgaa300
gatggttcagatttecattcatatacaacaggtacaaaattacgtgttgctactaagcaa360
ggtatcaaatcaactccagaagtgattgcattgaatgttgctggtggacttgacatcttt420
gatgacgttgaagttggtaagcaaatccttgttgatgatggtaaactaggtcttactgtg480
tttgcaaaagataaagacactcgtgaatttgaagtagttgttgagaatgatggccttatt540
ggtaaacaaaaaggtgtaaacatcccttatactaaaattcctttcccagcacttgcagaa600
cgcgataatgetgatatacgttttggacttgagcaaggacttaactttattgctatctca660
tttgtacgtactgctaaagatgttaatgaagttcgtgctatttgtgaagaaactggcaat720
ggacatgttaagttgtttgctaaaattgaaaatcaacaaggtatcgataatattgatgag780
attatcgaagcagcagatggtattatgattgctcgtggtgatatgggtatcgaagttcca840
tttgaaatggttccagtttaccaaaaaatgatcattactaaagttaatgcagctggtaaa900
gcagttattacagcaacaaatatgcttgaaacaatgactgataaaocacgtgcgactcgt960
tcagaagtatctgatgtcttcaatgctgttattgatggtactgatgctacaatgctttca1020
ggtgagtcagctaatggtaaatacccagttgagtcagttcgtacaatggctactattgat1080
aaaaatgctcaaacattactcaatgagtatggtcgcttagactcatctgcattcccacgt1140
aataacaaaactgatgttattgcatctgcggttaaagatgcaacacactcaatggatatc1200
aaacttgttgtgacaattactgaaacaggtaatacagctcgtgccatttctaaattccgt1260
ccagatgcagacattttggctgttacatttgatgaaaaagtacaacgttcattgatgatt1320
aactggggtgttatccctgtccttgcagacaaaccagcatctacagatgatatgtttgag1380
gttgcagaacgtgtagcacttgaagcaggacttgttgaatcaggcgataatategttatc1440
gttgcaggtgttcctgtaggtacaggtggaactaacacaatgcgtgttcgtactgttaaa1500
taa
1503
SeqID
54
atgactgcaactaaacaacataaaaaagttatcctcgttggtgatggtgcegtaggttct60
tcttacgcttttgcacttgttaaccaaggtattgcgcaagagttaggtatcattgaaatc120
ccagctttatttgataaagctgttggtgatgctgaagatctttcacatgcccttgcattt180
acatcacctaaaaaaatctacgcagctacttatgcagactgcgcagatgctgaccttgtt240
gtcattactgctggcgcacctcaaaaaccaggtgaaactcgacttgaccttgttggtaaa300
aacttagcaattaacaaatcaatcgtaactcaagttgttgaatcaggtttcaacggtatc360
ttcttagtagcggctaaccctgtagatgtacttacatattcaacttggaaattctcaggt420
ttccctaaggaacgcgttattggttcaggtacttcacttgactetgcacgtttccgtcaa480
gctttagcagataaaattggtgttgatgctcgttcagttcacgcatacatcatgggtgaa540
cacggtgactcagaatttgccgtttggtcacatgctaacgttgctggtgtccaacttgaa600
caatggttacaagaaaatcgcgatattgatgaacaaggacttgttgatttgtttatttca660
gttcgtgacgctgcatactcaatcatcaacaaaaaaggtgctacatattacggtattgct720
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
22/109
gtegcacttgctcgtattactaaagctatccttgatgatgaaaatgcagttcttccatta780
tctgtatatcaagaaggccaatacggtgatgttaaagatgtctttatcggtcagcctgca840
ategtaggtgcacatggtatcgttcgtccagttaatatcccattaaatgatgctgaactt900
caaaaaatgcaagcctcagctgaacaattaaaagatattattgacgaagcttggaaaaac960
ccagaattccaagaagcatcaaaaaactaa 990
SeqID
55
atgcaagataaaaatttagtagatgttaatctaactagtgaaatgaaaacgagttttatc60
gattacgccatgagtgtcattgttgctegtgcacttccagatgttagagatggtttaaaa120
cctgttcatcgtcgtattttatatggtatgaatgaactaggtgtgacacctgataaacct180
eataagaaateagcacgtattactggtgatgttatgggtaaataccatceacatggtgat240
tcatctatttacgaagcaatggtgcgtatggcacaatggtggtcatatcgtcatatgctc300
gttgatggtcatggaaactttggttcaatggatggggatggtgctgccgcacagcgttat360
acagaagCacgtatgagtaaaattgctCttgagatgcttcgtgatatcaataaaaataca420
gttgattttcaagataactatgatggcagtgaacgtgaacctcttgttttaccagcgcgt480
ttccctaatttattagtcaatggtgcaactggtattgctgtaggtatggcaacaaatatt540
ccaccacataatctaggtgagtctatagatgctgtcaagttggttatggataaccetgat600
gttactacacgggagttaatggaagttattcetggtccagattttcctactggtgecttg660
gtgatgggacgttcaggtattcaccgtgcctatgaaactggaaagggatcaattgtctta720
egttcacggactgaaattgaaacaacttcaaatgggaaagagcgtattgttgtcacagag780
tttccatacggtgttaataaaacaaaagtacacgagcatattgtacgtttagcacaagaa840
aagcgtattgaaggtattactgctgttcgtgatgaatcaagtcgtgaaggcgttcgtttt900
gttattgaagttcgtcgtgatgcttcagcaaatgtgattttaaataatcttttcaaatta960
actagcttgcagacaaattttagcttcaatatgcttgctattgaaaaaggtgttccgaaa1020
attttgtcattacgacaaatCattgataactatattgaacaccaaaaggaagttattgtc2080
cgtcgtactcagtttgacaaagctaaagcagaagctcgtgctcatatcttagaaggttta1140
cttgtggcgcttgatcacttggatgaagttatcacgattattcgtaatagtgagacagac1200
accattgctcaagcagagttgatgtcacgttttgaattatcggagcgtcagagtcaagca1260
attttagatatgcgtettcgtcgtttaactggattagaacgcgataaaatccaatcagaa1320
tacaatgacttgctagetttaattgctgatttagcagatatcttagctaagcctgaacgt1380
gttgttaccattataaaagaagagatggatgaggttaagcgtaagtatgetgatgcccgt1440
cgtacagaattaatgattggtgaagttttatcacttgaagatgaagaccttattgaggaa1500
gaagatgttcttattactctctcaaacaagggatatatcaagcgtctcgctcaagatgag1560
tttagagcacaaaaacgtggaggacgeggtattcaagggaetggagttaataacgatgat1620
tttgttcgtgaattggtttcaacaagtactcacgatactgtgcttttctttacaaattta1680
gggegtgtgtatcgtttgaaagcatatgaaattccagaatatggacgtacagctaaaggc1740
ctccctatcgttaaccttttaaaacttgacgaaggtgaaacaattcaaacaattattaat1800
gctagaaaagaagatgtcgctaataaatatttctttttcacaactcagcaaggtatagtg1860
aaacgtacaagtgtttctgaatttagtaacattcgtcaaaatggacttcgtgctattaat1920
ttgaaagagaatgacgagttgattaacgtcctcttgattgacgaaaatgaagatgttatt1980
atcgggacacgtacaggctactctgttcgcttcaaagtgaacgctgtacgtaatatggga2040
cgcacagcgactggggtacgaggcgttaatcttcgtgaaggtgataaagttgtgggagct2100
tctcgtatcgttaatggacaagaagtactgatcatcactgaaaaaggttatggcaagaga2160
acagaagcttcggaatatcctacaaagggtcgtggtggtaaaggaataaaaaccgctaat2220
attactgctaaaaatgggccattagcacgcttagtgacgattaatggaaatgaggacatc2280
atggtcattacagatacaggcgttattattcgaaccaatgttgctaatatttctcaaact2340
ggtcgttctactatgggtgttaaagtgatgagacttgatcaagaagetaaaatcgttact2400
gttgcgctagtggaacaagaaattgaagataagtctaatatagaggatacaaaagaatag2460
SeqID
56
atgacaatctttgatgaaagagagttaaaagaacgatttactcatgaaaatagggttagt60
ttttatgagtttgtggctaaatatgatgctcaaatggttcctgtgatgaaagcaaagggc120
tatcgatgtattcattcaatggagcgtacagtggtttttacttttggggaattcacgatt180
aggcgacgtcggtggcaaaaaggagaacattgggtggtgccagttgatgaaaagctagga240
ctgaaaaagaatgttcgctactctttagaattcatgtatcaaattgctagtttagcaacc300
atgatgccttatgaaaaagtgattaaggttgttcagatgatgtattgtattgtgattacc360
aaacctactgttgtgaaggcegttaagattagtcgtgaattgcttaaagaaaaggaagcg420
tatcgtttttttgatgaagatataccagtagataaagaaccagttgatatgatttatctt480
gaaggagatggagtcatggtcaaagctcgagaagaaggattagataatcgcaatgttgat540
ttgtctcatttcgtggttcatacgggtagtcagaaagtaggaagcaatcgctttgtctta600
caaaataaaaaagagtttgtgtcccttgataatcgtcaaacgcgtcaaaagattttggac660
tacctttacaatcatttttacattgccccaaacaccttgcttattaccaattcagatggt720
ggccatggctataccccatatgtttttaaagagattgcgaaagcactcaaagtgaagcaa780
cacgaacacttttgggataggtatcatgtcaatgaaaagatcaaaagtttttttaaactc840
tatccagtggaactgatgactggcgcttttcagagcattaaacagcatgataaagaaaag900
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
23/109
cttagaactgttttggatacgacagaagcattgatactgatggaagaagaaatggaaggg960
tttaaccagttcaaacgaaagttgttaaacaattttcaatatactaaatcagctgaattg1020
agaggtttcagtcgtgcaggaataggtgttatggagtcacaacatcgaaaaattacctat1080
cggatgaaaaagcgcgggatgtattggacaattcagggagctgagacgatgagtcaatta2140
attgtcctatcgtatgaaggacagctaagagatctcttctttggttcttggcgtgaagac1200
tatcagaaatatcaagagctagaaaaccttagtgcgggaaaaatcaaacatgaacagaat1260
aaaatcaataagagatatgatctccagacacttggtcggcttaggtacggtaggcatcgt1320
aatttatag 2329
SeCjID
57
atggcatatttatcaaaa.ttatccgatttggatccatcgttga.tggatgcggattctgaa60
caaatttatattcctaaagtcttgtttgagcataatgactttaaaggcttgacctacaaa220
gagattttattatattcttttttgttaaatcgtttaagagagccattagattttattcaa180
aaaggctatgatgataatgaagatacctatgttcactttaaggtcgaagatttatgtgaa.240
ctactcaaccagagtaagacaaccgttatttccttgaagaaaaggttagctcaatatggt300
ttgatagaagaagtgaaagcaggtagtcaccagecgaatcgtatttatttaacagataaa360
ttagttccatatattaaggggtaa 384
SeqID
58
atgacagataatcgctttgcccaattaaaagaaaactttgaaaagggatctcctaaaagg60
cgagttccaacgtctcgcccaatcgcagctcaaaaagcgcctgagagctataacaaaaag7.20
ggacggtatccattttcgctccaccaagatgtgegttatgataaattagaagcattagta180
gcttatcatggagctaagtctgcatcagattatctggagaggttgattgttcaggaatgg240
gaaaagatgcagcggaagcttaagaacaaagaaaaataa 279
SeqID
59
atgtttagttggttggaagctetttattacactctgatacaactggcaaaagtgaaccgg60
ttgaatgctcttttcttagttagcgttgtgggttatctttgttaccagggaataaaactc120
gtcagaaaaaccataagaaacttttttcagctgatgaagggtttcataggtgatagagag180
aacatcaagaaatgcatcaaaaacaagaaagaggcactagtccattcttggaaacatcgt240
caagatattgattggaaatcaactggaaaagataagagtaaacagttatggaatcttatg300
aagcgacttgcgacagttgctcettcatttttgttcttattattgggaaatgttctcttt360
cgtctcatttatcaactgccttttgtaaagcaagacagaaagcgatttgacaaggaaatg420
aagcccttgctctacttcaagaactatcgtagttttgtgttcatgggaataggtttcagt480
ttcatagcgtttattctcacaaactattttgtgacggttttaagggctgctattcgtttt540
ctatatttctcaatcatgacgttaagagataatagecaagtcgttagctttaacgttgat600
agtttgctcatccagaatttattcaatgctagggtatttgtgatagctcccattctagca660
gtgccaatctttctcattggtttagtcgtagcttggcggtctgcttgggttaactttgaa720
cagtaccgtgattataatcataatgaagaaggggatgatcgctttgcgactgtcaaagaa780
atccaccagcaatataagaaagttcctaataaaacggaaacttatccaggtgaaggaggt840
gtgcccgttcttcatgaaacaagaaagaatttgacaggcttaacgettaaatctcaaatg900
ctttggcaaaaccgtacctttagtcgctatttaacgaatgcggaaaggattttagggctc960
ttatcgacgccttcaggagattattacatcgatgatagcaccacaaacttgatcaccatg1020
gggattactcggtcaggtaagggagaagctcatattgcccctattattgatattaatagc1080
cgtgcggaaattcaaccgtcactgattattgcagaccctaaaggggaacattaccagtcc1140
tcttataaaaccatgcgtcggcgtggctatgatgttaatgtcctttctttccaaaacatg1200
gattggtccatgtcctataaccctttagctcttgcgattgcagcagctaagaagggttac1260
tatgaaatgacacagacaagggttaatgcggttgcagaagccatttatcgtaaaacgaaa1320
cctggtagcggtaatggcaatgcaaaatactgggaagatacctccatttccctctttaat1380
gccattgctatggcettaatggaccgtgctaatgaaaccgtcaggaatggtgaaaccgat1440
gcttgggataccgttacagttcgtaacattgccaagtttttgactgacttgggttctgaa1500
gaagtctttgtcaatgattttggagagattgttgagaatcctgataagaaccaacaagtg1560
aagaagaaatctaaaatcacggtttactttgataacttgegtaaaatcaatcaagaacaa1620
ttttccaaatttagagatatggctgatttaaactttaggtcttctgacttcgcttcagaa1680
gaaactaagggaaatgtcttctctagcatgatgtcaggtattaacttattcttgcaagat1740
aatattgctaaactaacctctaaaaactctattgacctagaatcggttggtttcccacgt1800
cgcttgtctatcaagtttcgttctagttccaatgtcgctatgcgtaacgaatacactcat1860
aagacggctaaggttaccattactagtcaagctgtttggggtaaaaccactaaacaagtt1920
atccacgtagatgctgcaacagctctgattgatggtgaaggctatctaacctatgtgatt1980
gaaccccagcttcctgatcaattcttggtaacaattgactttaatcacgaaaacaatggt2040
ggttcagctattcgtcacaaaactttccaattctcagctgagaaagtctataagaaacgt2100
ggtaacgttattacgttggatgactacacgaaaaaaccagttttggatcatatcaaagtt2160
actgttctcaacaagcaagatgataaccttctecagaaagaagatattgacctgatttat2220
tcagataatcctaaagtgatttacttggtaacacctccaaataggactgaatataatagt2280
attgtatctctgtttttggatcaattgtttaatgccaattatgagttagctctgtcaaat2340
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
24/109
ggtcgcaagtgtgtcaatcgaattcttcatatcctcgatgaattcacaaacattccaget2400
attcetcacatggataccaagatttccattggtcttggtcaaaatattctctactatctc2460
tggattcagaacttgaaacagttagtcagtgaatatggcgagaatacagcggaaaccatt2520
cgggagaactgttetttgaaagtttatatcaaatctactgccccagcgaccaacgagtac2580
ttcagtaaagagttggggactcggaccattacacgtcgcagaaggtcaagtaatattcta2640
gatgaagctaatccaaatgtttccattgaaaatcctagacaggaactcttaacaccgaca2700
cagctctcgaaactccaagaaggggaagcggttattttgcgtggtgttaaaggtcgagac2760
aatgcaggtcggaaaatcacaacggatccgattttcttgcatgagaaaacgagccttcct2820
tatcgctacatgttcttacaagaagaatttgaccagtcgatggctttggcagatattcca2880
gtggaaagtgggcatagggaCCttgacctgCaagatatagcagtaggggCaCaaagCaCt2940
tttaataagattattgattggcggatggctctaactgaccgtatgagaacaaatgggaag3000
atacctcaattagcatcaagaaaacaaacgattaaagctctaagtcaatctcaatttact3060
tctccagcagacctaacacaagctgtgattgcagaggtatttgatgaggaagatgatgac3120
gatcttttctttgtggatgatgtcatgtaa 3150
SeqID
60
atgaattctaacacaaaaggtcacggatttttccgcaagtcaaaagcatacggcttagta60
tgtgctattgcattagcaggtgcatttacattagctactagtcaagtgtctgctgatcaa120
gttacaactcaagcaacaactcaaacagtaacgcaaaatcaagcagaaacagtaacatca180
actcaacttgataaagcagtagctacagctaaaaaagcagctgtagctgttacaaccaca240
cctgcagttaatcatgegacaactactgatgcacaagctgatttagctaatcaaacacaa300
gctgttaaagatgttactgcaaaagcacaagctaatacacaagctattaaagatgctact360
gctgaaaatgcaaaaattgatgctgaaaacaaagcagaggcagagcgtgttgcaaaagaa420
aacaaggaaggtcaagcagccgtagatgcacgtaacaaagcaggtcaagcagccgtagat480
gcacgtaataaagcgaaacagcaagcgcaagacgatcaaaaagcaaaaattgatgctgaa540
aacaaagcagagtctcaacgtgtaagtcagttaaatgcacaaaataaagcaaaaattgac600
gcagaaaataaagatgcgcaagctaaagcaaatgcgactaatgcacaattacaaaaagat660
tatcaagctaaattageggaaatcaaatcagttgaagcttataatgcaggtgtacgtcaa720
cgtaataaagatgcacaagctaaagcagatgcgactaacgcacagttacaaaaagactat780
caagctaaattagcactttataatcaagctctaaaagctaaagcagaagcagataaacag840
tctattaataatgttgcttttgatatcaaagctcaagctaaaggtgttgataacgctgaa900
tatggaaactcaatcatgactgcaaaaactaaacctgacggaagtttcgagtttaaccat960
gatatgatcgatggtgtgaagacaatcggctatgggaaattgacaggtaaagttaatcat1020
cattatgttgctaacaaggatggctctgtgacagcatttgttgattctgtcactctttac1080
aagtacgagtatcgtaatgttgctcaaaatgctgctgttaaccaaaatattgtatttaga1140
gttttaacaaaagatggtcgtcctatttttgaaaaagctcataatggtaacaaaactttt1200
gcagaaactttaaacaaaactttacaactcaatcttaaatatgagcttaaaccacatgct1260
tccagcggtaacgtcgaagtctttaagattcatgatgactgggtacatgacacacatggg1320
tctgctttagtgtcttatgttaataataatgatgctgttcctaatgtggtcatcccagaa1380
cggccaactccaccaaagccagtgaaagttacacctgaagcagaaaaaccagtacctgaa1440
aagccagttgagcctaaattggtaacgcctacattaaaaacttatactccagtcaaattt1500
attccgcgagaatacaaaccagaaccaatcacccctgagacgtttacccctgagaaattt1560
actccagctcaaccaaaagtgaaaccacatgtgtctattcctgaaaagattaactactca1620
gttagtgttcatcctgttttagttccagctgctaatccttcaaaagctgtcattgatgaa1680
gcaggtcaatctgttaatggtaaaacegtattaccaaatgcaacattagactatgttgct1740
aaacaaaactttagtcaatacaaaggtattaaagcttctgcagaagcgatcgcaaaaggt1800
tttgcatttgtagatcaaccaaatgaagcgttagctgaattgactgttaagtctatcaaa1860
gcatctaatggtgatgatgtatcaagcttgttagaaatgcgtcatgttttatcaaaagat1920
actttagaccaaaaacttcaatctcttattaaagaggcaggaattagtccagttggtgag1980
ttttacatgtggactgcaaaagatccacaagctttttataaagcttatgttcaaaaagga2040
ctagatatcacttataatctatcctttaaaatcaaagctaactttactaaaggtcaaatc2100
aaaaatggtgttgcacagattgattttgggaatggatatacaggtaatattgtagtcaat2160
gatgttactgttccagaagtacataaggatatacttgataaagaggatggtaaatcaatt2220
aataatagtacggttaagttaggtgatgaagtgacctacaaacttgaaggatgggttgta2280
ccagcaaaccgtggttacgatctttttgaatacaaatttgtggatcaattacaacacaca2340
catgatctttacttacgtgataaagtggtcgctaaagttgatgtgacattaaaagatggt2400
acagtcattaaaaaagggactaatttaggagagtacacagaaacagtttacaacaaaacg2460
acaggtcattatgagcttgcctttaaaaaagagtttttagctaaggtttctcgtgaatca2520
gaatttggtgcagatgattttattgtagttaaacgtattaaggcaggtgatgtttacaat2580
actgctgatttatatgttaatggatataaagttaagtcagaagcagttgtgactcatact2640
actgagaaatcaaaaccagttgaaccacaaaaagcaactccaaaagctccagctaaagga2700
ctgccatcaactggtgaagctagtatgacgccacttactgcaattggagcaattatctta2760
tcagctctaggcctcgcaggctttaaaaagcgtcaaaaatas 2802
SeqID 61
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
25/109
atgaaacaaataaaaattatcacaggacttacagtcgcaacactatccgcagtggtaggg60
aatgtatacgcagaagatatcacaccgacagcaccagttaatgagccacaagtttcaagc120
gaaaccgcaaaaacgcctcaagttacagaaagtcaagttaatagcgcaaaagttactgcc180
gatcaagcaataagtgatgttaataaccaacaaattgtagttgatgaggctcaaaagcag240
aaagatcaatcacaacaaaa.tcttgtaaaagccacatcaacagtaactgaagctgaaaaa300
gtegctgctgaggcaacacctgaagttgttaaagaagctattaaagctgtcactgaagca360
aaggaagctgttacggatgctgaagctaatgtagtcgatgcacaaaagacggaacaaaaa420
gctaatcaagaagtacaatcgcaagctaagactgttgatgaaaatgttaaagttgttgct480
gataaagaatccgaagtgaaacaagcagagggtgttgtaactacagctcaagaagctatt540
gatagcaaaaccgctaacactaatgcatcagaagc~.ga~.~.aagcagtgactgagaagcaa600
acaaagcttgaaactgctgaaacaaatcttacagaggcacaaaaacaagatgccaaaatc660
gctgaagaaaaacgacttgcagaacaagaagttgttaataaacaattagctgtgacagat720
acacaaactcttttgaagaagcttgttactgagattaataacgagaaagtaagcactagt780
ttagaaaaccaagcctattttaaccaacgtgacggttcatgggcgggctattatggeaat840
tatacttttgccgctactggctgtgtaccaagtagtttagcaatggtatttacggagtta900
gctagacgccaaattaetccaactgaaatcgecaattatctttggaacaattcaaatgag960
tttaataaaaactatggtggaacaagtggcaaagggttagtacaagctactaaacatttc1020
ggttttgtaccaactcatttagcatctcaatctgctattgtggaagccttacaggcagga1080
caccatgtcctagcagctgtccaacaagataaattttctccttggggtatcaattacagc1140
catgagattgtcttacgtggttactcaaatggcaatacttatgtttacgatccttataat1200
cgagctaacattgggtggtaccctgttgctaatttatggaatgaacaaagtagagacgca1260
attgacacatctagtgtaggcgtaccatttttcaaaattacaacacaaaaaatggcccaa1320
ttagaagctcagaaagcacaagttcaatcttctctaaatacagctaaaaatcagttagct1380
aaaacacaagacgtattaagaacactagaagcaacacctcttaaaacaccagaagcacaa1440
gctaagcttaatcaagccaaagaagctctagctcttgcacaagcagactatactaaagcg1500
caagaagctgttaagttagctagtcaagacttagctgttaaagaagaaacacttaaaaat1560
gctcaggctgatttattaacgaaacaaacagccttgaaagatgctcaaactgttctcgtg1620
gctagtcaagttaaattagctgatcttaaagcaactttagctactgttgaaaataacgtt1680
aagaaagctcaagctactttaacagatgccaaagcaattgttggtcaaaaacaagcaaaa1740
ttacttgctttacaaaatgcccctaaaattctagcagatgctcaagctaaacttgtaact1800
gctaaaaatgatttagctaataaaatggctattttagatgaagcagtcgcaaaactaaaa1860
tccttacaagccgttcaagccgaagcccaaaaacaataccatgttgtttttgaagectat1920
aaagcagtacgagatgccaaagaacaagctaaacttgcagaaagctataaccatattatc1980
gcacgaggcggtgaggctatcccagttgttgacgaaacagataaaataactggatatgta2040
gatggtagccagaaagcagttgctaatgaagtgactcttgccttaactagtaacggtgca2100
ccccttgaaagtccagttaataaagaaaaccaaaacgtaacaaaatcatctcaagcttta2160
ccacatactggtgaagctggattatccattttatcagtattaggtgtaggtcttatctca2220
actttagggcttactagtttgaaaaaacgtcgcccacattas 2262
SeqID
62
gtgagattaacccacgtgagtttgtggatgccatcaaagagaagttggccgctcaaattg60
cagttgttaaggaaaggagtgattgagttggaagatgaactgaagacccCttatcttgatl20
caatacacagacaatttaacggctaaagtcactaaaaaatcggatgactaccaagtttat180
ggacgaaacaaggaggttcaatccgtcatcatctctcttctcagacgaaccaaaaataac240
cctattttagtaggagaagcaggggttggtaaatcagecattgtggaaggtataacgctt300
gctatcttacgtggccaagttcctgaacctttaaaaggtttaacggttcgttccctggag360
ttgtctagtttgatgagtgaagatgacgaaggctttattgctaagtttaagaagattatt420
gaagagatggttgctacacgtggtcataatcttctctttgtagatgaatttcatacgatt480
attggtgcgggtagccagaatggtcaagcccttgatgcaggaaatgtgattaaacctgtc540
ttagcacgtggtgatattcagctgattggagcaaccaccttagatgagttccatgagtat600
attgaaacagatagagccttggaacgtcggatgcagcctgttatggttgaagagccaacg660
atttcacaagctattaccattattgaacaagctaaagtcatttatgagaagtttcatggg720
attcaaatttcctcagatgctgtgcatcaagcaatccgtttatctgttcgctatttgaca780
gatcgattcttgccggataaggcctttgatttgatcgatgaagcggcgacgattgcttca840
gttgaagggaaaagtaaggtgacagaaaaagatattgctcaagttttaaaagataaaacg900
ggaattccagtcactactatcctaaagggagatcaagagcggttagagggtttcaaagaa960
aggctgatgaatcgagtcaaaggtcaagaagatgccattgaggccgttgtagatgcggta1020
acgattgctcaagctggtttacaaaatgaaaaaaggccgcttgcatcattccttttcctc1080
ggaecaactggcgttgggaaaacagaattagccaaagcaattgcagaagcactttttgat1140
gatgaagctgccatgattcgttttgatatgtetgagtacaaacaaaaagaagatgtgact1200
aaactcatcggcaatcgtgcgacaagaataaaaggacaattgactgaaggagtaaaacag1260
aagccttattgtgtcetgttactagatgagattgaaaaagcacacagtgaggtaatggat1320
cttttcttgcaagtgctagatgatggtcgtttaacagatagttcgggtegtttgattagc1380
tttaaaaacaccattgtgattatgaccaccaatattggcgctaaaaaaatcatcaataag1440
tgggagttgaaaggaaactttaaagatttaaccgatcgagatcggaaacaatttgaaaag1500
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
26/109
tcgatggacagtgagcttcaaaatgagtttcgtccagaatttctcaataggattgaaaat1560
aagctcatcttcaaccttttagaacgtgatgtgattgaaaaaattgcagaaaaaaatcta1620
tctgagattgcggataggatgaagcgccaaaatttaacactgtcatatgagcctagtctg1680
attcagtatctctctgatgttggtactgatgtgaaaaatggcgcacgteccttagaacga1740
ctgatgaaacgaaaagtgctggcacccatttctgtaaaaagcttacagttagataagtca1800
aagcaaggctataacgttcatctctgggttgagggacgggctccagacggcaatcatcgt1860
caagaacaacgtcaaattcacatggagatagagggagaaagagataacttttttagctga1920
SeqID
63
atggcagaagaaaatgcacaacagccatctttacgtggaaaaagccgtcgagaacgtgtt60
gaatttgctcgttcccgtgatattttagatgtggcccatgaattgaata.tggaacttttt120
cgagatggcaaaaattatcgttggaaagagcacgattctatggtaattacacctgcaact180
aatcagtggtactggttttcacaacgtcaaggaggtgatgtgattgcgettgtagagacg240
ataaaagaaatcggcttcaatcaagcatttgaatacctgaatgaaggtacatttaaagaa300
tttactgtggtcaatcaagtaaaagaacctttttcttattatttagaaccttacgaacag360
ctttttgttgaagcaagacgttatttgaaagagaatcgtggcttatcagatgacactatt420
gattttttttatgataaaggagtacttgctcaagccaatgccaaggtaggtgatatgatt480
gagcctgttttggtgtttaaaaacttggataagaacggccaagtggttggcgctgctcta540
caaggcttagtagctgcccccgataaatatttcggtcggggttacctcaaacaaatcatg600
aaaaattcccaaccttacaacggcatgcatgttgatattggcacaccaaacegcctagtc660
tttgcggaaagtagtattgatcttatgagttactatgaaatccacaaagatagcttatca720
gatgttcgtttagtttccctagaaggcttgaaaacaggaacaataggaaggcatctcatc780
caattaagagctgaaatggaacgtcgtcccctctcctccagttggactgatgaaatactt840
gctcagggattagatgaggctgtaaagcaaggctatttcaaagatggtaagaacagtcat900
etccttacgctagctgtagataatgatgtaaaaggtaaacaattgattgaagagttaaaa960
gataagagcatcccagtcattgatgccactcctcctaaagcagaaggtcaatctaaaatg1020
gattggaatgcctatttgcaggaaaccaaggctactttttctactgaaaaatatcaagaa1080
aagattgatcacctaatatcagatgttattttaggtgatgaaacttattatctttggcat1140
gatgatgagttggtaaatttaggagcaggagactctattatacaggcgtttcatcatcag1200
ctggaagacagacgttatgttattaatcaggcagaactttacgttgaagagtccagtaat1260
gatggggctactggctatctatcaattgaaggacatgtattagataaggatggtattagt1320
gactatttatctgatcaagctttaacagatgcggaaaaagtagcattcttagaaacttta1380
cagacagaactaccagatatttgggacgagatagtcaatcattatgacaaggtctttgaa1440
gaagttgtcgttaaatatggactcagagaaaaacatgcggacataattcaggaacaagag1500
ttggatttagaccctttagttgttccagaagcaaaagaaaagtcccttgaaatgaatcaa2560
gagactaacactggcggcgaactatttaatcgcaattccagttttttaggagaagattct1620
ccggggacagcaccgcagcccgttgagccaactgctcaacctgattttcctaccaatgtt1680
cgcttacattttaccactgatgatggaaatatgtcaaataaagcatttaggaaaaacatg1740
cgaaccttgaatttatatgctaatacgatgagagattcggcacaatggtacttatcagaa1800
atagccgatactacaatgagttatgtttataaaactcctcatgaagagggagtacaggtt1860
cttagtgtgcattttggtaaaaagaattggatgcacttaacaggagtgacaccagtatat1920
gaaaattgggtagattcactttctgaacaatttattgatgatattgctaatagtaaggga1980
cattttaaaaatctaaagtttgcactagggactcctgataagttaaaggttcttaactta2040
cttcctgaaattattgaatcagatacctttgtatttaatgatttatcatctgttcaaaag2100
ttaaataatcttgatttatcacaggcgcttaatcctgaagatagcgatttacttttgcta2160
tttagagatgaggggcttcatcaagtgcctgcttcgttgatgaggataaagggcgattta2220
gaagaaagattatctcatatagatagtgggacagtgttaggagtttaccgagaaagaaat2280
ggccaacttgagcaagtttctgtcaatgaggagtatgtcaaagatagtggtcaagaaatg2340
ctatctattttacagaataagcactatgaagaggctcttgatagtggtcaagaaatggtt2400
caaacggatggtttttcagccgaagatttcacaaaagttttggatgctgtctatcatgtt2460
ggtgttccagatgatttagcacgtgttccagaaggagtcttacctgtttggcaaaaatat2520
cttgaggtatcagaagagaatcaatgggacttagaacaaatgattgattatgcggataag2580
aacagtcttttagtaaaagattctgccttctataaagagtggaaagaggatatgatctat2640
aaaaatgactatcatgttcgcttacaatttgctgagaattgggataatggcgttgaactg2700
cctttccgtacagaacaattgattgattacaaaacgtttgtcacaggactttatgaagct2760
aatcaagctcatcatcaacgcagacaagaaagtcagcttccttatacaaaaacagagttt2820
gacatttatgctcctggcggacagctcattaaagataatgtccattatgctattggagat2880
gaaacaagacctgtttcacaactcatggggttaggttatcgtcgcctacctggctatcag2940
gaattagctgtgatagataacagtattctttctcagctggaaaataaggagctaaatcaa3000
gaaattgcttctgaagctaatgaacattccttaaattcacaagaaatacctaaagaagat3060
aactatccaagagaagctttcacttctcctaaacaagacatcaaaaaggggctagctcaa3120
cgagtagaagagattgtggcagaagatgctactaagattttagtatcttccattcctcaa3180
gttcaagagaatttatcagtcgaaggaaacttggtcggtactccacaagcggataatcgg3240
atgctatacactaacctagaagattttggccaagattatcaattagagcttgcagtttat3300
agtccaaaacgggttgactttttagaagatgtgcaggctccgtggaccttggccctaatt3360
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
27/109
agaaaagaaa aaaagatagg ttatttagcg tatggtagtg attgggcaaa agaatttcag 3420
attgaagaag agetagaaca tttagctgca caaattggag acgaaaaagt accagaggga 3480
ctctataaac aagctgaagt agaggctttt atagctagtc atcagggaaa tgaaagcctt 3540
caggaaccaa tacctactat tgtagctgaa ecgtttgact ataccagtgc ctccgcctat 3600
gagatcagcg aacacgcttt ccaaaagatt cgtgagtaca cacaatcccc tgaggacttg 3660
cttgagtaca tggatttcat gagtaagttc ccacaacttt cacctcgaaa tgtcgctctt 3720
atccatgaac aatggcgtgg cgcaaatgca gtcgcaactt acgaacaatg gaaagccatg 3780
ggagaagctc taggtattaa accagacgat gttgtccaaa caaaagcaac ttatgttaat 3840
aagcggacag gagagacgaa ggaagtcgtt catcaagggt tatctgttaa gactggcgaa 3900
aaatcgaaaa ttacgctctt tagaccgcta atggttaaaa tgatcccagt tcttgatgag 3960
aatggtcaac agctgaaaa~. tg~taa.aggt a~.tcca.aagt ataagaagct atcagaagcg 4020
tcacttcaag agaaagcttt agtaaaagac ggtaaacttc cagttcgtca atttcaggag 4080
agagattcaa aaactggtca accaaggttt acgacttaca aagtttttga gttgtcacaa 4140
actactctga agccaggaag ctatcctaag gctatgccaa accgtcattt caactttaat 4200
gtggataaag tcaagactaa agaggtatta gaagggcttt gtgactatgc ggaaaagatt 4260
ggggttagcc taatgaaaga tgatgctcat gttttggata atgccaaagg agctttttat 4320
tcagaagaac agctgattct tattaatcct aataatacac ctggagaaaa aattgcaact 4380
accattcatg agttagcaca tgcaaccctt cataatccta agttggaaaa acagtataaa 4440
gagttgccga aaggacaaaa agaatttgaa gctgagatga ccagttactt gttgtcaaaa 4500
cactttggcc tagatacgtc tgaaaaggca atccattata tggcaagttg gacagataat 4560
ctaaaagcgt tagaggataa acaattggca gactctctga aacgagttca tcaaacggtt 4620
tcgaaaatgt tgaagcaagt tgaaaaatat acgaaccctc accagctagg aagggggaaa 4680
gaacacggtc taaattttcc taaagcccca accaaagggt ctagtcgtta a 4731
SeqID
64
atggatgtatcgtctagtccgaatattacatttatgctgcaatacacagaggctaatcct60
caatatgtggactatactaacagagaagaggctgtcaaaattgatgaagaattgtcctta120
gaaacgaacaggcaaatgattgaaggattaactgaagacgagttgactcgtattcaggaa180
gctgtcectgaaacgcagttgaattttagggaatacattgattatatgaaccgctcgtat240
gcaactgaagaacaatctaaagaactaacagctatctttactcaagaagcagattatctt300
cagaaactacgattaatcgatctaaaaaataagttggaatcagcttatcaaaatggttca360
cttctctggcaaggagttatttcgtttgataatgcttttcttgcggaacagggattgtat420
gatgttgcgactggtcaagttgatcaaaaagcgattaaggcagtgatgcgtgatatgatg480
ccaacacttatccagaaagagggcctttctgattctgctttttggtgggggaatatccat540
ctgaatacagataatatccatatecattttgggctttctgaagttgaatctaaccgtgag600
aaaatattctatcagccacgtggacgtatggagtacaaaggtaacttctctcagaaaacc660
atcaaccggtttaaaagtggtgtgtatcatggattgctgaaagaagaaacaagatccaat720
cttctcagaaaagaacagattttagctaatctcaaagcggacttcataacatctatttac780
cagaaggacaagattacttcttcagctgaaaaaaattttttggaacaagcctacaatcat840
ttgccgctaaataagaagtggcgctatggttctaatgccagagattttgcggttagtaag900
ttctttcttgatcgctatttagattectatttaaacaatgaaggtagtgctgcctatcaa960
gaatttttgaaagagactagagattttcttcagacttatgaaggggtttattcagctgaa1020
aaaaataaaatctatgaaaaactacgtaaagttgatgggcaaacgatcagaacgcttgca1080
gaatcaaaaggatatgatttagaacatcatttggcacgtcgtgtaatggatttaagagag1140
cgtttagccaataatatcttacgttcgtttagagaagctgcaccccaaattcaagacgtt1200
cagetggaaaaaaatttagagagtttttctgttttgaaccagaagaaaattttagaacaa1260
catcctgaagcaagtgtggtaaaaagtcagaaagcttggcagaagttaggctactttgtg1320
aaggctggagagcagccacttgaaattataaggccagtctataaatcttatgataagcat1380
ggtaaaggtataggacggccagaatttgtatcagatactgtttatgatattagtcagcta1440
acagaaaatattcagctgaaaagtctaaccttgaaagacctctctctgttttcttctaac1500
gagttaaaagagttagtagatgctgctaagttaaagactaatccaacagagagagaacgc1560
cgtgaattaggtacctatcgttatgcgttgaaacttagcatattagaatctagtcagaag1620
gaattgcaggttcgtcaaaagctactagaacaggtacagccactagcgtctgatcaacca1680
tttttagattttaagaaacagttaatagctcaggaattacaagctatagcgctacaattg1740
actcctaattacaagctatcagaagatgataaagccttgaaaaatcgattgaagaggcag1800
tttgaagatagtgttgcgctacctgtttcaaaagctactcctggtgccatacaacttcct1860
attaggcaactttggactgagctaggattggttcatcacattcaagatgaaaacattcta1920
acgcttctgaaagggacatcaacgacgaaacaagcttatatagaagaacttcagactcat1980
atctctatttttcagttgaaatatcagattaacaatagaaacaagcagataagccagtta2040
tcggatgaagcaacaataaaggagatgaggatagctaatgctaaaggtttctctgagcta2100
aaacgtctatatgatacattacagccatcagatgatggtcaaaatcagattagtcaagct2160
gtttctaaacaattacaagaacgaaaagttatcaaaaaagctcaattacaacagacgcag2220
agaagcggaaaaatcaatacagacttcatgcgacaattgacagcttctcttaatcgttca2280
caacaagcaagtaaaaaagcattgatggaacgtgcacgtagtgatgaacgtgaggaacaa2340
gaagaacgtaggcaagctcaacgttaa 2367
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
28/109
SeqID
65 60
atgaagaaga
ataaatttct
attagtcagc
attgtattta
tcatcatttt
tgtggtacag
ccacaaaatt 120
ttcaatcttt
aaaaaatata
tttactcaaa
atgatatagc
tagtcaattg
aatatatcaa agaaaaaaat 180
gttcacctga gatggcttag
gaacggccta
tcaaacgeaa
aatgaagatt aagttttgat 240
tgaaatctaa ggtcaacatc
aagtcatagt
ggttaatgaa
aaagcacaat agagttgagc 300
ttacggcaga atgagaaatg
gttcatggga
aaaatacgat
aacctagattttttaaatcgtgttggggtc 360
gcagaagcta
tgttaggaaa
agagttaatg
ccaaaagaggcacgtcaggacatttcttca 420
gtcaaaccaa
ctggctggaa
aaataaaaaa
attaccttcaatggaaagcaagattatctctataatcgtt tggatttcag480
ctcacttaat
ttaagtggtgagaatgccaatgtgaaaaatctctttacag ccttaatgca540
gaacacgtgc
aactttaacgatgataaatcgtccatggtgtactatgaaa aaactacatt600
atgaggtcgc
aagaaaacaaatcatcatgttcgttatcgagtgaccccacttttcaaaaatgtggagtta660
gtagctcgtggcgtacgtatagaagcacaaagtattgaagatgagaccatctcatttgat720
gtctatatttttaatgggcaaccaggatatgacattgattatttgacgggatcatctgaa780
aaaataatgattacaaaatga 801
SeqID
66
gtgactaaagaaattaaaattagatccattccagaaaaaacatgggcacagctacatatg60
atttcggaagaatatgagtatecgtcttttaatgaatttatgcttgctcaattgcaacgg120
attgtcgaaaatggtggtcttgatttatatgataataaatttgcggaaaccttggcagtt180
attaaagaacaacaagcacaaatattggatcagctcctaaaaaacgaaatcaagttactg240
gcttatcatgcaaagcaagatatagtggaagagctaacaaccgactggttacgatttatg300
gatgatgttgatgcgctggctgcggaaagaggagcaggaggacgttga 348
SeqID
67
ttgttatattattttatttacttgataaaagtaattggaaatggccttaaattatcactg60
atttgtggtttaaattggctcatcaaaatagtattcaaaggacaattttatcttttctca120
gctgtcttttgtggcttgttgacctactatatgccacaagatattcaattatttacagtg180
agagttttagagctaatcatcatgctaaaagtgataatagatgttacccatacagctctt240
tcaagagattttaaacggatgaaaacgcctctttttttaggagtgatgtacgtcttcttt300
ctagctggtaacagttatattaaagcacatcttttgacagaagttatggttaatcatctt360
atttcgttttggcttatcagcctgttttttgccactcttgtaatagttattcagcccaga420
ttatttaagcattatctgttaaaaaaagtcattgataaggaatacttgggtatccgaaaa480
ttcacagactctcttcctccagaaatcaatttgtacaaggatgcggacgaagaagatgcg540
gacaaacggatgcgactgatcaaccagaatgtcatcaaacacccctatcaagaagttgtt600
gaactgagctttttgaatagagaagtgataacagctattggctataaagccgttccattt660
gaaaaagaaactgaacgtacttttatagacgatgataccatctattatcccatttttacg720
gttcaccctttcagaaatttggaagggaaatcagatttttatcacatactaatgaaactt780
aaactcagtcgaaaagcggcctttacaaaaaatggtgagcgattattaattagagatttt840
taa 843
SeqID
68
atgattagaaatgaattttataatcagttaatcaatagtgagccaataggttttattgat60
cctttcactgacttaggagaatttgattctattcagatgaagttcaaacaacctgttaga120
aatctggtaaataagtactctggtaaaccttataatcttagttggcaaaataagattgaa180
cagatgagagtgctatatattaaatatcagaaaagcttgaagctagaagatgaagaacaa240
gaggttcataaccgagttaaaaataaaaagtctaaaaaatatgttcatgaaatcgttaca300
acatatttgaagttaggattcaggtttaaagaaattgaagcaagggtatccctattcaat360
actcgtcttcgtcggaactggaaaagaagcgactatgtgacaactgataaecctgaattc420
tatttgaagaaggatctacagaatggttattgttctccaaattcatttcttcctcggagt480
atgaaaataaactaa 495
SeqID
69
atgaacgaaatcaaatgccctcattgtggaacagcttttgccatcaacgagtctgaatac60
catcaattactagaacaaattcgtggagatgcttttgacaaagaagtaagtgaacggttg120
gaaaaagaacgtctaatattaggggagcaagcaaaaaatcaattacaggaagttgttgta180
gaaaaagacaaggagatagctaaacttcagtacaaagtcaaacaatttcttatagaaaaa240
gacaatcttctcaaagacaatgagtaccaactcgctgagcaattaaatcaaaaagacatg300
atgcttcgcgaccttgaaaaccaaatcgatagactacgtttagagcatgaaaatagcttg360
caagaggcgctaacaaaagtegaacgagaaagagatgcaatacaaaatcagttgcacatt420
caagaaaaagaaaaagatttagctttagcttcagtaaaaagtgattatgaagtacaacta480
aaggcagccaatgaacaagtagaattctataaaaacttcaaagctcaacagtctactaaa540
gcagtaggagaaagtttaga gaaacagaatttaataaagtgcgacatttg600
acattatgct
gcctttcctaatgcttattttgagaaggacaatacattatcaagtcgtggctcaaagggg660
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
29/109
gactttatctategagaaaaggatgaaaat ttttaagtatcatgtttgaa720
gaccttgagt
atgaaaaatgagtctgatgatactatcaag atgaagattttttcaaagaa780
aagcataaaa
ttagataaagategtcgtgaaaaatcttgc ttttagtaactatgcttgaa840
gaatacgcag
gcagacaatgactattataatactggaatt gtcacaaataccctaaaatg900
gttgatgtta
tacgttatacgtccacaattttttatccaattaattggtattctaagaaatgcagcactc960
aataccttaaaatataaacaagagcttgctttgatgaaagaacaaaatattgacatcaca1020
cattttgaagaagatttagatattttcaaaaatgcatttgctaaaaattataattctgca1080
agcaaaaatttccagaaagcaatcgatgaaatagataaatctattaaacgtatggaagct1140
gttaaggctgctttaacaacgtctgaaaatcaactacgtcttgcaaataataaattagac1200
gatgtttctgtcaagaaattaacaagaaaaaatccaacaatgaaagcaaaattcgatgct1260
ctaaaagactas 1272
SeqID
70
atgaatcattttgaactatttaagcttaaaaaagetggactaacaaatcttaatatcaac60
aatattatcaactatctcaaaaagaatagtttaacttctctatctgttcgcaatatggcc120
gtagtatcaaaatgtaaaaatcctactttctttatagaaaattataaacagctagacctt180
aaaaaacttcgacaagaattcaaaaaatttccagttctatcgattttggattctaactat240
cctttagagttaaaagaaatatataatCCaCCagttCtaCttttttatcagggtaatatt300
gaacttctatctaaacctaaattagctgtagtgggggcaagacaggcatctcagataggt360
tgtcagtctgttaaaaagattatcaaggagaetaacaatcaatttgttatcgtaagtggt420
ttagcgcgtggcattgatacagcagcacatgttagtgctttaaaaaatggeggcagtagt480
atagctgttatcgggagtggtttagatgtttattatccaacggagaataagaaacttcaa540
gaatatatgtcatataatcatctcgtattatcagaatattttaccggagaacaacccttg600
aaatttcatttccccgaacgtaaccgtattattgcagggctgtgtcaaggtattgtggtt660
gccgaagctaagatgagatctggaagtttaattacctgtgaaagagcattagaagaggga720
cgagaagtttttgccattcccggaaatattatcgatggcaaatcagatggatgccaccat780
cttatccaagaaggagctaaatgcattatttcaggaaaagatatcctttctgaatatcag840
tag 843
SeqID
71
atgactgaacgaacattcgaagatattgaaettgacttaaagttattccaaataaagctt60
gataatgctgagaatagtaaaaggctcttacaaaaattgaaaaacgacgtcatggagtta120
caaatagagttactagaatcattaaaactcggtgatgcctatttaacagaatcagaagaa180
ttagaagagaataatgactttattctaacggtaaatagtgaaacactaagtttatcctat240
gacaataggataaacttagtttctaaagagattatggattatgaaaatgcattagataag300
ttgtattatgaaaaacagagtttgatgcaaaaaagtaatgaaagaaaaggaggttaa 357
SeqID
72
ttgttcaataaaataggttttagaacttggaaatcaggaaagctttggctttatatggga60
gtgctaggatcaactattattttaggatcaagtcctgtatctgctatggatagtgttgga120
aatcaaagtcagggcaatgttttagagcgtcgtcaacgtgatgcagaaaacagaagccaa180
ggcaatgttctagagcgtcgtcaacgcgatgcagaaaacagaagccaaggtaatgttcta240
gagcgtcgtcaacgtgatgcagaaaacagaagccaaggtaatgttctagagcgtcgtcaa300
cgtgatgcagaaaacagaagccaaggtaatgttctagagcgtcgtcaacgcgatgttgag360
aataagagccaaggcaatgttttagagcgtcgtcaacgtgatgcggaaaacaagagccaa420
ggcaatgttttagagcgtcgtcaacgtgatgcagaaaacagaagccaaggcaatgtttta480
gagcgtcgtcaacgcgatgttgagaataagagccaaggcaatgttttagagcgtcgtcaa540
cgtgatgcagaaaacagaagccaaggtaatgttctagagcgtcgtcaacgcgatgttgag600
aataagagccaaggtaatgttctagagegtcgtcaacgcgatgttgagaataagagccaa660
ggcaatgttttagagcgtcgtcaacgtgatgcagaaaacagaagecaaggtaatgttcta720
gagcgtcgtcaacgcgatgttgagaataagagccaaggtaatgttctagagcgtcgtcaa780
cgcgatgttgagaataagagccaaggcaatgttttagagcgtcgtcaacgtgatgcagaa840
aacagaagccaaggcaatgttctagagcgtcgtcaacgcgatgcagaaaacagaagccaa900
ggtaatgttctagagcgtcgtcaacgtgatgcggaaaacaagagccaagtaggtcaactt960
atagggaaaaatccacttctttcaaagtcaattatatctagagaaaataatcactctagt1020
caaggtgactctaacaaacagtcattctctaaaaaagtatctcaggttactaatgtagct1080
aatagacegatgttaactaataattctagaacaatttcagtgataaataaattacctaaa1140
acaggtgatgatcaaaatgtcatttttaaacttgtaggttttggtttaattttgttaaca1200
agtcgctgcggtttgagacgcaatgaaaattaa 1233
SeqID
73
atgaaaagactaacttattattttaaggggtatatcaaagaaactatctttggacccett60
ttcaaattattagaagcctcttttgaacttttggtaccaatcgttattgcaaaaatgatt120
gacgagaccattccacgaggggatagaagtagtttactgttgcaaattggattgattttc180
tttttggctgcggtgggtgttgtagtagegataactgctcaatattattcttcaaaagcc240
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
30/109
gcagttggttatacgagacaattgacagaggatctctaccaaaaagtcatgtcactgggg300
aaaaaagacagagatgaattgggaactgctagtttgattactcgtttaactgctgataca360
tttcaaatccaaactggtttaaatcaatttttacgtttatttttgagggctccgattatt420
gtttttggtgccataattatggctttttccattagcccctcattgactatttggttcttg480
gtaatggttgtcacgttatttatcattgtttttgtaatgtctcgactattaaatcctatt540
taccttaaaatcagaacttcaaccgattatttggtaaagttgactaggcaacaacttcaa600
ggtgtacgagttatccgtgcctttaatcaagtagatagagagagtgaagcatttaatgat660
atcaattatcattatacgaatttacaattaaaagcaggtaggctttctagtttagtaacg720
cctctaacatttctagttgttaatatcactttggttgtgattatttggcgtggtaattta780
aatatagctaatcatcttttatcacaaggaatgttggttgctttaattaattacttattg840
caaattcttgttgaattgttaaaaatgacaatgttggtgacatcactgaaccaaagttat900
atcagtgctaagcgaattatagccgtttttgaaagaccgtctgaaataattgatgacaaa960
cttgagccaaaatattcgaataaggctttagaagtacaagaaatggcattttcttatcca1020
aattcttctgaaaaagctttatctgatattactttttctatgaatgtaggagaaacttta1080
gggataattggtggaactggctctgggaaatcaaccttggttaatttactgcttcatatt1140
tataaagtgcaagaaggggatattgatatatatcatcagggaaaaagtccagatacaatt1200
tcaaattggcgtaccctggtaagagttgttcctcaaaatgctcagttgtttaaaggaact1260
attcgttctaacctttctttgggacttggtaaagttagtgaggaaaaactttggactgct1320
ttagaaatagcacaagctagtgattttgtaaaagaaaaagatggtcaacttgatgcccct1380
gtagagagttttggtagaaatttctctggtggtcaaaggcaaaggttgacgattgcaaga1440
gctttagttcaagataagataccatttttgattttagacgatgcaacatctgcattggat1500
tatttaacagaagctcgtttatttaaagccataactaaacatttcaaccaaactaatett1560
attattgtatcacagagaattaatagtatacaaaatgcagatagaatcttactccttgat1620
aaggggaaacaagttggttttgataatcatcaatctttattagctcataacaaagtttat1680
aagtccatttaccattcacaaaattttaaggaggaggagtas 1722
SeqID
74
atgaaatttaatgagcaaagtaactcgcaagcagcacttctaggcttgcaacacctgtta60
gctatgtatgcaggatccattcttgtacctatcatgattgctagtgctcttggttataat120
gctgagcaactaacttatcttattgcgacagatatttttatgtgtgggattgccacctta180
ttacaattacaattaagtaagcactttggagtgggtcttccagttgtattagggtgtgcc240
tttcagtctgtagctcctttatcaattattggtgcacaacaaggttccggctatatgttt300
ggagctttaattgcttcaggaatatatgtcgttttagttgctggcattttttctaaagtt360
gcaaatttctttcctccaattgtaacaggatcagttattaetacaattggtttgacatta420
ataccagttgcgatgggaaatatgggtgataatgcaaaagaaccgagcttacaatcttta480
actttatcactggtaacgattggtgttgttttattaattaatattttcgcaaaaggcttt540
ttgaagtcaatttcaatccttattggactcatatcaggtacaattcttgcagcatttatg600
ggcttagttgatgcttctgtggtagcagaagcaccacttgtacatattccgaagccattt660
tattttggagctcctagatttgaatttacttctattttaatgatgtgtattattgcaaca720
gtttctatggtagaatcaacaggtgtttaccttgcgctttcagatattacaaacgataaa780
ttagacagtaagagacttcgtaatggttaccgttcagaaggattggcagtattacttggc840
ggcttatttaatacctttccatataccggtttttctcaaaatgtgggactggtacagata900
tctgggatacgtacgcgtaagccgatatattttacagctctcttcttagttatacttggc960
ttgttacctaaatttggcgcaatggctcaaatgattccaagtccagttcttggtggtgct1020
atgttagttttatttggtatggtagcacttcaagggatgaaaatgcttaatcaggttgat1080
tttgagcataatgagcataactttatcattgcagccgtatcaattgcagcaggagtaggt1140
tttaatgggacaaatctcttcattagtcttcctaatactttacaaatgtttttgacaaat1200
ggtattgttatctcaaccetgacagctgttgttttaaatatcattttgaatggattgcct1260
aaaaaattaatatga 1275
SeqID
75
atggctaatacatacgatttaatttcacagcgtattgaagcacaacgacagaaactcatc60
gctatagatattgtggccgttgcgagctcactaggacttaacttgaaacaaggttcaggt120
ggacatctctattgggatgaacatgatagttttcatatttacccccaaactaacaccttt180
cgttggtggtcaagaagcatggggaccaataccattgatttagtccaagtcatccaagaa240
gagctaacaggaaagaaacctagctttcgagaaactgtcaactttttagaaacagggcaa300
tttgaatcggttacggtaacaccagtcgttagagaaccctttaagcactacctcgctcct360
tatgaacatcacaattttgacttagggcgacagtatcttaaagaagaacgagggctatet420
gatgagaccattgattttgctttggcatcaggtagtatgagctctgcgacattgaaaaag480
ggtgattattttgaacctgttattatctttaaaagttttgcggaagacggecgaatgatc540
ggcggtagccttcaggggatcgttgaaaataaagtccagcatcctgaacgtggccgtctc600
aaacaaatcatgaagcattcagacggtctagcaggttttcatttggacgttggaacacct660
aaacgtctcgtgttttcggaagctcctattgaccttctctcttattatgaattacataag720
gagagtttacagaatgtccgcttagtcgctatggatggggtcaaaaaaggggtgattagt780
cgctatacggctgatttattgacagatggccagtattctcaaaccatgcccagagagtcg840
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
31/109
attagaggag cgatagatgc cattaaccaa acgactagaa tccttaaaaa caatcccaat 900
atgattacca ttgccgttga taatgacgag gcaggccgaa actttattaa ggagttacag 960
gaagatggca ttccaattaa cgtagacctc ccaccacgga aagaacacca gagtaaaatg 1020
gattggaata attatctgaa acaaaagaaa ggattactaa aaatgccaca aacagaaggc 1080
acacaaaaag ccccagaaca agttctggag catgaaaaaa tggataggag ccaaattagt 1140
tcgggctctt tagaggacga ccctcaaggc agtgccaaac ctgtatccaa aagggatacc 1200
tttgagcaag ctgttaccag ccacccgact ttctcctatc ctttactaca gtttagcaca 1260
gaagaagcct ttgtgtcaaa cgttagagat ggctaccaca tcgcaagtga ggaggatatt 1320
cggaatctca attactatgc ccctagtctC Caacaaacgg ctaactggta tcgggataat 1380
ctggcagacc gtcaagtgac ttatatgtta aaaggggata aggagataaa ggCgcttcag 1440
gtcagttttg ccaaggata.a gtttgccca.c ttaa.ccggta ttcgtccgat tggaaaaggg 1500
ttgtcagctg aaaaactgtt agatgatttt gcgaaaggtc gaggttccta tcctaatctg 1560
accttatcaa atggttttaa tgacaagata caagttttgc caatgattca agaactatct 1620
caatccaagt cttttgtctt tacagattta gaggaagttc aaaaaatgag aaacttaaag 1680
gccagtcatg cgattcaatc caataatcgg agtttagtcg tcgctttaaa aactattgat 1740
gatgtcacct ttccttcgtc cctcctaaga ggaaaaaaga atctaaatga tgatctgatt 1800
caaaaggcga aagaaaatga agttctaggt gtactcagtg agaaagatgg gaacatcacg 1860
gtgctgtccg ttaacgataa gtacatccaa gatggtgggc aagccttaaa agatatgatt 1920
aaaaatggcg aacttgaacc actccaaatg gagacgatac agcgacatgt tcctcatgag 1980
aatgcctatc ctaaggattc tgacggtgat ggcttaaccg atgatgaaga aatcgctcta 2040
ggcaccaatc cctttagttc tgatagtgat ggtgatggga ctccagataa tgtcgaaaag 2100
gcaaatggaa cagaccccac caatgcttct gataatgagg tgacaaggca acaagaagcc 2160
aataaacgtg acttcacttt gtcagaaatg attaaagcca aaaataccgc agcgctgaat 2220
caacacttac aagacggcat caaacagtat tttgatagtg atacctataa gcaatacetg 2280
gaagggatgg cccacttcaa taactactcg ccacgaaata ttcaattgat tatgtcacaa 2340
tttccagaag catcgatggt tgcgtctttc caagagtgga ggaagcgaaa tggttcggtt 2400
aaaaaaggtg agaaggccat ctatatccaa gcccctgttt ctgttatgaa aaaagatgag 2460
aatgggaaac ctatccttaa tcctgaaacg ggagaaaagg agaccatcac ttactttaaa 2520
cctgtccctg tctttgacat taaacaggtc tctccccaag aaggaaaaga actcaatctc 2580
cctaaagcca tgggaactat tccagaacaa ttggataaag aatactacca aaatgtctat 2640
cgtagcttaa gagatatttc tcagaataac aataaggttc ccattcgatt tagagaactt 2700
ggacaagaag atgggttcta tagtccacag acaaatgaaa ttgttattaa gaaagggatg 2760
tcttatgaac gaacettgte aacgctgatt catgaaatgg ctcattcgga attacacaac 2820
aaacaaagtt tgacggaacg etttgatggt aaactaacaa gaagtaccaa agaacttcaa 2880
gcggaatcca ttgcttatgt tgtatccagt catctaggtt ttgataccag tcaagagtca 2940
tttccttatt tagcgtcttg gtcaaaagaa aaagacgggc ttgccaactt aacagcacaa 3000
ttggaaatcg tgcaagaaga agccaaaaac ttaatggaac ggattgatca acagttaagt 3060
caatatcaaa cagtaacact gaataaagaa acccaacaat tgactaaaca agaaatgaaa 3120
aagcagactc atccctttta tcaaagttta gcagccgcta aaacatcaag agcacaagtc 3180
accactcagg agaaggaagc aagcgtaaaa aaagacaatc gacctacgat gccgtag 3237
SeqID
76
atgaattcacaagaaacaaaaggtcacggattttttagaaaatcaaaagcatatggttta60
gtatgtgggattgcactagcaggtgcatttacattagctactagtcaagtgtctgctgat120
caagttacaactcaagcaacaactcaaacagtaacgcaaaatcaagcagaaacagtaaca180
tcaactcaacttgataaagcagtagatacagctaaaaaagcagctgtagctgttacaacc240
acaacagcagttaatcatgcgacaactactgatgcacaagctgatttagctaatcaaaca300
caagctgttaaagatgttactgcaaaagcacaagctaatacacaagctattaaagatgct360
actgctgaaaatgcaaaaattgatgctgaaaacaaagcagaggcagagcgtgttgcaaaa420
gctaataaagcaggtcaagcagaagtagatgctcgtaataaagcaggtcaagcagccgtt480
gatgcacgtaataaagcaaaacagcaagcgcaagacgatcaaaaagcaaaaattgatgct540
gaaaacaaagcagagtctcaacgtgtaagtcagttaaatgcacaaaataaagcaaaaatt600
gacgcagaaaataaagatgcgcaagctaaagcagatgegaataatgcacaattacaaaaa660
gactatcaaacaaagttagcaaacattaaatctgttgaagcttataatgcaggtgtacgt720
caacgtaataaagatgcacaagctaaagcagatgcgactaacgcacagttacaaaaagac780
tatcaagctaaattagcactttataatcaagctctaaaagctaaagcagaagcagataaa840
cagtetattaataatgttgcttttgacattaaagcccaagctaaaggtgttgataacgct900
gaatatggaaactcaatcatgactgcaaaaactaaacctgacggaagtttcgagtttaac960
cacgatatgatcgatggtgtgaagacaatcggctatggtaagcttacaggtaaagttaat1020
catcattatgttgctaacaaggatggctctgtgacagcatttgttgattctgtcactctt1080
tacaagtacgagtatcgtaatgttgctcaaaatgctgctgttaaccaaaatattgtattt1140
agagttttaacaaaagatggtcgtcctatttttgaaaaagetcataatggtaacaaaact1200
tttgcagaaactttaaacaaaactttacaactcaatcttaaatatgagcttaaaccacat1260
gcttccagcggtaacgtcgaagtctttaagattcatgatgactgggtacatgacacacat1320
gggtctgctttagtgtcttatgttaataataatgatgctgttcctaatgtggtcatccca1380
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
32/109
gaacagccaa ctccaccaaa accagaaaaa gttacacctg aagcagaaaa accagtacct 1440
gaaaagccag ttgagcctaa attggtaacg cctgttttaa aaacttatac tccagtcaaa 1500
tttattccgc gagaatacaa accagtccca agtacccctg agacgtttac ccctgagaaa 1560
tttactccag ctcaaccaaa agtgaaacct catgtgtctg tacctgaaaa aattaactat 1620
aaagtagcgg tgcatccagt acagatacca aaggccacac caactaagaa agttctagat 1680
gaaaacgggc aatctattaa cggtaaatct gtattaccaa atgcaacatt agactatgtt 1740
gctaaacaaa actttagtca atacaaaggt attaaagctt ctgcagaagc tatcgcaaaa 1800
ggttttgcat ttgtagatca accaaatgaa gcgttagctg aattgactgt taagtctatc 1860
aaagcatcta atggtgatga tgtatcaagc ttgttagaaa tgegtcatgt tttatcaaaa 1920
gatactttag accaaaaact tcaatctctt attaaagagg caggaattag tccagttggt 1980
gagttttaca tgtggactgc aaaagatcca caagcttttt ataaagctta tgttcaaaaa 2040
ggtctagata ttacttataa cttateattt aaagttaaaa aagagtttac taaaggtcaa 2100
atcaaaaatg gtgttgcaca gattgatttt gggaatggat atacaggtaa tattgtagtc 2160
aatgatttga caactccaga agtccataaa gacgtgttag acaaagaaga cggcaagtct 222~
attaacaatg gtactgtcaa actcggtgac gaagtcactt acaagcttga aggatgggtt 2280
gtaccagcga accgtggtta egatcttttt gaatacaaat ttgtagatca cttacaacac 2340
acacacgatc tttacctaaa agataaagta gtcgctaaag tagcaattac acttaaagat 2400
ggcactgtaa ttccaaaagg gacaaatcta gttcaatata ctgagactgt ctataataag 2460
gaaacaggtc gctatgagtt agcctttaag gcagacttcc tcgcacaagt ttcacgttct 2520
agtgcctttg gggcagatga ctttattgta gttaaacgta tcaaagcggg tgatgtttac 2580
aataccgcag acttctttgt caatggcaat aaggtaaaaa ctgaaactgt ggtaacacat 2640
actcctgaga aaccaaaacc agttatgccg caaaaagtaa ctcctaaagc accagcttta 2700
ccatccacag gagagcaagg ggtatctgtc ctaacagtac ttggtgccgc cttactetca 2760
ctcttaggcc ttgtagggtt taaaaagcgt caacagtaa 2799
SeqID 77
atgaatcaga taaaaattat cacaggactt acagtcgcaa cactatccgc agtggtaggg 60
aatgtatacg cagaagatat cacaccgaca gcaccagtta atgaaccaca agtatcaagc 120
gaaaccgcaa aaacgcctca agttacagaa agtcaagtta acagcgcaaa agttactgcc 180
gatcaagcaa caagtgatgt taatgcacaa aaaaatgtag ttaataatgc tcaaaatcaa 240
aaaaatcaag cacaacaaaa acttgttaac gcaactacaa cgttaaatga aacacaaaaa 300
ttagtgcaag aatctaccaa tcaaaatcaa gtacaacaaa cagttgattc cgcaaagcaa 360
aggttgtcgc agacagaagc taatcaaaaa attactcaaa ctgaacaagt caaagctcaa 420
aatcaagtta atgcacaaca aacagttgtt gttaacaatg agcatgatgt tgcaactaag 480
acagctgatg ttaaacaagc tcaagcatca gtcgatacag ctaaagatgc tttgactaat 540
actatagtta atagtgattt aaataaagca cagtcaaacg tcacaactaa gacagctgat 600
gttaaaactg cgacagatgc acttacaaaa gcacaagcga ctgataaaac acttactaat 660
caaaaagcaa aagcacaaca aatagttgat tcagcaaaac aaaacttatc tgctaaagat 720
acacagcttt cacaagctaa tgctgaggtc aatcatcaca agtttaaaac ggctctaggg 780
caaagtcatt attacaatca acgtgataat gcttgggctg gggtatatgg agggcataca 840
tttgcttcaa ctggatgtgt cccatcagca ttagcaatgg tttactctga tttatcaaat 900
cggacaataa cgcegagaga gatagctgat tacttataca acaacacaga tgaattcaat 960
aaacgtttcg gtggcacaag tgggaaaggt attatttctg ctactaaagc gtttggttat 1020
gttgtgactc atttggctag caaaaatgct ataactgaag cattaaaagc aggtcatcat 1080
gttgttgctg ctgtacaaaa taataaattc agtccctggg ggcctcaata cagtcacgaa 1140
attgtattga gaggtagttc taatggcaat acgtatgttt atgatccgta taaccgtgat 1200
aacaatggtt tttacagtgt tgaccgcatt tggaatgaac agtcacgaga tagtattgat 1260
actgctggtg taggtgtacc gtttttegca attatgacta aaaatatggc taatgcttta 1320
actaagcagt cacaagcttt agcaagccaa caagttgctc aaaaacaatt aaatgatgca 1380
caagctaaag caacaggtct taatgcagta actatgcaga caccgattgc acaagctaat 1440
ttgattaaag cacagtcaaa tttaaaagat gctcaaaagc gattagcaga agcacaagca 1500
tcagtcaaat tagctaatca agataatgtt aaaaaacaag ctgacttaac aaaagcagag 1560
tctaaattaa aagatgctca aaagcaatta gcagcagcac aagctaaatt gacaacaagc 1620
aaaacaaaac ttaatcaatt aaaacaagtg ttagcagaag caagtcaaca agtagcccaa 1680
gcaaatcaag attacaagca agctaaagat aatctaacac aaaaaactgc ttatctaaca 1740
aatctacgca atgcacaagc taatttgatt aaagcacagt ctgatgtagc acaagctaaa 1800
gataacttag caaataagat tgctaagtta caaagagaag tagcttattt acaagagtta 1860
aaaactaaag cagtagatgc gcaatcacag tatcaaaaag ttttatcagc ttataagtca 1920
gttttatcag ctaaagcaag tttaaaatta gcggaagaga aagctcgact tgataaaaag 1980
ggtcacgaag cagtagcagt agttgacgaa acaggtaaaa ttactagcta tattacttct 2040
aaacacaaaa tagaaatgaa atctcttgtt gcaactaaga caactgatgt taaacaagta 2100
tcagttgcta aagcaagcgt gttgccaagt actggtgatg ttaaacaagt atcagttgct 2160
cttctgggta tgttattaac gttctctggt tttttaggta tacgtaaaca aagtaaaaaa 2220
gttattaatt as 2232
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
33/109
SeqID
78 '
atgatatcacgtaaagttgcgcttgtgacg ctggttttgg 60
ggggcatetg tgcagctatt
gttactaaattagtttcagatggttatagc gtgctegtcg 120
gttattggtt aatggataaa
ttaaaatgctttggagaaaagttttcagag atccacttca 180
ggttactttt aatggatatt
acaagtagagaatcggttgacaaagcttta ctaaaaattt 240
gaaagtctgc gcaatcaatt
gatttgttggttaataatgcaggtttagcacttggattggataaatcatatgaagctgat300
tttgaagattggatgactatgattaatactaacgttgtaggattaatttacttgacacga360
tgcattttaccgaaaatggtagaagttaatagagggttaattatcaatttgggatcaact420
gcaggaacaattecttatecaggagctaatgtctatggegcatcaaaagcttttgtaaaa480
CaattttCtCtCaaCttgCgtgCCgatttagCtggaaCtaaaatc~g~.~'ttaCtaaCCta540
gaacceggtttatgtgaagggacagaattttcaactgtacgtttc~.a~.ggagatcataaa600
agagttgaaaaactttatgaaggtgegcatgcaattcaageagaggatattgctaatacc660
gtgtcatgggttgctagccaaccagaacacattaatattaatcgcatagaaataatgcca720
gtcagtcaaacttatggacctcaacctgtttatcgtgattas 762
SeqID
79
atgatttatttagaeaatgctgctactaccgctetaaceccatctgttattgagaaaatg60
accaatgtcatgacaagtaaetatggtaatccatctagtatacatacctttgggcgtcaa120
gcaaatcaacttttacgtgaatgtcgacaaattattgctgaatatctaaatgttaattca180
cgtgaaattattttcacttctgggggaactgagagcaacaatacagctatcaaagggtat240
gctettgcaaatcagctaaaaggtaaacatattattacctctgaaattgaacatcattca300
gtcctacatactatgacttaettatcagagcgatttggttttgatattacttacttaaaa360
ccaaaccatggacaaattactgcaaaagacgttcaagaagctttacgagatgatactatt420
atggtatctctcatgtttgctaataatgaaaccggggactttttaccaattcaagagatt480
ggtcagettctcaggaaccaccaagctgtttttcacgttgatgccgttcaagtctttagc540
aaaatggaacttgatcctcattctttaggaattgactttttagctgcttctgcccataaa600
tttcacggtccaaaaggtgttgggatactttactgtgctccccatcactttgatagtcta660
cttcatggtggagaccaagaggaaaaaaggcgtgettcaactgaaaatataattggtatt720
gctggaatgtctcaagctcttactgatgctacgactaacacccttaaaaattggactcac780
attagtcagctgagaacgacctttttagatgctatttcagaccttgacttctatcttaat840
aacggtcaagactgettacctcatgtacttaatataggttttcetagacagaataatggc900
ttgttattgacacagttagatttagctggattcgcagtttcaacaggttctgcatgtact960
gcaggaacagtcgaacctagtcatgtcttaacaagcttgtatggagccaactcaccacgt1020
ctaaatgaatcaatacgtattagtttttcagaactaaatacccaagaagaaattcttgaa1080
ttagctaaaaccttaagaaaaattataggagattaa 1116
SeqID
80
atgtctaggaaaacatttaaacatatactatcgattggagtttgcacgctcgtactatcg60
atgagtctttattacactgaaaaagcccacgctattgctggtcctagtgacegccaatac120
gtagaaaacccaaatcctcacattattgtaaatgttacaggtactgatcaaaacggaaat180
agcattttaccgcattacategaagtcaatgtaaagatgggacaaactttaagtaaagaa240
gaaattctagattatattgctcgaaatttaaactctagtgttggaggagaaagtaaaaac300
gttcaatacagcaacatcgagtttaaggaaagtgcttatctgaagcgtcaattagatgat360
ggcaagacagaagaaatagcaattgataacgacggtgttactgtacctaaagacggtcca420
aacaaattttggattgacgttccagtaacttgtactgttaetcctatcgtaacagaaaca480
catgaagttcgatgggggactccagtcgctatatcacaccgtatttactttgttgaagaa540
tcttctggaaaagttttagatgaatacacaaatctacacactgctgattcggaacttaac600
ggttatcgtgttggagattatatcacagactatgcactttctaagtctgcttacgaagct660
tttttaaactctcgtttagataaagaaggttacaaacttcaacatcgtattagcacgaat720
gtacgacaaaaccttcaaattgataaattgattttcaattatgactttaatgaggaaaat780
atttactaccaaatcgggaatatecgtccactattaagtcgctcatcagctgaagtagaa840
tctgacatcattacagaacgctactatgtttctaaaaatgctaaaagtttagcacgtaca900
gaatcaaccatttcgattaaaatggttgatgccaaaactgaacaaccgctatttaaccac960
acattaactggttatcaattggcaactgtctcccatgtctataacagactctttgaagaa1020
aatcttatcccaactacaaaatcaggagaaagatattttattcaaaatatgaaaaaaaca1080
getgaacaagaatatactgtttacctttcagaaacaccttattctaaagagaacgctecc1140
gtaatttcttatgatgcaagacctgttgattgggattatcactcaggcgcttcaggatca1200
cttgaaaatcagcctaacatctatactgaagaagattcaactgaatttttgggtaataaa1260
ccacaagcagcttgttatccaaacaaacaatttgcttgcgaaaatactgactctaaatac1320
aactatagetatttagaaaaatag 1344
SeqID
81
atgaatcctttaataattggaatgaatgataaacaagcagaagcggtacaaacgacagac60
ggaccgcttttgattatggcaggagctggctctggaaaaacacgtgttctgactcatcgt120
attgcttatttaatagatga aatccttggaatattttagcgattactttt180
aaaatatgtt
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
34/109
actaataaagcagcgcgtgaaatgcgtgaacgtgctatcgccttgaatccagctacccaa240
gatactttgattgcaacttttcatagtatgtgtgttcgtattttacgtcgtgaagctgat300
tatattggatataatcgtaactttacaatcgttgatccaggtgagcagcgtactttaatg360
aagcgaatcattaagcaattaaatttggacacaaaaaagtggaatgaacgttcaatttta420
ggtacaatctctaatgctaaaaatgaccttcttgatgaaattgcatatgagaagcaagcc480
ggagatatgtatacacaggtaattgctaaatgctataaagcttatcaagaggaattacgt540
agaagtgaggccatggatttcgatgacttgattatgatgacacttcgattatttgatcag600
aataaagatgttttggcctattaccaacagaggtatcaatatatccatgtagacgagtat660
caagatactaaccaegctcaataccaattagttaagttattagcttcgcgtttcaaaaat720
atttgtgttgttggtgatgccgatcaatccatttacggatggcgtggagctgatatgcaa780
aatattcttgattttgaa.aaggactatccgcaagccaaagttgtattattagaagaaaat840
tatcgatcgactaagaaaatacttcaagctgctaataatgtgattaatcataataaaaat900
cgccgtcccaaaaaattatggactcaaaatgatgaaggtgagcaaattgtatatcataga960
gctaacaatgagcaagaagaagccgtttttgtagcatcaactattgataacatcgttcga1020
gaacaaggaaaaaatttcaaagattttgccgttctttatcgtacgaatgcgcaatctcgt1080
actattgaggaagcacttttaaaatccaatattccatatacaatggttggtggaacaaaa1140
ttctatagtcgtaaagaaattcgagatgttattgcttatctcaatatccttgcaaatact1200
tctgataatatttcttttgagcggattgtaaatgaacctaaaagaggggttgggccaggc1260
actttagaaaaaatacggtcatttgcctatgaacagaacatgtctcttcttgatgcctct1320
tcaaatgtcatgatgtcgcccttaaaagggaaggctgctcaagctgtttgggatttagct1380
aatctgattttgactctacgtagtaagctagatagtttaactgtaacggagattacagaa1440
aacctactggataagacaggatatctagaagcacttcaagttcaaaatacattagaaagt1500
caagcgcgtattgaaaatattgaagaattcttgtcagtgactaaaaattttgacgataac1560
cctgagattacagtagagggtgaaactggtttagatcgtctatcgcgttttttaaatgat1620
ttagctttaatagcagatactgatgatagcgccactgaaacggctgaggtcactttaatg1680
acattacatgctgccaagggtctagaatttccagttgttttcttaatcggtatggaagaa1740
ggagtatttcctttatcgcgtgcaatagaggatgctgatgaattagaagaagagcgtcgt1800
ttagcttatgtcgggattacgagagcagaacaaatacttttccttaccaatgctaatacc1860
cgtactttatttggtaaaactagttataatagaccaacccgttttatacgtgagattgat1920
gatgagctgatacaacatcaagggttggctcgaccagttaattcttcatttggtgtgaaa1980
tattcaaaagaacagcctacacaatttggtcaaggaatgagtcttcaacaagcgcttcag2040
gcacgtaaaagtaattcacaacctcaagtaactgcccaactccaggctcttaacgcgaac2100
aatagccatgagacatcatgggagattggtgatgttgcaactcataaaaaatggggggac2160
ggtacggtgcttgaagtttcaggtagcggaaagactcaagagttaaaaataaattttcca2220
ggtattgggttaaagaaattattagcgagtgtcgctcctattagtaaaaaggaaaactaa2280
SeqID 82
atgaaattatacgttcaattaatggttattttaaccttttcattcgctggtgaggttcta60
tctactatattcaacttacctgtaccaggtagtattattggattaatattactattccta120
gcgttaaaatacaaaatcatcaggctcaggcatattgatgccgtggggaattttctatta180
gcaaatatgaccattttatttttaccaccagcagttggactgatggagcactttcaagac240
ataaaaccctatctttttgggatagctatcattatcttaggagcgctatttctcaatatt300
ctaactattggactggtatcccaatggatcaaaaagagatatgaaggagattatccagaa360
attggaggtaaaaatggcaactttaacgaataa 393
SeqID 83
atgatttttgtcacagtggggacacatgaacagcagttcaacegtcttattaaagaagtt60
gatagattaaaagggacaggtgctattgatcaagaagtgttcattcaaacgggttactca120
gactttgaacctcagaattgtcagtggtcaaaatttetctcatatgatgatatgaactct180
tacatgaaagaagctgagattgttatcacacatggcggtccagcgacgtttatgtcagtt240
atttctttagggaaattaccagtcgttgttcctaggagaaagcagtttggtgaacatatc300
aatgatcatcaaatacaattttttaaaaaaattgcccacctgtatcccttggcttggatt360
gaagatgtagatggacttgcggaagtgttgaaaaggaatatagctacagaaaaatatcag420
ggaaataatgatatgttttgtcataaattagaaaaaattataggtgaaatatga 474
SeqID
84
atggtgatgaaaatcatagagttaaaagaagcaaccgtacaagtcagtaatggtttagca60
gaaatgaaaacgatattagaccatgttaatttgagtatttatgaacatgacttcattaca120
atattgggtggaaatggagctggaaaatcaacgctttttaatgtaattgcaggtaccttg180
atgttaagcggtggaaatatttacatcatgggacaagatgttactaatttaccagcagaa240
aaacgagctaaatatttatcacgggtatttcaagatccgaaaatgggaacagcacctagg300
atgacagttgctgaaaatttattagttgctaaatttcgaggtgaaaagagaccgttagtt360
cctagaaagattactaactataccgaagaatttcaaaaattgattgctagaactggtaat420
ggacttgatcgccatttagagacacctacaggtttattatcaggtggacaaagacaagca480
cttagtttattaatggcaactttgaaaaaaccaaatctgttattattggacgaacacaca540
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
35/109
gcagegcttg atcctagaac aagtgtttcg cttatgggct tgactgatga gtttatcaaa 600
caagattcgt tgactgcctt aatgattaca catcatatgg aagatgctct caaatatgga 660
aatcgtatat tagtaatgaa agatggcaag attgtcagag atttaaatca ggcacaaaaa 720
aacaagatgg ctatagctga etattatcaa ttatttgatt as 762
SeqID
85
atggaaatcaaaaagaaacategtattatgctttattcagcccttattttaggaacaata60
ttggttaacaatagttaccaagctaaagctgaagagcttaccaaaactacctcaacgtcc120
caaataagagatactcaaactaataatattgaagttctccagactgaaagtaccactgtc180
aaagagactagcaccacaaccacacaaeaagatctgtetaaccccacagcttcaaccgca240
actgcaacagccactcatagcacaatgaaacaagtagtagataatcaaactcaaaataag300
gagctggtgaaaaacggagattttaatcaaactaaccctgtatctggaagctggtcacat360
acaagcgctagggaatggtctgcttggattgataaagaaaatactgctgataaatcacct420
attatccaacgtaccgaacaaggccaagtaagcctatccagcgacaaaggctttagaggt480
gctgtaacaeaaaaagtgaacattgatcccactaaaaaatatgaggtcaagtttgatatt540
gaaacaagtaacaaggctggacaagctttccttcgtattatggagaaaaaagaoaacaat600
aCgCgaCtttggCtttCtgagatgaCCagCggtaCtaCtaaCaaaCataCCttaaCaaag660
atatataaCCCaaagttaaatgtCtCCgaggtgaCaCttgaactttattatgaaaaagga720
actggttctgctacttttgataatatatcaatgaaagcaaaaggccctaaagactcagag780
catccacaacccgtcacaacacaaattgaagaaagcgttaatacggctttaaacaaaaat840
tacgtttttaataaagctgactaccaatacactctaaccaatcegtctatcgggaaaatt900
gttggtggaatattgtatccaaacgctactggttcaacaactgttaaaatatctgataaa960
tctggtaaaataattaaagaagtaccgttatcagttacagcttcaacagaagataagttt1020
acaaaactcctcgacaaatggaacgacgtgactattggtaatcatgtttacgatactaat1080
gattcgaacatgcaaaagattaatcagaaattagatgaaactaacgccaaaaacatcaaa1140
actatcaaactggattctaatcacactttcctttggaaagatttagataatctcaataat1200
tcagcacagttaaccgctacttatcgtcgtttggaagatttagctaaacaaatcaccaat1260
ccccactctactatttacaaaaatgaaaaagctattcgtaetgtaaaagagagtctggct1320
tggcttcatcaaaacttctacaatgttaataaagatatagaaggctctgccaattggtgg1380
gattttgaaatcggtgtccctcgctcaattacagctaccctagctctcatgaataactac1440
ttcactgacgctgaaataaaaacttataccgacccaattgaacactttgttcctgatgca1500
ggatatttccgtaaaacgcttgacaatccatttaaagcccttggtggtaatctagtcgat1560
atggggcgcgttaaaatcattgaaggtttaettcgtaaagacaatactattatcgaaaaa1620
acttctcattatctaaaaaatctttttactactgctactaaagctgaaggtttctatgct1680
gacggttcttacatcgaccatacaaatgttgcttatactggcgcctatggtaatgttctg1740
atagatggtttgacacaattgctgcctatcattcaagaaactgactataaaatctctaat1800
caagaacttgatatggtttataaatggattaatcaatcatttttacctttaattgtaaaa1860
ggtgagttaatggatatgagtcgtggacgctcaattagtagagaggcagcttcttcgcat1920
gcggctgcagttgaagttctcagaggtttcctcagattggctaacatgtctaatgaagag1980
cgaaacttagacctcaaatcaactattaaaacgattatcacttcaaataaattctacaat2040
gtcttcaataacctcaaatcgtattccgatattgccaacatgaataagatgcttaatgac2100
agtacagtcgctactaaacctttaaaaagtaatttatoaacctttaatagcatggaccgc2160
ttagcttattataatgccgagaaagactttggtttcgcgctttcattacattctaaacgt2220
accctcaactatgaaggaatgaatgatgaaaatacacgtgattggtataccggagatggt2280
atgttctatctttataatagtgatcaatctcattatagtaatcatttttggccaaccgtc2340
aatccttataaaatggctggaacaactgaaaaagatgctaagcgtgaagataccactaag2400
gaattcatgagcaaacatagcaaagacgctaaagaaaaaaccggtcaagttacaggaaca2460
tctgactttgttggttccgtcaaacttaatgatcactttgctcttgccgctatggatttt2520
actaactgggatcgcaccttaacagcacaaaaaggttgggttatcttaaatgataagatt2580
gtctttttaggtagcaacatcaagaatactaacggcattggaaatgtttctacaacaatt2640
gatcaacgaaaagacgattctaaaacaccttatactacatacgtcaatggaaaaactatt2700
gatttaaaacaagcaagttctcaacaatttacagatacaaaaagtgtctttttagaatca2760
aaagaacctggtcgcaatattggttatatcttctttaaaaatagcactattgatattgaa2820
cgcaaagagcaaacaggtacttggaacagcattaatcgtacttctaaaaatacctcaatc2880
gttagcaatccttttatcactataagccaaaagcatgacaacaaaggtgatagctatggt2940
tacatgatggttccaaacattgatcgcacaagttttgataaattagccaacagcaaagaa3000
gtagaattactagaaaatagttcaaaacaacaagttatctatgataaaaacagtcaaact3060
tgggctgttatcaaacacgataatcaagagagtctcattaacaatcaattcaaaatgaat3120
aaagcgggactttacctagtacaaaaagttggtaatgactatcaaaatgtctattaccaa3180
cctcaaaccatgacaaaaacagaccaattagctatctaa 3219
Seq=D 86
atgcattctt tttctaatcc tggatatcct tatgataatg ccgtaactga agcatttttc 60
aagtatttaa agcatagaca aatcaaccga aaacattatc aaaatatcaa acaggttcaa 120
ttagactgct ttgaatacat tgagaatttt tataacaatt acaacccaca tacggctaat 180
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
36/109
ctaggactaa cccctaatca gaaagaagaa aattatttta acgcaataaa ataa 234
SeqID
87
gtgaagaaaacatatggttatatcggctcagttgctgccattttactagctactcatatt60
ggaagttaccaacttggtaagcatcatatgggtctagcaacaaaggacaatcagattgcc120
tatattgatgacagcaaaggtaaggcaaaagcccctaaaacaaacaaaacgatggatcaa180
atcagtgctgaagaaggcatctctgctgaacagatcgtagtcaaaattactgaccaaggc240
tatgtgacctcacatggtgaecattatcatttttacaatgggaaagttccttatgatgcg300
attattagtgaagagttgttgatgacggatcctaattaccgttttaaacaatcagacgtt360
atCaatgaaatCttagaCggttaCgttattaaagtCaatggCaaCtattatgtttaCCtC420
aagCCaggt~gtaagCgCaaaaaCattCga~CCa~.aCaaCaaattgCtg~'~-.gCac'~.gtagCC4$0
aaaggaactaaagaagctaaagaaaaaggtttagctcaagtggcccatctcagtaaagaa540
gaagttgcggcagtcaatgaagcaaaaagacaaggacgctatactacagacgatggctat60D
atttttagtccgacagatatcattgatgatttaggagatgcttatttagtacctcatggt660
aatcactatcattatattcctaaaaaggatttgtctccaagtgagctagetgctgcacaa720
gCCtaCtggagtcaaaaacaaggtcgaggtgctagaccgtctgattaccgcccgacacca780
gccccaggtcgtaggaaagccccaattcctgatgtgacgcctaaccctggacaaggtcat840
cagccagataacggtggctatcatccagcgcctcctaggccaaatgatgcgtcacaaaac900
aaacaccaaagagatgagtttaaaggaaaaacctttaaggaacttttagatcaactacac960
cgtcttgatttgaaataccgtcatgtggaagaagatgggttgatttttgaaccgactcaa1020
gtgatcaaatcaaacgcttttgggtatgtggtgcctcatggagatcattatcatattatc1080
ccaagaagtcagttatcacctcttgaaatggaattagcagatcgatacttagctggccaa1140
actgaggacaatgactcaggttcagagcactcaaaaccatcagataaagaagtgacacat1200
acctttcttggtcatcgcatcaaagcttacggaaaaggcttagatggtaaaccatatgat1260
acgagtgatgcttatgtttttagtaaagaatccattcattcagtggataaatcaggagtt1320
acagctaaacacggagatcatttccactatataggatttggagaacttgaacaatatgag1380
ttggatgaggtcgctaactgggtgaaagcaaaaggtcaagctgatgagcttgctgctgct1440
ttggatcaggaacaaggcaaagaaaaaccactctttgacactaaaaaagtgagtcgcaaa1500
gtaacaaaagatggtaaagtgggctatatgatgccaaaagatggtaaggactatttctat1560
gctcgtgatcaacttgatttgactcagattgectttgccgaacaagaactaatgcttaaa1620
gataagaagcattaccgttatgacattgttgacacaggtattgagccacgacttgctgta1680
gatgtgtcaagtctgccgatgcatgctggtaatgctacttacgatactggaagttcgttt1740
gttatcccacatattgatcatatccatgtcgttccgtattcatggttgacgcgcgatcag1800
attgcaacagtcaagtatgtgatgcaacaccccgaagttcgtccggatgtatggtctaag1860
ccagggcatgaagagtcaggttcggtcattccaaatgttacgcctcttgataaacgtgct1920
ggtatgccaaactggcaaattatccattctgctgaagaagttcaaaaagccctagcagaa1980
ggtcgttttgcaacaccagacggctatattttcgatccacgagatgttttggccaaagaa2040
acttttgtatggaaagatggctectttagcatcccaagagcagatggcagttcattgaga2100
accattaataaatctgatctatcccaagctgagtggcaacaagctcaagagttattggca2160
aagaaaaatactggtgatgctactgatacggataaacccaaagaaaagcaacaggcagat2220
aagagcaatgaaaaccaacagccaagtgaagccagtaaagaagaaaaagaatcagatgac2280
tttatagacagtttaccagactatggtctagatagagcaaccctagaagatcatatcaat2340
caattagcacaaaaagctaatatcgatcctaagtatctcattttccaaccagaaggtgtc2400
caattttataataaaaatggtgaattggtaacttatgatatcaagacacttcaacaaata2460
aacccttaa 2469
SeqID
88
atgaaaaaaggtttttttctcatggctatggttgtgagtttagtaatgatagcagggtgt60
gataagtcagcaaaccccaaacagcctacgcaaggcatgtcagttgtaaccagcttttac120
ccaatgtatgcgatgacaaaagaagtatctggagacctcaatgatgtgaggatgatccaa180
tcaggtgcaggcattcattcctttgaaccgtctgtaaatgatgtggcagctatttatgac240
gcggatttgtttgtttaccattcacataccttagaagcttgggcaagggatctagaccct300
aatttaaaaaaatcaaaggttgatgtgtttgaagcgtcaaaacctttgacactagataga360
gtcaaagggctagaagatatggaagtcacacaaggcattgaccctgcgacactttatgac420
ccacatacctggacggatcccgttttagctggtgaggaagctgttaatatcgctaaagag480
ctaggacgtttggatcctaaacacaaagacagttacactaaaaaggctaaggctttcaaa540
aaagaagcagagcaactaactgaagaatacactcaaaaatttaaaaaggtgcgctcaaaa600
acattcgtgacgcaacacacggcattttcttatctggctaaacgattcggcttgaaacaa660
cttggtatctcgggtatttctccagagcaagagccetctcctcgccaattgaaagaaatt720
caagactttgtcaaagaatacaacgtcaagactatttttgCagaagaCaaCgtCaatCCC780
aaaattgctcatgctattgcgaaatcaacaggagctaaagtaaagacattaagtccactt840
gaagctgctccaagcggaaacaagacatatctagaaaatcttagagcaaatttggaagtg900
ctctatcaacagttgaagtaa 921
SeqID 89
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
37/109
ttgcgtaaaaaacagaaactaccatttgataaacttgccattgcgcttatgtctacgagc60
atcttgctcaatgcacaatcagacatcaaagcaaatactgtgacagaagacactcctget120
accgaacaaaccgtagaaactccacaaccaacagcggtttctgaggaagcaccatcatca180
aaggaaactaaaaccccacaaactcctagtgatgcaggagaaacagtagcagatgacgct240
aatgatctagcccctcaagctcctgctaaaactgctgatacaccagcaacctcaaaagcg300
actattagggatttgaacgacccttctcaggtcaaaaccctgcaggaaaaagcaggcaag360
ggagctgggactgttgttgcagtgattgatgctggttttgataaaaatcatgaagcgtgg420
cgcttaaca.gacaaagccaaagcacgttaccaatcaaaagaagatcttgaaaaagctaaa480
aaagagcacggtattacctatggcgagtgggtcaatgataaggttgcttactaccatgac540
tatagt~.aagatggtaaaaccgctgtcgatcaagagcacggcacacacgtgtcaggaatc600
ttgtcaggaaatgctccatctgaaacgaaagaaccttaccgcctagaaggtgcgatgcct660
gaggctcaattgcttttgatgcgtgtcgaaattgt2.aatggactagcagactatgctcgt720
aactacgctcaagctatcagagatgctatcaacttgggagctaaggtgattaatatgagc780
tttggt~atgctgca.ctagcttacgccaaccttccagacgaaaccaaaaa.agcctttgac840
tatgccaaatcaaaaggtgttagcattgtgacctcagctggtaatgatagtagctttggg900
ggcaagacccgtctacctctagcagatcatcctgattatggggtggttgggacacctgca960
gcggcagactcaacattgacagttgcttcttacagcccagataaacagctCactgaaact1020
gctacggtcaaaacagccgatcagcaagataaagaaatgcctgttctttcaacaaaccgt1080
tttgagccaaacaaggcttacgactatgcttatgctaatcgagggacgaaagaggatgat1140
tttaaggatgtcaaaggtaagattgcccttattgaacgtggcgatattgatttcaaagat1200
aagattgcaaaagctaaaaaagctggtgctgtaggagtcttgatctatgacaatcaggac1260
aagggcttcccgattgaattgccaaatgttgatcagatgcctgcggcctttatcagtcga1320
aaagatggtctcttattaaaagacaatccccaaaaaaccatcaccttcaatgcgacacct1380
aaggtattgccaacagcaagtggcaccaaactaagccgcttctcaagctggggtctgaca1440
gctgacggtaatattaagccagatattgcagcacccggccaagatattttgtcatcagtg1500
gctaacaacaagtatgccaaactttctggaactagtatgtctgcgecattagtagcgggt1560
atcatgggactgttgcaaaagcagtatgagacacagtatcctgatatgacaccatcagag1620
cgtcttgatttagctaaaaaagtattgatgagctcagcaactgccttatatgatgaagat1680
gaaaaagcttatttttctcctcgccaacaaggagcaggagcagtcgatgctaaaaaaget1740
tcagcagcaacgatgtatgtgacagataaggataatacctcaagcaaggttcacctgaac1800
aatgtttctgataaatttgaagtaacagtaacagttcacaacaaatctgataaacetcaa1860
gagttgtattaccaagcaactgttcaaacagataaagtagatggaaaacactttgccttg1920
gctcctaaagcattgtatgagacatcatggcaaaaaatcaeaattccagccaatagcagc1980
aaacaagtcaccgttccaatcgatgctagtcgatttagcaaggacttgcttgcccaaatg2040
aaaaatggctatttcttagaaggttttgttcgtttcaaacaagatcctaaaaaagaagag2100
cttatgagcattccatatattggtttccgaggtgattttggcaatctgtcagccttagaa2160
aaaccaatctatgatagcaaagacggtagcagctactatcatgaagcaaatagtgatgcc2220
aaagaccaattagatggtgatggattacagttttacgctctgaaaaataactttacagca2280
cttaccacagagtctaacccgtggacgattattaaagctgtcaaagaaggggttgaaaac2340
atagaggatatcgaatcttcagagatcacagaaaccatttttgcaggtacttttgcaaaa2400
caagacgatgatagccactaetatatccaccgtcacgctaatggcaagccatatgctgcg2460
atctctccaaatggggacggtaacagagattatgtccaattccaaggtactttcttgcgt2520
aatgctaaaaaccttgtggctgaagtcttggacaaagaaggaaatgttgtttggacaagt2580
gaggtaaccgagcaagttgttaaaaactacaacaatgacttggcaagcacacttggttca2640
acccgttttgaaaaaacgcgttgggacggtaaagataaagacggcaaagttgttgctaac2700
ggaacctacacctatcgtgtccgctacactccgattagctcaggtgcaaaagaacaacac2760
actgattttgatgtgattgtagacaatacgacacctgaagtcgcaacatcggcaacattc2820
tcaacagaagatcgtcgtttgacacttgcatctaaaccaaaaaccagccaaccggtttac2880
cgtgagcgtattgcttatacttacatggatgaggatctgccaacaacagagtatatttct2940
ccaaatgaagatggtacctttactcttcctgaagaggctgaaacaatggaaggcgctact3000
gttccattgaaaatgtcagactttacttatgttgttgaagatatggctggtaacatcact3060
tatacaccagtgactaagctattggagggccactctaataagccagaacaagacggttca3120
gatcaagcaccagacaaaaaaccagaagctaaaccagaacaagacggttcaggtcaaaca3180
ccagataaaaaaacagaaactaaaccagaaaaagatagttcaggtcaaacaccaggtaaa3240
actcctcaaaaaggtcaaccttctcgtactctagagaaacgatcttctaagcgtgcttta3300
gctacaaa.agcatcaacaagagatcagttaccaacgactaatgacaaggatacaaatcgt3360
ttacatctccttaagttagttatgaccactttcttcttgggattagtagctcatatattt3420
aaaacaaaacgccaaaaagaaactaaaaaatag 3453
SeqI77
90
tttagtgtaacctattcacagtctgaacgtacggttgttttctcttttggagaaataaca60
tttagtaggagtcgctggacaaatggetttgaaactagaataccagtagatgagtggtta120
ggtcttgaaaaatataagagatattcaatagaattcttatatcatgttgcaaaattggct180
acaatgatgccttatcgtcaagtttgcaaagtaatagatagcactttgcaaacaatcata240
acaaaagactgtgttttaaaagcagtaaaatttgtagaaaaattgttaaaagaaaaagaa300
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
38/109
cgctatcgtt tttatttgga agagccaccc gaacgtaaaa aagtgaaaaa actgtatgtt 360
gagggtgatg gagtcatgat taaaagcaca gattctagag aggaaagaag gtatttagat 420
ttaacacatt ttgttattca tacaggctca aaaaaagttt ctactaaaag atatgaattg 480
caggacaagc acgaaatatt acagcttaat tatgataaag ctaaatataa tcttttagat 540
tatatttata ataactatga agtagatgac gatactattt taatcactaa ctctgatatg 600
ggtaaaggct atactagtag agtttttaag gaattaggaa aagcacttaa ggtaaagaaa 660
catgagcatt tttgggatat ctatcatgtt aaagaaaagt taagttcata ccttagaaaa 720
tatccaattg aattaaccga ttttgcttta gatgcggtaa aaaaatataa ttctgataag 780
cttgaattag tttttgatac tgttgaatca ctgatttgtg atgaacttga agatcaagaa 840
tttcagaagt ttaagaaaaa agtattaaat aatttcaaat atataaaacc agctcatctt 900
a.gaaatcttt caaatcgtgg tattggtatc atggaatcac aacacagaaa gataacgtat 960
agaatgaagc gacgtggcat gtattggtca aagtggggaa tctccacaat ggcaaatatg 1020
attatacttg aaagagct~.a. cggtttacga gaattatttt teggttcttg gagaaaggta 1080
tacagtgagt ataaagaagg ttcatttagt gcagggcgac tttttaaaaa gacagatgaa 1140
ttagataaat tttctaagcc ccttctaaaa aatggcagaa aatggagtat aacaggaatc 1200
aaaacaaaat ag 1212
SeqID 91
aaagcaagca geggtgatta tggcacaaaa agggaaataa tcactgctaa taaggataaa 60
tacagcattt caaagatgtg tcgctggctg aatatgccac gctcaagtta ttactatcaa 120
gccgtggagt cagtatctaa aacggagttt gaagaaacta ttaaaagaat ttttctcgat 180
agcgagtcta gatacggatc cagaaaaatc aaaatatgct tgaataacga aggtatcaca 240
ctttcacgtc gtcggattcg acgcattatg aagcgactca atttggtttc tgtttatcag 300
aaagccacct tcaaaccaca ttctagaggc aagaatgaag cccctattcc caaccactta 360
gacaggcaat ttaagcaaga aagaccacta caagccttag tcactgactt aacctatgtt 420
cgtgtaggca atcgttgggc ttatgtttgc ctcatcattg acctatacaa ccgtgaaatc 480
atcggcctgt ctcttggttg gcacaagacc gctgaactcg ttaagcaagc catacaaagc 540
atcccttacg ccctgaccaa agtcaagatg ttccattcag atcgtggcaa agagtttgat 600
aatcagttaa ttgatgaaat attggaagcc tttggaatca cacgttcgct tagtcaggct 660
ggttgtcctt atgacaatgc cgtagctgaa agtacgtatc gtgctttcaa aattgaattt 720
gtttatcaag aaacctttca atcgctggaa gaactagctc ttaagactga aaaggcaaca 780
cttttctgta caacatttat aaagtgttgc cttttcaggt ttttaccaat gctataa 837
SeqID 92
atgaagacaa gaaatcgtaa aggtggttat ttagcgaata ctgcaaatga gtacatcgac 60
tctaaacagg caattcattg cttgagtgta gaacttgaac cgcaaattag gtttgaagag 120
ggtcagccta ctggggagat tatcgcttat aaggcttggt tctctcaaaa agggcttccg 180
ccttttatgg tgaagtttga aaatgaagtg acactaccag catatatggt aatggtgcaa 240
tttgagaatc ttcaagcttg tgaggttggg ttcaatgttt atttcaaggc agacaatctc 300
aaggaggtca aataa 315
SeqID 93
ttgtccactt ttgattcagt tacaggaagg accaatcact tggaagctta tgaagggctg 60
aacctttctg aaaaatttgc cattttaagt cactttgaca aacttagaaa tgagctgcag 120
acaccatcta ttcagctagg ggagtttgat agggaaatgg aagctttttc aatcactttg l80
ggaaatgaac tgttgggtta tttagaggca aatggcagcc cctatgagtt gaagcgagaa 240
ttgaatcagg ccgaaatgat ggcagtcctt gagcttagcc gtcaactggt tgcaaaattt 300
tctacaaaac tagaggagct gggaattgat ttgggttcat ttcaaccaga ccaagtcaac 360
atcttattgg atgccgttgg tcgttttcgc ttgaaaaatg cggacattgc tttattaggc 420
ggttatccaa aagcgagtgt ttcccagcta gctcttgcga cagaactcct ccagatggga 480
ctaagtcatg ataaggtaga atttttetta accagtcagc ttcagttaga ggatatgcga 540
caggtcgctt ttgctttcct acatgaaagc ttgaccagag aagaagcaga gcaatttgaa 600
acagaccgct ttcgtcatac aagcttaaac tttcgagaat ggcgagaact tctagaaaag 660
caagagccag aaatggtgga gatgtcagac gtcagcccgc ttgttcggga agtcttgcat 720
cattatccac ttggttcaag ggtcacttat aaaggacagg agtttgagat cttgtctatt 780
gaagctgcgg acatggataa tctgattcga atagagcttc aaaatgattt ttcatatctc 840
attgaacaaa atcccgttct ctatttccaa aacttggcag aaatcaggca agttcttcat 900
ttgtctcgtt cggaaattgt agaaagagag gaacaacctg aggaagaatg gactctcttt 960
tcgtttatgg atgaggggac agaggataac gaaaaggaac ctgagattgt ttttgaatct 1020
accgataaag ttgttacatt agatagtcag ccagcacaag taagtgagac tatatccgaa 1080
tcagttcctg aaaccaaaga ggtgattgaa gcagaacaag caatagcagt tgattttagc 1140
tttcctgaag atttgactaa tttttacccc aaaacagcta gggataaagt agtggcgaat 1200
ctcgtagcta ttcgtcttgt aaaagaatta gaaagtgcta atcaatcagc aacacctaat 1260
gaacaagaaa ttcttgccaa atatgtgggt tggggtggtc ttgccaatga attctttgat 1320
gagtacaatc cgaagttttc taaggaaaga gaggagttga aaactctcgt ttctgataaa 1380
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
39/109
gagtattccgatatgaaacaatcatctctaacggcctactatacggatccgcttttaatt1440
cgtcagatgtggtctaagttagaacaagacggctttagtggtggaaaaatattagaceca1500
tcaatgggaacagggaatttctttgcggctatgccagctcatttgagggaaaagagtgag1560
ctgtgtggggttgagttagatactateacaggagcgatagctaagcagcttcattcaaat1620
gtccatattgaagtaaagggatttgagacggttgcttttaatgataatagttttgatttg1680
gttatttcaaatgttccctttgccaatatccgtatcgcggataatcagtacgataagccc1740
tatatgattcatgactactttgtcaagaaatctcttgatttggtacatgatggtgggcaa1800
gtagccattatttcctccacaggaaccatggacaaacggacagaaaatattetccaagat2560
attcgtgagacgacggattttcttggtggcgtgcgtttgccagatacggcttttaaggcc1920
attgcaggtacaagtgtgacaacggatatgcttttctttcagaaacatctgaacaaaggc1980
tatcaagcagatgacattgccttttcaggttctgttcgttatgacaaggacgagcgtatt2040
tggctcaatccctactttgatggggagtataatgcccaggttcttggaaggtatgagatt2100
aaaaactttaacggtggaaCaCtttCggttaaggaaaCgaCtgataaCCtgattgCgagt2160
gttcgagaagccttgcaacatgtaaaagcaccaagggttattgataaaacaga.agtcatg2220
attaactcggatgtgattgcaagacaggtcatagataccaccattccacctgaaattaga2280
gaaaaccttgaacaatatagctatggttacaaaggttctaccatttattatcgtgataat2340
aaggggattcgtgttgggacaaaaacggaggaaattagctattatgtggatgatgaggga2400
aactttcaggcttgggagtccaagcattcacaaaaacagattgaccgttttaataactta2460
gaagtcacagatagcacagctcttgatgtttatgtgactgaagaacctgcgaaacgtggg2520
caatttaaaggatatttcaaaaaggcggttttttatgaagctcetttgtctgaaaaagaa2580
gtggcacggattaaaggaatggtagatattcgcaatgcctatcaagaggtcattgctatt2640
caacgcaattatgattacgataagaatgagtttaaccgcttgttaggaaacctcaatcgc2700
acetatgatagctttgtcaaacgctatggctttttgaacagtccagttaaccgaaattta2760
tttgatagtgatgataagtattcgcttttagctagtctcgaagatgaaagtcttgaccca2820
agtgggaagacggtcatttatacgaagtcactggcttttgaaaaagccttggtccgtcct2880
gaaaaaatggttaaagaggtgtcaaccgctcttgatgcactcaactccagtcttgcggat2940
ggtcgtggagttgactttgattacatggcttccatctatcaaacagcatctaaggcagct3000
ttgattgaggagetgggagatcagattataccagatccagaaagttatttaaaaggacag3060
ctgacctatgtatctcgccaggagtttttatcaggagatattgtgacaaaattagaagtt3120
atggacttactgttaaagcaagacaatcatgattttaactgggcgcattatggtaatttg3180
ttagaaagtgttcgtccagcacgagtgatgttggcagatattgattatcgaattggttca3240
cgttggattcctttagctgtttatggaaaatttgtccaagaagcctttatggggaagaat3300
tatgacttaacggctacagaagtggaagaggtcctctctgtcagcccgattgatgggacg3360
atggaatttcggacacggtttgcctatacctactcaacagcgaaggatagaagcctgggt3420
gtagcaggctcacgctatgatagtggtcggaaaatctttgagaatctgcttaactccaat3480
cagccaaccatcacgaagcagattcaagagggagataagaaaaagaatgtgacagatgtg3540
gagaagacaaccgttctgcgtgctaaagaagcacaaatccaagacctctttcaagatttt3600
gtcgcaagctatcctgaagcccaacagatgattgaggatacctataatagtctctataat3660
cgtaccgtctctaaagtttatgatggcagccgtttggagattgatggtttggctcaaaat3720
atttcgcttcgtcctcatcaaaaaaatgccattcagcgaatcgtggaggaaaaacgggct3780
cttttagctcatgaagtgggttcaggcaaaactttaaccattcttggagcaggctttaaa3840
ctgaaagagttaggtatggtacataaaccgctttatgtggtaccttctagcttgaccgct3900
cagtttggtcaagaaatcatgaagttcttcccaacgaagaaagtctacgtgacgacaaag3960
aaagattttgccaaagctcggcgcaagcagtttgtctcacgtattattacaggggattac4020
gatgccattgtcatcggggactcccagtttgaaaaaatccccatgagtcaggaaaaacag4080
gtgacttatattcaagataagttggaacaattacgggagataaagcaaggaagcgatagt4140
gactacacagtcaaagaagcggagcgttcgattaaaggtttggaaaaccaattggaagaa4200
ctccagaaactagatcgagatacctttattgaatttgaaaatcttggcattgattttctc4260
tttgtggacgaagcccatcatttcaaaaatattaggccgattactggtctgggaaatgta4320
gcgggaattaccaacacgacttctaaaaagaacgtggatatggaaatgaaagtgagacag4380
attcaggcagagtatggagatagaaatgtcgtttttgcgacaggaacgecggtgtctaat4440
tccattagtgaactctatactatgatgaactatattcagccagatgtcctagaacgctac4500
caagtttctaactttgactcctgggttggagcttttggcaatatcgaaaattcgatggag4560
ctagcgccaacaggagataagtatcaacccaagaaacggtttaaaaagtttgtgaatcta4620
cctgaactcatgcggatttataaagaaaccgctgatattcaaacgtcagatatgttggat4680
ttacctgtacctgaagccacagtcattgcggtggaaagtgaactcacagaagctcagaaa4740
aactaccttgaagaattggtggaccgttcagatgcgattaaatcaggaagcgttgaccct4800
agtgtcgataacatgttaaaggtgataggcgaagccagaaagctagccattgatatgcgt4860
ttgattgaccctgcctataccttatctgacaatcagaagattatgcaagtagtggataac4920
gtggaaCggatttaCCgtgagggcaadggagataaggctacaCagatgattttCtfagac4980
attggcacgcctaaaagtaaagaagaaggatttgatgtctataatgaattgaaagccctc5040
ttagttgaccgaggaattccaaaagaagaaattgcctttgtccatgacgctaatacggat5100
gagaagaaaaattctttgtcacgaaaggtcaatagtggggaagtaaggattctcatggct5160
tcaactgaaaaaggaggaacaggattaaacgtgcaagcacgcatgaaagctgttcaccat5220
ttagacgttccttggcgtccctcagacattcagcaacgcaatggacgtttgattagacaa5280
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
40/109
ggaaatcaacatcagaatgtagagatttatcattatattaccaaaggttcatttgataac5340
tatttgtgggctacacaagagaataagttgcgttatattaaacaaattatgacttcaaaa5400
gatcctgttcggtcagcagaagatattgacgagcaaaccatgaccgcttcagatttcaaa5460
gcgttagctactggcaatccctatctcaaactcaaaatggagttagagaatgaattgacc5520
gtcttagaaaatcagaaacgtgctttcaatcgctccaaagatgaatacaggcacactatt5580
tcctattgcgagaaaaacttacctgttatggaaaaacgattaaggcagtatgacagagat5640
attgagaaatcacaagcaacgaagaatcaagagtttatcatgcggtttgataaccagaca5700
attgaCaatCgCagCga3gCtggggattatttaCgaaaaCtcatC~.CCtataatCgttCC5760
gaaaccaaagaagtcagaaccttagcgacctttagaggctttgagcttaaaatggcta.ca5820
cgaagtcetggtgaacccttgtctgacatggtgtctctaactatttcaggggataaceag5880
tattca.gtttcccttgatttaaaatcagacgtgggaacgattcaacggattaacaacgcc5940
attgaccatatcctagaggataaggaaaagacagaagagatgacaaacaaectcaaagat6000
aagctagcagtcgcaagagttgaagttgagaaagtctttgcaaaggaagaggaatatcag6060
ttggtaaaggccaagtatgatgtacttgccccattagtggaaagagaagcagacttagaa6120
gaaattgacgtagcactttcccaatttagtagctctgacccatgcttgaaaaaagatcaa6180
cagttagtccttgacatttaa 6201
SegID 94
atgaccacaa aatgcaatca tcattttctc atcaatcagg agaaaggcga aaagtatgtt 60
tttcgtaaaa gtaagcaata tcgcacgctg tgttcggttg ctttaggaac agttgtgatg 120
gcattcgtag ctttggccgg accgatggtg caggcggatg aagtagggag aactgttgcg 180
acaagtgtac agacggaaac gaatcctgca acaaatttaa aagaaaatca gccaagtccg 240
attgcggaac aaaaagatag tcttgcagca accggtcaat caactggaac ggtgacagtc 300
actgttccac atgataaggt gacacaagct gtcgataagg caaagaccga aggaataaaa 360
gcagtacaag acaagecgat ggacttaggc aatacagtat ccgcagctga aaccagccaa 420
caactcaaaa aggcagaaga agatgccaca aaccaaacaa caactatttc taaaactgtt 480
gaaatctaca agtctgataa agcaacttat gaagctgaaa agaagtgggt agagaagcgt 540
aatgaagagt taactgctgc ttatgataag gcagaacaaa cagggactgg cttaaaccat 600
tcggttgata cgactgtttc agaattgaag tcgcaagacc aaaacgctca tgtgaccgtg 660
aacacacaaa cagtaaaatc aggagatggg acgagtgttt caggctatca ggagtacgtc 720
aagtctgttg cggccattga taagaagaat aaagcgaact tagctgatta tcggactaag 780
aaacaagecg cagacgctgt tgtggctaag aatcaactca ttcaaaaaga gaatgaagct 840
gggcttgcta aggcaaaagc agaaaatgaa gcgattgaca gacggaataa agaagggcaa 900
aaagctgttg atgaagcaaa taaggctggg caagccgcag tagagcaagc gaaccaagaa 960
aaacaaaaac aggccgcaaa ccgtgctttt gaaattgcga caattaccaa acggaataaa 1020
gaaagagaag aagtcgcaaa gaaagaaaat gcagcgattg atgcttataa tgcgaaagaa 1080
tggatccgct ataagcggga tttagcaaac atctcaaaag gggaggaagg ctacatttca 1140
gaagcccttg cgcaggctct agatttaaat catggcgaac cgcaggtcaa acatggtgca 1200
ggtactcgaa atccagatcg aatcatttca aagggagatg ccatgttggg tggctattct 1260
aacattcttg attcaacggg tttctttgtc tacaatcact ttaaaacagg tgaaacgctg 1320
aactttacct atcaaaatct gaagcatgca cgttttgatg ggaagaaaat tacagccata 1380
acttatgata ttaccaatct ggtttcacca actggaacca atgcggtgca gttagttgtt 1440
ccaaacgacc caacagaagg ctttattgct tatcgcaatg atggcgctgg aaattggcgg 1500
acagataaga tggagttccg tgtcaaagct cggtatttct tagaagacgg ttcacaagtg 1560
acctttacta aagaaaaacc aggtgtcttt acccactcgt cactcaatca taatgatatt 1620
gggcttgaat atgttaaaga ctcatcaggt aaatttgttc etattcatgg ttcaagtgtg 1680
caagtaacca atgagggctt ageccgttcg ttaggttcaa accgagcgag tgacttgaag 1740
ttgccagaag aatgggatac gacttctagt cgctatgctt ataaaggagc gattgtatca 1800
acagtcacat cggggaatat ttataccgta acctttggcc aaggagatat gccaacccaa 1860
gtgggaggga agacctattg gtttgcttta aatactttgc cagtcgcaaa aacagtgact 1920
ccctacaatc caaagactca tgtaagacca cagctggatc cagttcctga accgataaaa 1980
gttacaccag aaacttatac tcctaaaatc tttactcctg aaaaaccagt aacctttact 2040
ccaaaatcag tagaaaaagt gccccaacct agtttgacct taacaaaagt cacactacca 2100
acaaatctga agctagaacc attacccaaa gctccacaaa agccaaccgt tcattaccac 2160
gattacctct taaccacaac acccgctatc gcaaaagaag tgatgaatgt tgacaaagtt 2220
aatcttcatg gtaaacaggt ggctaaggat tccactgtta tttatccctt gacagtagat 2280
gttttatctc caaatcgttc caagataacc agtcttatct ttgaagatta tctgcctgct 2340
ggttatgcgt ttgatatgac gaagacacaa gcggagaata gcgactatga cttaaccttt 2400
gataaaaata agaactttgt gaccttgaaa gcgaaagata gcttacttca aacgttgaat 2460
aaagagttaa acaagtctta tcaactgtct gctccaaaac tttatggttc agttcaaaat 2520
gatggggcga ettattctaa tagctataaa ctccttatta acaaggacac cccaaacacc 2580
tatacggtta tttcaaacgt agttagaatt cggactccag gagacggtga aacgaccagc 2640
cgaatccggc ctaaaaagga caatgaaaat gcggacggtg tgttgataaa tgatacggtt 2700
gttgctctta gtacaaccaa tcattaccgt ttgacctggg atttggatca gtacaagggg 2760
gatacttctt caaaagatac cattgcacga ggattccttt ttgtagatga etacccagaa 2820
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
41/109
gaagcacttg acttggtaga taaagggaca gttatcacca cccttgatgg taaagctgtt 2880
tcaggtattt ctgtatacag ctatacatcc cttgataaag caccaaaaga gctacaagat 2940
aaattagctc gtgcgaacat ttcgccaaaa ggagegttcc aggtctttga accggacaat 3000
catcaagcgt tttacgatac ttacgttaag actgggcagt ctttagecct tctcacaaaa 3060
atgaaggtaa aagatagttt gtacggtcag actgtcagat acaaaaataa agectaccaa 3120
gttgattttg gcaatggcta tgaaactaag gaagtcgtca atacagtcgt tcatccagag 3180
cctaagaaac aaaatctcaa taaggacaag gtggacatca atggcaaagc gatgcttgtc 3240
ggctcccaaa acttctatac gctttcttgg gatttagatc agtatcgtgg cctacaagcg 3300
gataagagtc agattgctca aggcttttac tttgtggacg attatcecga agatgttctt 3360
ettcctgaca caaaagccat tcaaattatg acgaaagacg ggaaagetgt taaaggaatg 3420
gagataaaaa cctatcatca actetcagat gctecaaagg 2~attgcaggc agctcttgcc 3480
aaacgtaata tcacgcccaa aggcgctttt caagtcttta tgccaaaaga tccacaagct 3540
ttttataaag cttatgtgac aactggtcaa aacttgacta ttgtgaatcc gatgacggtt 3600
cgtgaagcag tatacaactc agggaagtct tatgataatg tggcctatca agtggacttt 3660
ggacaggcct atgaaacgaa tatagtgacc aatcacgtgc caacagtaaa cccgcataag 3720
tccaatacca ataaagaagg tgtgtcaata gaaggtaaga cagtccttcc gaatacggtc 3780
aactactata aaattgttct agattatagt cagtacaaga atatgattgt gacagatgat 3840
gtcctcgtca aaggttttta tatggtggat gattacccag aagaagcact taCtcetcat 3900
ccagatggga ctcaagtgat ggatcagaac gggaaatttg tcagaggcct gtctgttcga 3960
acttacgcaa gtttggcaga tgcaccgaaa gcagtacaag aagcaatgaa atctcgaaat 4020
ttcattecta aaggagctat tcaggtcttt caggcagatg acccaaaaac tttctttgaa 4080
acttatgtga aaacaggaca aaaattggtt gtgacaacac cgatgacagt gaagaatgaa 4140
cggattcaaa caggcggtca gtatgagaat acagcttatc agattgattt tggcatcgct 4200
tatgtaacgg aaacagttgt gaataatgta ccaaaattag aacctcaaaa agatgtggtc 4260
attgacttat ctcaaaaaga taagagttta aacggaaaag caatcgcttt ggatcaggtc 4320
tttaactacc gcttggtagg ttcacttatc ccacgcaatc gtgcgacagc cttggtggaa 4380
tacagtttta aagatgacta cgatgaaaag cacgatgaat ataagggtgt ttataaagcc 4440
tatactttgc gtgatgtaac cttaaaagat ggcacagtat taaagcaggg gacagaagtg 4500
acgaaataca ccttacaaag tgttgataag gcaaaaggaa cgattgcgat tcgttttgat 4560
acagcttttt tggaaaatat agctgatgaa tcagagtttc aggctgagct ttatcttcag 4620
atgaaacgca ttgcttcagg tgatgttgaa aatacagtta ttcatagtgt caatggttat 4680
aatattcgct ctaacacggt taagaccaca accccacaac cagagtcacc gactcctgat 4740
aacccaccgt caccccaacc gccagtteca accacagaat ccccagttca agetagtgtc 4800
ctaccaagta caggggaaag tcaatccctt ttggcgctca ttggaggagg tctcctgctt 4860
ggcctcgctt acggactttc taaacgaaaa aaggagaaaa actaa 4905
SeqID
95 ataatttttataatcgtgacecttttggaaatatggatgatatttttaat60
atggcaaata
tctctaatgggaaatatggggggctataatagtgagaataaacgatacttaatcaatgga120
cgggaagttactcctgaagaattcagtcaatatcgtcaaactggaaaactccccggtcaa180
gagctaaataaccaaaatactcctacaaaccaagtctctgcagatagtgttttgactaaa240
ttaggaactaatttaaccgatcaagcacgtcagcatttgctagatccagttattggacga300
aacaaagaaattcaggaaactgaagaaattctagctcgtcgtactaaaaataatcctgtt360
ctagttggtgatgcaggtgttggtaaaacagctgttattgaaggtttggcacaagcaatt420
ataaatggtgatgtccctgctgctatcaaaaataaagaaatcatttcgatagatatctct480
agccttgaagctggcacccaatataggggtagttttgaagaaaatattcaaaatatcata540
aaagaagttaaggaaacaggaaatattattctcttctttgatgaaatacaacaaatatta600
ggagccggttcaactggtggtgatagtggctctaaggggctcgcagatatacttaagcct660
gcactttcacgtggtgaattaacggttataggtgcaactactcaagatgaatatcgtaac720
accattctcaagaatgctgccttagcacgccgctttaacgaagttaaagtcaatgcacct780
tctgcacaagatactttcaatatccttatggggataagaaacctctatgagcaacatcat840
aatgttgttttacctgactctgttttgaaagcagctgtagatttatctattcaatacata900
ccacaaagaagtctccctgataaagcaattgaccttattgatatgactgctgcacaccta960
gctgcgcaacatcccgtaactgaccttaaatccttagaaaaagaaatcgctgcgcaaaga1020
gacaagcaagaaaaagctgtcaatactgaagattttgaagaagctcttaaggtcaagaca1080
cgcattgaagagttacaaaaccagattgataatcataccgaaggacaaaaagtcactgca1140
actatcaatgatatcgctatgtcaattgagcgtctaactggagttcctgtatcaaatatg1200
ggtgctagtgatattgaacgcttaaaagaacttggcaatcgtctaaaaggtaaagtcatt1260
ggtcaaaatgatgctgttgaggcagttgcaagagctattcgcegaaatcgtgctggtttc1320
gatgatggtaatcgtccgattggtagctttctatttgttggaccaactggagttggtaaa1380
actgagctagcaaagcaattagcttttgatatgttcggatcaaaggatgctatcgttaga1440
cttgatatgtctgaatataatgatcgtactgcagtttctaagctaattggagcgactgct1500
ggttacgttggttatgacgacaatagtaatacactaacagaacgtatccgtcgaaatcct1560
tattctattgttcttcttgatgaaatcgaaaaagetgacccgcaagttatcacgcttctc1620
cttcaagttctagatgatggtcgtttaactgatggtcaaggaaacactattaactttaaa1680
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
42/109
aatactgtta 1740
tcattgcaac
ctcaaatgca
ggttttggaa
acgaagcatt
tacaggtgac
agcgataaag 1800
acttgaaaat
tatggaacga
atttctccat
atttccgtcc
agaatttcta
aatcgtttca 1860
atggtgttat
tgaattctet
cacctaagca
aagatgactt
aaacgaaatt
gtagatttga 1920
tgcttgatga
agttaaccaa
acaattggca
aaaaaggaat
tgaccttgtg
gtagatgaaa 1980
atgttaaatc
acacttaatt
gacctgggtt
atgacgaagc
aatgggagta
cgtccattgc 2040
gccgtgtcat
cgagcaagaa
attcgagatc
gcatcacaga
ctactatctc
gatcatacag 2100
atgttaaaca
cctaaaagct
aatttgcaag
atggccaaat
cgtcatttct
2109
gaaagataa
SeqID
96 ttaaagaact cggtgccttg60
atgggaagattttagagagt
a~.a~.aagctc
tcatcctaca
gggaccgagcttgagagtagaggttgtgat agacaaatat120
gtttetggta
aactttggtc
ctgattgaggatccagcagctattcagaccattcatgaag tgctggcgct180
attatatteg
gatattgtgaegacatcaacttatcaggcgactttacaag agttggtgtc240
ggctagctca
tctgaaagtcaggcagaagacttgattcgcttgactgttcagttggcaaaagctgtgcgt300
gagcaagtttggaaaagtttgacaaaagaagaaaaatcagaaagaatctatcctttgatt360
tctggggatgttggtccctacgetgcctttttggcggacggttctgagtacacagggctc420
tacgatatttataaggaaggtctcaaaaatttccatcgccatcgtattgagcttctttta480
gatgagggtgttgacettctggcacttgaaaccattccaaatgctcaggaggctgaggct540
cttattgagctacttgtcgaggatttccctcaggttgaggcttatatgtcattcacctct600
caagatggtaagaccatctcagatggtagtgctgttgcaggcttggcgaaagctattgat660
gttagcccacaggtcgtggcgctgggcattaactgttcaagtccatcgttagttgctgat720
ttcttgcaagcaatagcagagcagacggacaagcctcttgtgacctatecaaactctgga780
gagatttatgatggggcaagccaatcttggcaatctagccgagatcattcacacacccta840
cttgaaaatacaagtgactggcaaaaacttggcgcccaagttgtcggaggttgttgccga900
actagaccagctgatattgctgacctctcagaacatttgacataa 945
SeqID
97
atgaaaataggaattgataagattggttttgcaaccagtcaatatgtccttgaaatgact60
gatttggctattgctcgecaagttgaccctgaaaaattcagcaagggattattgttagat120
tcacttagtattacgccagttacagaagatatcgttacacttgcagcctctgcagctaat180
gatattttatctgatgaggacaaagaaactattgatatggtgattgtcgctacagaatca240
agtatcgatcagagtaaggcggcttctgtctatgtacatcaacttttagagattcaacct300
ttcgcaaggtcattcgagatgaaagaagcatgctatagcgcaactgetgctcttgattac360
gctaaattacatgtagaaaaacatccagattctaaagtattagtgatagcttcagatatt420
gctaaatatggcattaaatctactggagaatccactcaaggtgcaggcagtatcgctatg480
cttattagtcaaaacccatccattetagagctaaaagaggaccgtctagcgcaaacccgt540
gatattatggacttttggcgaccaaattattctgatgttccttatgttaatggcatgttt600
tcaacaaaacaatatctagatatgctaaaaactacttggaaagaatatcaaaaacgtttt660
aatactagtctaagtgactatgctgetttttgtttccatatcccttttccaaaattagct720
ttaaagggctttaataaaattctagataataacctagatgaacaaaagaaagctgaacta780
caagaaaattttgagcactctattacttatagtaagaaaattggaaattgctatactggc840
tcattgtatctaggacttctatcgttactagaaaatagtcaaaatttaaaagcaggtgat900
caaattgccttcttttcatacggtagcggagctgttgctgaaatttttaceggtcagtta960
gtagacggctaccaaaataaacttcagagcgatcgtatggatcaactcaataaacgtcaa1020
aaaattacagtaactgagtatgagaaactcttctttgaaaaaacaatcctagacgaaaat1080
ggaaatgccaacttcaacacctaccgtactggcactttttctctagactctatttgcgaa1140
catcaacgtatctacaagaaaattaataattaa 1173
SeqID
98
atgaaaagtgcttatatcttttttaatccaaaatetggtaaagatgaacaagcattggca60
caagaagtaaaatcttatttaatagaacatgattttcaagacgattatgttegtatcatt120
acaccttcatctgttgaggaagctgtcgccttagcaaaaaaagcatcagaagaccatatc180
gacttggttattcctttagggggagatggcactattaataaaatctgtggtggtgtctac240
gctggtggtgcttatcctactatcggactagtacctgccgggaccgtcaataacttttca300
aaagctttgaacatcccacaagagaggaatctcgctcttgaaaaccttctaaacggtcat360
gtaaagtccgtagatatctgtaaagttaacgacgattacatgattagcagtttaacactt420
gggctccttgctgatattgctgctaatgtcacttctgaaatgaagcgtaaattaggacct480
tttgctttcgtaggtgatgcctaccgtatattaaagegtaatcgatcatattctattact540
cttgcttacgataataatgtacggtctttacgcacgcggttactacttattaccatgacc600
aattcgattgccggtatgccagccttctctccagaagcaacaattgatgatggacttttt660
agagtctacactatggaacatattcacttcttcaaattattgttgcatctaagacaattt720
cgtaagggagattttagtcaagcaaaggagataaaacattttcataccaataatctgact780
atttcaacttttaaacgtaaaaaatcagctatccctaaagttcgtattgatggcgatcca840
ggtgaccaattgcctgtaaaagttgaagtcatccctaaagccttaaagtttatcattcct900
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
43/109
aactcattac cataa 915
SeqID
99
atgacaacatttactgctaaatttattgaccaagagtgggaagtcccagtagaatcaggt60
cgctaccatatgattgttggggaattttgtccttatgcacaacgtccgcagattgcacgc120
caactgcttggtttggataaacatatttctatcagttttgtggatgatgttccaagtgat180
ataggacttatttttagccaaccagaacaggttactggtgctaagtcgcttcgtgatatt240
tatcatttgactgaccegacctacaaaggtccttatactatcccaattttaattgacaag300
actgataatcgtattgtctgtaaggaatctgcagatatgcttcgactttttactacagat360
ttetctgatttgcatcaagaggatgctcctgtccttttcagccaagaaactgcttcactt420
attgataatga.tattaaagacattaataataacttccaaagctta.atgtataagttagct480
tttcttgataaacaagcagattatgatacttatagtaaggaattcttcacttttctagat540
caaaaagaa.cacttactaggacaacgtcctttcttgctcggagataatctaagtgaggtt600
gatattcatttctttacaccattagtccgctgggatattgctgggcgtgatcttctacta660
cttaatcagaaagcgctagaagactacccaaatattttttcttgggctaaaactttatac720
aatgactttaatttaaaaacattaaccaatccacaatccataaaaaataactattactta780
ggcaaatttggaagagctgttcgtcatcataccatcgtaccaacaggtccaaatatggta840
aaatgggaaaaataa 855
SeqID
100
atgaaaaagaaaattattttgaaaagtagtgtccttggtttagtcgctgggacttctatt60
atgttctcaagegcattcgctgaccaagtcggcgtccaagttataggcgtcaatgacttt120
catggtgcacttgacaatactggaacagcaaatatgcctgacggaaaagttactaatgct180
ggcactgctgctcaattagatgcttatatagatgatgctcaaaaagatttcaaacaaact240
aaccctaatggtgaaagcattagagttcaagctggtgatatggttggagcaagtccagct300
aactcagggcttcttcaagatgaaccaaccgttaaaacatttaatgcaatgaatgttgag360
tatggcacattaggtaaccatgaatttgatgaaggtttggcagaatacaatcgtatcgtt420
actggaaaggcccctgctccagattctaatataaataatattacgaaatcatacceacac480
gaagctgcaaaacaagaaattgtagtggcaaacgttattgataaagttaacaaacaaatc540
cettacaattggaaaccttacgctattaaaaatattcctgtaaataacaaaagtgtgaac600
gttggctttatcggaatcgttaccaaagacatcccaaaccttgtcttacgtaaaaattat660
gaacaatatgaatttttagatgaagctgaaacaatcgttaaatacgecaaagaattacaa720
gctaaaaatgtcaaggctattgtagtccttgctcatgtacctgcaacaagcaaggatgat780
attgctgaaggtgaagcagcagaaatgatgaaaaaagtcaatcaactcttccctgaaaat840
agcgtagatattgtctttgctggacacaatcatcaatatacaaatggtcttgttggtaaa900
actcgcattgtacaagcgctctctcaaggaaaagcctatgctgacgtacgtggtgtccta960
gatactgatacacaagatttcattgaaaccccttcagctaaagtagttgcagttgctcct1020
ggtaaaaaaacaggtagtgccgatattcaagecattgttgaccaagctaatactatcgtt1080
aaacaagtaacagaagctaaaattggtactgccgaggtaagtggcatgattacgcgttct1140
gttgatcaagataatgttagtccagtaggcagcctcatcacagaggctcaactagcaatt1200
gctcgaaaaagctggccagatatcgattttgccatgacaaataatggtggcattcgtgct1260
gacttactcatcaaaccagatggaacaatcacctggggagctgcacaagcagttcaacct1320
tttggtaatatcttacaagtcgtcgaaattactggtagagatctttataaagcactcaac1380
gaacaatacgaccaaaaacaaaatttcttccttcaaatagctggtctgcgatacacttac1440
acagataataaagagggcggagaagaaacaccatttaaagttgtaaaagcttataaatca1500
aatggtgaagaaatcaatcctgatgcaaaatacaaattagttatcaatgactttttattc2560
ggtggtggtgatggctttgcaagcttcagaaatgccaaacttctaggagccattaatccc1620
gatacagaggtatttatggcctatatcactgatttagaaaaagctggtaaaaaagtgagc1680
gttccaaataataaacctaaaatctatgtcactatgaagatggttaatgaaactattaca1740
caaaatgatggtacacatagcattattaagaaactttatttagategacaaggaaatatt1800
gtagcacaagagattgtatcagacactttaaaccaaacaaaatcaaaatctacaaaaatc1860
aaccctgtaactacaattcacaaaaaacaattacaccaatttacagctattaaccctatg1920
agaaattatggcaaaccatcaaactccactactgtaaaatcaaaacaattaccaaaaaca1980
aactctgaatatggacaatcattccttatgtctgtctttggtgttggacttataggaatt2040
gctttaaatacaaagaaaaaacatatgaaataa 2073
SeqID
101
atggcatatatttggtcttatttgaaaaggtaccccaattggttatggcttgatttacta60
ggagctatgctttttgtgacggttatcetaggaatgcccacagccttagcgggtatgatt120
gataatggcgttacaaaaggtgatcggactggagtttatctgtggacgttcatcatgttt180
atatttgttgtactaggtattattgggcgtattacgatggettacgcatctagtcgctta240
acgacaacaatgattagagatatgcgtaatgatatgtatgctaagcttcaagaatactcc300
catcatgaatatgaacagataggtgtatcttcactagtgacacgtatgacaagcgatact360
tttgttttgatgcaatttgctgaaatgtctttacgtttaggcctagtaactcctatggta420
atgatttttagcgtggttatgatactaattacgagtccatctttggcttggcttgtagcg480
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
44/109
gttgcgatgcetcttttggtaggagtcgttttatatgtagctataaaaacaaaacettta540
tctgaaagacaacagactatgcttgataaaatcaatcaatatgttcgtgaaaatttaaca600
gggttacgcgttgttagagcctttgcaagagagaattttcaatcacaaaaatttcaagtc660
gctaaccaacgttacacagatacttcaactggtctttttaaattaacagggctaacagaa720
ccacttttcgttcaaattattattgcaatgattgtggctatcgtttggtttgctttggat780
cccttacaaagaggtgctattaaaataggggatttagttgcttttatcgaatatagcttc840
catgctctcttttcatttttgctatttgccaatctttttaetatgtatcctcgtatggtg900
gtatcaagccatcgtattagagaggtgatggatatgccaatctctatcaatcctaatgcc960
gaaggtgttacggatacgaaacttaaagggcatttagaatttgataatgtaacattcget1020
tatccaggagaaacagagagtccegttttgcatgatatttcttttaaagctaagcctgga1080
gaaacaattgcttttattggttcaacaggttcagga.aaatettctcttgttaatttgatt1140
ccacgtttttatgatgtgacacttggaaaaatcttagtagatggagttgatgtaagagat1200
tataaccttaaatcacttcgccaaaagattggatttatcceceaaaaagetettttattt1260
acagggacaataggagagaatttaaaatatggaaaagctgatgctactattgatgatctt1320
agacaagcggttgatatttctcaagctaaagagtttattgagagtcaccaagaagccttt1380
gaaacgcatttagctgaaggtgggagcaatctttctgggggtcaaaaacaacggttatct1440
attgctagggctgttgttaaagatecagatttatatatttttgatgattcattttctgct1500
ctcgattataagacagacgctactttaagagcgcgtctaaaagaagtaaccggtgattct1560
acagttttgatagttgctcaaagggtgggtacgattatggatgctgatcagattattgtc1620
cttgatgaaggcgaaattgtcggtcgtggtacccacgcteaattaatagaaaataatgct1680
atttatcgtgaaatcgctgagtcacaactgaagaaccaaaacttatcagaaggagagtga1740
SeqID
102
atgaaaaaaggacaagtaaatgatactaagcaatcttactctctacgtaaatataaattt60
ggtttagcatcagtaattttagggccattcataatggtcacaagtcctgtttttgcggat120
caaactacatcggttcaagttaataatcagacaggcactagtgtggatgctaataattct180
tccaatgagacaagtgcgtcaagtgtgattacttccaataatgatagtgttcaagcgtct240
gataaagttgtaaatagtcaaaatacggeaacaaaggacattactactcctttagtagag300
acaaagccaatggtggaaaaaacattacctgaacaagggaattatgtttatagcaaagaa360
acegaggtgaaaaatacaccttcaaaateagccecagtagctttctatgcaaagaaaggt420
gataaagttttctatgaccaagtatttaataaagataatgtgaaatggatttcatataag480
tctttttgtggcgtacgtcgatacgcagctattgagtcactagatccatcaggaggttca540
gagactaaagcacctaetcctgtaacaaatteaggaagcaataatcaagagaaaatagca600
acgcaaggaaattatacattttcacataaagtagaagtaaaaaatgaagctaaggtagcg660
agtccaactcaatttacattggacaaaggagacagaattttttacgaccaaatactaact720
attgaaggaaatcagtggttatcttataaatcattcaatggtgttcgtegttttgttttg780
ctaggtaaagcatcttcagtagaaaaaactgaagataaagaaaaagtgtctcctcaacca840
caagcccgtattactaaaactggtagactgactatttctaacgaaacaactacaggtttt900
gatattttaattacgaatattaaagatgataacggtatcgctgetgttaaggtaccggtt960
tggactgaacaaggagggcaagatgatattaaatggtatacagctgtaactactggggat1020
ggcaactacaaagtagctgtatcatttgctgaccataagaatgagaagggtctttataat1080
attcatttatactaccaagaagctagtgggacacttgtaggtgtaacaggaactaaagtg1140
acagtagctggaactaattcttctcaagaacctattgaaaatggtttagcaaagactggt1200
gtttataatattatcggaagtactgaagtaaaaaatgaagctaaaatatcaagtcagacc1260
caatttactttagaaaaaggtgacaaaataaattatgatcaagtattgacagcagatggt1320
taccagtggatttcttacaaatettatagtggtgttcgtcgctatattcctgtgaaaaag1380
ctaactacaagtagtgaaaaagcgaaagatgaggcgactaaaccgactagttatcccaac1440
ttacctaaaacaggtacctatacatttactaaaactgtagatgtgaagagtcaacctaaa1500
gtatcaagtccagtggaatttaattttcaaaagggtgaaaaaatacattatgatcaagtg1560
ttagtagtagatggtcatcagtggatttcatacaagagttattccggtattcgtcgctat1620
attgaaatttas 1632
SeqID
103
atggaaaattggaagtttgccctatcatcgattetagggcacaagatgcgtgcttttctg60
accatgttagggatcatcattggggttgcatcagttgtgttaattatggccttaggtaag120
ggcatgaaagattcggttacaaatgagattacaaagtctcagaagaaccttcagatttat180
tataaaacaaaagaagaccaaaaaaatgaggataactttggagctcaaggggctttCatg240
caaggtagtgataccaaccgtaaggaaccaattattcaagaatcatggttaaaaaagatt300
gctaaggaagtagatggtgttagtggctactatgtaaccaatcaaacaaatgctccagta360
gcttaccttgaaaaaaaggcaaagacggttaatataacaggagttaaccgcacttacctt420
ggtatcaaaaagttcaaaattaaaagtggtcgtcaattccaagaggaggattataaccaa480
ttctcgagagttattttactagaagaaaaattagctcagagattattccagacaaatgaa540
gcagcgttaaataaggtggtgactgtaaaaaataaatcttacttagtagtgggggtttat600
tcggatecagaagctggttcaggcttatatggaagtaattctgatgggaatgctatttta660
accaatacacagttagcttcggagtttggtgctaaagaagcagaaaacatatattttcat720
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
45/109
cttaatgatgtatcgcaatccaatcgcattggtaaagaaataggcaaacgtttaacagae780
attagtcatgctaaggatgggtactatgataattttgacatgacatctatagttaaatct840
atcaatacccaagttggtattatgacaggtgttattggagcgattgcagcaatttctctc900
ctagttggtggtatcggagtgatgaatattatgttagtctctgtaactgagcgcacgaga960
gaaattggccttcgtaaagcccttggggcaactcgacgtaaaattttagctcaattttta1020
attgaatcaatggtcttaacgattttgggtggattaattgggttattactagcctatgga1080
ggtacgatgttaattgctaatgcgcaagataagattactccttctgtgtcacttaacgtg1140
gctataggcagtttaattttctcagcatttattggaattatatttggtttattacctgct1200
aataaagccagcaaattaaacccaattgatgctttacgatatgaataa 1248
SeqID
104
atgcagtattcagaaattatgattcgttatggagaaetctctactaagaagaaaaaccgt60
atgcgcttcateaataagttaaaaaataatatggagcatgtactctccatttatccagat120
gtttcagtaaaaacagatcgtgatagaggacatgtatatctcaatggtacagattatcat180
gaagttgcagagtccttaaaagagatttttggtatccaagctttttctccatettttaaa240
gtagaaaaaaatgttgatacattggtaaaagctgtccaggaaattatgacttccgtttat300
aaagatgggatgacttttaaaattaccgcaaaacgtagtgaccactcatttgaattggat360
agccgtgctctaaatcatactttaggagatgccgttttttcagtcttgccaaatattaag420
gctcagatgaagcaaccagatatcaatcttaaagtcgagatacgagatgaggctgcttat480
atttcatatgagaatattaggggtgcaggaggattaccggtaggaacatctggaaaaggg540
atgctgatgttgtctggtgggattgattctccggtggcaggttacctagcgttaaaacgt600
ggtgtagatatagaagcagttcattttgcaagtcctccttatactagcccaggtgcattg660
aaaaaagcacatgatttaacacgtaaattgacaaaatttggtggtaatattcaatttatt720
gaagttccattcacagaaattcaagaggaaattaaggaaaaagctcctgaagcctacttg780
atgacgttaacacgtaggtttatgatgcgtattacagatcgtattcgtgagaaccgaaat840
ggtcttgttattattaacggtgaaagtttagggcaggtggcaagccaaacgctagaaagt900
atgcaagccattaatgctgtcactgcaacaccgattattcgtcctgtggtcacgatggat960
aagctagaaattattgatattgctcaaaaaatagatacttttgatatttcaattcaacca1020
tttgaggattgctgtacgatttttgcaccagatcgcccaaaaactaaccctaaaattaag1080
aatacagaacagtatgagaaacgtatggatgtagaaggtctggtagagagggcagttgca1240
gggattatggtaactactattcaacctcaagcagatagtgatgatgttgatgacttgatt1200
gacgatttattataa 1215
SeqID
105
atggctcgtgttaaaggtggagttgtttcacgtaaacgtcgtaaacgcgtacttaaatta60
gctaaaggttactatggtgcaaaacatatcttgttccgtactgcaaaagaacaagtaatg120
aattcttactactatgcataccgtgaccgtcgtcagaaaaaacgtgacttccgtaaatta180
tggatcactcgtatcaatgcggctgctcgtatgaatggtttatcatattcgcaattgatg240
cacggtttgaaattagctgaaatcgaagttaaccgtaaaatgcttgctgatttagcagtt300
aacgatgcagcagctttcacagctcttgcagatgcagctaaagctaaacttggtaaataa360
SeqID
106
atgtttaaagcttcaaaaaaactcgttcaaaaaaataagtcaaatcatttttggcttgtt60
tttttcataacacttatactatttcttattggttgttacgccagcttacgatttggtgct120
atcaatttcaagactagtgatttaataactgttttaaaaaatcccttaaaaaactctaat180
gctcaggatgttatttttgacattagactaccacgcataattgcagctatcttagtaggt240
gcagctatgtcacaagcaggtgctattatgcagggagtcactcgaaacgccattgctgat300
cctggactactaggtattaacgccggagctgggttagcccttgttgttgcatatgctttt360
ttagggagcatgcactatagtacgattctcattgtctgcttactagggtctgtcatttct420
tatcttttagtcttcacactctcttatacaaagcaaaagggttaccaccaactacgactc480
attttagctggagcgatgatctccacactttttacgtctgttggacaagtggttacatta540
tactttaaactcaatcgaactgttatcggttggcaagcaggtggtttatcccaaattaac600
tggaaaatgctaatcataatagcacctatcattattttaggtttacttatttcacaactc660
ctagcacatcaattaactatcttgagccttaatgaatctgtggccaaagcattgggacaa720
aaaactcaattaatgactgcgtttctattacttattgttttgtttttatcggcttcatca780
gtcgcgttgataggaaccgtttctttcattggattgattattccacattttattaagctt840
tttattcccaaagattatcgtctgttattacctttaataggattttcaggggctactttc900
atgatctgggtagacttatcatctcgtattataaatcccccttcagagacaccaattagt960
tctataatcagtatogtagggcttccatgtttcctatggttaattagaaaagggaaaaat1020
ctatga 1026
SeqID
107
atgattaaaagaccaattcatctttctcatgattttttagcagaagttattgataaagaa60
gcaataacgcttgatgcaactatgggaaatgggaatgatactgtttttttagcgaaaagt120
tctaaaaaagtttatgcatttgatattcaagaagaagcaatagcaaaaacgaaagcaaag180
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
46/109
ctcacggagcaagggatttctaacgetgaacttatettggatgggcatgaaaatttggaa240
cagtatgttcatacacctttaagagcggctatatttaatctgggatacttaccctcageg300
gataaaacagttattacaaaacctcacacaactatcaaggcaatcaaaaacgttttagac360
attttagaagtaggtggacgtctatcacttatggtttattatggtcatgatggtggaaaa420
agtgagaaagatgcggtgatagcattcgtggaacaattaccacagaataatttcgctaca480
atgctttatcaaccactcaatcaagttaatacgcccccctttttaattatggtagaaaag540
ttacaatcatatgaaaatgaggtgtaa 567
SeqID
108
atgcgagtacatattacaagtatatatgggcagtcaccgcgtagcattgcccttatatca60
caaaaactagttaaggatgtcggacgtcaaCttggttatgatgaaatgggaatctacttt120
tataatgatcatgctgaaacgcatggtgaaagaagtactaggatggatggtatcattgcg180
ggattaggcagaggggatattgttgtttttcaagtacctacatggaattcaacagaattt240
gatgaactttttctagataaattacaggcatacggtgctagaattataacttttgtacat300
gatattgttcccttaatgtttgagtctaatttttatttattagatagagtaattgacatg360
tataatcgttcggatgttgttattctacctacaaaagcgatgcatgattatctaattgaa420
aaagggatgactacctctaaagttctttatcaagaagtatgggatcatccagttaatata480
gacctccctcgtccagaatgtcaaaaa.gtccttagttttgcaggcgatattcaacgcttt540
ecctttgtcaatgactggaaggaaaatatcccgctcatctattatggagacggaagcaga600
ctcaattctgaggcaaatgttcatgctcagggatggaaagatgatgtagaattgatgcta660
agtctttctaagcggggaggatttggcctgtgttggagtgaagatagagaggagttagtc720
gagegtcgttattcgaggatgaatgcctcgtataaattatctactttcttggctgctgga780
cttccaattattgctaaccatgatatttcaagtagagactttatcaaacaacacggatta840
ggatttacagttgaaacgctagaagaagctgttgaaaaaattaataatatggaaaaagag900
acttatgacagctatgtggaaaatgttgagaagatagcaactctcttgcgaaatggttat960
atcactaaaaaattgttgatagatgctgtgcatatgctttatagatag 1008
SeqID
109
atgtcccaaaagacttttggcaagcagttaacagttgtagatactaagagtagagtcaag60
atgcataaatcaggaaaaaactgggtaagaacagtaatgtcgcattttaatctatttaaa120
gcgattaaagggagagcaactgttgaagcagatgtgtgtattcaagatgttgaaaaagaa180
gaccgactatcttcaggaaatttgacctatctcaaaggaatactagctgccggagctctg240
gtaggtggagcgagtttaaccagtcgtgtttatgcagatgagactecagttgttcaagaa300
caatcaagttctgtaccaacactggcagaacaaacggaagtgactgttaaaacaactact360
gttcaaaatcatcaagatgggacagtatcgaaaaacattattgattctaatagtgtatct420
atgtcagagtcagcctcaacaagtactagtgaatctgtaagtatgtctatgtcagggtca480
actttaacaagtgtaagtgaatctgtaagtacatctgctttaacaagtgcttcagaatcg540
ataagcacgtcagcctcagaaagtgtttcaaaatctacaagtattagtgaggtttcaaat600
attcttgaaactcaagcttctttaactgataaaggaagagagtcgttttcggcaaaccag660
atagtaacagaaagtagcttagttactgatgctggtaaaaatgcttcagtatctagccta720
attgaaattacaaaaccaaaatcggagttacagacttccaaaatgtcaaatgagtcgctt780
ataactccagagaaatcccaagtaatgattgcaagcgataaaactgggaatgagagtcta840
actccgacaattagattaaaatcagttattcagccaaggagtatgaacttgatgactttg900
agttcggagatggacttgataccactagaagaagtgtctgatactgaaatgttaggtaaa960
gatgtatcaagcgagttgcagaaagttaatattgcgttaaaagataacactcttagtgag1020
cctggaacagttaaattagatagttcagaaaaccttgttttgaactttgccttttcaatc1080
gcttctgttaacgagggagatgtctttactgtaaagctttctgataaccttgacacacaa1140
gggattggtactattctaaaagttcaagatataatggatgaaacggggcagttattagcg1200
actgggtcatatagtcctttaacacataatattacatacacctggacaaggtatgcttet1260
acgttgaataatattaaagctagagtcaatatgccagtttggcctgaccagagaataatt1320
tctaaaacaacttcagataagcagtgctttactgcaacattgaacaatcaagttgcttca1380
attgaggaacgtgttcagtataatagtacttcagtgacagaacatactaatgttaagaca1440
aatgtaagatctcggatcatgaagcttgatgatgaaagacagacagaaacttatattact1500
caaattaatcctgaaggtaaggaaatgtatttegcatcaggacttgggaatctatatact1560
attateggttcagatggaacatcaggttcaccagttaatttattaaatgcggaagtaaag1620
attctaaaaactaattcaaaaaatcttacagatagtatggatcaaaattatgattcgcct1680
gagtttgaagatgtgacttcccagtatagttatactaacgatggttctaaaattaccata1740
gattggaaaacaaattctatttcttccactacatcttatgttgttttggtcaaaatacet1800
aaacaaagtggtgtattgtattcaactgtttctgatataaatcaaacatatggttctaaa1860
tattcttatgggcatacgaatataagtggtgactcagatgcgaatgccgaaattaaactt1920
ttatcagaaagtgcttctacgagtgcgtcgacgtcagcaagtaccagcgcttccatgagt1980
gcctcgacatcagcaagtaccagegettccatgagtgcctcgacatcagcaagtaccagc2040
gcttccatgagtgcgtcgacgtcagccagcaccagcgcttcaaccagcacctcaacgagt2100
gcctegacatcagccagcacaagtgcttcaacaagtgcaagtatgagtgcttcaacaagt2160
gcaagtacgagtgcatccacgtcagcaagtactagcgcttccacaagtgccagcaccagc2220
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
47/109
gcctcaacgagtgcctcaacgtcagccagcactagcgectcaacgtcagccagcaccagc2280
gcctcaaceagtgcttcaaccagtgcttccacatcagccagcactagcgcctcaatgagt2340
gcgtcgatgtcagccagcacaagtgcttcaatgagtgcctcgacgtcagccagcactagc2400
gcctcaaceagtgcttcaaccagtgcttcaaecagtgcttccacctcagcaagtatgagc2460
gcctcaacaagtgcaagtactagcgcttcaacaagtgcaagtatgagcgcctcaaccagt2520
gcaagtactagtgcttcaacaagtgccagtaccagtgcctcgacgtcaacaagtactagc2580
gettccacgtcagcaagtaccagtgcatccacatcagcaagtatgagcgcatccacgtca2640
gccageaccagcccctca.accagtgcttcaaccagtgcttcaaccagtgcttcaaccagt2700
gcttccacatcagccagcactagcgcctcaatgagtgcatccacgtcagcaagtactagc2760
gcctcaatgtcagccagtactagcgcctcaaccagtgccagtaccagtgcttccacctca2820
gcaagtatgagcgcctcaacaagtgcaagt~.ctagcgCttccacaagtgcaagtatgagc2880
gcctcaaccagtgcaagtactagtgcttcaaccagtgccagtaccagtgcctcgacgtca2940
acaagtactagcgcttccacgtcagcaagtaccagtgcatccaeatcagcaagtatgagc3000
gcatccacgtcagcaagtaccagtgcatccacgtcagcaagtatgagcgcctccacaagt3060
gcaagtatcagtgcatccacgtcagcaagtatgagcgcttccacaagtgcaagtaccagt3120
gcatcgacgtcagccagtactagcgcctcaatgagtgcatcgacgtcagccagcaccagt3180
gCttCCaCaagtgCaagtaCtagCgCCtCaatgagtgCatCgaCatCagCaagtaCCagC3240
gCttCCaCaagtgC~.~.gtaCgagtgCttCCaCatCagCaagtactagcgcctcaacateg3300
gcaagtacaagttcttccacaagtgcaagtaccagtgcatcgacateagccagcactagc3360
gcctcaatgagtgcctcgacgtcagccagcacaagtgcttccatgagtgcgtcgacgtca3420
gccagcactagcgcctcaacgagtgcgtcaatgtcagccagcacaagttcttcaacaagt3480
gcctcgatgtcagccagcactagcgcttcaatgagtgcctcgacgtcagctagcactagc3540
gcctcaacgagtgcgtcaatgtcagccagcacaagttcttcaacaagtgcctcgatgtca3600
gccagcactagcgcttcaatgagtgcgtcgacgtcagccagcaccagcgcttcaacgagt3660
gcgtcaatgtcagccagcactagcgcttcaatgagtgccacgacgtcagccagcaccagc3720
gtctcaacgagtgcatcgacatcagcaagtaccagcgcttccacaagttcttcaagctca3780
gtgacttctaattcatcaaaagagaaggtgtattctgccttaccttctacgggtgaccaa3840
gattattctgtaactgctactgccttaggtttaggtttaatgactggtgcaacccttttg3900
ggacgaaaaaaatctaaaaaagataaagactaa 3933
SeqID
110
atgatagatagaaaagatactaaccgatttaaattagtttccaaatatagcccttcggga60
gatcaacctcaagctattgaaacgttggttgacaatattgaaggaggagaaaaagctcag120
attttaaaaggtgctactggtactggtaaaacctacacaatgagccaagttatcgcccaa180
gttaacaagccaaccttggtgattgcacataataaaaccttagcaggtcaactttatgga240
gagtttaaagaattttttcctgacaatgccgtagagtactttgtttcatattatgattat300
tatcaaccagaagcttatgtgccttcttcggatacttatattgaaaaagatagttcagtc360
aatgacgaaattgacaaattacgtcactcagcgacttcttcgttattagaaagaaatgac420
gttattgttgtagcatctgtttettgtatttacggtttaggttetectaaagagtatgca480
gacagtgttgttagccttaggccaggtcaagaaatttcacgtgatcagttattgaacaat540
ctcgttgatattcaatttgagcgtaacgatattgattttcaacgtggaaaatttcgcgtt600
cgtggcgatgttgtagaagtttttcctgcgagtcgtgatgagcatgcctttcgaattgaa660
ttttttggtgatgaaattgatcgtataagagaaatagaatcgttaacagggcgtgtgcta720
ggagaagtggaacatttagctattttcccagcaacacactttatgacaaatgatgaacat780
atggaagaagctatttcaaaaatacaagctgaaatggaaaatcaagtagaactttttgaa840
aaagaagggaaattgattgaagcgcaacgtattcgacaaaggacagaatatgatattgaa900
atgcttcgtgaaatgggatatacaaatggtgttgagaactactcacgtcacatggatggt960
agaagtgaaggtgagccaccttttactttgttagatttcttcccagaagattttttgatt1020
atgattgatgagagtcacatgacaatggggcaaatcaaagggatgtataatggagaccgt1080
tcgcgtaaagaaatgttggttaattacggtttccgtttaccatctgccttagataaccgt1140
ccacttcgtcgtgaagaattcgaaagccatgtccatcaaattgtctatgtatetgcaacg1200
ccaggagactatgaaatggagcaaacagatacagttgttgagcaaattatccggecaaca1260
ggacttcttgatccagaagttgaagttagaccaagtatggggcagatggatgacttgctt1320
ggtgaaatcaatttgaggactgaaaaaggtgagcgtacctttattacaacattgacaaag1380
cgtatggcagaagacttaacagattatctcaaagaaatgggagttaaagttaagtatatg1440
cacagcgatattaaaaccttagaacgtacagagattattcgtgatttacgacttggtgtg1500
tttgatgttttaattggtattaatctcttacgtgaaggaatagatgttcctgaggtttcc1560
cttgttgcaatcttagatgctgataaggaaggtttccttcgtaatgagcgtggtcttatc1620
caaacaatcggacgtgcagcacgtaacagtaatggtcatgttattatgtatgctgataaa1680
ataacagattctatgcaaagagctatggatgaaacegctcgccgtcgtcgtttacaaatg1740
gattataatgaaaagcatggaattgtgccacaaacaattaaaaaagaaatccgtgattta1800
attgctattactaaaagtaatgacagegataagcctgaaaaagttgtcgattacagtagt1860
ttatctaaaaaagaaaggcaagctgaaattaaagctcttcaacagcaaatgcaagaagca1920
gctgaattattggactttgagctagctgcacaaatccgagatgttatcttagaactaaaa1980
gcaategattas
1992
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
48/109
SeqID
111 agttaaaagcttttacgcttgctttactctcaatattetttgtgtttggt60
atgaagcaca
ggaaaggtcagtgcagaaactgtgaatattgtttctgatacagcatacgctccattcgaa120
tttaaagattctgatcaaacttataaaggaatcgatgttgacatcgttaacgaagtcgct180
aagcgtgctggctggaatgttaacatgacgtacccaggttttgatgccgcagttaacgct240
gttcaatctggacaggcagacgcgctaatggccggaactactgttactgaagcacgtaaa300
aaagtctttaatttctcagatacttattacgatacttccgttattctttatactaaadat360
aataataaagtcacaaactacaaacaactaaaaggaaaagtagtcggtgtaaaaaatg~ga420
acagCtgctcaaagcttcttagaggaaaataaatctaaatacggctataaagttaaaa.ca480
tttgatacaagtgacctaatgaataacagCcttgattctggttctatttacgccgcta.tg540
gacgatcaaccagttgtgcaatttgcgataaatcaaggaaaagcttacgccattaacatg600
gaaggcgaggcagttggtagctttgcatttgetgtcaaaaaaggtagtggacacgataac660
ctaattaaagaatttaacacagcttttgcacaaatgaaatcagatggcacttataatgac720
atcatggataaatggcttgggaaagacgctacaaaaacaagcggcaaagcaacaggtaat780
gccaatgaaaaagcaactcctgtaaagccaagttataaaattgtttctgattcttcattc840
gcaccattcgaatatcaaaacggtaaagggaaatatactggttttgatatggaattaatc900
aagaaaattgctaaacagcaaggttttaaacttgatatctcaaatccaggttttgatgcc960
gctttaaatgctgtccaatctggacaagctgacggtgttattgcaggagctacaatcaca1020
gaagcacgccaaaaaatctttgatttttctgatccttattacacatctagcgttatctta1080
gcggttaaaaaaggaagcaatgtcaaatcataccaagatttaaaaggaaaaacagttggt1140
gctaaaaatggtactgcctcatatacttggttatcagaccacgcagataagtacaactat1200
catgttaaagcatttgatgaagcatctacaatgtatgatagtatgaactcaggttcaatt1260
gatgctctaatggatgacgaagcagttcttgcttacgctattaatcaaggtcgtaaattt1320
gaaacacctatcaaaggtgaaaaatcaggcgatatcggatttgcagtgaaaaaaggggca1380
aatccagaattaattaaaatgtttaacaacggtcttgcttcactcaaaaaatcgggtgag1440
tacgataaacttgttaaaaaatacctttccacagccagcacctcttcaaacgataaagct1500
gctaaacctgtagatgaatcaactattttagggttaatttctaataactacaaacaattg1560
ctatctggtattggaactactttaagtttaactcttatctcatttgcgattgctatggtt1620
attggtattatctttggtatgatgagcgtatcaccaagtaatactctccgcacaatttca1680
atgatttttgttgatattgtccgtggtattccactcatgattgtggccgcttttattttc1740
tggggtattcctaatttaatcgaaagcatcacaggtcaccaaagtccaattaatgacttc1800
gttgctgetactatcgctctttctttaaatggtggtgcgtacattgctgaaattgtacgt1860
ggtggtattgaagctgttccttctggtcaaatggaagcaagtcgtagtttaggtatttct1920
tacggcaaaactatgcaaaaggttatcttgcctcaagcagtacgccttatgttaccaaac1980
tttatcaaccaatttgtcatctcattaaaggatacaacaattgtatcagcaatcggactt2040
gtggaactcttccaaactggtaaaatcataattgcacgtaactatcaatcattccgtatg2100
tatgctatccttgcaattatgtatcttgtaatcattacccttctcacccgtctagcaaaa2160
cgtttagaaaagaggcttaaataa 2184
SeqID 112
atgggagata aaccgatatc atttcgtgat aaagatggga attttgtttc agcggccgat 60
gtctggaatg ctgaaaaatt agaagaactc tttaacacat taaatcctaa tcgtaaactt 120
cgtttagaac gcgaaaaatt agcaaaagaa aaaggatag 159
SeqID
113
atggaaacatatactctatcgaatactcttaacattcctaaaattggttttgggacatgg60
caactaactgaaggtgaagaagcttataaggcagtgactcatgctttaaaagttggttat120
actcatattgatactgctcagatttatggcaacgaacacagtgttggacgtgctataaga180
gacagtggtttggcgcgagaaagtatctttttgacaactaagatttggaatgacaaacat240
gactatcatttagccaaagcttctattgatgaatctctgcagaaattaggtgttgattat300
attgatcttcttttgattcattggecaaatccaaaagctcttcgtgaaaatgatgcgtgg360
aaagctgggaatgcaggcacttggaaagcgatggaagaagcttataaagaaggaaaggta420
aaagctattggtgtttcgaatttcatgaaacatcacttagaggctttatttgaaactgcc480
gaaataaaacctatggttaatcaaattatcctagcaccaggttgtgctcaagaggatttg540
gttcgcttctgtaaaggaaatgatatcttattagaagcttacagtccatttggaacaggt600
gctatttttgaaaatgaatetataaaagctattgctgaaaaatatggtaaatcagttgca660
caagtagctcttcgctggtcacttgataatggctttttaccattacctaagtcagcgact720
cccaaaaatattgaagcaaaccttgatatttttgattttcaattaaacgaagatgatatt780
actaccttaatacaactagattcaggtattaaacccaaagatccagataatgtctcattt840
taa 843
SeqID 114
atggttaaag gtcaaggaaa cgttgtagca caaaataaaa aagcgcatca cgactatact 60
atcgttgaaa caatagaagc aggaattgtt ttgacaggaa cagaaatcaa aagtgtccgc 120
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
49/109
gcagcgegtattacattgaaagatggatatgcacaaataaaaaatggtgaagcgtggttg180
attaatgttcatattacaccatacgatcaaggtaatatatggaatcaagatcctgatcgt240
acacgaaagttattactaaaaaaacgtgagattgaaaaaatatcaaatgaactgaaaggg300
actggtatgactctggtacctctaaaagtttacttaaaagatggttttgctaaagttcta360
ttgggtttggcaaaaggaaaacatgattatgataagcgagagtctatcaaacgtcgtgag420
caaaaccgtgatattgccegtcagttaaaaaactataattcacgatga 468
SeqID
115
atggaccatttcacaaaactctggcaagatttctctaaacttccaaatgttgttgctata60
gcactcggaggetcacgctctggtgacagttttgaccaatettccgattatgatttgtat120
gtttattgtgcagcaa.CtcctgatatcactagtCgtaaacgta.tCCttaaCaagcactgt180
cattacattgaacttaacaatcattactgggagcttgaagataatggtactttaaacgac240
ggaactgatattgatattctctatcgtaacatagata.actttttatcagacttagaagat300
gtcgttgaacaccacaattctegaattggatacactacttgtttttggcataacctcatc360
aattgccaaatactetatgatcctgaaaatcaattacaatcactcaaagagagattcgaa420
gtttcttatcccagtcagttacaaaaacaaattatcattcaaaatcgtaacttattaact480
ggcaagcttccctcttacgataaacaaattataaaagcccttaaacgccaagactttgtt540
agta.ctcaccatagaactactgctttcttagattcctactttgatattatttttgcactt600
aataagttgacacatcctggegaaaaaagaatgatttcctatgctaagaagaatgetaca660
ttgcttcctaaacatttcgaagaaaatatcattaaactatgtcatcacaactecaacgaa720
cacactgttaaagaaacattaaacgatataataatgcatctcgacgtcatgcttaaagaa780
aattttcaacactttataggttaa 804
SeqTD
116
atgaaaaaaattatttatettggtttagcctgtgtcagtatattaactttaagtggttgc60
gagtcaattgagcgttctctaaaaggagaccgttatgttgaccaaaaactagctgaaaac120
tcttcaaaggaagctactgaacaactaaacaaaaaaactaagcaagccttaaaagctgat180
aaaaaagcttttcctcaattggacaaggctgttgccaaaaacgaggcacaagtgcttata240
aaaacctctaaaggtgatataaatatcaagttatttccaaaatatgctcctttagctgtt300
gaaaattttctaacacatgcaaaagaaggatactataatgggttaagtttccacagagtt360
atcaaagattttatgatacaatctggtgaccctaatggagacgggaceggtggaaaatct420
atatggaatagcaaagataaaaagaaagattctggaaatggttttgttaatgaaatatcc480
ecttacetctacaatatcaggggaagtttagcaatggcaaatgctggagctgatactaat540
ggcagccaattctttatcaatcaaagccagcaagateattccaaacaactgtcagataaa600
aaagttcctaaggtgattattaaagcctattcagagggaggaaatccaagtttagatggt660
ggttatacegtctttggacaagtaatctctggcatggaaactgtggataaaattgettcg720
gtagaagttacaaaatcagatcaaceaaaagaaaaaattactattacaagtateaaagtt780
attaaagactacaaatttaaataa 804
SeqTD
117
atgaaaattggaattattgcagccatggaggaagagttaaaactccttgtggaaaatctt60
gaggataaatctcaagagacagtattatcaaatgtatattacagtggacgttatggtgaa120
catgagcttgttttagtacagtctggtgttgggaaagtcatgtcagcgatgagtgttgct180
attttagtagaaagctttaaagttgatgctattattaatacaggatcagctggtgcagta240
gcaacaggattgaatgtaggagacgtcgttgtcgcagatacattagtttatcacgatgta300
gatttaaccgcctttggttatgactatggacaaatgtcaatgcagccactttattttcat360
tcggataagacttttgtttccacttttgaagcagttttatctaaagaagaaatgactagt420
aaagttggtttaattgcaactggggatagttttattgctggccaggaaaagattgatgtt480
attaaggggcattttccacaggttttagctgtcgagatggaaggtgcagcaattgcccaa540
getgctcaagctacaggaaagccctttgtggtggtacgtgctatgagtgatactgcagct600
catgatgccaatatcacatttgatgaatttatcattgaagctggtaaacgetctgeccaa660
gtattaatggcatttttgaaagcattataa 690
SeqID
118
atggaaaagagacttagtttaggagctcttgttttagctagtacagttcttttagcagca60
tgtggaaatgtcggaggaggagcatcttegacaggaacaaaaatagggaaagatattaag120
gtagggtataactgggaattatcaggaaacgtttcttcgtatggaaattcaatgaagaat180
ggagctgacttagcagtaaaagaaattaatgetgctggaggggttggcggcaagaagtta240
aaagtcctatCacaggataataaatcagaaaatgcagaggcagcaaeggttgccacaaac300
ttggttaccaaaggagctaatgtcattatcggaccagcaacatcgggtgcagetgcatct360
tcaactccaaaagtaaatgcagcagcagttccaatgattgcacctgctgcgacacaagac420
aatttagtctatggttctgatggaaaaaccttaaatcagtatttcttcegagctactttt480
gtcgataattatcaaggaaagctattgtetcagtatgctacagacaaccttaaagctaaa540
aaagttgttctattttatgataattcatcagattactcaaagggggtagcaaaatcattt600
aaggaaagttatagtggaaaaattgttgatagcatgacattctcegctggtgatactgat660
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
50/109
ttccaagcgtcattgactaagttgaaagggaaagaatatgatgctattgtgatgccaggt720
tactataccgagacaggattaatagttaagcaagcgcgtgatttaggtatctctaaaccg780
gttcttgggcctgatggttttgatagtccgaaatttgtgcaatcggcaacacctgtggga840
gcttcaaacgtttattatttgacaggtttcactacacaaggatcaaccaaagetaaagct900
ttccatgatcattacgttaaggcatatggtgaagaaccatccatgttctcggctttatca960
tacgatgccgtgtatatggcagctaaatctgctaaaggagctaaaacttcaattgatctt1020
aaaaaagctttagctaagctgaaagattttaaaggtgtgacagggaaaatgtctattgat1080
aaaaatcataatgttgttaaatcagcttacgttgtcaaattagacgatggaaaaacaagt1140
agcgttaacattatttcagcaaaataa 1167
SeqID
119
atggagaatcataattctattaaacagacctatggattaatgactacaattgctatgatt60
gtaggtgtagtgattggttcaggcatttattttaaagttgatgacatccttaaatttact120
ggtggagatgtctttttaggcatggtaattttagtactaggttctttttcgattgttttt180
ggaagtttgtcaatttctgagctagctattagaacgagtgaaagtggtggtattttttct240
tactacgaaaaatatgttagCCCagCtttagcagcaactttaggcttgtttgegtctttt300
ttgtatcttccaactttaacagcaatcgtttcatgggtagctgcattttatactttaggt360
gaatcateaagtttggaatcacagattattttagctgctgtttatattttagcacttagt420
ctcatgaatatctttgctaagcgtattgcagggggattccaatctttaacgacetttgta480
aaaatgattcctttagtcctaattgctttaattggtgctttttggtctgataaagctcca540
caacttccacaacatttaacagctattcagccgtcaaatgttggatggagttgggtgtca600
ggtctggtaccattgtattttgcatatgatggttggacaatttttgttagtattgcacca660
gaagtcaagaatcccaagaagaatttaccacttgcctttgtcattggtccagcgcttatc720
ttattatcatatttggcatttttctatggtttgacacaaattttaggtgctagctttatt780
atgacaaccggtaatgatgctattaattatgcagctaacattattttcggtcctagtgtt840
gggcgtttattatctttcattgttattttatctgtattaggtgttgccaatggactttta900
cttgggacgatgcgtctacctcaagcttttgcggaacgcggatggatcaaaagtgagagg960
atggctaacataaatttgaagtatcaaatgtcattgccagctagtttgacggtgacggct1020
gtagctattttttggctttttgttcactttatggttacaaaatttaatttattgccgggt1080
agtgatattagtgaaattgctgtggtgtttaataatactagtttaatcattctttatgtt1140
ttagtactcagcctttatctcaaaaaagatattaaaaataaatttaccggcttagtttca1200
ccgattctagcaattttaggcggtttgatcctctttatcgggagtttgttaagtaatttc1260
tttacggttttaattttccaatgtttttgcttattattatgtttgatttgtcattatatc1320
tatcaaaaaaataacccaaaaactcatgaatag 1353
SeqID
120
ttgaccgaatttaatgacgatcagcattctaaccatgatcagaaaagttttaaagaacaa60
attctggcagagttagaagaagctaaccgtttgagaaagttgcgtgaagaagaactctat120
caaaaagagcaagaagccaaagaagctgctcgcagaacagcacaattgatggcagattat18D
gaagcgcaacgtttgaaagacgaacaagaagctagagcaaaggcgctagagactaagcaa240
cgcttagaagagcaagagaaggctcggattgaggcgaaacttctggcagaagctgctcga300
gaagaagaaagacgtcaggcggaacaagcattagcttcccaagaagaacaagttatcaat360
caagggatggaaccttcaagagagcttgatagcggctccaaatctagtgaatttaggaca42D
actgaaaatgtacctgacatagatttaaaagcagataagactgatgttgcaactgctgtg480
cctaatcaagaaacggaagaaatctttcttgtgagagcaacagatattcctacagaaggt540
gaaaatgtaaaacttggtgagacatcagagttagagcccgtagcaaaggaacctatccga600
gtagaggatttgtcaaaagaagaagaggatatagctttgtcagccaagaacaaacataac660
aagcgtgaaagacgtcagaaagcagataatgtggcaaaacgaattgcacgtattctgata720
tcaattatcatacttgtattgctcttgacagcatttgtaggttatcgttttgtagatagt780
gctattaaacctgttgattccaattcaaataaatttgtacaagttgaaattccgatagga840
tctgggaataaattaattggtcaaattttagaaaaagcaggagtcattaagagcgccaca900
gtctttaattactattccaagttcaaaaactatagtaattttcaaagtggatactacaat960
cttaaaaaaagtatgactttagatcagattgctgctgaattggaaaaaggcggaactgca1020
gaaccgacaaaaccagctttaggtaagatattaattaccgagggttacactattaaacag1080
attgctaaagctattgagtctaataaaattgatacaaagactacaagtacaccttataaa1140
gctgatgatttcttgaaacttgttcaagatgaaacgtttattaaaaaaatggtagctaaa12D0
tatccaaatttactaggaagtctacctgataaatcaaaagctatttatcaattggaagga1260
tatttattcccagctacttacaactattataaagatacaaccttagaaggacttgttgaa1320
gatatgatttcaacaatgaatactaagatggcaccttactataacactattaaagcgaag1380
aatatgtctgtaaatgatgttttgacattatcatctcttgttgaaaaagagggatcaaca1440
gacgaagatcgccgtaaaatagcaagtgtcttttataaccgattatcagccggtcaagctl5oD
cttcaaagtaacattgcaattttgtatgctatggggaaattaggtgataaaacaagttta1560
gctgaagatgctcaaattaatacttcaattaaatcaccatacaacatctatactaatact7.620
ggtttgatgcctggaccagttgatagtccaagtatetcagcaattgaagcgactataaaa1680
cctgcttcaacagattatctttattttgtcgctgatgtgaagaccggaaatgtatactac1740
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
51/109
gctaaagact ttgaaacaca caaggctaac gttgaaaaat atatcaatag tcaaattaac 1800
taa 1803
SeqID
121
atgagtagaatgattccaggacgtattcgaaatcaaggtatagaactctaegaacaaggt60
ttggtgtccttgatttctcaagaaggtaatctattaaaagctaaagttggggattgtcag120
attgaatattcattagtaacagaagaaacaaaatgttcttgtgatttttttgcaagaaaa180
ggctattgtcaacatttagctgctctggagcatttcttgaaaaacgacccagagggtaaa240
gcaatcttatctaaagttcaagttcaacaagaaagtcaacaagaaactaagaagaaaacc300
tcttttggtagtgtttttttagatagtctaattattaatgaagatgatactataaaatat360
caactatcggctcaagc~agaacaaaatccttatgctaatgatatctggtggactttaaaa420
attagacgactgcctgatgatagaagttatgttattcgtgacatcaaagcttttttaaat480
actgttcgaaaagaagcttattatcagattggaaaacaatactttgaaactttgtctttg540
atacagtttgatgagaccagtcaagaattgatagaatttttatggaggctcattccaagt600
cattcaagcaaaattgatctagagtttattttaccaaatcaaggtcgtcaccttagtctc660
actcgtggtttttttgaagagggcgttactttgatgaatgctttagaaaatttttcattt720
gaaagtgattttcatcaatttaatcacctctactttaaggaattagaaggtgaggatcat780
ctttatcaatttaaggttattgtccataggcaatcaattgaattagaaatcaaagagaaa840
gacttaaaaccactatttgcgaattcttatttgttttatcgcgatactttctaccatctt900
aatttgaagcaagaaaagatggtaacggctattcgtagtcttcccattgagggagattta960
gcaaaacatatccattttgatttagatgatcaagataagttagcagctcatttactggat1020
tttaaggagattggactagtagatgctccacggagcttctctattcatgattttaaggta1080
aattttgagttcgatattaatagtcaaaatgaaattttattgcaaatggtatttgattat1140
ggtaatgatttaactgttcataatcgtcaagaactagaacagttaacatttgctagtcac1200
ttcaaacatgaagaaaaaatatttaaactcttagaaagatatggctttgcaccccacttt1260
tcaaccagccatccagcatacagtgcacaagaattatacgatttttatacctatatgctt1320
ccacaatttaaaaaaatgggaacagtgagcttatccgcaaaattggaaagttatcgtctc1380
atagaacgaccgcaaattgatattgaagctaagggaagcctgctagatatttcttttgat1440
ttctctgatttactggaaaacgatgttgatcaagctctggtagctttgtttgacaataat1500
ccttattttgtgaataaatcagggcaattagttatttttgatgaagagactaagaaagta1560
agtgcaactttgcaagggttgagagctagacgagcaaagaatgggcatattgaattagat1620
aatattgcagcatttcaattatcagaactgtttgcaaatcaagataatgttagcttttca1680
caacatttttaecaattgattgaagatttgagacacccagaaaagtttaaaatacctggt1740
ctatctgtttcagcttccttgcgcgattatcagcttacaggtgtccgttggttaagtatg1800
ttagatcattatggctttgcagggattttagctgatgatatggggcttggaaaaacactt1860
caaacgatttcatttttaagtacaaaactaactagagattctcgtgtgcttattttatca1920
ccatcaagtttaatttataattggcaagatgaattccacaaatttgcgccagacgtagat1980
gtagcagttgcctatggttctaagattcgtagagatgaaattattgctgaacgtcatcaa2040
gtaatcattacaagttattcatcatttaggcaggattttgagacttattctgaaggaaat2100
tatgattatttaattttggatgaagcacaggttatgaaaaatgctcaaactaaaatagcc2160
catagcttgagatcttttgaggtcaaaaactgttttgcattatcgggaacacctattgag2220
aataaactgttagaaatttggtccattttccagatcattttacctggtttattacctggt2280
aagaaagagtttttgaagttgaaccctaaacaagttgctcgttatatcaaaccatttgtg2340
atgagacgtcgaaaagaagaagttctcccagaattaccggatttgattgaaatgaactat2400
ccaaatgaaatgacagacagtcaaaaagttatctatttggcgcaattacgccaaattcaa2460
gaaagtatccaacattctagtgacgctgacttaaatcgtcgtaaaattgaaattttatct2520
ggcatcacacgattacgtcaaatttgcgacactccacgtctttttatggattatgatggt2580
gaaagcggtaagttagaaagcctacatcaacttttaacacaaattaaggaaaatggacat2640
cgtgctctgattttttctcagttcaggggtatgttagatatcgcagaacgtgagatggta2700
gctatggggcttacaacttataaaattactggttctacaccagcaaatgaacgtcatgaa2760
atgaccagagcatttaatgcaggatcaaaagatgctttcttgatttctttaaaagctggt2820
ggcgttggtctcaaccttacaggagctgataccgttgttctgattgacttgtggtggaat2880
ccagctgttgaaatgcaggcgattagtcgcgcacataggttggggcaaaaagagaatgtc2940
gaggtttatcgcttgattactagaggcacaatcgaagaaaaaattctagaaatgcaagaa3000
actaaaaaacatttggttacaacagttctggatggaaatgaaacccatgctagcatgagt3060
gtagatgatattcgagagatacttggagtttctaaataa 3099
SeqID 122
gtgttactta cagaaatcaa aaaatcacca gaggggcttt attttgataa aaaaatagat 60
atcaaagagt cgcttatgga gcgtcattca gagataatgg atatttctga tattcaagtt 120
tcaggtcatg tggtgtatga agatggtctc tatctacttg actataatat ggcttacgat 180
attacattac cgtctagtcg ttctatgaaa ccagttgttt tatctgaaaa gcaaactatt 240
aatgaagttt ttattgaagc tgaaaatgtt agcactaaaa aagagctcgt tgatcaggat 300
ttggtcttaa tattagagga agatgatatt aatttagaag aaagcgttat cgataatatc 360
ttgttaaata tacctcttcg tgttctggca gctgatgagg ttggggtaga agcggattta 420
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
52/109
tcaggtaaaa attggtcgtt aatgactgaa aagcagtatg aagaaaaaca agctaaagaa 480
aaagaaaaat ctaatccttt cgcagcctta gaaggtatgt ttgatagtga ttag 534
SeqID
123
atggaagtaaaaactgcaatagaatggatgcacacttttaaccaaaaaattcaatccaac60
aaggactatttatecgaactagatactccaataggtgatggcgaccatggtggcaatatg120
gcgcgtggtatgactgctgttattgaaaaccttgataacaatgaatttagtagtgctgcc180
gatgttttcaaaaccgtatccatgcaacttttaagcaaagtaggcggagcatctggacca240
ctctatggttctgcatttatgggaattacaaaagctgaacagagtgaaagtaecatttca300
gaggcacttggcgcaggacttgaaatgattcaaaaacgtggtaaagctgaacttaatgaa360
aaaacaatggttgatgtttggcaCggtgttattgaagcgattgaaaaaaatg~.attgact420
gaagaccgtattgattccttagtagatgctacaaaagggatgaaagcaaeaaaaggacgc480
gcttcttatgttggagaacgctcattaggacacattgatccagggtcattttcttcagga540
ttattatttaaagcattactagaagttggaggtgtctaa 579
SeqID
124
atgcaagataaattaatgataagaggagcaagagetcacaatttaaaaaatataagtgtc60
gacatcceacgagacaagttagttgtcgttacgggactatcaggatcaggtaagtctagt120
ttggcctttgacactatctatgcagaaggacaacgtcgttacgttgaaagtctttctgct180
tacgcgcgccaatttttgggaaatatggaaaagcctgatgtagattctattgatggcctt240
agtccagctatttctattgatcagaaaacaacaagtaagaatcctcgctctactgttggg300
actgtaacagaaattaacgattatttacgtttgctttatgctcgtgttggaaccccatat360
tgtatcaatggtcacggagccatcacagcatcttctgtagagcaaattgtggataaggta420
ctagcgcttccagagcgaacaaagatgcaaattttagccccaattatacgtcgaaaaaaa480
ggacaacacaaatcaacatttgagaaaatacaaaaagatggttacgttcgtgttcgtatt540
gatggtgatattcacgatgttactgaggtgcctgaattatcaaaaagtaagatgcacaat600
attgatattgtagtagatcgattaattaataaagagggcattcgttcecgcttatttgat660
tccgttgaagcggctetacgtttgtcggatggttatgtcgttattgatacaatggatggc720
aatgagttattgttttcagagcattattcttgtcctgaatgtggttttactgttcctgaa780
ttagagccacgccttttttcttttaatgctccctttggttcttgtacgacctgtgatggc840
ttaggaattaagttagaagtggatatagatttggttattccagataaaagcaagaccctt900
agagaaggggccttagttccttggaatccaatttcatcaaattattatccaacgatgcta960
gagcaagctatgactcaatttgatgttgatatggatacgccatttgaaaaattaagcaag1020
gcggagcaggacctagccctatatggttcaggcgaacgagagttccatttccattatatt1080
aacgattttggaggcgagagaaatattgatttgccttttgaaggggttgtcaataatatt1140
aatcgtcgttaccatgaaactaatagcgattacacacgcaatgttatgcgagaatatatg1200
aacgagctaaaatgtaacacttgtcatggctatcgtctcaatgatcaagcactttgcgta1260
agagttgggggagaagaaggtcttaatattgggcaagtctcagatttatagatagcagac1320
catttagaacttttagaaacgttgcgtttatcttcaaatgaacaattaattgctcgacca1380
attatcaaagaaattcatgaccgcctaagtttcttaaataatgttgggcttaattattta1440
aatctgtcacgttetgcaggaacgctttccgggggcgagagtcaacgtattcgtttggct1500
actcaaattgggtctaatttatcaggtgtcctttatgtacttgatgaaccgtccattgga1560
cttcatcagcgagacaatgaccgtttgattgatagtcttaagaaaatgcgtgatttgggt1620
aatacgcttattgttgttgaacatgatgaagatacaatgatggcagctgattggttaatc2680
gatgtgggacctggcgctggtgcgtttggtggtgagattgtggcctctggcacaccgaag1740
caagtagetaaaaatactaaatctattacaggacaatatttgtcaggtaagaaagtgatt1800
cctgtgccatctgaacgaagagtaggcaatggtcgctttttagaaatcaaaggtgcggca1860
gaaaacaacctacaaaatttagatgtcaagttccctctcggtaaatttattgccgtaact1920
ggtgtctcaggttctggaaaatcaaccttaattaatagtattttgaaaaaagctgttgcg1980
cagaagcttaaccgtaactcagataaaccaggtaaatatgtttctttagaaggcattgaa2040
tatgttgatcgattgattgatattgaccaaagtccaattggtcggaccccacgttctaat2100
accgcaacctatacaggtgtttttgatgatattcgtgatctttttgctcaaactaatgag2160
gcaaaaattcgaggttataaaaaaggacgcttctcatttaacgtcaaaggtggacgttgt2220
gagtcttgttctggtgatggtatcatcaaaattgagatgcattttttaccagatgtctac2280
gttccttgtgaagtatgccacggcacgcgctataatagtgagactctggaagtacattac2340
aaagaaaaaaatattgcacaaattcttgatatgacagtgaatgatgcagttacatttttt2400
gcagctattcctaaaattgctcgtaagttacagactattaaggatgttggtttgggatat2460
gtcactttggggcaaccagctacaaccttatcaggaggagaagctcagcgaatgaagttg2520
gcaagtgaattacataagcgttcgacaggtaagagtctttacatattagacgaaccaaca2580
acggggcttcatgcagatgatattgctcgcttacttaaggttttggatcgttttgtagat2640
gatggtaatacagtgcttgttattgagcataaccttgatgttattaaaactgctgaccac2700
attattgatctcggccctgaaggaggtattggtggcggacaaattgtagctatcggaaca2760
ccagaagaagttgctgaaaatcctaaatcctatacaggatattatttaaaagagaagtta2820
gcaagatag 2829
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
53/109
SeqID
125 aagatagaatcgcttcttttcgtcgcacacttttagggtggtatgaccaa60
atgtggcctg
gaaa~.acgtgatctcccttggcgaagaactactaatccatactatatttgggtttctgaa120
atcatgttgcaacaaacacaagttaatacagtaatcccttattataaacgttttctagag180
tggtttcctcaaataaaagatttggcagacgctcctgaagaacaattactaaaggcatgg240
gagggactaggttattattctcgggtgcgtaatatgcaaaaggctgcacagcaagtgatg300
gttgattttggtggcatatttcctcacacttatgatgatattgcttcattaaaagggatt360
ggtCCttataCtgCaggtgCtatCgCCagCatCtCattCaaCttaCCagagCCtgCCgtt420
gatggcaatgtgatgcgtgtcatggctcgtttgtttgaagttaattatgacatcggtgac480
cctaaaaatcgtaaaatttttcaagctattatggaaatactaattgaecctgacagaccc540
ggtgattttaaecaageacttatggatctgggtacagacatcga~.tccgctaagacacct600
agacctgatgaaagccctattcgtttetttaatgctgcttatttgaatggtacttatagt660
aaatatcccataaaaaatcctaagaaaaagcctaaaccaatgcgaattcaggcttttgtc720
attcgtaaecaaaatggccaatatctactggagaaaaatactaaagggagacttctaggg780
ggtttttggtcatttcctattatcgaaacgtcacctctttctcaacaattagatttattt840
gatgacaatcaatccaaccccataatctggcaaacccaaaatgaaactttccaaagagaa900
tatcaattaaagccccaatggactgataatcactttcceaatattaagCacacttttagt960
caccagaagtggacaatagaactcatagagggggtggtcaaagcaacagatttacctaat1020
gctcctcacctaaagtgggcagcaattgaggacttttctctgtatccctttgcaacgcca1080
caaaagaaaatgctggagacctacttaaaacagaaaaatgcttaa 1125
SeqID
126
ttgatcgaaatcacttggactgtgaagtatatcacagaatttatcgcaaccgcttttctt60
atcatcttaggaaatggggctgtagctaacgttgacttaaaaggcacaaaaggaaataat120
tcaggttggattattattgcaattggttatggtttaggtgttatgatgccagcgettatg180
tttggtaatgtctctggaaaccatattaacccagctttcacacttggattggcattttca240
ggtcttttcccttgggcacacgttggacaatacattcttgcacaaattttgggagcaatg300
tttggacagttagttgtcgttatggtttatcaaccttactttgttaagacagaaaatcca360
aatcatgttcttggatcattttcaactatttctgcattagatgatggacagaaatcaagt420
cgtaaagcggcttacattaatggtttcttaaatgaattcgttggttcttttgttcttttc480
tttggagctttggctttaacgaagaactatttcggtgtagaacttgttggtaaacttgtt540
caagctggttatgaccaaacgacagcagcgacaaggatttcaccatacgtaactggttca600
cttgctgtagctcacttaggtattggtttcttggtaatgactctagttgcttctttaggt660
ggaccgactggacctgcattgaaccctgcgcgtgaccttggtccacgtattgttcaccgc720
ttattaccaaaacaaattcttggacaagctaaagaagattcaaaatggtggtatgcatgg780
gtgccagttttagcaccaatcgtagcaagtatactcgctgtagccttgttcaaactatta840
tatctttaa 849
SeqID
127
atgtcatcttattggaataactatcctgaacttaaaaaaaatattgatgaaaccaatcaa60
ctaattcaagaaagaatacaggtcagaaataaagatattgaagcggcgctaagccaactc120
acagctgcgggaggaaaacagctcagaccagcattcttttaccttttttctcaacttggt180
aataaggagaatcaagatactcagcaactaaagaaaatcgctgcttctttagaaatcctt240
cacgttgctacattaatccatgatgatgtcattgatgactcaccactaagacgtggaaat300
atgaccattcaaagcaagtttggcaaagacatcgcagtttatactggggatttacttttc360
acagtctttttcgatcttattttagaatctatggctgatacaccatttatgaggattaat420
gcaaaatctatgcgtaaaattctcatgggagaattggaccagatgcaccttcgttacaat480
caacaacaaggtatccatcactatttacgtgcgatttcaggtaagacagccgaactcttt540
aaattagctagcaaagaaggagcttactttggtggtgcagagaaggaggttgttcgtcta600
gcaggccatatcggctttaacattggtatgacattccaaattttggatgatatcctggat660
tatactgcagataaaaaaacatttaataagcctgtcttagaggatttaacacaaggcgtt720
tacagccttcctctacttcttgccattgaagaaaatcctgatattttcaaacctatttta780
gataaaaaaacagatatggctactgaagacatggaaaaaattgcttatctcgtcgtttcc840
catagaggtgttgacaaagctcgccatctagctcgtaaatttactgagaaagctattagt900
gacataaataagctaccccagaactctgcaaaaaaacagttgctacaattaactaattac960
cttttaaaacgcaaaatttaa 981
SeqID
128
atgtttaaaatccctttgtttaaagaattaaagacagatcaatgggtaaaaccatttttc60
aaacaatataaagtttccttagtaattgctcttttccttggttttatgactttcttttct120
gccagtgctcttatgtttaattcgggctatctgattagtaagtcagcttcactaccgagt180
aatattcttctagtatatgttccaattgtactaacacgtgcttttggtattggacgtcct240
gtttttcgttatatagaacgcctaacgagtcacaattgggtattacgaatgacttcacaa300
ctgcgcttgaagctttaccattccttagaaagcaatgctatetttatgaagcgtgatttt360
cgtttaggagatgttatggggcttttagcggaggatattaattatttgcaaaatttgtat420
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
54/109
cttaggacaatatttccaacgattatagcgtggttattatatagctttattattattgca480
acaggcttcttttctctatggtttgctttaatgatgttgctttatttagctattatgatt540
tttctttttccactttggtcgattttagctaatggtgctcgtcagactcgtgaaaaagaa600
ttaaaaaatcatctttatactgatttgacggataatgtcttaggtatttcagactggatt660
tttagtcaacgtggtcaagagtacgtcgccttgcatgaacgttcggaaagtgaactaatg720
gctattcagaaaaaaattcgttcctttaataatcgtagagctcttattgtggaattagtt780
tttggctttctagctattttggttattatttgggctagtaatcagtttattggtcacaga840
ggtggcgaagctaactggattgcagcatttgttctaacagtatttcccttgtcagaggca900
tttgctggtttgtctgctgctgctcaagaaacaaataaatattctgattcaattcatcgt960
cttaa.tgaattatcagaaacgtattttgaaacaactcaaaatcaattgcctaataagcca1020
tatgatttttccgtcaagaatttaagtttccagtataagccacaagagaaatgggttttg1080
catcatttagatttggatattaaagaaggagaaaaaattgctattttagggcggagtggt1140
tctggcaagagtaccttagctagtctacttcgtggcgacttgaaagcaagtcaagggaag1200
attaccctaggcggtgctgatgtttcaatagttggtgattgcatttctaactatattgga1260
gtgatacaacaagcgccctacctttttaatacaaccctgctaaataacattcgcattgga1320
aacca.agatgetagtgaagaagatgtatggaaagttcttgaacgagttggattgaaagag1380
atggtcactgatttatcagatggtctctatacaatggttgatgaagctggacttaggttt1440
tcaggtggcgaaaggcatagaattgctttggctagaatcttactaaaagatgtcccaatt1500
gttatcttagatgagccaactgttggacttgatcctattactgaacaagccttactaagg1560
gtatttatgaaagaattggaaggtaagaccttagtttggattacacatcacttaaaaggt1620
attgaacatgctgatcgtatcttatttatagaaaatgggcaattagagttggaaggttct1680
cctcaagaattgtctcaaagtagtcaacgttaccgtcagctgaaagccgctgatgatggt1740
gatctatga 1749
SeqID
129
atgaaaaaacttattacagaaaaaaaagtcaacaacgtctcaactgttaaetatttgaaa60
ctcggtcttgtctcagcaatgtttgctggaggagcattcgtagctcttggttctacacaa120
ggtgtttcagcttcaactttcacagcaccgcaagcaacacatccaaaagcagaacgtcag180
ttaacagattcagaaatctatgaacgtgcccaaaaacaagtgttaceaaaatatatccaa240
ggttctctctcaggtatccttaaccaacattcaacactttacaaacaacaaaacgcagca300
gtgacaccgcaagtatcaagccccaaagcagaacgtcagttaacagattcagaaatctat360
gaacgtgcccaaaaacaagtattgccaaaatatattcaaggttctctctcaggtatcctt420
aaccaacattcaactttgaatgcttaa 447
SeqID
130
atggaggaaaacatgaacataaaacaattaaagtctaaaacaatgcttggaacagtggct60
ttggtgtccgctttttcatttgcttcaacaaatgcagatgcgaatacatataactatgca120
gtagatgtagactacctagcaagtgcggaggaaattgctcaagcacatccagctagtaat180
acgtttccactaggtcaatgcacatggggtgtaaaggagatggcaacatgggcaggtaac240
tggtggggaaacggtggtgattgggctgcgagcgccgcatcagctggttatacagtagga300
acacaacctcgcgtgggttctatcgtatgttggactgatggtagttatggacatgtggct360
tatgttacagctgtagatcctgtcactaataaaattcaggttttagaatctaattatgca420
ggtcatcaatggattgataattatcgtggttggtttgatccacaaaatacagcgacacca480
ggggtagttagctacatttatccgaattaa 510
SeqID
131
atgaaaattaaccaaatgaaaaaagacgagCtttttgaggggttttaccttataaagaaa60
gcagaagttcgtaaaacgcgtgcaggtaaagactttattgcctttacctttcgagatgat120
actggcgaaatttcaggaaatatgtgggatgcacaaacctataatgtagaagagtttgta180
gccggtaaaattgttcatatgaaagggegtcgtgaagtttataatggaactCCCCaagtC240
aaccaaattacattaagaaacatcaaagatggtgaacctaatgatcctagagattttaaa300
gaaaaacctccaatcaatgttgacaacgtgagagagtacatggaacaaatgctctttaaa360
attgaaaatgcaacctggcagcgtgtggtaagagcactttatcgtaaatacaataaggaa420
ttttttacctatccagccgccaaaacaaaccaccacgcctttgaatcaggattggcatat480
cacacggcaacgatggttcgtttggcagatagtattggagatatctatccagaacttaat540
aaaagtttgatgtttgctggtattatgctacatgatttagccaaggtcattgagttatcg600
ggtcctgataatacagaatatactattcgaggtaaccttatcggtcatatttcacttatt660
gatgaggaattaacaaaaatactagcagagcttaatattgatgatacaaaagaagaggtt720
acagtgttacgccatgttattctgagtcaccatggacaattagaatatggaagcccggtt780
cgtcctagaatcatggaggcagaaattatccatatgatcgataacattgatgcaaatatgs40
atgatgatgacaacagctttaaatcgtgtcaacgaaggtgaaatgacaaatcgcattttt900
gccatggataaccgttctttttataaaccgaacattaaatas 942
SeqID
132
atgttggttgacaagaagtggcgttttgaagatagtgcaagttatttcgcttgtectaaa60
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
55/109
tgtcaaaatcccttgataaaagaaagtaacagcctcaaatgctctgataatcattgtttt120
gatttatccaaatttggatatgttaatcttcttggaggaaagaagatagatgaacattat180
gataaaaaatcatttgaaaatcggcagcttgtcttagaaaacgggtattataatcatatt240
ttagaagetatttcaaaggttttggaaaataattctcagtttcattcggttttagatatt300
ggttgtggagagggcttttattctcgtcaattagttaacaagtatgagaagactttcttg360
gcttttgatatttctaaagattcgattcaattagctgctaaaagtgatcaatctaggctt420
gtgaaatggtttgtttctgatttagctaaccttcctattcaagactcatcaattgatatc480
attttagacattttttctcctgcaaattataaagaatttaggcgggtactgagtgatgat540
ggtatccttgtaaaggttgttcctgtagctgaacatgtccaagaattgcgagaaaaagct600
agtcaatacttg~.aac~.gaaagattactctaatcaaaaaattctagatcactttagagaa660
aattttgaaattatttctgagcagaaagttgtteaa~.gtt~.t~.actgttctcaacaagaa720
cgtcaagcttttattgatatgacaccgttgttattcagcgtagataaaaegactattgat780
tgggcgagtate.tcagaaattacagtaggtgccttaatagtaattggaaaaaagcgcagt840
gtatctaaatas 852
SeqID
133
atgtgtcttatttgtcaacgtattgaaatgattgaaegaaatgagaatccttattttgtg60
aaagaatatgaaacgggttatcttgttctgggagaccatcaatattttcaaggttattgc120
ctttttctctctaaaaaacacgtaacagagttacatgaattgcctagagattggcgaaat180
cagtatctttccgaaatggcagatgcttctgaaatagttgctaaggcttttagagcagat240
aagatgaatattgagagtttgggaaatggagacgctcatctacattttcatctttttcca300
agaaaaacaggtgatttaaggaactatgggcataatggaaaaggtccagtttggtggtat360
ccttttgagaagatgtatgcagatagtgtcagagcaactggtgcagaaatagaaaaatta420
aaagagaaattgttagatgtcttaggatag 450
SeqID
134
atgtttagtgatttacgcaaaaaatttgtctttttgaccatgtcaatccttattgtcgtt60
gttctctttetctttgcagtgagtaatcgctacaatcaatattgggatgaatatgatgca120
tataggattgttaaattagttgccaaaaatgattatttaggaataccaggcgatgaaccg180
attgctttggtgactatagataaccaaaagatggttaagattcaaagcaataatactgat240
ttgacaaatgatgttatcgaaaaatctagtttgaagctccttgagcaaggaaagaagtca300
cgaaaatggaagtcttttatatattccataaaagaatataaagataaaacctacaccata360
gctattatggatttggctagttatgaagtcccttatgcaaggcgttttctaattcttgtt420
tttactatttttggattttgtttattagcagctgtaagtctttatctttctcgatttatc480
gtagggcctgtagagacagaaatgactcgcgaaaaacagttcgtttcagatgcgagtcat540
gagctgaagacccctattgcagctatacgagccaacgttcaggttctggaacagcaaatt600
ccaggaaatcgttatctggatcatgttgtttcggagactaagcgaatggagtttttaatt660
gaagatttgcttaatttgtctagacttgatgaaaaacgctccaaggtaaatttcaaaaag720
ttaaacttatctgtcttatgtcaagaagtacttctgacatatgaaagtttggcatatgaa780
gaagaaaagtgtttaaatgatacgattgaagatgatgtctggattgttggagaagagagt840
cagattaagcaaattttaataattcttttggataatgctattaggcattctttgtcaaaa900
tcagaaatccagtttagtcttaaacaggctcgaagaaaagctattctgacaatatcaaat960
ccaagtgetatctattccaaagaggttatggataatctctttgagcgtttttatcaagct1020
aaagatgatcatgcagattctctcagttttggtctaggcttatctattgctaaggcaatc1080
gtggaacgccataaggggagaattagagcatatcaagaaaaagaccaattacgtcttgaa2140
gtccagttaccaattgatggattttggaccaataccatgattaattaa 1188
SeqID
135
ttgattattctcgataaaaaaagttatgacctcctcttttacctattgaaattagaggaa60
cctgaaacagttatggcaattgccaacgcacttaatcagtctaggcgtaaagtgtattat120
cacttagagaagataaacgatgcactgcctagcgatgtgcctcagattgttagttatcca180
egtgtaggaatcttgctaaccgaaaaacaaaaagcagcctgtcgtcttttattagatgaa240
gtaactgattatagttacgtcatgaaaagtagtgagaggttgcagctgtctttagtatct300
ategtggtagctaaggaccgcataacgattgataggttgatgcaaetaaacgatgtttet360
cgaaatactatcttaaacgatttaaacgaattaagaagtgagttagcagagaaagaatat420
aatttacagttacaatcaacaaaatgtcgcggttattttttagatggtcacccattgtcc480
attatccagtacttatataagctcttagatgatatctaccataatggaagtagtagtttt540
atagacctttttaatcataaactgtctcaagcttttggtgccagcacatatttttctaaa600
gaggttettgattattttcaccattatctcttcatttctcaacgaagtctaggtaagaaa660
atCaaCagtCaagatggtCagtttatgattcagattttgCf.''ttttataCtaatggCttat720
cgtaagatgcgattaagtcctgaagtacagacctctcttaatagtgattttagcttggtt780
tggcaacgtaaggaatatgagattgctaaagagttggctgatgagctggaagaaaatttt840
cagttatcactggatgagattgaagtgggactagtggccatgcttatgcttagtttccgc900
aaggaccgtgacaatcatttagagagccaggattatgatgatatgcgagctactctaacc960
agttttttgaaagaattggaagaacgatatcaccttcactttgttcataaaaaggactta1020
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
56/109
ctaagacaacttctaactcactgcaaggcaetettatatcgtaaacgttatggtattttt1080
tctgttaatcctttaacagagcatattaaagacaaatatgaagaactttttgccataacc1140
tcgtcttctgtaaagcttttagagaaagcttggcaaatcaaattgaccgatgatgatgta1200
gcatatctaacgattcatttaggaggggaacttcgtaatagtcaacaatctcctaataaa1260
cttaagttagttattgtatctgatgaaggaatagcgattcagaaacttcttttaaagcaa1320
tgtcaacgctacttaacaaacagtgatatagaagctgtttttacaaccgaacagtaccaa1380
agtgtgagtgatcttatgcatgtagatatggttgtctctactagtgacgctttagaatct1440
cgttttccgatgttagtagttcaccctgttttgacagatgatgatattattcgcttgatt1500
cgcttttcaaaaaaaggtaactgtgcaaatagtaatcaatttaccaatgaaettgaaaaa1560
acgattgctcaatatgtcaaggaagatagtgaacgctacgtgctgaaatctaagattgag1620
aaacttattcatcaagaattgctccaagacgtccttccecttcaaagtacagtttgttaa1680
SeqID
136
atgaaatactttttagatactgccgatgtttctgaaattcgtcgtcttaatcgtttagga60
atcgttgatggtgttactaccaatccgactattatttcacgtgaggggcgtgaetttaaa120
gaagttattaacgaaatttgCcaaatcgttgatggcccagttagtgcagaagtgacaggt180
ttaacttgtgatgaaatggttaccgaagctagagaaatcgctaagtggtcaccaaatgtt240
gttgttaaaattccaatgactgaagaaggtttagcagcagtttcacaattatcaaaagaa300
ggtataaagacaaatgtgacattaatatttactgtggctcaaggtctttcggcaatgaaa360
gctggtgcaacatttattagtccttttgtgggtcgtcttgaagatattggaacagatgct420
tatgctttgattcgtgaccttcgtcacattattgatttttatggtttccaatctgagatt480
attgctgctagcattcgtggattggcgcatgtggagggcgtcgctaaatgcggtgcgcac540
attgccactattccagataaaacatttgcatcactatttactcacccgcttactgataaa600
gggattgaaactttcttaaaagattgggatagtttcaagaagaagtag 648
SeqID
137
atgagtcattattccataaaattacaagaagtattcagattggcgcaatttcaagcagca60
cgctatgaaagtcactatttagaaagctggcatcttcttttagcaatggttttagttcat120
gattcagtagctggtttgacatttgctgaatatgagtctgaagttgcaattgaagagtac180
gaagcagcaacaattttagctttaggtagagcaccgaaagaagagattaccaattatcaa240
tttttagagcaatcaccagctttgaaaaagatcttaaagttagcagaaaatattagtatc300
gtagtaggagctgaagatgtgggtactgaacatgtcttgcttgctatgttggttaataaa360
gatttattagccacacgtatcttagagttagttggctttagaggtcaagacgatggtgaa420
tcagttcgtatggttgatttacgtaaggctctagaacgtcatgccggttttacaaaagat480
gatatcaaagcaatttatgaattacgtaatcctaaaaaagcaaagtcgggtgcttctttt540
tctgatatgatgaaaceaccgagtactgctggtgatttagctgatttcacacgtgattta600
tcacagatggcggttgatggggaaattgaacctgttattgggcgtgataaagaaatttca660
cgtatggtecaagtcttaagtcgtaaaacaaagaataatcctgtcttagttggagatgcg720
ggtgtcggtaaaacagctttggcgtacggtctagcacaacgtattgctaatggaaatatt780
ccttatgagcttagagatatgcgtgttctagagttagatatgatgagcgttgttgctgga840
actcgttttcgtggtgattttgaggaacgtatgaatcaaatcattgcagatattgaagaa900
gacggtcatattattcttttcattgatgaactgcatactattatgggttctggctctggt960
attgatagcacacttgatgctgctaatattttaaaaccagctttggcccgaggcacttta1020
cgcactgttggagcaacaactcaagaggaatatcaaaagcatattgaaaaagatgctgct1080
ttatctcgtcgctttgcaaaagttttagtagaagaaccaaatcttgaagacgcatatgaa1140
attctacttggattgaagccagcgtatgaagcctttcataatgttactatttcagatgaa1200
gcagttatgactgctgtaaaagtggctcatcgttatttgacaagtaagaatttaccagac1260
tcagctatagacttacttgatgaagcttctgccactgtgcaaatgatgattaagaaaaat1320
gctccttcgcttttaacagaagttgaccaagctattttagatgatgatatgaaatctgct1380
tctaaagctctaaaagcaagttataagggtaaaaagcgtaagcctattgccgtaacagaa1440
gatcatattatggcaactctcagtcgtctatctggtattcctgttgaaaaattgacacaa1500
gctgatagtaaaaaatacctcaatttagaaaaagaattgcataaacgtgttatcggtcaa1560
gatgatgcagttactgccattagtcgtgctatccgtcgcaatcaatctggcattcgtact1620
ggtaagcgtcctattggttcctttatgttcttgggaccaactggtgttggtaagacagag1680
ttagcaaaagccttggcagaagtgttgtttgatgatgaatcagccctaattcgttttgat1740
atgtcggaatatatggaaaaattcgcagettctcacctgaatggggcacctccaggttat1800
gttggttatgatgaaggaggagagttgactgaaaaagtacgcaataaaccatattcagtt1860
ttactttttgatgaagttgaaaaagctcatccagatatttttaatgtattattacaagtg1920
cttgatgatggcgttttaacagatagtcgaggacgaaaagttgatttttcaaatactata1980
atcattatgacttctaatttaggagcaactgcattacgtgacgataaaacagttggtttt2040
ggagctaaggatatcagccatgattatactgctatgcaaaaacgtattatggaggagctt2100
aaaaaagcttatcgaccagagtttatcaatcgtattgatgagaaagttgtattccatagt2160
ctcagtcaagataatatgcgtgaagttgtgaaaattatggttaaacctttaattttagcg2220
cttaaagataaaggtatggatctgaaattccagcettcagccttgaaacacttggcagag2280
gatggctatgatatagaaatgggtgctcgtccactgcgtagaactattcaaacgcaagta2340
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
57/109
gaggatcatt tatcagaact actattggca aatcaagtga aagaggggca agtaattaag 2400
attggcgtat ccaaaggcaa attgaaattt gatattgcaa aatcataa 2448
SeqID
138
atggtettagataaagaaatcaaggctcaattagcgcaatatttagatttgctagaatct60
gatattgtattacaagctgatttaggagataacgataattctcaaaaagtaaaggatttt120
ctagatgaaattgtcgctatgtctgatcgcatcagccttgaatcaacacatttaaaacgt180
caacctagttttggaattgcaaaaaaagggcatgaaagtcgcgttattttttcaggcttg240
ccaatggggcatgaattcacatctttcattttagctttgttgcaagtctctggtcgcgca300
cCaa~.agttgatgaagatattatcaaacgaattaaggggattgagaaaactatcaatcta360
gaaacttatgtttcattaacttgccataattgtccagatgtcgttca~.gcctttaatata420
atggctgttttgaatccgaatateactcatactatgattgaaggaggcatgtatcaagac480
gaagtcaaatcaaaaggtatcatgtctgttcctactgtttataaggaccaagaagaattt540
acttctggccgtgctacaattgaacagcttttagaacaactagatggacctcttgatgct600
gaagcatttgctgacaaaggtgtctatgatgttctagttattggtggtggtcctgcaggt660
aacagtgctgcaatttatgccgcccgtaaagggttaaaaacaggtattttagcagaaact720
tttggtggacaagttatcgaaacagttggtattgagaacatgattggtacactgtacaca780
gaaggccctaaattaatggctcaaattgaagagcataccaaatcttacgatattgatatt840
atcaagagtcaattagcaactggcattgagaaaaaagaattagttgaggtaacactggct900
aacggagctattttacaagctaaaactgctatcctagctetgggtgctaagtggegaaat960
atcaacgttcctggcgaggaagaattccgcaataaaggtgttacttactgtccacattgt1020
gatggccctcttttcgaaggaaaagatgttgctgttataggtggtggtaattcaggtatg1080
gaagctgctttagatctagccggtgtcactaaacatgttacagtcctagaattcttacct1140
gagctcaaagcagaccaagtactgcaagaacgagcagctaaaactgacaatttaactatt1200
cttaagaatgttgctactaaagatatcgttggtgaagatcatgtcactggtttaaactat1260
accgatcgtgatacaaacgaagaaaaacacattgatttagaaggtgtttttgtacaaatt1320
ggtcttgtaccaagtacatcttggctcaaggatageggcattgaactcaatgaacgtcaa1380
gaaattgtcgttgataaatttggctcaacaaatatccctggtatttttgctgcaggtgac1440
tgtacagatgctgcctacaagcaaatcattatttccatggggtctggtgccacagctgcc1500
attggcgcatttgattatttaatcagacaataa 1533
SeqID
139
atgataaaatatcaagatgatttttaccaageggttaatggggagtgggctaagacaget60
gttattcctgatgacaaaccaaggacaggtggtttttctgatcttgctgatgacattgaa120
gcattaatgctgtcaacgacagataagtggctggctgatgaaaataaaccaagtgatacg180
attttaaatcattttattgcttttcataaaatgacagetgattatcaaaaacgtgaagag240
gtaggagtatcaccagtattaccattaattgaagaatataaaggcctacaatctttctct300
gagtttgcatcaaaagttgcagaatatgaactagagggtaaaccaaatgaatttccattt360
ggtgtggctcctgactttatgaatgctcaattgaatgtactttgggctgaagcgcctggg420
attattttaccagatacaacttattatagtgaagataatgaaaaaggaaaggaactcctt480
gctttttggcgtaaaagtcaagaagacetactgcctttgtttggcctttcagaacaggaa540
attaaagatatcttggataaggttttagcattggatgcaaaattggcacaatatgtctta600
tctcgcgaagagagtteggaatatgttaaactttaccatccttataactgggaagatttc660
acaaaattagcacctgaacttccattagatgctattttccaaaagatattaggacaaaaa720
ccagataaagttattgttcctgaagaacgtttctggacagaatttgcatctgactattac780
tcagaatctaattgggaattattaaaggcagatcttattttatcagctgcgaatgcctat840
aatgcttacttaactgatgatattcgtatcaaatcgggagtttacagtcgagctttatca900
ggcacaccacaagcaatggataagaaaaaagcagcttactaccttgcttcaggaccttac960
aatcaagetctaggtttgtggtatgcaggagaaaaattetctecagaagetaaagetgat1020
gttgagcataagattgcaacgatgattgatgtctataagtcacgcttagaaaaggcggat1080
tggcttgcacagtcaacgcgagaaaaagctattatgaaacttaatgttatcacaccacat1140
attggataccctgagaaactaccagagacttatactaaaaaaatcattgatcctaaacta1200
tcgcttgtcgaaaatgctactaatttagacaaaatttcaatagcctatggttggagtaaa1260
tggaataaaccagttgatagaagtgaatggcatatgcctgcccacatggtcaatgcgtat1320
tatgatccacaacaaaaccaaattgtcttcccagcagccattttacaagaaccattttat1380
gctttagagcaaagttcatcagcaaattatgggggaattggtgcagtgattgcacatgaa1440
atatcacacgcttttgacactaatggagcttcatttgatgaacatggaagtttgaataat1500
tggtggactgatgaagattttgaagctttcaaaaaaettacagataaagtagttgagcag1560
tttgatggactggaatcttatggcgcaaaagtcaatggtaaactaacagtatcagaaaat1620
gttgcagatttaggtggagttgcttgtgctttagaagctgcgcagcgtgagtcagatttt1680
tcagcgagggatttctttattaactttgcgacaatttggcgtatgaaggcacgtgatgag1740
tatatgcaaatgttagctagtgtagatgttcacgccccagcacaatggcgaactaatatt1800
acagtaacgaattttgaagaattccataaagagtttgatgttaaagatggtgataacatg1860
tggcgtecagttgaaaaacgtgttattatttggtaa 1896
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
58/109
SeqID
140
atgtctaagattetttttttcggtgaacctctcattcgcatcactccaaaagaaaatgac60
tattttgcagatagtatctcaactaaactattctatggtggctctgaagttaataccgca120
agagctctacaaggctttgggcaagatactaaactcctctcagccttacccaataatccc180
ataggtaatagttttcttcaatttttaaaagcacagggtattgatactcattctattcag240
tgggttggagaacgtgttgggttatattttttagaagattcctttgcttgcagaaaaggt300
gaggtggtctacgaccgcgatcatagtagtttacatgactttaggataaatcaaattgat360
ttcgatcaattatttgaaggagtttctctctttcattttagtggtattacactatcattg420
gatgagtctatccaagagataacactgcttcttttaaaagaagctaaaaaaagagagata480
acaatctccttagatctcaattttcgcagtaaactaatttctcctaaaaatgccaaaatc540
cttttttctca.gttcgctacctttgcgga.tatttgttttggt~.ttgaacctcttatggtt600
gactcacaggacactaccttcttcaatcgcgatgaagctaoaatagaggacgtcaaagaa660
cgaatgatttcgcttataaatcactttgactttcaagtcattttccatactaaacgtcta720
CaggatgaatggggaCgaaaCCaCtaCCaagCttaCatagCaaatCgt~~.aCaagagttt780
gtCaCttCaaaagaaatCaCCaCagCtgtaaaCCagagaattggaagCggagatgCtttt840
gtggcgggagcgctatatcaactacttcagcactcagacagcaagacagtcattgatttc900
gCtgtCgCtagtgcatctttaaaatgtgctttggaaggggaCaatatgtttgagaCCgtt960
accgcagttaacaaagtactaaatcaatcgaaagacattattcgttag 1008
SeqID
141
atgaaaagtcgaaaaaaagataaattggtattgaggttaacaacaacactattggttttt60
ggtttgggtggggtttggttttataattataaaaatgataatgtcgaaccgacagtcact120
agtgcatcggatcaaacgacgaattttattcaaacgatttetccaacagctattgaaatt180
tctaagacctatgatttgtatgcgtcagtcttattagcacaagctattttggaatcatcc240
agtggacaatcagatttgtctaaggctcctaattataacctctttggcatcaaaggagaa300
tataaaggtaaatctgtccaaatgcctactttagaagatgatgggaaaggcaatatgact360
caaatccaagctccttttcgcgectatccaaattattctgcttcaetatatgattatget420
gagttagtatctagtcaaaagtatgcatetgtttggaaatcaaatacctcttcttataag480
gatgctactgcagctctaacaggtctttatgcgacagatactgcttatgctagtaaatta540
aaccaaattattgaaacctacagtctagatgcttatgataaatag 585
SeqID
142
atggcagacgtgaaggtagtgaataatgaggattctagaggtcaaaagcaagacttaaag60
gctaaactatttcatattaagatagggtcagttcccctaccagtatatgtttgtttagca120
ttattgattcttctagcaggctttttacaaaaattgccagtcaatatgctaggaggattt18D
gcagttatcttaacaatggggtggttcttagggactatcggagctageattcctggtttt240
aaaaacttcggtggcccagctattttatctttattagtaccatctattttggtgtttttc300
aacctcattaataaaaatgttttagaatcaacaaatatgttgatgaagcaagctaacttt360
ctttatttttatattgcttgtttagtgtccggtagtattttagggatgaatcggaaaatg420
ttgattcagggattgctaagaatgattttccccatgttattaggaatggtttgtgcgatg480
atggtagggacatttgtcggtgttattttaggcttagagtggcgacacactttgttttat540
atcgtaacacccgttttagctggtggtattggtgaaggtattttaccattatcgttaggc600
tatagttcaattaccggtgtagctagtgaacaactagttgctcaactcatcccagccact660
attattggtaatttctttgccattttatgtactgcactattgaatcgtttgggagaaaag720
aaaccacacttgtctggtcaagggcaattagtaaggttaaataaaggagaggacatgtca780
gatattattgctgatcattctggeccaattgacgttaagaaaatgggtggaggtgtttta840
acagcatgtagtctctttatttttggacatttgttgcagcaattaactggatttcctggt900
cccgtattaatgattgttgcagcagctattttgaaatatattaatgttattcctagagaa960
acacaaaatggagctaagcaactttataaatttatttetggtaattttacatttectcta1020
atggcagggctaggattgctttatatcccgttaaaagatgttgtggcaacgcttagcata1080
caatatttcatagttgttattagtgttgtatttacagttatttctgttggattctttgta1140
tcgcgattccttaatatgaatcctgttgaagcaggtattatttcagcttgtcaaagtggt1200
atgggaggaacaggagatgttgccattttaagtacagcagaccgaatgaacttgatgcca1260
tttgetcaagttgctacgcgtttaggaggagctattactgttatcacaatgacagccatt1320
ttacgcatgttattctaa 1338
SeqID
143
agaggcaaaaaagctggtaaatacacaacatctgatggttacatttttgatgccaaagat60
attaaaaaagatacaggtacaggttatgtcattccacatatgacacatgagcattgggta120
ccaaagaaagatttatcagagtcgg2attaaaagcagctcaagaatttctttcaggaaaa180
tctgaagcaaatcaagacaaaccaaaaacaggtaaaacagctcaagaaatetatgaggca240
attgaaccaaaagcaattgttaaacctgaagatttattatttggaattgcacaagcgaca300
gactataagaatggtacatttgtaattcctcataaagatcattaccattatgtggaatta360
aaatggtttgatgaagaaaaagatcttttagctgattcagataagacatattctttagaa420
gactatttagctacggctaaatattacatgatgcacccagaaaaacgtcctaaagttgaa480
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
59/109
ggatggggtaaagatgctgaaatttataaggaaaaggactctaataaagcagataaacca540
agtcctgcaccaactgataataaatcaacatcaaattctagtgacaaaaacttaagtgct600
gcagaagtattcaaacaagcaaaaccagaaaaaattgtaccgcttgataaaattgctgct660
cacatggcatatgcagttggatttgaagatgatcaattgattgttcctcatcatgatcat720
tatcataatgttcctatggcatggtttgacaagggtggtttatggaaagcaccagaaggc780
tatacattacaacaactcttctcaacaattaaatactacatggaacatcctaatgaatta840
ccaaaagaaaaaggttggggacaegacagtgatcataacaaaggctcaaataaagacaat900
aaagccaaaaattatgctccagatgaagaacctgaagattcagggaaagtaactcacaac960
tatggtttttatgatgttaataaaggttcagacgaagaagaaccagaaaaacaagaagat1020
gaatcagagctag~.tga.atatgaactaggaa.tggcacaaaatgctaagaaata.tggtatg1080
gata.g~.ca.atcttttgaaaagcaactcatccaattatcaaataaatatagtgtaagtttt1140
gaaagctttaattatattaatggtagtcaagttcaagttactaaaaaagatggctctaaa1200
gtgCttgttgatatt~cl.~.a.CaCtaa.Caga.agtga~ata.~l 1239
SeqID
144
atgaatcgtaaaaaaacagttatta.ttagtgctttatcagtagctctatttggtactggt60
gtaggtgcttaccaattaggtagctataatgeccaaaaatcagacaatagtgtttcttat120
gtgaa.aa.ca.gataaatctgatagcaa.agcacaagcaacagctgtaaataaaacgcccgac180
caaatcagtaaagaagaaggcatatctgcagaacaaatcgttgttaaaattactgacgac240
ggttatgtgacttctcatggagaccattaccattattacaatgggaaagtgccatatgat300
gccatcattagtgaagaattgattatgaaagaccctagctatgtctttaataaagetgat360
gtcattaatgaagtcaaagatggttatattatcaaagttaacggtaagtattacctctat420
cttaaagaaggtagcaaacgaacaaatgttegtacaaaggaacaaatccaaaagcaacgc480
gaagaatggtctaagggtggttctaagggagaatcaggaaagcatagtagtgcaaaaact540
caagctttatcagccagegtacgtgaagcgaaagctagcggtcgctatactacagatgat600
ggttatgtttttagtccaacagatgtcattgatgacatgggagatgcctttttagtacca660
catggcgatcatttccattatatcccgaaagctgatttatctccatcagagttatcagcc720
gcacaggcatattggaacegcaagactggccgatcaggtaatagctcaaaaccatcaaat780
tcaagttcatacattcatgcaagtgcaccaagcggtaatgtatcaacaggaagacatgct840
aatgcccctatttetattccaagagtcactcacgcaaatcactggtcaaaaccagctggt900
aatcatgetacggcaccaaaacaccatgcacctacaaccaaaccaatcaacaaagattct960
gctttagacaaaatgttgaaacgtttatatgctcaaccgttatatgetcgtcacgtagaa1020
agtgatggtttggtttatgacccagcacaagttaatgctttcacagcaatcggtgtttct1080
attccgcacggtaatcatttecactttattcactataaggatatgtctccattagagtta1140
gaagcaacaaggatggtggcagagcatagaggacatcatattgatgcattagggaaaaaa1200
gattctacagagaaaccaaagcatatttctcatgaacctaataaggaacctcacacagag1260
gaagaacaccatgcagtaacaccgaaagaccaacgtaaaggcaaaccaaatagccagatt1320
gtctacagtgctcaagaaattgaagaggcaaaaaagctggtaaatacacaacatctgatg1380
gttacatttttgatgccaaagatattaaaaaagatacaggtacaggttatgtcattccac1440
atatga 1446
SeqID
145
atggctaaatttggatttttatcggtactagaagaagaattggataagcatttacagtat60
gactttgccatggattgggataagaaaaatcatactgtagaagtcacttttatattagaa120
gcacaaaacagctctgctattgaaaccgtggacgaccagggggagacgagtagcgaggac180
atcgtttttgaggactatgtactcttttacaaccctgtcaagtctcgctttgatgetgag240
gactatctggtgactatcecctatgagcctaagaagggcttgtcgcgtgagtttctggct300
tattttgcggagactctcaacgaggttgccactgaagggttgagcgacctcatggacttc360
ctcaccgatgacagtatcgaagagttcggtctttettgggatacggatgcttttgaaaat420
ggcagagcagaactgaaagagacagagttttacccttatccgagatattag 471
SeqID
146
atgaacacaaaacagcgtttttcaatccggaaatataagttaggtgccgtatetgtactt60
ttgggaaccctattttttttaggtggtatcacaaatgtagetgctgattctgtcataaat120
aagccatctgatattgcagttgaacagcaagtaaaagacagtccaacgagcatagcaaat280
gagacacctactaacaacacgtcatcagcccttgcgtcgacagctcaagacaatcttgtt240
acaaaggctaataatagtccaacagaaacacaaecagtagctgagtctcactctcaagcc300
accgagacattttccccagtcgcaaatcaaccggttgaaagcactcaagaagtttctaaa360
actcctttaaccaaacaaaatttagcagtcaaatctacaccagctatttctaaagaaacc420
cctcaaaacattgatagtaataaaattatcactgtccccaaagtatggaacacaggctac480
aaaggagagggaactgttgtagcaattattgactcaggactagatatcaatcacgatgct540
ctccaattaaatgattcgacaaaagcaaaataccaaaacgaacagcaaatgaatgctgct600
aaagcaaaagctggtataaactatggaaaatggtataacaacaaagtaatctttggtcac660
aactatgttgatgtcaatacagagctaaaagaggtgaaaagcacttctcatggtatgcac720
gtaaccagtatcgcaacagctaatcctagcaagaaagatacaaatgaattaatctatggt780
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
60/109
gttgctcctg aagcacaagt aatgtttatg agagtettct ctgatgaaaa aagaggaact 840
ggaccagccc tttatgttaa agctattgaa gatgccgtta aactcggtgc tgacagcatt 900
aatttaagtt taggtggagc taatgggtct ttagttaatg ccgatgaccg acttataaaa 960
gctttagaga tggctagact cgctggcgtt tctgttgtta tagcagcagg taacgacggt 1020
acatttggga gtggagcatc aaagccttct gctctttatc ctgattatgg tttagttggt 1080
agtccatcaa cagctcgtga ggccatttct gtagcatcat ataataatac aacactggtt 1140
aataaagtct tcaacattat cggattagaa aacaacagaa atctcaacaa cggattagct 1200
gcttatgcag atcctaaagt tagtgataag acctttgaag tagggaaaca atatgattat 1260
gttttcgtag gaaaaggaaa cgacaatgat tataaggaca aaactttaaa tggtaaaatc 1320
gccttaattg aacgtggaga tattactttt acaaaaaaag tcgtcaatgc tattaatcae 1380
ggtgctgtgg gagctattat cttta~.taac aaagetgggg aagctaatct aacaatgagt 1440
ttagatcctg aagcaagtgc tattcctgct atttttaccc aaaaagagtt tggagatgtt 1500
ttagCtaaaa aCaaCtataa aattgtattt aaCaatatCa aaaataaaca agccaaccct 1560
aatgcaggtg tcctatctga cttttcaagc tgggggttaa cageagacgg acaattaaaa. 1620
cctgacttat ctgctcctgg aggctctatt tacgccgcta tcaatgataa tgaatatgat 1680
atgatgagtg ggacaagtat ggcttctccc catgtcgctg gtgctactgc tctagttaaa 1740
caatacttat tgaaagaaca tccagaactt aaaaaaggtg acattgaaag aactgtcaaa 1800
taccttetta tgagtactgc taaagcacac ctaaacaaag atacaggcgc ttacacetca 1860
ccacgccaac aaggagcagg tattatcgat gtcgcagcag cagttcagac aggattatac 1920
ctaactggtg gggaaaacaa ctatggcagc gttacattag gaaatattaa agataaaatt 1980
tcctttgatg ttactgttca taatatcaat aaagttgcaa aagatttaca ctatacaacc 2040
tatttaaata ctgatcaagt taaagatggc tttgtcacat tggctcctca acaacttggt 2100
acatttacag ggaaaacgat acggattgaa ccagggcaaa cccaaacgat tacaattgat 2160
atagatgttt cgaaatacca tgacatgtta aaaaaagtaa tgccaaacgg ctatttccta 2220
gaaggctacg tacgttttac agaccctgtt gatggtgggg aagttcttag tattccttat 2280
gttggattta agggagaatt ccaaaactta gaagttttag aaaaatecat ttataagett 2340
gttgetaaca aagaaaaggg attttatttc caaccaaaac aaacaaacga agttcctggt 2400
tcagaagatt atactgcctt aatgactaca agttcagagc ctatctactc aacagacggt 2460
actagtccta tccaattgaa agccttggga agctataagt ctatagatgg aaaatggatc 2520
ttacaactag atcaaaaagg ccagcctcat ctagccattt cacctaatga tgaccaaaat 2580
caagatgccg ttgcagtgaa aggtgttttc ttacgtaatt tcaataattt aagagccaaa 2640
gtctatcgtg cagatgatgt taatttacaa aaaccactat gggtaagtgc tccccaagca 2700
ggagataaaa attactacag cggaaatact gaaaatccaa aatctacatt tttatatgac 2760
acagaatgga aaggaaccac tactgatggt attcctttag aagatggaaa atacaaatac 2820
gttttaactt attactctga tgtccctggc tctaagccac aacaaatggt gtttgatatc 2880
actttggata gacaagctcc tacactaaca acagcaactt atgacaaaga tagacgtatc 2940
ttcaaagctc gtcctgcagt agaacacggg gaatctggta tctttagaga acaagtttgt 3000
tacttaaaaa aagataaaga tggtcattat aatagcgtct tacgtcaaca aggagaagac 3060
ggtatccttg ttgaagataa caaagtattt atcaaacaag aaaagaatgg tagctttatt 3120
ctacctaaag aggttaacga tttctctcat gtctactata ctgttgaaga ttatgcaggc 3180
aatctagtat cagcaaaact cgaagatttg atcaatattg gcaataaaaa tggtttagta 3240
aacgtcaaag tgtttagccc tgagcttaac agtaatgtcg atattgattt ctcttactct 3300
gtcaaagatg acaaaggtaa tatcatcaaa aagcaacatc acgggaaaga cctcaattta 3360
ttgaaattgc cttttggtac ctatacgttt gatctattct tatacgatga ggaacgagca 3420
aatctaatca gtcccaaaag tgtcactgta actatttctg aaaaagatag ccttaaagac 3480
gtcttattta aagttaactt actcaagaaa gcagccttac tcgttgaatt tgacaagett 3540
ttaccaaaag gagcaacagt ccagttggtt actaagacaa atactgttgt tgatctacca 3600
aaagcaactt attctcctac tgactatggt aaaaacatac ctgtaggaga ctatcgttta 3660
aacgtaacgc tgcctagtgg gtatagcact ttagagaact tagatgattt acttgtatcc 3720
gtaaaagaag atcaggtaaa cctaacaaaa ttgacgctga ttaataaagc tcctctgatt 3780
aatgccctag cagaacaaac tgatattatt acccagcctg tgttttataa tgctggaact 3840
cacttaaaaa ataattacct agctaatctt gaaaaggcac aaactttaat taaaaataga 3900
gtggaacaaa caagtattga taatgctatt gctgctttga gagaaagtcg ccaagctctt 3960
aacggtaaag aaacagatac ttctttactg gcaaaagcta ttttagctga aacagaaatc 4020
aagggaaact atcaatttgt taatgctagt ccattaagcc aatcaactta tatcaatcaa 4080
gtccaattgg cgaaaaacct tctacaaaaa cctaacgtca ctcaatcaga agtagacaaa 4140
gccttagaaa atcttgatat tgctaaaaat caattaaatg gtcatgaaac tgattactct 4200
ggtttacacc atatgataat taaagcaaac gttctgaaac aaacatcatc taaatatcag 4260
aacgccagtc aatttgctaa agaaaattat aataacctta tcaagaaagc agaattgctg 4320
ctttccaata gacaagctac acaagctcaa gttgaagagt tattaaacca aataaaagca 4380
accgaacaag agcttgatgg ccgtgataga gtttcttccg cagagaatta tagtcaatca 4440
ctcaatgata atgactctct caataccaca cctatcaatc cgccaaatca gccccaggcg 4500
ttgatattca aaaaaggcat gactaaagaa agtgaggttg ctcagaagcg tgtcttaggg 4560
gtgactagcc aaaccgataa tcaaaaggta aagacaaaca agcttcctaa aacaggcgaa 4620
agcactccta aaataaccta tacaatattg ctatttagtc tctctatgct aggtctggca 4680
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
61/109
acaatcaaac taaagtctat caaaagagaa taa 4713
SeqID
147 acgaaaaaaaagtaaaatactttttaagaaaaacagcttatggtttggcc60
atgaataata
tcaatgtcagcagcgtttgctgtatgtagtggtattgtacacgcggatactagttcagga120
atatcggcttcaattcetcataagaaacaagttaatttaggggcggttactctgaagaat180
ttgatttctaaatatcgtggtaatgacaaagctattgctatacttttaagtagagtaaat240
gattttaatagagcatcacaggatacacttccacaattaattaatagtactgaagcagaa300
attagaaatattttatatcaaggacaaattggtaageaaaataaaccaagtgtaactaca360
catgctaaagttagtgatcaagaactaggtaagcagtcaagacgttctcaagatatcatt420
aagtcattaggtttcctttcatcagaccaaaaagatattttagttaaatctattagctct480
tcaaaagattcgcaacttattcttaaatttgtaactcaagccacgcaactgaataatgct540
gaatcaacaaaagctaagcaaatggctcaaaatgacgtggccttaataaaaaatataagc600
cccgaagtcttagaagaatataaagaaaaaattcaaagagctagcactaagagtcaagtt660
gatgagtttgtagcagaagctaaaaaagttgttaattccaataaagaaacgttggtaaat720
caggccaatggtaaaaagcaagaaattgctaagttagaaaatttatctaacgatgaaatg780
ttgagatataatactgcaattgataatgtagtgaaacagtataatgaaggtaagctcaat840
attactgctgcaatgaatgctttaaatagtattaagcaagcagcacaggaagttgcccag900
aaaaacttacaaaagcagtatgctaaaaaaattgaaagaataagttcaaaaggattagcg960
ttatctaaaaaggctaaagaaatttatgaaaagcataaaagtattttgcctacacctgga1020
tattatgcagactctgtgggaacttatttgaataggtttagagataaacaaactttcgga1080
aataggagtgtttggactggtcaaagtggacttgatgaagcaaaaaaaatgcttgatgaa1140
gtcaaaaagcttttaaaagaacttcaagaccttaccagaggtactaaagaagataaaaaa1200
ccagacgttaagccagaagccaaaccagaggccaaaccaaatattcaagtacctaaacaa1260
gcacctacagaagctgcaaaaccagctttgtcaccagaagccttgacaagattgactaca1320
tggtataatcaagctaaagatctgcttaaagatgatcaagtaaaggacaaatacgtagat1380
atacttgcagttcaaaaagctgttgaccaagcttatgatcatgtggaagagggaaaattt1440
attaccactgatcaagcaaatcaattagctaacaagctacgtgatgctttacaaagttta1500
gaattaaaagataaaaaagtagccaaaccagaagccaaaccagaggccaaaccagaagct1560
aagccagaagctaagccagaagctaagccagaagctaagccagaggccaaaccagaagct1620
aagccagacgttaagccagaagctaaaccagacgttaaaccagaggctaagccagaagct1680
aaaccagaggctaagtcagaagctaaaccagaggctaagctagaagctaaaccagaggcc1740
aaaccagcaaccaaaaaatcggttaatactagcggaaacttggeggctaaaaaagctatt1800
gaaaacaaaaagtatagtaaaaaattaccatcaacgggtgaagccgcaagtccactctta1860
gcaattgtatcactaattgttatgttaagtgcaggtcttattacgatagttttaaagcat1920
aaaaaaaattas 1932
SeqID
148
atggcaaaagatattaaattttcagcagatgcccgctcagcaatggtgcgtggtgttgat60
attttagctgatacagtcaaagtaacattaggtcctaaaggccgtaatgttgttcttgaa120
aaagcatttggttctcctttaattacaaatgatggtgtgacaattgctaaagaaattgag180
ctagaagatcactttgaaaatatgggagctaaacttgtgtcagaagtggcttcaaaaact240
aatgatattgcaggggatggcactacaactgctactgttttgacccaagctattgtacgg300
gaaggtcttaaaaatgtaactgcaggggcaaatccgattggcattcgtcgtggtattgaa360
acagctgtttcagcagcagttgaagagctaaaagagattgcacaaccagtttcaggcaaa420
gaagctattgctcaagttgcggctgtgtcttcacgttctgaaaaagttggggaatacatt480
tctgaagctatggggcgcgtgggtaatgatggtgttatcactattgaagaatcgcgaggt540
atggaaacagagcttgaagttgtggaaggaatgcagtttgaccgtgggtacttgtcacag600
tatatggtaactgataacgagaaaatggtctctgaacttgagaatccgtatatccttatt660
acagataagaaaatttcaaatatccaagaaattttaccattattagaagaggttcttaaa720
acaaatcgtccgttgctaatcatcgetgatgatgttgatggagaagctctcccaacgctt780
gttcttaacaaaattcgtggaactttcaatgtcgtagctgttaaagcgcctggatttggt840
gatcgtcgtaaagccatgctggaagatattgctatcctaacaggaggaactgtcgttact900
gaagaccttggtttagacttaaaagatgctactatgcaagttttaggacagtctgctaaa960
gtaacagtagataaagattctactgttattgtcgaaggtgccggtgactcatcagcaatt1020
gctaatcgcgtagctatcattaagtcacagatggaggctacaacttctgattttgatcgt1080
gaaaaattacaagaacgacttgctaagttagccggtggtgtagcagtaattaaagttggt1140
gcagcgactgaaacagaattaaaagagatgaaacttcgcatcgaagatgcgttaaatgca1200
acgcgtgctgcagttgaagaaggtattgtttcaggtggaggtacggctcttgtgaacgtt1260
attgaaaaagtagcggcactgaaacttaatggtgatgaggagactggacgtaatattgtt1320
cttcgtgctctcgaagagcctgttcgtcaaattgcttacaatgctggatatgaaggttca1380
gttattattgaacgtttaaaacagtctgaaattggtacaggatttaatgcggccaatgga1440
gaatgggtagatatggttaccacaggtatcattgaccctgtcaaagtaacacgttctgca1500
cttcaaaatgcggcatctgtagcaagtcttatcttgactacagaagcagtagtagcaaat1560
aaacctgaaccagaagctcctacagctcctgcaatggatccatctatgatgggtggcttc1620
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
62/109
taa
1623
SeqID
149
gtggtagaaaacctagaaaaaccaattggagtgagctataaaaatagcccatcaatgagt60
aaacgaacggctatcagaatgaagaaatctagtcgattttcaattttactatatagtgtt120
ttgtcaactctcttagcaattgcaaatcctttattgacttattttgcaaatggtttgcag180
actcagaatctctatacaggtttgatgatgaccaaaggacagatcccttatagtgatgtt240
tttgctacaggaggatttttatactatgtaacgattgctctaagttaccttttagggtct300
agtatctggttacttattgtacagtttattgcttactatgtatctggaatttatttttat360
aaattagtttattatgtggcacaaagtgaaattgtctcgataggcatgacgttgattttc420
tatataatgaatattgtettaggattcggtggtatgtacccaatacagtgggcattacct480
tttatgctcatttcgctatggtttttaattaaattttgtgtcgataatatcgttgatgaa540
gcatttatattttatggcattttagcagcattctcactatttatagatccccaaacactg600
attttttggctttgctcttttgttctcttaacagcaaccaatattaagcaaaagcagtca660
ctacgaggattttatcagtttttatgcgttgtttttggtatgattttaattgcttatact720
gttggttactttatgtttaatctacagattatctcttcttatattgacaaagctattttt780
tacccctttacgtatttcgctaggacaaaccactcattccttcttagtttagcaattcaa840
attgttgtccttctagggtcaggttgtctctttggactatgggattttattcaaaatcgt900
aaaaaagcatcttatcaaatcggcttgaactttattgcctgtatttttattatttacgct960
ataatggccattttttcaagagattttaacctttaccactttttacctgctttaccattt1020
ggtcttttgctaacgagtaataaaattactattctttaccaaaaagtgattgacagacgt1080
tcacatagacgtcagtatttctctggtaaatctcttatcgtagacctttttgtaaagaaa1140
acatattatttgcccctcttactagtttccttatcgatagggttactagtttataatact1200
tatcaaaatgttactcttagtaaagaaaggcgtgacatttcacattatttgactacaaaa1260
attgatagagatggtaagatttatgtttgggacaaagttgctagcatttatagccagact1320
cggttaaaatctgcttctcaatttgttttgccacatattaatacagcgcaaaaaaataat1380
gagaaaattttgaaggacgagctgcttcagcatggggctaaatactttatcttaaataaa1440
aatgagaagttaccaaatgaactgaaatctgatattaagaagcactaccaagaagttcct1500
ctatcaaatatcactcattttgttctatatcgtttcaaatag 1542
SeqID
150
atggccaagccaacgatatcaccgggaatgcaacagtatctggatataaaagagaattat60
ccagatgcttttttgctttttagaatgggtgatttttatgaattattttatgatgatgcg120
gtaaaagcagcacaaatcctggaaattagcttgactagtcgaaataagaacgcagaaaag180
ccaatcccaatggcaggagttccctatcactcagctcaacagtatattgacgttttagtt240
gaattaggttacaaagtagccattgctgagcagatggaagatcctaaaaaagetgtggga300
gtggtcaagcgtgaggtagtgcaagttgttaccccaggaacggttgtggagtcaacgaag360
ccggatagtgctaataatttcttagtagcgattgattcgcaagatcaacaaacatttggt420
ctagcatatatggatgtctcaactggagagtttcaggcaacccttttaacagattttgag480
tccgtccgtagtgaaatactaaatttaaaagctcgtgagattgtagtaggatatcaattg540
acggacgaaaaaaatcacctactgacgaagcagatgaacttgcttttatcatacgaagac600
gaacgacttaatgatattcatttgattgatgagcagttaactgatttggaaatatctgct660
gcggaaaaacttttacaatatgtgcatagaacacaaaagcgtgaacttagtcatttacag720
aaagtagttcattatgaaataaaggactatttacaaatgtcatatgcaacgaaaaatagt780
ctagatttactggagaatgctagaacaagcaagaagcatggaagtctttactggttgtta840
gatgagactaaaacagcgatgggaactcgaatgctgagaaettggattgacaggcctttg900
gtaagtatgaatcgaatcaaggaacgtcaagatattattcaagtgtttcttgattatttt960
tttgagagaaacgatctcacagaaagtttaaagggtgtatatgatattgaacgcctagca1020
agtcgagtatctttcggaaaagccaaccctaaagatctattgcaactcggacagacctta1080
tcacaaattcctcggattaaaatgattttacagtccttcaatcaacctgagcttgacatc1140
attgtcaacaaaattgacactatgcctgaattagaaagtttaattaatacggcgatagcc1200
ccagaagcacaggctactatcactgagggaaacattatcaagtctggatttgataagcaa1260
ttggataattatcgaacagtgatgcgtgaaggtacaggttggattgctgatattgaagct1320
aaggaaagagcagcaagtggtatcggtactcttaaaattgattataataaaaaagacggt1380
tattacttccatgttaccaattccaatttatcactagtaccggagcattttttccgtaaa1440
gcgacattaaaaaattctgaacgctatggaacagcagaactagccaaaattgaaggtgaa1500
atgctcgaagctcgcgagcaatcttcaaatttagaatatgatatttttatgcgtgttcgt1560
geccaagtagaatcttatattaaacgtcttcaagagttagcaaagacgattgcaaccgtt1620
gatgttctacagagtttggcagtagttgcagaaaattatcactatgttcgtcccaaattt1680
aatgatcaacatcagattaagattaagaatgggcgtcatgcaactgttgaaaaagtgatg1740
ggagtgcaagaatatattcccaatagcatctattttgatagtcagacagatatccagttg1800
attacaggaccaaatatgagtggtaagtcgacctatatgcgccagttagctttgacagtt1860
attatggcacaaatgggaggttttgtatcggcagacgaagttgatttgcctgtatttgat1920
gcaatatttactaggattggtgctgctgacgacttaatttctgggcaatcaacctttatg1980
gtagaaatgatggaagcgaatcaagctgtaaaacgagccagtgataaatctttgattctt2040
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
63/109
tttgatgaattaggtcgagggacagccacttatgatggtatggcattagctcaatcgatt2100
atagaatatattcatgaccgtgttagggcaaaaacaatgtttgcgactcattaccatgag2160
ttgacagatttatctgaacagttgacaaggcttgtcaatgtacacgtggctactttagag2220
agagatggagaagttaccttcttacataaaattgaatctggacctgcggataagtcttat2280
gggatacacgtcgcaaaaatagctggtttaccaattgacttattggatagggcaactgat2340
attttatcacagttggaagctgatgcagtacagttgatcgtatcgccctcccaagaagct2400
gttactgctgacttaaatgaggaactagattctgagaagcaacaaggacaattatcgctt2460
tttgaagaaccttcaaatgcaggtagggttattgaggagttagaagcgatagatataatg2520
aatctaactccaatgcaagctatgaatgctatatttgacttaaagaaattattataa 2577
SeqID
151
atgttgaaactggatttaaaaacaaagataaaagaagctattttaattgcctttggtgtg60
gCtCtCtat~CtttCggCtttgtCaaatttaatatggCtaatCatttggCtgaaggaggt120
atttccggtgtcactttgattatccatgcacttttcggagttaatccagcactttcatca180
cttctccttaatatcccgttatttatattaggggctaggattttagggaaaaaatcctta240
ttattaactatatatggtacagtgttaatgtcttttttoatgtggttttggcaacaaatc300
cctgtaacagtccctttgaaaaacgatatgatgttagttgcagtagctgctggaatttta360
gcaggaactggtagtggtttagtatttagatatggtgcaactacaggtggtgcagatatt420
attggtcgtattgtagaggaaaaatctggaataaaattagggcaaaccttattgtttatt480
gatgetatagttctaacgtcttcacttgtttatattaatttacaacagatgctatatacg540
ttagtagctagctttgtatttagtcaagtgttaacaaatgttgaaaatgggggctacact600
gttcgtggaatgatcattattaccaaagaatcagaatctgcagcagcaaccattttgcat660
gaaattaataggggtgtaacttttttacggggccaaggtgcctactcaggtagagagcat720
gatgtcttgtacgtagctcttaacccaagtgaagtgcgtgatgtgaaagaaatcatggct780
gatttagacccagatgcttttatttctgttataaatgtagatgaagttattagctcagat840
tttaaaattcgacgaagaaattacgataaataa 873
SeqID
152
atgaaacgtagtatgtatgctgggcgtgttcgtagtgagcacataggaacatcgattact60
ttaaaaggatgggttggtcgtcgtcgtgaccttggaggccttatttttattgatcttcgc120
gatcgcgagggaatcatgcaattagttattaatcctgaagaagtagcagcctcagttatg180
gcaaccgcagaaagtctccgtagtgaatttgttatagaggttagcggtgtagtgacagca240
cgagaacaagctaatgataatttaccaacaggagaagttgaattaaaagtgcaagaatta300
tcggttcttaatacctcgaaaacaacaccatttgaaattaaagatggtattgaggcaaat360
gatgatacacgcatgcgttaccgttacttggatcttcgtcgtccggaaatgcttgaaaat420
ttcaaattacgtgcgaaagtaacacactcaatccgtaattaccttgacaacttagagttt480
attgatgtcgaaactccgatgctaacaaaatcaactccagagggggcacgagactatttg540
gttccatcacgtgtcaaccaaggacatttttatgcccttccacaaagccctcaaattaca600
aaacagetattgatgaatgcaggatttgatcgttattatcaaattgtcaaatgttttcgt660
gatgaggatttacgtggagatcgtcaacctgagtttacacaagttgacttagagacatca720
ttccttagtgatcaagaaattcaagacattgttgagggtatgattgctaaagtaatgaaa780
gacactaaaggtttagaggtttctttaccattcccaaggatggcatatgatgatgcaatg840
aataactacgggtctgataagcctgatacaaggtttgatatgcttttacaagacttgaca900
gaaattgtaaaagaagttgaettcaaggtgttctcagaagettcagtagttaaagcgatt960
gttgtcaaagacaaggcggacaagtactctcgaaaaaatattgataaattaacagaaatt1020
gcaaaacaatacggtgccaaaggtttagcatggctaaaatatgtagataatactatttca1080
ggtccggttgctaagttcttgacagctattgaaggtaggttgacagaagctttgcagcta1140
gagaataatgacttaattctatttgtagcagatagtcttgaagtagctaacgagacttta1200
ggagcgcttcgtacacgcattgcaaaagaacttgaactcattgattattctaaatttaat1260
ttcctatgggttgttgattggccaatgtttgagtggtcagaagaagagggacgatatatg1320
tcggctcatcatccattcaccttgccaacagcggagacagcgcatgagttggaaggggat1380
ttggctaaagtacgtgcagttgcctatgatattgttttgaatggatatgagttaggcggt1440
ggtagcctacgtattaaccaaaaagatacacaagagcgtatgttcaaggctttaggattt1500
agcgctgaatcagctcaggaacagtttggtttcttacttgaagctatggattacggcttc1560
ccaccacatggtggattggcaataggccttgaccgctttgttatgttgttagcaggcaag1620
gacaatattcgagaagttattgcattccctaaaaacaataaggctagtgatccaatgact1680
caagctcctagtctcgtttcagaacaacaattagaagaattatcacttactgtagaaagt1740
tatgaaaactag 1752
SeqID 153
aaagaaaaaggaaaactaataaagaaaaaaattctagaaaataatactgatattattcca 60
aaaattatagaaaaaagtcctcaaaatcttattcttacaagtaattacaacagagttaat 120
attgataaaataaaaaatataaaaaattttgataaaggattcgaactaggctttccactt 180
tttgaaaaaggagaaattctgagaaaagaaggcgaaataactagtgcaattgaattattt 240
gataaagcacgtgaactaggatattttgtacccgccttatacaattcttatgcgatggct 300
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
64/109
tttaggaaaa 360
taaagaatta
tgatgatgaa
attetaatac
tacaagaagg
aattgaaaga
ttcaaaaaaa 420
gcaccctgtc
atcaaatatt
aacccaaaga
caatcgatag
atggagtact
cgtatttcta 456
gagctaaaga
tttaaaatgt
aaataa
SeqID
154 60
ttgaatgtaa
aaaaacatca
tttagcttat
ggagctatca
etttagtagc
ccttttttca
tgtattttgg 120
ctgtaatggt
catctttaaa
agttcacaag
ttactactga
atctttgtca
aaagcagata 180
aa.gttegcgt
agecaaaaaa
tCaaaaatga
CtaaggCgaC
atCtaaatCa
aaagtagaag ccttctcagg 240
atgtaaaaca catctaatga
ggctccaaaa agccccaaaa
tcaagttctc cagcaacaag tgaagaggca300
aatctacaga ttactgcgag
agctaattct
gctgtagaac acecctgcta acaacaagct360
aagca.gttgt ccagtcaggc
aa~caga.aaac
tatgctgttactgagacaac getcaacacc ccaagtattg420
ttatagacct agacgagtgg
agtaatggaa.atactgcagg tcagcagctg ggetgctgca480
ggctattggc cagcacaaat
acaggagtccctcagtctacttgggaacatattattgccc tggtaatcct540
gtg~atcaaa
aatgttgctaatgcctcaggagcttcaggacttttccaaacgatgccaggttggggttca600
acagctacagttcaggatcaagttaattcagctattaaagettatcgtgctcaaggttta660
tcagcttggggttactag
678
SeqID
155 gggatactaagtttttgaaaaaaggttttacttttgatgatgttctgctt60
atgtcaaatt
attcctgctgaaagccatgttttaccaaatgaagttgatatgaagacaaagttggctgat120
aatttgacattaaacattccaatcattacagctgcaatggatacagttacagatagtaag180
atggctattgCtattgcacgtgctggtgggcttggtatcattcataaaaatatgtcaata240
gttgatcaagcagaagaagttcgtaaagttaaacgctcagaaaatggtgttattattgac300
ccattcttcttgacaccagataatactgtctctgaagctgaggaattgatgcaaaactat360
cgcattagtggagttcctattgtagagacactcgagaatcgtaaattagttggaattatt420
actaaccgtgatatgcgtttcatttctgattataaacaactaatctcagagcacatgaca480
agtcaaaatcttgtaacagctcctattggtacagatcttgaaactgcagagcgtattett540
catgagcatcgtattgaaaagctacctttagtagatgatgagggacgtctttcaggactt600
attactattaaggatatcgaaaaagttattgaatttcctaaggcagcaaaagatgaattt660
ggacgtctcttagttgcaggtgcagtaggtgtaacctctgatacttttgaacgtgcagaa72D
gctttgtttgaagcaggtgcagatgetattgtcattgatacagcacatggacattcagct780
ggtgtgctccgtaaaattgctgaaattcgtgctcacttccctaatcgcacattgattgcg840
ggaaatattgetacagcagaaggagcgcgtgcactttatgatgcaggtgtggatgtcgtt900
aaagttggtattggtccaggttcaatttgtacgactcgtgtcgttgctggggtaggtgtt960
cctcagattacagctatttacgatgcagcggctgttgcgcgtgagtacggtaagactatc1020
attgctgatggtggtattaaatattcaggtgatattgtaaaagcacttgcagcaggtgga1080
aatgcagttatgctaggttcaatgtttgcaggaacagatgaagcgccaggagaaacagaa1140
attttccaagggcgtaagttcaagacataccgtggtatgggctcaattgcagcaatgaaa1200
aaaggttcaagcgatcgttatttccaaggttctgtaaacgaggctaacaaattggttcca1260
gaaggtattgaaggtcgtgtagcatacaaaggttcagtagccgatattgttttccaaatg1320
cttggtggcattcgetctggtatgggatatgtaggtgcagcgaacataaaagaacttcat1380
gataatgctcaatttgttgaaatgtcaggagctggcttgaaagaaagccatccccatgat1440
gttcaaattacaaatgaggcaccaaattattcagtacaotas 1482
SeqID
156
atgacaattaaccactataagcttcgtataccttactatacaataagctttctacttccc60
ttcataatcatagtctgtatectctttactaagaatatttattggggaagtccaacaacc120
atattagcaagcgatggctttcatcaatatgttatctttaatcaagcattaagaaatatt180
cttcatggttcaaacagettattctatacctttacaagcggtttaggtttaaatttttat240
gctctgagtagttaatatttgggaagttttttatccccaatagtttatttctttaaccta300
aaaaatatgcctgatgctatctaccttttaacaatatgtaaaatagggttgataggtttg360
tcaatgtttgtcactctttgtaaacgtcattgtaaagttaatcgtgtcttacttttagta420
atttctacttgctatagcttaatgagtttctcaattagccaaattgaaattaatatgtgg480
ctagatgtatttattctaattccccttgttgttttaggagttgatcagctactatgggaa540
agaaaacctataetttatttcctctctctgacagccttattcatccaaaactattatttt600
ggttttatgactgccatctttactagcctttacttcatcgtacaaataa.accgtaatact660
gatagtaaggttgcatttaaacaatttcttcattttacctttttatctcttttagctggt720
atgactagtagcattatgattttgccaacttattttgatttaactactcatggtgaaaag780
ttgacaaaggtatcgaagatgtttacagaaaattcttggtacatggatttgtttgetaaa840
aatatgattggagectatgatacaacaaaatttggctetattcctatgatttatgtaggt900
ttacttcctttactcctttctttactttaotttacaataaaggaagttcctcgaaggact960
agattagcatatggatttttaataatatttgttattgctagtttttatataacacctcta1020
gatttattttggcaagggatgcatgctccaaatatgtttctccatcgctactcttgggta1080
ctttcagtacttatctgtctgctagctgctgaatgccttgagtatttagacaacatttct1140
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
65/109
tggaaaaaga ttttaggggt caatttaatt ttagtaagtg gtttcataat cacgttttta 1200
tttaaaaagc attatcatta ccttaatctt gaattacttc ttttaacctt aactttcctc 1260
tcagcttata ttattctaac tattagtttt gtcagtaagc aaatccctaa attagttttt 1320
tatccctttc ttattggttt tgttgtatta gagatgacat taaacacctt ttaccaacta 1380
aatagtctta acgatgaatg gatatttcca tctaggcaag gatatgctaa atataatcac 1440
agcattagca aacttgtcag aaagactgag agaaataact ctacattctt ccgtacagag 1500
cgetggttag gacaaaccgg caacgactct atgaaatata attataatgg tatttcacaa 1560
ttttcatcta ttagaaatcg ttcttcaagt caagtgcttg atagacttgg ctttaaatca 1620
gatggtacaa atttaaattt acgttatcaa aataatactt tgatcgcaga tagtctattt 1680
ggtgtgaagt ataaccttac agaatatcct tttgataaat ttggttttat caaaaaagct 1740
CaagataaaC aaaCCattCt ttaCaaaaat CagtttgCCa gtCaattagC tataCtaaCg 1800
aatcaagtat atcaagataa accatttact gtgaatactt tggataatca gacaactctt 1860
ttaaatcaat taagtggttt gaaagagacg tattttgagc atcttattcc aaatagcgtt 1920
tctgggcaaa ccactcttaa taaacaagta tttgttaaaa agaataaaca agggaatact 1980
gaaattacet ataacataac tatccctaaa aacagtcagt tatatgttag tatgccgttt 2040
ataaatttta ataatgagga aaataaaatt gttcaaatct ccgttaataa tggaccattt 2100
gtacctaata ctcttgataa tgcttattca ttttttaata ttggttcctt tgctgaaaac 2160
agtcgtatca aagtaaaatt tcaatttcca cacaatgatc aagtttcttt cccaattcct 2220
cacttttatg ggctcaagtt agaagcttat caaaaagcta tgactgttat taataaacga 228~
aaagtaaaag taagaactga tcacaataaa gttattgcta attatacaag tcctaataga 2340
agttctcttt tcttcactat tccctatgat aggggttgga aagcttatca aaataataaa 2400
gaaataaaaa ttttcaaagc tcagaaaggt tttatgaaaa taaatattcc taaaggaaaa 2460
ggcaaagtaa cattaatttt tatcccttac ggctttaaat ttggggtagg cctatctatt 2520
actggaatag tattatttac tgtctattat tttaaatttg gaaaaaataa aataggatga 2580
SeqID 157
tggtttatga agcactcggt tgggaagcgc cacaatttgg tcaca 45
SeqID 158
atgaaagatc acctaaggtg cttcetccat taccgatcca aaaacgttgg gaaaaatgga 60
acgagattga agggaggaaa gcctaatgac 90
SeqID 159
gacaaacagc ttttccaatg cgtgcagggc ttccaaataa ggaacctcaa tggcaagaag 60
catgggatca agctgatatt tataaaaaac gtcaagcat 99
SeqID 160
aacgaggaag ccatagatgg ggtgtccaag cttgggaaaa aaatcaccat tctaggaaat 60
aattcatacc tttcttcc 78
SeqID 161
atcaaacaat ggctattggt gatgaagaaa atgaccgtgc tatgcttgaa gttgttggaa 60
atcctgttgt tatgcaaaac ggcaatcctg aac 93
SeqID 162
aggcgcattt caaacaatct aggagtttta aaggaagcga ccgttataca cgccgta 57
SeqID 163
gagctctgcc taaagctgag caacgtcaag ccaatctata tgccttggca cttcgagcaa 60
atcagtttga aaaaacaggt ttcaagggtt tatcacgctt tattcgaa 108
SeqID 164
agaagctgct tcagtaggtg ctatccaaga tttaacagat tcagatatca ttttctcaaa 60
ccaccgtgga cacggacaaa ctattgcaaa aggtat 96
SeqID 165
agatggtttg gttttagata tgacgatggc agaaaattta gctttacaaa Cttatta 57
SeqID 166
cccttaaaaa gtttgtcgat gacatcaaga atgaagctat tgaggttatc acaaagaaaa 60
gctatg 66
SeqID 167
aggcacttgc gaaagagaca aaagcaaaat catttaatga atttatgctt tctatgtgcc 60
gtgaaaaaat tgaaaaagga caatttaatt 90
CA 02522986 2005-10-17
WO 2004/099242 PCT/EP2004/004856
66/109
SeqID
168
aagttatttattcagcctattcaggaaaatatgaagcagccaatcgagat tatatcaaat60
tactatgcaaagcttgggttaatgaaaatc 90
SeqID
169
tatcaaacgtattcgaaaaaggcaagaaaatttggttccgtttggcttaa acctaag 57
SeqID
170
acgctgttattccagatacttctectgctttctcatttgaaaaagaacat ctttctggag60
tggaatatgcacgctacttacast 84
SeqID
171
aagaagttttacgaaataatattagcaaccaagtaccacacatcagtgtt caaatggagt60
ttaaaactcaagaacaagttgacgaataccaaaaaaatctcggaagcatc atecgggaaaI20
ttggagatacacttggaacagcaactgaattcaatgccaaaagtaacatt agcacttata180
ctettggtggacaaatccaacgcattattg 210
SeqID
172
ttaaagcaaatgttcegtcgcgtattgcatttgetgtttcaagtggtact gatagccgta60
cgatccttgatgaaaatggtgctgaaaagctcttgggacggggtgacatg ctctttaagc120
ctattgatgagaatcatccagtacgactacaaggttcctttatttcagat gatgatgttgI80
aaaggatcgttggttttatcaaagaccaagccgaggctgactatgatgat gcctttgatc240
ctggagaagtatctgaaacagataacggctctggtggtggcggcggagta cctgaaagtg300
atcctctttttgaagaagccaagggactcgttt 333
SeqID
173
ggccggaaaattaattttagtcgtccatcacgatttgag 39
SeqID
174
agagttaagtataaaaaatgggaacctttatcaatateccgttcctgcta tgaaaaatct60
tcgtcaacatcaagcagaatt 81
SeqID
175
acttggtcaagatgttgtattcccaggtgttactcgtggtgcaaaattag aagaagcaat60
caatgctttggaagatggacaagttcttttggt 93
SeqID
176
aaggagaatttcgttcaaaggttgaggagtctattgaaagcaatcagcaa aaatataatc60
atttatagtctagtttctctaccattagctagacacttg 99
SeqID
177
agtataatcaatattaaactagaaatatatgacatatgtcctaaaactat ctcaaatagg60
gagtcaatacatggatatagaaaactactgccaagactactgtttggaga ctatctttcc120
aaaacattatttcaaggatttacaagtaatcaccctaactgceggccaat ccgtctg 177
SeqID
178
etttctttcagaagaagtcggcgaattggctcaagccattcgcaaata 48
SeqID
179
ttcattttcaaggataggtttaaaatgagacacttcacggac 42
SeqID
180
gggttgatttgtgcttgtaaagcctttatctctgccatactggctaactt attttgttcc60
tctgttatecccattgccagttgtcctgaaaatatttgcgctaaaccaag gactaggttt120
tcctccacctcagacattgtcttatctcctgcaaagtacatttttaaggc acccacagtt180
ttatcatttatttttagaggaactacaatagcagaatttaac 222
SeqID
181
tcctcctctttggacacccattacaaacatagggagcttttcttagtagc ggacagtcta60
ggcagtctttggttgattctcttagttgcttatttcgtt 99
SeqID
182
cacctggtgcccactcaatatcataaacagaatctacctcttgaatataa gaggctaaac60
gctctagtccataag 75
DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 A 157
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des
brevets
JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 157
NOTE: For additional volumes, please contact the Canadian Patent Office
NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:
